Novel mutations that enhance the DNA cleavage activity of acidaminococcus sp. CPF1

Abstract

The present disclosure concerns polynucleotides and amino acids of Acidaminococcussp. Casl2a (Cpfl) and methods for their use for genome editing in eukaryotic cells. 20 24 20 14 49 05 M ar 2 02 4 A B S T R A C T 2 0 2 4 2 0 1 4 4 9 0 5 M a r 2 0 2 4

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application is a divisional application of Australian Patent Application No. 2019319230, which is the national phase of International Application No. PCT / US2019 / 045813, which in turn claims benefit of priority under 35 U.S.C. 119 to U.S. Provisional Patent Application Serial Number 62 / 870,268, filed July 3, 2019 and entitled“OPTIMIZED CAS12A (CPF1) PROTEINS FOR EFFICIENT GENOME EDITING IN EUKARYOTIC CELLS,” U.S. Provisional Patent Application Serial Number 62 / 749,607, filed October 23, 2018 and entitled“DEEP- SCANNING MUTAGENESIS UNCOVERS NOVEL MUTATIONS THAT ENHANCE THE DNA CLEAVAGE ACTIVITY OF ACIDAMINOCOCCUS SP. CAS 12 A / C AS 12A AT NON-CANONICAL TTTT PAM SITES” and U.S. Provisional Patent Application Serial Number 62 / 716,138, filed August 8, 2018 and entitled“NOVEL MUTATIONS THAT ENHANCE THE DNA CLEAVAGE ACTIVITY OF ACIDAMINOCOCCUS SP. CPF1,” the contents of each application are herein incorporated by reference in its entirety. FIELD OF THE INVENTION

[0002] This invention pertains to the ability to cleave double-stranded DNA of living organisms at precise positions with the CRISPR / Cas12a (Cpfl) nuclease system. In particular, a series of recombinant Cas12a proteins are described that are useful in a eukaryotic cell context. SEQUENCE LISTING

[0003] The instant application contains a Sequence Listing that has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on ____, is named ____, and is ____ bytes in size. BACKGROUND OF THE INVENTION

[0004] Cas12a is an RNA-guided endonuclease found in bacterial species including Acidaminococcus sp. and is part of the Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) adaptive immune system. Cas12a is guided to a 2l~24-nt DNA target 2024201449   05 Mar 2024 sequence, or commonly referred as protospacer, by a target site-specific 21~24-nt complementary RNA. The Casl2a-gRNA ribonucleoprotein (RNP) complex mediates double-stranded DNA breaks (DSBs), which are then repaired by either the non-homologous end joining (NHEJ, typically introduces mutations or indels at the cut site), or the homology directed repair (HDR) system for precise editing if a suitable template nucleic acid is present.

[0005] Critical to the recognition of correct DNA target for Cas 12a includes both crRNA and the canonical “TTTV” protospacer adjacent motif (PAM), which is a 4-bp sequence immediately upstream of the protospacer. Compared to the 2-bp NGG PAM of Cas9 from Streptococcus pyogenes, Cas 12a expanded the targetable loci in genome editing, particularly over the AT-rich sites that are inaccessible to the Cas9 system. However, due to its relatively low enzymatic activity, the likelihood that efficient genome editing can be achieved for a given site is much lower than that of the Cas9 system, which restricts its broader application. As the consequence, the Casl2a system is frequently considered as an alternative approach only when the genomic site is not targetable by Cas9.

[0006] Protein engineering by mutagenesis can alter the preference of PAM sequence of CRISPR system. Through a structural-guided mutagenic screening of residues in proximity of PAM sequence, previous study has identified two AsCpfl variants that are compatible with TYCV and TATV PAMs, respectively. Although these variants collectively expanded the targetable sites of Cpfl system over the coding region of the human genome by 3-fold, the utility of each individual variant is still limited, due to their mutually exclusive requirement of PAM sequences (TYCV vs TATV vs TTTV). Identifying Cpfl variants with shorter PAM and greater sequence flexibility without sacrificing the activity at canonical PAM sites is highly desirable.

[0007] Thus, there is a need to enhance the utility of Cas 12a. One aspect of the present application is to enhance the utility of Cpfl by broadening its PAM compatibility. In this regard, certain novel AsCasl2a variants with enhanced activity have been discovered. Another desired objective is to maximize delivery of the bacterial protein to the eukaryotic nucleus while simultaneously avoiding disruption of basic Cas 12a function. Since the Cas 12a is a bacterial protein, certain molecular genetic obstacles must first be overcome before one can achieve successful delivery of the protein to eukaryotic cells. This invention provides unique solutions to achieving these objectives. 2024201449   30 May 2026 BRIEF SUMMARY OF THE INVENTION [0007a] In a first embodiment, the present invention provides a CRISPR-associated protein consisting of a wild-type AsCas12a polypeptide sequence of SEQ ID NO: 462 and comprising at least two amino acid substitutions: M537R and F870L. [0007b] In a second embodiment, the present invention provides an isolated nucleic acid encoding the CRISPR-associated protein of the first embodiment. [0007c] In a third embodiment, the present invention provides a composition comprising the CRISPR-associated protein of the first embodiment. [0007d] In a fourth embodiment, the present invention provides a composition comprising the isolated nucleic acid of the second embodiment. [0007e] In a fifth embodiment, the present invention provides an engineered CRISPR / Cas endonuclease system, comprising: a. the CRISPR-associated protein of the first embodiment; and b. at least one guide RNA that hybridizes to a target sequence of a DNA molecule in a eukaryotic cell. [0007f] In a sixth embodiment, the present invention provides an engineered CRISPR / Cas endonuclease system, comprising: a. the isolated nucleic acid of the second embodiment; and b. at least one guide RNA that hybridizes to a target sequence of a DNA molecule in a eukaryotic cell. [0007g] In a seventh embodiment, the present invention provides a complex, comprising: a. the isolated mutant Cas12a variant of the first embodiment; and b. at least one guide RNA that hybridizes to a target sequence of a DNA molecule in a eukaryotic cell. [0007h] In an eighth embodiment, the present invention provides a method of performing genome editing in a eukaryotic cell, comprising introducing the CRISPR / Cas endonuclease system of the fifth or sixth embodiment or the complex of the seventh embodiment into a eukaryotic cell. [0007i] In a ninth embodiment, the present invention provides a method of performing genome editing in a eukaryotic cell, comprising introducing a CRISPR / Cas endonuclease system into the eukaryotic cell, wherein the CRISPR / Cas endonuclease comprises an expression cassette encoding the Cas12a variant of the first embodiment. 2024201449   30 May 2026

[0008] In a first aspect, A CRISPR-associated protein comprising a polypeptide encoding a variant of AsCpfl is provided. The variant of AsCpfl is selected from the group consisting of M537R (SEQ ID NO.: 472), F870L (0SEQ ID NO.: 473), and M537R / F870L (SEQ ID NO.: 465).

[0009] In a second aspect, a CRISPR ribonucleoprotein complex is provided. The CRISPR ribonucleoprotein complex includes a guide RNA and a CRISPR-associated protein. The CRISPR-associated protein including a polypeptide encoding a variant of AsCpfl . The variant of AsCpfl is selected from the group consisting of M537R (SEQ ID NO.: 472), F870L (SEQ ID NO.: 473), and M537R / F870L (SEQ ID NO.: 465).

[0010] In a third aspect, a method of increasing efficiency of gene editing at TTTN PAM sites in a cell with a CRISPR ribonucleoprotein complex is provided. The method includes the step of contacting a cell with the CRISPR ribonucleoprotein complex. The CRISPR ribonucleoprotein complex includes a guide RNA and a CRISPR-associated protein. The CRISPR-associated protein including a polypeptide encoding a variant of AsCpfl . The variant of AsCpfl is selected from the group consisting of M537R (SEQ ID NO.: 472), F870L (SEQ ID NO.: 473), and M537R / F870L (SEQ ID NO.: 465).

[0011] In a fourth aspect, a kit comprising a guide RNA and a CRISPR-associated protein is provided. The CRISPR-associated protein includes a polypeptide encoding a variant of AsCpfl .

[0012] In a fifth aspect, CRISPR-associated protein comprising a polypeptide encoding a variant of AsCas12a, wherein the variant of AsCas12a is selected from the group consisting of at least one variant amino acid selected from amino acid positions 499-640 and 840-913, provided that the variant AsCas12a provides an improvement in CRISPR / AsCas12a-associated nuclease activity at non-canonical TTTT PAM sites.

[0013] In a sixth aspect, a CRISPR ribonucleoprotein complex is provided. The CRISPR ribonucleoprotein complex includes a guide RNA and a CRISPR-associated protein. The CRISPR-associated protein includes a polypeptide encoding a variant of AsCas12a, wherein the variant of AsCas12a is selected from the group consisting of at least one variant amino acid selected from amino acid positions 499-640 and 840-913, provided that the variant AsCas12a provides an improvement in CRISPR / AsCas12a-associated nuclease activity at non-canonical TTTT PAM sites. 2024201449   05 Mar 2024

[0014] In a seventh aspect, a method of increasing efficiency of gene editing at non-canonical TTTT PAM sites in a cell with a CRISPR ribonucleoprotein complex is provided. The method includes a step of contacting a cell with the CRISPR ribonucleoprotein complex that includes a guide RNA and a CRISPR-associated protein. The CRISPR-associated protein includes a polypeptide encoding a variant of AsCasl2a, wherein the variant of AsCasl2a is selected from the group consisting of at least one variant amino acid selected from amino acid positions 499-640 and 840-913, provided that the variant AsCasl2a provides an improvement in CRISPR / AsCasl2a-associated nuclease activity at non-canonical TTTT PAM sites.

[0015] In an eighth aspect, a kit including a guide RNA and a CRISPR-associated protein comprising a polypeptide encoding a variant of AsCasl2a is provided. The variant of AsCasl2a is selected from the group consisting of at least one variant amino acid selected from amino acid positions 499-640 and 840-913, provided that the variant AsCasl2a provides an improvement in CRISPR / AsCasl2a-associated nuclease activity at non-canonical TTTT PAM sites.

[0016] In a ninth aspect, a nucleic acid encoding a CRISPR-associated protein comprising a polypeptide encoding a variant of AsCasl2a is provided. The variant of AsCasl2a is selected from the group consisting of at least one variant amino acid selected from amino acid positions 499-640 and 840-913, provided that the variant AsCasl2a provides an improvement in CRISPR / AsCasl2a-associated nuclease activity at non-canonical TTTT PAM sites.

[0017] In a tenth aspect, a polynucleotide sequence encoding a Casl2a polypeptide is provided. The polynucleotide sequence includes one member selected from the group consisting of SEQ ID NOs.: 5-17.

[0018] In an eleventh aspect, an amino acid sequence encoding a Cas 12a polypeptide is provided. The amino acid sequence includes one member selected from the group consisting of SEQ ID NOs.: 18-30.

[0019] In a twelfth aspect, a CAS endonuclease system comprising an expression cassette encoding a polynucleotide sequence encoding a Casl2a polypeptide is provided. The includes one member selected from the group consisting of SEQ ID NOs.: 5-17. 2024201449   05 Mar 2024

[0020] In a thirteenth aspect, CAS endonuclease system comprising an amino acid sequence encoding a Casl2a polypeptide is provided The amino acid sequence includes one member selected from the group consisting of SEQ ID NOs.: 18-30.

[0021] In a fourteenth aspect, a method of performing genome editing in a eukaryotic cells is provided. The method includes the step of introducing an CAS endonuclease system into the eukaryotic cell, said CAS endonuclease system comprising an expression cassette encoding a polynucleotide sequence encoding a Casl2a polypeptide, comprising one member selected from the group consisting of SEQ ID NOs.: 5-17.

[0022] In a fifteenth aspect, a method of performing genome editing in a eukaryotic cell is provided. The method includes the step of introducing an CAS endonuclease system into the eukaryotic cell, said CAS endonuclease system comprising an amino acid sequence encoding a Casl2a polypeptide comprising one member selected from the group consisting of SEQ ID NOs.: 18-30.

[0023] In a sixteenth aspect, an CRISPR-associated protein comprising a fusion polypeptide is provided. The fusion polypeptide includes an AsCasl2a open reading frame, a nuclear localization signal, optionally an amino acid linker and optionally an affinity tag.

[0024] In a seventeenth aspect, a method of performing genome editing in a eukaryotic cell is provided. The method includes the step of introducing an CAS endonuclease system into the eukaryotic cell, said CAS endonuclease system comprising a CRISPR-associated protein of according to the sixteenth aspect. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] FIG. 1 depicts multiple recombinant forms of Cas 12a yields a spectrum of editing efficiencies. A series of recombinant Casl2a proteins with differing composition and arrangement of NLS sequences, purification tags, and linkers (A-M; corresponding to SEQ ID NOs. :18-30) were cloned and purified to homogeneity. The resulting purified Casl2a derivatives were delivered into HEK293 cells by electroporation complexed to RNA guides that target the HPRT-38186 (SEQ ID NO.: 1) and HPRT-38228 loci (SEQ ID NO.:2). DNA was isolated from genome editing experiments 48 hr later, and editing efficiencies were determined by PCR amplification of edited loci using HPRT-FWD (SEQ ID NO. :3) and HPRT-REV (SEQ ID NO. :4) primers and the Alt-R Genome Editing Detection Kit (Integrated DNA Technologies). The following abbreviations apply for the illustrated constructs: V5 refers to V5 epitope tag (SEQ ID NO.: 485); SV40 refers to a nuclear 2024201449   05 Mar 2024 localization signal from simian virus SV40 large tumor antigen (SEQ ID NO.: 475); Casl2a refers to a Casl2a coding sequence; HIS refers to a hexahistidine tag (SEQ ID NO.: 487); OpT refers to an optimized nuclear localization signal (SEQ ID NO.: 477); aNLS refers to an alternative nuclear localization signal(SEQ ID NO.: 479); BIP1 refers to a first bipartite nuclear localization signal (SEQ ID NO.: 481); and BIP2 refers to a second bipartite nuclear localization signal (SEQ ID NO.: 483). The arrows provided in the constructs depict transcriptional start sites for mRNA transcripts originating from the DNA.

[0026] FIG. 2 shows exemplary results of M537R and F870L mutations with enhanced the cleavage activity of Cpfl in a bacterial-based activity assay. The screening E. coli strains were transformed with Cpfl expression vectors and the crRNA targeting HPRT-38346 site on the toxin expression plasmid. The apparent activity of Cpfl for TTTT or TTTC PAM can be estimated by the number of survived colonies under arabinose selection when equivalent amount of plasmids is delivered. Clearly, both mutations increased the survival rate at TTTC and TTTT PAM sites, indicating an improved cleavage activity over the WT-Cpfl.

[0027] FIG. 3A shows an exemplary SDS-PAGE analysis of AsCpfl variants used in the in vitro cleavage assay and subsequent genome editing in human cell lines. Indicated quantity of protein was loaded, and no difference was observed comparing to the WT-Cpfl. These results demonstrate M537R and F870L mutations can increase the in vitro cleavage activity of Cpfl at non-conical TTTT PAM site while maintaining high activity at canonical TTTV site.

[0028] FIG. 3B shows exemplary DNA cleavage activities of Cpfl variants at HPRT-38346 site with TTTC or TTTT PAM. Both variants resulted in a higher percentage of DNA cleavage at TTTT PAM site than WT-Cpfl. These results demonstrate M537R and F870L mutations can increase the in vitro cleavage activity of Cpfl at non-conical TTTT PAM site while maintaining high activity at canonical TTTV site.

[0029] FIG. 4 shows a summary of results showing exemplary results of M537R and F870L mutations having broadly enhanced the genomic targeting efficiency of AsCpfl at TTTN PAM sites in human cell line. The genomic targeting efficiencies of Cpfl variants were tested in a human cell line model using T7 endonuclease I assay (T7EI). Twenty-four crRNAs targeting the CTNNB1 gene with TTTN PAMs were synthesized, assembled with Cpfl variants as RNP complex, and delivered by nucleofection (Lonza). The genomic DNA was collected 48 hours post-delivery to assess the formation of indels by T7EI. Not only 2024201449   05 Mar 2024 enabled DNA cleavage at all TTTT PAM sites that many were not targetable by WT-Cpfl, the reported variants, particularly the double-mutant (M537R / F870L), broadly enhanced the targeting efficiency of Cpfl at 22 of 24 tested sites regardless of PAM sequence.

[0030] FIG. 5A shows exemplary correlation of relative survival rate of M537R / F870L-AsCasl2a under condition 1 (X-axis) vs. relative survival rate of M537R / F870L-AsCas72a condition 2 (Y-axis). Consistent phenotype measurement was obtained (p ~ 0.7).

[0031] FIG. 5B shows exemplary correlation of relative survival rate of M537R / F870L-AsCasl2a under condition 1 (X-axis) vs. relative survival rate of WT-AsCas 12a under condition 3 (Y-axis). Consistent phenotype measurement was obtained (p ~ 0.7).

[0032] FIG. 5C shows exemplary correlation of relative survival rate of M537R / F870L-AsCasl2a under condition 2 (X-axis) vs. relative survival rate of WT-AsCasl2a under condition 2 (Y-axis). Consistent phenotype measurement was obtained (p ~ 0.7).

[0033] FIG. 5D shows exemplary variant scores of phenotype (relative survival rate) of single point mutations of a selected number of AsCasl2a at positions 537 and 870 under conditions 1 and 2.

[0034] FIG. 5E shows exemplary variant scores of phenotype (relative survival rate) of single point mutations of a selected number of AsCasl2a at positions 537 and 870 under conditions 1 and 2. FIGs. 5D and 5E show that M537R and F870L are the optimal substitutions at respective positions, which is consistent with the result of our previous screening and mutant characterization.

[0035] FIG. 5F shows exemplary variant scores of phenotype (relative survival rate) of single point mutations of a selected number of AsCasl2a at positions 505, 510, 569 and 599 under conditions 1, 2 and 3.

[0036] FIG. 6A shows survival rate of E. coli resulting from DNA cleavage activity of WT-AsCas 12a at TTTT PAM. The cleavage activity of AsCasl2a variants at TTTT PAM site was measured by bacterial-based activity assay. The petri dish plated with the initial bacterial plating is shown on the left, while the petri dish having the surviving bacterial colonies is shown on the right. The survival of E. coli under selection is dependent on the success cleavage of a toxin-expressing plasmid containing a TTTT PAM site.

[0037] FIG. 6B shows survival rate of E. coli resulting from DNA cleavage activity of L505K-AsCasl2a variant at TTTT PAM. The presentation of petri dishes and experimental details are as set forth in FIG. 6A. 2024201449   05 Mar 2024

[0038] FIG. 6C shows survival rate of E. coli resulting from DNA cleavage activity of S510L-AsCasl2a variant at TTTT PAM. The presentation of petri dishes and experimental details are as set forth in FIG. 6A.

[0039] FIG. 6D shows survival rate of E. coli resulting from DNA cleavage activity of M537R-AsCasl2a variant at TTTT PAM. The presentation of petri dishes and experimental details are as set forth in FIG. 6A.

[0040] FIG. 6E shows survival rate of E. coli resulting from DNA cleavage activity of P569D-AsCasl2a variant at TTTT PAM. The presentation of petri dishes and experimental details are as set forth in FIG. 6A.

[0041] FIG. 6F shows survival rate of E. coli resulting from DNA cleavage activity of P599G-AsCasl2a variant at TTTT PAM. The presentation of petri dishes and experimental details are as set forth in FIG. 6A.

[0042] FIG. 7A shows survival rate of E. coli resulting from DNA cleavage activity of M537R / F870L-AsCasl2a at TTTT PAM. The cleavage activity of M537R / F870L-AsCasl2a variants at TTTT PAM site was measured by bacterial-based activity assay. The petri dish plated with the initial bacterial plating is shown on the left, while the petri dish having the surviving bacterial colonies is shown on the right. The survival of E. coli under selection is dependent on the success cleavage of a toxin-expressing plasmid containing a TTTT PAM site.

[0043] FIG. 7B shows survival rate of E. coli resulting from DNA cleavage activity of L505K / M537R / F870L-AsCasl2a variant at TTTT PAM. The presentation of petri dishes and experimental details are as set forth in FIG. 7A.

[0044] FIG. 7C shows survival rate of E. coli resulting from DNA cleavage activity of M537R / F870L-AsCasl2a variant at TTTT PAM. The presentation of petri dishes and experimental details are as set forth in FIG. 7A.

[0045] FIG. 7D shows survival rate of E. coli resulting from DNA cleavage activity of P569D / M537R / F870L-AsCasl2a variant at TTTT PAM. The presentation of petri dishes and experimental details are as set forth in FIG. 7A.

[0046] FIG. 7E shows survival rate of E. coli resulting from DNA cleavage activity of P599G / M537R / F870L-AsCasl2a variant at TTTT PAM. The presentation of petri dishes and experimental details are as set forth in FIG. 7A. 2024201449   05 Mar 2024

[0047] FIG. 7F shows survival rate of E. coll resulting from DNA cleavage activity of S510L / M537R / F870L-AsCasl2a variant at TTTT PAM. The presentation of petri dishes and experimental details are as set forth in FIG. 7A. DETAILED DESCRIPTION

[0048] The present invention concerns compositions of Cas 12a variants and methods to enhance the utility of Casl2a and variants thereof for expression in eukaryotic cells. Definitions

[0049] When introducing elements of aspects of the disclosure or particular embodiments, the articles “a,” “an,” “the,” and “said” are intended to mean that there are one or more of the elements. The terms “comprising,” “including,” and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements. The term "or" means any one member of a particular list and also includes any combination of members of that list, unless otherwise specified.

[0050] As intended herein, the terms “substantially,” “approximately,” and “about” and similar terms are intended to have a broad meaning in harmony with the common and accepted usage in the art to which the subject matter of this disclosure pertains. It should be understood by those of skill in the art who review this disclosure that these terms are intended to allow a description of certain features described and claimed without restricting the scope of these features to precise numerical ranges provided. Accordingly, these terms should be interpreted as indicating that insubstantial or inconsequential modifications or alterations of the subject matter described and claimed are considered to be within the scope of the invention as recited in the appended claims.

[0051] Definitions pertaining to certain terms and phrases applicable herein may be found in related US patents and publications, such as U.S. Patent Application Serial Nos. 14 / 975,709, 15 / 299,549, 15 / 299,590, 15 / 299,593, 15 / 881,684, 15 / 729,491, 15 / 821,736, 15 / 964,041, 15 / 839,817, 15 / 839,820, 62 / 716,138, and U.S. Patent No. 9,840,702.

[0052] The term “substantially purified,” as applied to a composition, refers to a composition having at least 90% purity or greater, including 90% purity, 95% purity, 99% purity and greater than 99% purity.

[0053] The adjective “isolated,” when modifying a composition, such as a polynucleotide, a polypeptide or a ribonucleoprotein complex refers to a substantially purified composition, or in the case of a ribonucleoprotein complex, at least one component 9 2024201449   05 Mar 2024 being a substantially purified component. In further respect to an isolated ribonucleoprotein complex, preferably all components are substantially purified.

[0054] The terms “nucleic acid” and “polynucleotide” are interchangeable have the same meaning.

[0055] The terms “amino acid sequence,” “polypeptide,” and “protein” are interchangeable have the same meaning.

[0056] The term “affinity tag” refers to a ligand that permits detection and / or selection of an oligonucleotide sequence to which the ligand is attached. For the purposes of this disclosure, a bait may include an affinity tag. In particular, the affinity tag is positioned typically at either or both the N’-terminus and / or C’-terminus of a polypeptide through the use of conventional chemical coupling technology or recombinant DNA technology. Exemplary affinity tags include biotin, digoxigenin, streptavidin, polyhistine (for example, (Hise),), glutathione-S-transferase (GST), HaloTag®, AviTag, Calmodulin-tag, polyglutamate tag, FLAG-tag, HA-tag, Myc-tag, S-tag, SBP-tag, Softag 3, V5 tag, Xpress tag, a hapten, among others.

[0057] The term “eukaryotic cell,” includes those cells of or derived from a particular organism, such as a plant or a mammal, including but not limited to human, or non-human eukaryote or animal or mammal as herein discussed, e.g., mouse, rat, rabbit, dog, livestock, or non-human mammal or primate. In some embodiments, processes for modifying the germ line genetic identity of human beings and / or processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes, may be excluded. Preferred human cells include cells derived from somatic cells and germ line cells. Exemplary somatic cells include cells from every major organ and tissue system, including the immune system and hematopoietic system.

[0058] As set forth herein, the Conditions 1, 2 and 3 refer to different combinations of background strain and the amounts of gRNA introduced in the background strain before selection of the variants. Condition 1 is a M537R / F870L background that includes an introduced amount of gRNA (100 pmol per 10 microliter transformation / plating experiment) in which variants were selected. Condition 2 is a M537R / F870L background that includes an introduced amount of gRNA (50 pmol per 10 microliter transformation / plating experiment) in which variants were selected. Condition 3 is a Wild-type AsCpfl background that includes 2024201449   05 Mar 2024 an introduced amount of gRNA (200 pmol per 10 microliter transformation / plating experiment) in which variants were selected. Casl2a polypeptides having eukaryotic nuclear localization signals

[0059] Since Casl2a is a bacterial protein, it has no native targeting mechanism to reach the eukaryotic nucleus, where the target DNA resides.

[0060] To more efficiently target proteins to the eukaryotic nucleus, short protein sequences called nuclear localization signals (NLS) are commonly added to the amino- or carboxy-terminal ends of a given open reading frame. NLSs are recognized by import proteins on the eukaryotic nuclear envelope that first bind to the nuclear membrane, and subsequently permit pore translocation into the nucleus by an energy-dependent process. While recombinant protein tags like an NLS can greatly improve localization, any addition of exogenous amino acid sequences stands a reasonable chance of perturbing protein function. As such, discovering a recombinant Casl2a protein sequence that facilitates the highest amount of nuclear delivery without negatively affecting its activity will ultimately result in the most potent Casl2a genome editing solution, which is non-trivial and highly desirable.

[0061] To improve nuclear delivery of Cas 12a without perturbing its function, several different recombinant versions of Cas 12a were constructed in which the identity, location, and number of protein tags (NLS, hexahistidine tag (an exemplary affinity tag)) were varied. Whereas hexahistidine and V5 tags were added to Casl2a constructs to aid in protein purification and / or detection, the NLS tags were added to assist in delivery to the eukaryotic nucleus. Domain-breaking linker sequences were also varied in composition and location to empirically determine the best arrangement and context of tagged sequences. All constructs were first expressed in E. colt. and recombinant Cas 12a proteins were purified with immobilized metal affinity chromatography (IMAC) followed by ion exchange chromatography as described previously. AsCpfl polypeptide variants having novel cleavage activities

[0062] Amino acid substitutions in AsCpfl that enhance the cleavage activity at both canonical (TTTV) and non-canonical (TTTT) PAM sites using a bacterial screening approach are described. This screen contained two components: i) a toxin plasmid encoding an arabinose-inducible cell proliferation toxin and a CRISPR / Cpfl on-target cleavage site (HPRT-38346) with TTTT PAM, and ii) a chloramphenicol resistance plasmid containing a randomly-mutagenized region within the AsCpfl sequence (~5 mutations per kb). The screen 2024201449   05 Mar 2024 was performed as follows: E.coli BW25141(ZDE3) was transformed with the toxin plasmid containing the HPRT-38346 target site in the absence of arabinose, where the toxin is not produced and cell survival is permitted. Cells with stably replicating toxin plasmid are then transformed with the AsCpfl expression plasmid and crRNA targeting HPRT-38346, and then cells were plated on media containing both chloramphenicol and arabinose. Bacteria that grew were those that i) successfully transformed with the AsCpfl expression plasmid, ii) expressed sufficient AsCpfl variant to cleave the toxin plasmid at HPRT-38346 site using TTTT PAM. The AsCpfl expression plasmids within the survived cells were recovered and used in the subsequent round of selection. After multiple rounds of selection, the identities of enriched AsCpfl variants were determined by DNA sequencing, and carried forward for analysis in mammalian cells.

[0063] The disclosure provides following two novel point mutations and the combination in the AsCpfl gene that enhances the cleavage activity: M537R and F870L. The cleavage activity of individual mutant was first tested in a bacterial-based activity assay. Next, purified proteins were further tested in vitro and in human cell lines. In summary, both substitutions significantly enhanced the DNA cleavage activity of Cpfl at TTTT PAM sites in all assays. Further, the combination of M537R and F870L broadly enhanced the targeting efficiency of AsCpfl in human cell line. Overall, the present invention identifies novel amino-acid positions in the AsCpfl gene that can be mutated to improve its cleavage activity at all TTTN (N = A / G / C / T) PAM sites.

[0064] As explained in the Background section, the prior art consists of using wild-type Cpfl protein or two variants that are compatible with TYCV and TATV PAMs. As stated previously, these variants have limited utility due to the complex and mutually exclusive requirement of PAM sequence. Further, none of the variants showed any improved cleavage activity at TTTT PAM, which is unfortunately more frequent than other TTTV PAM sites (V = G / A / C) throughout the human genome. In contrast, not only enabling efficient cleavage at TTTT PAM, the mutations reported in this invention (M537R and F870L) broadly enhanced the cleavage activity of Cpfl at canonical TTTV sites tested in human cell line. Together, the enhanced activity and broadened PAM flexibility (TTTN) of this invention makes it a superior CRISPR enzyme, which could directly replace the current wild-type Cpfl in the application genomic editing. 2024201449   05 Mar 2024 High-Throughput generation of AsCasl2a variants having cleavage activity towards a TTTT PAM-containing target site.

[0065] The phenotype of all point mutations in the following regions of AsCasl2a'. 499640 and 840-913 in the bacterial screening measuring the DNA cleavage activity at non-canonical TTTT PAM is described. Three sets of screening were performed to measure the phenotype of each point mutation, in the background of both WT-AsCasl2a and M537R / F870L-AsCasl2a. Cross-comparison of three datasets revealed consistent phenotype measurements, which enabled us to isolate novel AsCasl2a variants with enhanced activity beyond M537R and F870L.

[0066] The high-throughput characterization of Cas 12a activity at a TTTT PAM site provided the functional consequence of every possible single amino acid change within targeted region. The unbiased strategy of the present invention enables one to identify a large collection of mutants to further enhance the cleavage activity of AsCasl2a over our previous invention (M537R / F870L).

[0067] To improve the coverage and efficiency of the screening, we generated an AsCasl2a deep-scanning mutagenesis library containing all possible point mutations on the protein level in the targeted regions (490-640 and 840-913), with most clones contain only one mutation. This type of library allowed us to directly evaluate the phenotype of each point mutation, by measuring their relative survival rates over the reference protein in the bacterial screen. Briefly, the screening strain harboring the toxin plasmid was transformed with AsCasl2a library with TTTT PAM-containing target site on the toxin plasmid. After transformation, cells were plated on selective media. AsCasl2a expression plasmids carried by the survived E. coli cells were extracted and purified. Both input and selected plasmid libraries were PCR amplified, and sequenced on Illumina MiSeq with 1~2 million reads per library. The frequencies of each AsCasl2a variant in both libraries were determined using Enrich 2, and normalized to the reference protein (WT or M537R / F870L). The relative survival rate of each point mutation over reference was calculated as the ratio of normalized frequency between selected and input library. Since the degree of cell survival is indicative of the DNA cleavage activity of each AsCasl2a variant, any variants with higher survival rate than the reference protein would be those with enhanced activity at TTTT PAM.

[0068] As presented herein, codon-optimized Cas 12a polypeptides are provided, including codon-optimized Casl2a polypeptides for CRISPR ribonucleoprotein complexes. 2024201449   05 Mar 2024 An example of a codon-optimized sequence, is in this instance a sequence optimized for expression in eukaryotes, e.g., humans (i.e., being optimized for expression in humans), or for another eukaryote, animal or mammal as herein discussed. Whilst this is preferred, it will be appreciated that other examples are possible and codon optimization for a host species other than human, or for codon optimization for specific organs is known. In some embodiments, an enzyme coding sequence encoding a CRISPR Casl2a polypeptide is a codon optimized for expression in particular cells, such as eukaryotic cells. The eukaryotic cells may be those of or derived from a particular organism, such as a plant or a mammal, including but not limited to human, or non-human eukaryote or animal or mammal as herein discussed, e.g., mouse, rat, rabbit, dog, livestock, or non-human mammal or primate. In some embodiments, processes for modifying the germ line genetic identity of human beings and / or processes for modifying the genetic identity of animals which are likely to cause them suffering without any substantial medical benefit to man or animal, and also animals resulting from such processes, may be excluded.

[0069] Preferred human cells include cells derived from somatic cells and germ line cells. Exemplary somatic cells include cells from every major organ and tissue system, including the immune system and hematopoietic system.

[0070] In general, codon optimization refers to a process of modifying a nucleic acid sequence for enhanced expression in the host cells of interest by replacing at least one codon (e.g. about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) of the native sequence with codons that are more frequently or most frequently used in the genes of that host cell while maintaining the native amino acid sequence. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available. See Nakamura, Y., et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nucl. Acids Res. 28:292 (2000). Computer algorithms for codon optimizing a particular sequence for expression in a particular host cell 2024201449   05 Mar 2024 are also available, such as Gene Forge (Aptagen; Jacobus, Pa.), are also available. In some embodiments, one or more codons (e.g. 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more, or all codons) in a sequence encoding a Cas 12a correspond to the most frequently used codon for a particular amino acid.

[0071] Additionally, codon-optimized Cas 12a polypeptides are provided, including codon-optimized Cas 12a polypeptides for CRISPR ribonucleoprotein complexes, wherein the Cas 12a polypeptide sequence optimized for expression in prokaryotes, such as bacteria (e.g., E. coli). Applications

[0072] This invention is useful for either basic research or therapeutic fields for any CRISPR / Casl2a DNA cleavage and / or gene editing experiments or treatments. The superior activity of these recombinant variants could be applied to Cas 12a from any species or potentially any CRISPR enzyme.

[0073] In a first aspect, A CRISPR-associated protein comprising a polypeptide encoding a variant of AsCpfl is provided. The variant of AsCpfl is selected from the group consisting of M537R (SEQ ID NO.: 472), F870L (SEQ ID NO.: 473), and M537R / F870L (SEQ ID NO.: 465). In a first respect, the CRISPR-associated protein corresponds to a variant of AsCpfl is M537R. In a second respect, the CRISPR-associated protein corresponds to a variant of AsCpfl is F870L (SEQ ID NO.: 473). In a third respect, the CRISPR-associated protein corresponds to a variant of AsCpfl is M537R / F870L (SEQ ID NO.: 465).

[0074] In a second aspect, a CRISPR ribonucleoprotein complex is provided. The CRISPR ribonucleoprotein complex includes a guide RNA and a CRISPR-associated protein. The CRISPR-associated protein including a polypeptide encoding a variant of AsCpfl. The variant of AsCpfl is selected from the group consisting of M537R (SEQ ID NO.: 472), F870L (SEQ ID NO.: 473), and M537R / F870L (SEQ ID NO.: 465). In a first respect, the CRISPR ribonucleoprotein complex includes the variant of AsCpfl being M537R. In a second respect, the CRISPR ribonucleoprotein complex includes the variant of AsCpfl being F870L (SEQ ID NO.: 473). In a third respect, the CRISPR ribonucleoprotein complex includes the variant of AsCpfl being M537R / F870L (SEQ ID NO.: 465).

[0075] In a third aspect, a method of increasing efficiency of gene editing at TTTN PAM sites in a cell with a CRISPR ribonucleoprotein complex is provided. The method includes the step of contacting a cell with the CRISPR ribonucleoprotein complex. The CRISPR 2024201449   05 Mar 2024 ribonucleoprotein complex includes a guide RNA and a CRISPR-associated protein. The CRISPR-associated protein including a polypeptide encoding a variant of AsCpfl. The variant of AsCpfl is selected from the group consisting of M537R (SEQ ID NO.: 472), F870L (SEQ ID NO.: 473) and M537R / F870L (SEQ ID NO.: 465). In a first respect, the TTTNPAM sites consists of one selected form the group of TTTA, TTTT and TTTC PAM sites.

[0076] In a fourth aspect, a kit includes a guide RNA and a CRISPR-associated protein is provided. The CRISPR-associated protein includes a polypeptide encoding a variant of AsCpfl. The variant of AsCpfl is selected from the group consisting of M537R (SEQ ID NO.: 472), F870L (SEQ ID NO.: 473), and M537R / F870L (SEQ ID NO.: 465). In a first respect, the variant of AsCpfl is M537R. In a second respect, the variant of AsCpfl is F870L (SEQ ID NO.: 473). In a third respect, the variant of AsCpfl is M537R / F870L (SEQ ID NO.: 465).

[0077] In a fifth aspect, a CRISPR-associated protein comprising a polypeptide encoding a variant of AsCasl2a, wherein the variant of AsCasl2a is selected from the group consisting of at least one variant amino acid selected from amino acid positions 499-640 and 840-913, provided that the variant AsCasl2a provides an improvement in CRISPR / AsCasl2a-associated nuclease activity at non-canonical TTTT PAM sites. In a first respect, the variant of AsCasl2a is selected from the group consisting of SEQ ID NOs.: 59-245. In a second respect, the variant of AsCasl2a, as described in the first aspect or the foregoing first respect of the first aspect, further comprises mutations of M537R / F870L (SEQ ID NO.: 465).

[0078] In a sixth aspect, a CRISPR ribonucleoprotein complex is provided. The CRISPR ribonucleoprotein complex includes a guide RNA and a CRISPR-associated protein. The CRISPR-associated protein includes a polypeptide encoding a variant of AsCasl2a, wherein the variant of AsCasl2a is selected from the group consisting of at least one variant amino acid selected from amino acid positions 499-640 and 840-913, provided that the variant AsCasl2a provides an improvement in CRISPR / AsCasl2a-associated nuclease activity at non-canonical TTTT PAM sites. In a first respect, the variant of AsCasl2a is selected from the group consisting of SEQ ID NOs.: 59-245. In a second respect, the variant of AsCasl2a, as described in the second aspect or the foregoing first respect of the second aspect, further comprises mutations of M537R / F870L (SEQ ID NO.: 465). 2024201449   05 Mar 2024

[0079] In a seventh aspect, a method of increasing efficiency of gene editing at non-canonical TTTT PAM sites in a cell with a CRISPR ribonucleoprotein complex is provided. The method includes a step of contacting a cell with the CRISPR ribonucleoprotein complex that includes a guide RNA and a CRISPR-associated protein. The CRISPR-associated protein includes a polypeptide encoding a variant of AsCasl2a, wherein the variant of AsCasl2a is selected from the group consisting of at least one variant amino acid selected from amino acid positions 499-640 and 840-913, provided that the variant AsCasl2a provides an improvement in CRISPR / AsCasl2a-associated nuclease activity at non-canonical TTTT PAM sites. In a first respect, the variant of AsCasl2a is selected from the group consisting of SEQ ID NOs.: 59-245. In a second respect, the variant of AsCasl2a, as described in the third aspect or the foregoing first respect of the third aspect, further comprises mutations of M537R / F870L (SEQ ID NO.: 465).

[0080] In an eighth aspect, a kit including a guide RNA and a CRISPR-associated protein comprising a polypeptide encoding a variant of AsCasl2a is provided. The variant of AsCasl2a is selected from the group consisting of at least one variant amino acid selected from amino acid positions 499-640 and 840-913, provided that the variant AsCasl2a provides an improvement in CRISPR / AsCasl2a-associated nuclease activity at non-canonical TTTT PAM sites. In a first respect, the variant of AsCasl2a is selected from the group consisting of SEQ ID NOs.: 59-245. In a second respect, the variant of AsCasl2a, as described in the fourth aspect or the foregoing first respect of the fourth aspect, further comprises mutations of M537R / F870L (SEQ ID NO.: 465).

[0081] In a ninth aspect, a nucleic acid encoding a CRISPR-associated protein comprising a polypeptide encoding a variant of AsCasl2a is provided. The variant of AsCasl2a is selected from the group consisting of at least one variant amino acid selected from amino acid positions 499-640 and 840-913, provided that the variant AsCasl2a provides an improvement in CRISPR / AsCasl2a-associated nuclease activity at non-canonical TTTT PAM sites. Highly preferred nucleic acids encoding a CRISPR-associated protein include isolated nucleic acids encoding a CRISPR-associated protein. In a first respect, the variant of AsCasl2a is selected from the group consisting of SEQ ID NOs.: 59-245. In a second respect, the variant of AsCasl2a further includes mutations of M537R / F870L (SEQ ID NO.: 465). In a third respect, the nucleic acid is operably linked to suitable transcription elements to express the nucleic acid. In a fourth respect, the nucleic acid is DNA or RNA. 2024201449   05 Mar 2024

[0082] In a tenth aspect, a polynucleotide sequence encoding a Casl2a polypeptide is provided. The polynucleotide sequence includes one member selected from the group consisting of SEQ ID NOs.: 5-17.

[0083] In an eleventh aspect, an amino acid sequence encoding a Cas 12a polypeptide is provided. The amino acid sequence includes one member selected from the group consisting of SEQ ID NOs.: 18-30.

[0084] In a twelfth aspect, a CAS endonuclease system comprising an expression cassette encoding a polynucleotide sequence encoding a Casl2a polypeptide is provided. The includes one member selected from the group consisting of SEQ ID NOs.: 5-17.

[0085] In a thirteenth aspect, CAS endonuclease system comprising an amino acid sequence encoding a Casl2a polypeptide is provided The amino acid sequence includes one member selected from the group consisting of SEQ ID NOs.: 18-30.

[0086] In a fourteenth aspect, a method of performing genome editing in a eukaryotic cells is provided. The method includes the step of introducing an CAS endonuclease system into the eukaryotic cell, said CAS endonuclease system comprising an expression cassette encoding a polynucleotide sequence encoding a Casl2a polypeptide, comprising one member selected from the group consisting of SEQ ID NOs.: 5-17.

[0087] In a fifteenth aspect, a method of performing genome editing in a eukaryotic cell is provided. The method includes the step of introducing an CAS endonuclease system into the eukaryotic cell, said CAS endonuclease system comprising an amino acid sequence encoding a Casl2a polypeptide comprising one member selected from the group consisting of SEQ ID NOs.: 18-30.

[0088] In a sixteenth aspect, an CRISPR-associated protein comprising a fusion polypeptide is provided. The fusion polypeptide includes an AsCasl2a open reading frame, a nuclear localization signal, optionally an amino acid linker and optionally an affinity tag. Highly preferred CRISPR-associated proteins include isolated CRISPR-associated proteins. In a first respect, the AsCasl2a open reading frame is selected from the group consisting of SEQ ID NOs.: 59-245. In a second respect, the nuclear localization signal is selected from SEQ ID NOs.: 475, 477, 479, 481 and 483. In a third respect, the CRISPR-associated protein is encoded by SEQ ID NOs.: 488-491. In a fourth respect, the CRISPR-associated protein is selected from SEQ ID NOs.: 492 and 493. 2024201449   05 Mar 2024

[0089] In a seventeenth aspect, a method of performing genome editing in a eukaryotic cell is provided. The method includes the step of introducing an CAS endonuclease system into the eukaryotic cell, said CAS endonuclease system comprising an CRISPR-associated protein of according to the sixteenth aspect. Highly preferred CRISPR-associated proteins include isolated CRISPR-associated proteins. EXAMPLES Example 1. Recombinant Caslla proteins with varying tags / linker sequences yield a spectrum of editing efficiencies

[0090] The following Example demonstrates that recombinant Cas 12a proteins with only modest changes in tag sequences at the amino- and carboxy-termini results in proteins that demonstrate a wide range of editing efficiencies in human cells (FIG. 1).

[0091] Briefly, the method of site directed mutagenesis (SDM) was employed to create the expression constructs having As Cas 12a coding sequences with different nuclear localization signals (NLS’s). Site directed mutagenesis was performed by designing complimentary primers that encompass the desired nucleotide base change(s), along with flanking plasmid vector sequence, wherein each flanking region has a melting temperature (Tm) of at least 60°C. A polymerase chain reaction (PCR) run was then performed using standard cycling conditions for a total of 16 cycles. The restriction enzyme, DPN I, was added to digest away the starting plasmid vector material so only the new product containing the base changes remain. After DPN I treatment, a small amount of the PCR product was transformed into competent E. coli cells, recovered in SOC media and plated onto kanamycin resistance Luria Broth (LB) agar plates. Colonies were screened using the Sanger sequencing method to verify correct base changes in selected clones.

[0092] The results indicate that the ideal sequence and placement of NLS sequences on Casl2a is not obvious, and that a highly efficient Casl2a genome editing solution must be empirically determined as was done in this study. Proteins were tested using guides that target the HPRT-38186 (SEQ ID NO.: 1) and HPRT-38228 (SEQ ID NO. :2) loci in human cells. SEQ ID NOs.: 1-4 are depicted in Table 1. 2024201449   05 Mar 2024

[0093] Table 1. Sequence of oligonucleotides used as crRNAs or PCR primers. Name Sequence SEQ ID NO. KP.RT-38186-S rUrArArUrUrUrCrUrArCrUrCrUrUrGrUrArGrArUrUrArArUrGrCrCr CrUrGrUrArGrUrCrUrCrUrCrUrG SEQ ID NO. 1 KP.RT-38228-S TUrArArUrUrUrCrUrArCrUrCrUrUrGrUrArGrArUrUrArArUrUrArAr CrArGrCrUrUrGrCrUrGrGrUrGrA SEQ ID NO. 2 KRRT-FWD AAGAAT GT T GT GATAAAAGGT GAT GCT SEQ ID NO. 3 HTRT-REV GAGGCAGAAGTCCCATGGATGTGT SEQ ID NO. 4

[0094] The following nucleotide sequences that encode preferred Cas 12a polypeptides of this Example are depicted below:

[0095] SEQ ID NO . :5

[0096] ATGGGCAGCAGCAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGCTAGCATGACTGGT GGACAGCAAATGGGTCGGGATCCAGGTAAACCGATTCCGAATCCGCTGCTGGGTCTGGATAGCACCGCACCG AAAAAAAAACGTAAAGTTGGTATTCATGGTGTTCCGGCAGCAACCCAGTTTGAAGGTTTCACCAATCTGTATC AG GTTAG CAAAACCCTG CGTTTTGAACTG ATTCCG CAG G GTAAAACCCTG AAACATATTCAAG AACAG G G CTT CATCGAAGAGGATAAAGCACGTAACGATCACTACAAAGAACTGAAACCGATTATCGACCGCATCTATAAAACC TATGCAGATCAGTGTCTGCAGCTGGTTCAGCTGGATTGGGAAAATCTGAGCGCAGCAATTGATAGTTATCGCA AAGAAAAAACCGAAGAAACCCGTAATGCACTGATTGAAGAACAGGCAACCTATCGTAATGCCATCCATGATT ATTTCATTG GTCGTACCG ATAATCTG ACCG ATG CAATTAACAAACGTCACG CCG AAATCTATAAAG G CCTGTTT AAAG CCG AACTGTTTAATG G CAAAGTTCTG AAACAG CTG GG CACCGTTACCACCACCGAACATGAAAATGCAC TGCTG CGTAG CTTTG ATAAATTCACCACCTATTTCAG CG G CTTTTATG AG AATCG CAAAAACGTGTTTAG CG CA GAAGATATTAGCACCGCAATTCCGCATCGTATTGTGCAGGATAATTTCCCGAAATTCAAAGAGAACTGCCACA TTTTTACCCGTCTG ATTACCG CAGTTCCGAG CCTG CGTG AACATTTTG AAAACGTTAAAAAAG CCATCG G CATC TTTGTTAGCACCAGCATTGAAGAAGTTTTTAGCTTCCCGTTTTACAATCAGCTGCTGACCCAGACCCAGATTGA TCTGTATAACCAACTGCTGGGTGGTATTAGCCGTGAAGCAGGCACCGAAAAAATCAAAGGTCTGAATGAAGT G CTG AATCTG G CCATTCAG AAAAATG ATG AAACCG CACATATTATTG CAAG CCTG CCGCATCGTTTTATTCCG C TGTTCAAACAAATTCTGAGCGATCGTAATACCCTGAGCTTTATTCTGGAAGAATTCAAATCCGATGAAGAGGT GATTCAGAGCTTTTGCAAATACAAAACGCTGCTGCGCAATGAAAATGTTCTGGAAACTGCCGAAGCACTGTTT AACGAACTGAATAGCATTGATCTGACCCACATCTTTATCAGCCACAAAAAACTGGAAACCATTTCAAGCGCACT GTGTGATCATTGGGATACCCTGCGTAATGCCCTGTATGAACGTCGTATTAGCGAACTGACCGGTAAAATTACC AAAAGCGCGAAAGAAAAAGTTCAGCGCAGTCTGAAACATGAGGATATTAATCTGCAAGAGATTATTAGCGCA GCCGGTAAAGAACTGTCAGAAGCATTTAAACAGAAAACCAGCGAAATTCTGTCACATGCACATGCAGCACTG GATCAGCCGCTGCCGACCACCCTGAAAAAACAAGAAGAAAAAGAAATCCTGAAAAGCCAGCTGGATAGCCTG CTGGGTCTGTATCATCTGCTGGACTGGTTTGCAGTTGATGAAAGCAATGAAGTTGATCCGGAATTTAGCGCAC GTCTGACCGGCATTAAACTGGAAATGGAACCGAGCCTGAGCTTTTATAACAAAGCCCGTAATTATGCCACCAA AAAACCGTATAGCGTCGAAAAATTCAAACTGAACTTTCAGATGCCGACCCTGGCAAGCGGTTGGGATGTTAAT AAAG AAAAAAACAACG GTG CCATCCTGTTCGTG AAAAATG G CCTGTATTATCTG G GTATTATG CCG AAACAG A AAGGTCGTTATAAAGCGCTGAGCTTTGAACCGACGGAAAAAACCAGTGAAGGTTTTGATAAAATGTACTACG ACTATTTTCCG G ATG CAG CCAAAATG ATTCCG AAATGTAG CACCCAG CTG AAAG CAGTTACCG CACATTTTCA GACCCATACCACCCCGATTCTGCTGAGCAATAACTTTATTGAACCGCTGGAAATCACCAAAGAGATCTACGAT CTGAATAACCCGGAAAAAGAGCCGAAAAAATTCCAGACCGCATATGCAAAAAAAACCGGTGATCAGAAAGGT TATCGTGAAGCGCTGTGTAAATGGATTGATTTCACCCGTGATTTTCTGAGCAAATACACCAAAACCACCAGTAT 2024201449   05 Mar 2024 CGATCTGAGCAGCCTGCGTCCGAGCAGCCAGTATAAAGATCTGGGCGAATATTATGCAGAACTGAATCCGCT GCTGTATCATATTAGCTTTCAGCGTATTGCCGAGAAAGAAATCATGGACGCAGTTGAAACCGGTAAACTGTAC CTGTTCCAG ATCTACAATAAAG ATTTTG CCAAAG G CCATCATG G CAAACCG AATCTG CATACCCTGTATTG G AC CGGTCTGTTTAGCCCTGAAAATCTGGCAAAAACCTCGATTAAACTGAATGGTCAGGCGGAACTGTTTTATCGT CCGAAAAGCCGTATGAAACGTATGGCACATCGTCTGGGTGAAAAAATGCTGAACAAAAAACTGAAAGACCAG AAAACCCCGATCCCGGATACACTGTATCAAGAACTGTATGATTATGTGAACCATCGTCTGAGCCATGATCTGA GTGATGAAGCACGTGCCCTGCTGCCGAATGTTATTACCAAAGAAGTTAGCCACGAGATCATTAAAGATCGTCG TTTTACCAGCGACAAATTCTTTTTTCATGTGCCGATTACCCTGAATTATCAGGCAGCAAATAGCCCGAGCAAAT TTAACCAGCGTGTTAATGCATATCTGAAAGAACATCCAGAAACGCCGATTATTGGTATTGATCGTGGTGAACG TAACCTGATTTATATCACCGTTATTGATAGCACCGGCAAAATCCTGGAACAGCGTAGCCTGAATACCATTCAGC AGTTTGATTACCAGAAAAAACTGGATAATCGCGAGAAAGAACGTGTTGCAGCACGTCAGGCATGGTCAGTTG TTGGTACAATTAAAGACCTGAAACAGGGTTATCTGAGCCAGGTTATTCATGAAATTGTGGATCTGATGATTCA CTATCAGGCCGTTGTTGTGCTGGAAAACCTGAATTTTGGCTTTAAAAGCAAACGTACCGGCATTGCAGAAAAA GCAGTTTATCAGCAGTTCGAGAAAATGCTGATTGACAAACTGAATTGCCTGGTGCTGAAAGATTATCCGGCTG AAAAAGTTG GTG GTGTTCTG AATCCGTATCAG CTG ACCG ATCAGTTTACCAGCTTTG CAAAAATG G G CACCCA GAGCGGATTTCTGTTTTATGTTCCGGCACCGTATACGAGCAAAATTGATCCGCTGACCGGTTTTGTTGATCCGT TTGTTTGGAAAACCATCAAAAACCATGAAAGCCGCAAACATTTTCTGGAAGGTTTCGATTTTCTGCATTACGAC GTTAAAACG G GTG ATTTCATCCTG CACTTTAAAATG AATCG CAATCTG AGTTTTCAG CGTG G CCTG CCTG GTTT TATGCCTGCATGGGATATTGTGTTTGAGAAAAACGAAACACAGTTCGATGCAAAAGGCACCCCGTTTATTGCA G GTAAACGTATTGTTCCG GTG ATTG AAAATCATCGTTTCACCGGTCGTTATCG CG ATCTGTATCCG G CAAATG AACTGATCGCACTGCTGGAAGAGAAAGGTATTGTTTTTCGTGATGGCTCAAACATTCTGCCGAAACTGCTGGA AAATGATGATAGCCATGCAATTGATACCATGGTTGCACTGATTCGTAGCGTTCTGCAGATGCGTAATAGCAAT G CAG CAACCG GTG AAG ATTACATTAATAGTCCG GTTCGTG ATCTG AATG GTGTTTGTTTTG ATAG CCGTTTTCA GAATCCGGAATGGCCGATGGATGCAGATGCAAATGGTGCATATCATATTGCACTGAAAGGACAGCTGCTGCT GAACCACCTGAAAGAAAGCAAAGATCTGAAACTGCAAAACGGCATTAGCAATCAGGATTGGCTGGCATATAT CCAAG AACTG CGTAACCCTAAAAAAAAACG CAAAGTG AAG CTTG CG GCCG CACTCG AG CACCACCACCACCA CCACTGA

[0097] SEQIDNO.6

[0098] ATGGGCAGCAGCAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGCTAGCATGACTGGT G G ACAG CAAATG G GTCG G G ATCCAG CACCG AAAAAAAAACGTAAAGTTG GTATTCATG GTGTTCCG G CAG CA ACCCAGTTTG AAG GTTTCACCAATCTGTATCAG GTTAG CAAAACCCTG CGTTTTG AACTG ATTCCG CAGG GTAA AACCCTGAAACATATTCAAGAACAGGGCTTCATCGAAGAGGATAAAGCACGTAACGATCACTACAAAGAACT GAAACCGATTATCGACCGCATCTATAAAACCTATGCAGATCAGTGTCTGCAGCTGGTTCAGCTGGATTGGGAA AATCTGAGCGCAGCAATTGATAGTTATCGCAAAGAAAAAACCGAAGAAACCCGTAATGCACTGATTGAAGAA CAGGCAACCTATCGTAATGCCATCCATGATTATTTCATTGGTCGTACCGATAATCTGACCGATGCAATTAACAA ACGTCACG CCG AAATCTATAAAGG CCTGTTTAAAG CCG AACTGTTTAATG G CAAAGTTCTG AAACAG CTG G G C ACCGTTACCACCACCG AACATG AAAATG CACTGCTG CGTAG CTTTG ATAAATTCACCACCTATTTCAG CG G CTT TTATGAGAATCGCAAAAACGTGTTTAGCGCAGAAGATATTAGCACCGCAATTCCGCATCGTATTGTGCAGGAT AATTTCCCGAAATTCAAAGAGAACTGCCACATTTTTACCCGTCTGATTACCGCAGTTCCGAGCCTGCGTGAACA TTTTGAAAACGTTAAAAAAGCCATCGGCATCTTTGTTAGCACCAGCATTGAAGAAGTTTTTAGCTTCCCGTTTT ACAATCAGCTGCTGACCCAGACCCAGATTGATCTGTATAACCAACTGCTGGGTGGTATTAGCCGTGAAGCAGG CACCGAAAAAATCAAAGGTCTGAATGAAGTGCTGAATCTGGCCATTCAGAAAAATGATGAAACCGCACATATT 2024201449   05 Mar 2024 ATTG CAAG CCTG CCG CATCGTTTTATTCCGCTGTTCAAACAAATTCTG AG CG ATCGTAATACCCTG AG CTTTATT CTGGAAGAATTCAAATCCGATGAAGAGGTGATTCAGAGCTTTTGCAAATACAAAACGCTGCTGCGCAATGAA AATGTTCTGGAAACTGCCGAAGCACTGTTTAACGAACTGAATAGCATTGATCTGACCCACATCTTTATCAGCCA CAAAAAACTGGAAACCATTTCAAGCGCACTGTGTGATCATTGGGATACCCTGCGTAATGCCCTGTATGAACGT CGTATTAGCGAACTGACCGGTAAAATTACCAAAAGCGCGAAAGAAAAAGTTCAGCGCAGTCTGAAACATGAG GATATTAATCTGCAAGAGATTATTAGCGCAGCCGGTAAAGAACTGTCAGAAGCATTTAAACAGAAAACCAGC GAAATTCTGTCACATGCACATGCAGCACTGGATCAGCCGCTGCCGACCACCCTGAAAAAACAAGAAGAAAAA GAAATCCTGAAAAGCCAGCTGGATAGCCTGCTGGGTCTGTATCATCTGCTGGACTGGTTTGCAGTTGATGAAA GCAATGAAGTTGATCCGGAATTTAGCGCACGTCTGACCGGCATTAAACTGGAAATGGAACCGAGCCTGAGCT TTTATAACAAAGCCCGTAATTATGCCACCAAAAAACCGTATAGCGTCGAAAAATTCAAACTGAACTTTCAGATG CCG ACCCTG G CAAG CG GTTG G G ATGTTAATAAAG AAAAAAACAACG GTG CCATCCTGTTCGTG AAAAATG G C CTGTATTATCTGGGTATTATGCCGAAACAGAAAGGTCGTTATAAAGCGCTGAGCTTTGAACCGACGGAAAAA ACCAGTGAAGGTTTTGATAAAATGTACTACGACTATTTTCCGGATGCAGCCAAAATGATTCCGAAATGTAGCA CCCAGCTGAAAGCAGTTACCGCACATTTTCAGACCCATACCACCCCGATTCTGCTGAGCAATAACTTTATTGAA CCGCTGGAAATCACCAAAGAGATCTACGATCTGAATAACCCGGAAAAAGAGCCGAAAAAATTCCAGACCGCA TATGCAAAAAAAACCGGTGATCAGAAAGGTTATCGTGAAGCGCTGTGTAAATGGATTGATTTCACCCGTGATT TTCTGAGCAAATACACCAAAACCACCAGTATCGATCTGAGCAGCCTGCGTCCGAGCAGCCAGTATAAAGATCT GGGCGAATATTATGCAGAACTGAATCCGCTGCTGTATCATATTAGCTTTCAGCGTATTGCCGAGAAAGAAATC ATGGACGCAGTTGAAACCGGTAAACTGTACCTGTTCCAGATCTACAATAAAGATTTTGCCAAAGGCCATCATG G CAAACCG AATCTG CATACCCTGTATTG G ACCG GTCTGTTTAG CCCTG AAAATCTG G CAAAAACCTCG ATTAA ACTGAATGGTCAGGCGGAACTGTTTTATCGTCCGAAAAGCCGTATGAAACGTATGGCACATCGTCTGGGTGA AAAAATGCTGAACAAAAAACTGAAAGACCAGAAAACCCCGATCCCGGATACACTGTATCAAGAACTGTATGA TTATGTGAACCATCGTCTGAGCCATGATCTGAGTGATGAAGCACGTGCCCTGCTGCCGAATGTTATTACCAAA GAAGTTAGCCACGAGATCATTAAAGATCGTCGTTTTACCAGCGACAAATTCTTTTTTCATGTGCCGATTACCCT GAATTATCAGGCAGCAAATAGCCCGAGCAAATTTAACCAGCGTGTTAATGCATATCTGAAAGAACATCCAGAA ACGCCGATTATTGGTATTGATCGTGGTGAACGTAACCTGATTTATATCACCGTTATTGATAGCACCGGCAAAAT CCTGGAACAGCGTAGCCTGAATACCATTCAGCAGTTTGATTACCAGAAAAAACTGGATAATCGCGAGAAAGA ACGTGTTG CAG CACGTCAG G CATG GTCAGTTGTTGGTACAATTAAAG ACCTG AAACAG G GTTATCTG AG CCA GGTTATTCATGAAATTGTGGATCTGATGATTCACTATCAGGCCGTTGTTGTGCTGGAAAACCTGAATTTTGGCT TTAAAAG CAAACGTACCG G CATTG CAG AAAAAG CAGTTTATCAG CAGTTCG AG AAAATG CTG ATTG ACAAACT GAATTGCCTGGTGCTGAAAGATTATCCGGCTGAAAAAGTTGGTGGTGTTCTGAATCCGTATCAGCTGACCGAT CAGTTTACCAGCTTTGCAAAAATGGGCACCCAGAGCGGATTTCTGTTTTATGTTCCGGCACCGTATACGAGCA AAATTGATCCGCTGACCGGTTTTGTTGATCCGTTTGTTTGGAAAACCATCAAAAACCATGAAAGCCGCAAACA TTTTCTGGAAGGTTTCGATTTTCTGCATTACGACGTTAAAACGGGTGATTTCATCCTGCACTTTAAAATGAATC GCAATCTGAGTTTTCAGCGTGGCCTGCCTGGTTTTATGCCTGCATGGGATATTGTGTTTGAGAAAAACGAAAC ACAGTTCG ATG CAAAAG G CACCCCGTTTATTG CAG GTAAACGTATTGTTCCG GTG ATTG AAAATCATCGTTTCA CCGGTCGTTATCGCGATCTGTATCCGGCAAATGAACTGATCGCACTGCTGGAAGAGAAAGGTATTGTTTTTCG TGATGGCTCAAACATTCTGCCGAAACTGCTGGAAAATGATGATAGCCATGCAATTGATACCATGGTTGCACTG ATTCGTAGCGTTCTG CAG ATG CGTAATAG CAATG CAG CAACCG GTG AAG ATTACATTAATAGTCCG GTTCGTG ATCTGAATGGTGTTTGTTTTGATAGCCGTTTTCAGAATCCGGAATGGCCGATGGATGCAGATGCAAATGGTGC ATATCATATTGCACTGAAAGGACAGCTGCTGCTGAACCACCTGAAAGAAAGCAAAGATCTGAAACTGCAAAA CGG CATTAG CAATCAG G ATTG G CTG G CATATATCCAAG AACTG CGTAACCCTAAAAAAAAACG CAAAGTG AA GCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGA 2024201449   05 Mar 2024

[0099] SEQIDNO.7

[0100] ATG CCG AAAAAAAAACG CAAAGTG G GTATTCATG GTGTTCCG G CAG CAACCCAGTTTGAA G GTTTCACCAATCTGTATCAG GTTAG CAAAACCCTG CGTTTTG AACTG ATTCCG CAG GGTAAAACCCTG AAAC ATATTCAAGAACAGGGCTTCATCGAAGAGGATAAAGCACGTAACGATCACTACAAAGAACTGAAACCGATTA TCG ACCG CATCTATAAAACCTATG CAG ATCAGTGTCTG CAG CTG GTTCAG CTG G ATTG G G AAAATCTG AG CG C AGCAATTGATAGTTATCGCAAAGAAAAAACCGAAGAAACCCGTAATGCACTGATTGAAGAACAGGCAACCTA TCGTAATGCCATCCATGATTATTTCATTGGTCGTACCGATAATCTGACCGATGCAATTAACAAACGTCACGCCG AAATCTATAAAG G CCTGTTTAAAG CCG AACTGTTTAATG G CAAAGTTCTG AAACAG CTG GG CACCGTTACCAC CACCG AACATG AAAATG CACTG CTG CGTAG CTTTG ATAAATTCACCACCTATTTCAG CG G CTTTTATG AG AATC G CAAAAACGTGTTTAG CG CAG AAG ATATTAG CACCG CAATTCCG CATCGTATTGTG CAG G ATAATTTCCCG AA ATTCAAAGAGAACTGCCACATTTTTACCCGTCTGATTACCGCAGTTCCGAGCCTGCGTGAACATTTTGAAAACG TTAAAAAAG CCATCG G CATCTTTGTTAG CACCAG CATTG AAG AAGTTTTTAG CTTCCCGTTTTACAATCAG CTG CTGACCCAGACCCAGATTGATCTGTATAACCAACTGCTGGGTGGTATTAGCCGTGAAGCAGGCACCGAAAAA ATCAAAGGTCTGAATGAAGTGCTGAATCTGGCCATTCAGAAAAATGATGAAACCGCACATATTATTGCAAGCC TGCCGCATCGTTTTATTCCGCTGTTCAAACAAATTCTGAGCGATCGTAATACCCTGAGCTTTATTCTGGAAGAA TTCAAATCCGATGAAGAGGTGATTCAGAGCTTTTGCAAATACAAAACGCTGCTGCGCAATGAAAATGTTCTGG AAACTGCCGAAGCACTGTTTAACGAACTGAATAGCATTGATCTGACCCACATCTTTATCAGCCACAAAAAACT GGAAACCATTTCAAGCGCACTGTGTGATCATTGGGATACCCTGCGTAATGCCCTGTATGAACGTCGTATTAGC GAACTGACCGGTAAAATTACCAAAAGCGCGAAAGAAAAAGTTCAGCGCAGTCTGAAACATGAGGATATTAAT CTGCAAGAGATTATTAGCGCAGCCGGTAAAGAACTGTCAGAAGCATTTAAACAGAAAACCAGCGAAATTCTG TCACATGCACATGCAGCACTGGATCAGCCGCTGCCGACCACCCTGAAAAAACAAGAAGAAAAAGAAATCCTG AAAAGCCAGCTGGATAGCCTGCTGGGTCTGTATCATCTGCTGGACTGGTTTGCAGTTGATGAAAGCAATGAA GTTGATCCGGAATTTAGCGCACGTCTGACCGGCATTAAACTGGAAATGGAACCGAGCCTGAGCTTTTATAACA AAGCCCGTAATTATGCCACCAAAAAACCGTATAGCGTCGAAAAATTCAAACTGAACTTTCAGATGCCGACCCT G G CAAG CG GTTG G G ATGTTAATAAAG AAAAAAACAACG GTG CCATCCTGTTCGTG AAAAATG G CCTGTATTA TCTGGGTATTATGCCGAAACAGAAAGGTCGTTATAAAGCGCTGAGCTTTGAACCGACGGAAAAAACCAGTGA AGGTTTTGATAAAATGTACTACGACTATTTTCCGGATGCAGCCAAAATGATTCCGAAATGTAGCACCCAGCTG AAAGCAGTTACCGCACATTTTCAGACCCATACCACCCCGATTCTGCTGAGCAATAACTTTATTGAACCGCTGGA AATCACCAAAGAGATCTACGATCTGAATAACCCGGAAAAAGAGCCGAAAAAATTCCAGACCGCATATGCAAA AAAAACCGGTGATCAGAAAGGTTATCGTGAAGCGCTGTGTAAATGGATTGATTTCACCCGTGATTTTCTGAGC AAATACACCAAAACCACCAGTATCGATCTGAGCAGCCTGCGTCCGAGCAGCCAGTATAAAGATCTGGGCGAA TATTATGCAGAACTGAATCCGCTGCTGTATCATATTAGCTTTCAGCGTATTGCCGAGAAAGAAATCATGGACG CAGTTG AAACCG GTAAACTGTACCTGTTCCAG ATCTACAATAAAG ATTTTG CCAAAG G CCATCATG G CAAACC GAATCTGCATACCCTGTATTGGACCGGTCTGTTTAGCCCTGAAAATCTGGCAAAAACCTCGATTAAACTGAAT GGTCAGGCGGAACTGTTTTATCGTCCGAAAAGCCGTATGAAACGTATGGCACATCGTCTGGGTGAAAAAATG CTGAACAAAAAACTGAAAGACCAGAAAACCCCGATCCCGGATACACTGTATCAAGAACTGTATGATTATGTGA ACCATCGTCTGAGCCATGATCTGAGTGATGAAGCACGTGCCCTGCTGCCGAATGTTATTACCAAAGAAGTTAG CCACGAGATCATTAAAGATCGTCGTTTTACCAGCGACAAATTCTTTTTTCATGTGCCGATTACCCTGAATTATCA GGCAGCAAATAGCCCGAGCAAATTTAACCAGCGTGTTAATGCATATCTGAAAGAACATCCAGAAACGCCGATT ATTGGTATTGATCGTGGTGAACGTAACCTGATTTATATCACCGTTATTGATAGCACCGGCAAAATCCTGGAAC AGCGTAGCCTGAATACCATTCAGCAGTTTGATTACCAGAAAAAACTGGATAATCGCGAGAAAGAACGTGTTG CAG CACGTCAGG CATGGTCAGTTGTTG GTACAATTAAAG ACCTG AAACAG G GTTATCTG AG CCAG GTTATTCA 2024201449   05 Mar 2024 TGAAATTGTGGATCTGATGATTCACTATCAGGCCGTTGTTGTGCTGGAAAACCTGAATTTTGGCTTTAAAAGC AAACGTACCGGCATTGCAGAAAAAGCAGTTTATCAGCAGTTCGAGAAAATGCTGATTGACAAACTGAATTGC CTGGTGCTGAAAGATTATCCGGCTGAAAAAGTTGGTGGTGTTCTGAATCCGTATCAGCTGACCGATCAGTTTA CCAGCTTTGCAAAAATGGGCACCCAGAGCGGATTTCTGTTTTATGTTCCGGCACCGTATACGAGCAAAATTGA TCCGCTGACCGGTTTTGTTGATCCGTTTGTTTGGAAAACCATCAAAAACCATGAAAGCCGCAAACATTTTCTGG AAG GTTTCG ATTTTCTG CATTACGACGTTAAAACG G GTG ATTTCATCCTG CACTTTAAAATG AATCG CAATCTG AGTTTTCAGCGTGGCCTGCCTGGTTTTATGCCTGCATGGGATATTGTGTTTGAGAAAAACGAAACACAGTTCG ATGCAAAAGGCACCCCGTTTATTGCAGGTAAACGTATTGTTCCGGTGATTGAAAATCATCGTTTCACCGGTCGT TATCGCGATCTGTATCCGGCAAATGAACTGATCGCACTGCTGGAAGAGAAAGGTATTGTTTTTCGTGATGGCT CAAACATTCTGCCGAAACTGCTGGAAAATGATGATAGCCATGCAATTGATACCATGGTTGCACTGATTCGTAG CGTTCTGCAGATGCGTAATAGCAATGCAGCAACCGGTGAAGATTACATTAATAGTCCGGTTCGTGATCTGAAT GGTGTTTGTTTTGATAGCCGTTTTCAGAATCCGGAATGGCCGATGGATGCAGATGCAAATGGTGCATATCATA TTGCACTGAAAGGACAGCTGCTGCTGAACCACCTGAAAGAAAGCAAAGATCTGAAACTGCAAAACGGCATTA GCAATCAGGATTGGCTGGCATATATCCAAGAACTGCGTAACCCGAAAAAAAAACGCAAAGTGCTCGAGCACC ACCACCACCACCACTGA

[0101] SEQIDNO.8

[0102] ATG ACCCAGTTTG AAG GTTTCACCAATCTGTATCAG GTTAG CAAAACCCTG CGTTTTG AACT GATTCCGCAGGGTAAAACCCTGAAACATATTCAAGAACAGGGCTTCATCGAAGAGGATAAAGCACGTAACGA TCACTACAAAGAACTGAAACCGATTATCGACCGCATCTATAAAACCTATGCAGATCAGTGTCTGCAGCTGGTT CAGCTGGATTGGGAAAATCTGAGCGCAGCAATTGATAGTTATCGCAAAGAAAAAACCGAAGAAACCCGTAAT GCACTGATTGAAGAACAGGCAACCTATCGTAATGCCATCCATGATTATTTCATTGGTCGTACCGATAATCTGAC CG ATG CAATTAACAAACGTCACG CCG AAATCTATAAAG G CCTGTTTAAAG CCG AACTGTTTAATG G CAAAGTT CTGAAACAGCTGGGCACCGTTACCACCACCGAACATGAAAATGCACTGCTGCGTAGCTTTGATAAATTCACCA CCTATTTCAGCGGCTTTTATGAGAATCGCAAAAACGTGTTTAGCGCAGAAGATATTAGCACCGCAATTCCGCA TCGTATTGTGCAGGATAATTTCCCGAAATTCAAAGAGAACTGCCACATTTTTACCCGTCTGATTACCGCAGTTC CG AG CCTG CGTG AACATTTTG AAAACGTTAAAAAAG CCATCG G CATCTTTGTTAG CACCAG CATTG AAG AAGT TTTTAGCTTCCCGTTTTACAATCAGCTGCTGACCCAGACCCAGATTGATCTGTATAACCAACTGCTGGGTGGTA TTAGCCGTGAAGCAGGCACCGAAAAAATCAAAGGTCTGAATGAAGTGCTGAATCTGGCCATTCAGAAAAATG ATG AAACCG CACATATTATTG CAAG CCTG CCG CATCGTTTTATTCCG CTGTTCAAACAAATTCTG AG CG ATCGT AATACCCTGAGCTTTATTCTGGAAGAATTCAAATCCGATGAAGAGGTGATTCAGAGCTTTTGCAAATACAAAA CGCTGCTGCGCAATGAAAATGTTCTGGAAACTGCCGAAGCACTGTTTAACGAACTGAATAGCATTGATCTGAC CCACATCTTTATCAG CCACAAAAAACTGG AAACCATTTCAAG CG CACTGTGTG ATCATTG G G ATACCCTG CGTA ATGCCCTGTATGAACGTCGTATTAGCGAACTGACCGGTAAAATTACCAAAAGCGCGAAAGAAAAAGTTCAGC GCAGTCTGAAACATGAGGATATTAATCTGCAAGAGATTATTAGCGCAGCCGGTAAAGAACTGTCAGAAGCAT TTAAACAGAAAACCAGCGAAATTCTGTCACATGCACATGCAGCACTGGATCAGCCGCTGCCGACCACCCTGAA AAAACAAGAAGAAAAAGAAATCCTGAAAAGCCAGCTGGATAGCCTGCTGGGTCTGTATCATCTGCTGGACTG GTTTGCAGTTGATGAAAGCAATGAAGTTGATCCGGAATTTAGCGCACGTCTGACCGGCATTAAACTGGAAAT GGAACCGAGCCTGAGCTTTTATAACAAAGCCCGTAATTATGCCACCAAAAAACCGTATAGCGTCGAAAAATTC AAACTGAACTTTCAGATGCCGACCCTGGCAAGCGGTTGGGATGTTAATAAAGAAAAAAACAACGGTGCCATC CTGTTCGTG AAAAATG G CCTGTATTATCTG G GTATTATG CCG AAACAG AAAG GTCGTTATAAAG CG CTG AG CT TTGAACCGACGGAAAAAACCAGTGAAGGTTTTGATAAAATGTACTACGACTATTTTCCGGATGCAGCCAAAAT GATTCCGAAATGTAGCACCCAGCTGAAAGCAGTTACCGCACATTTTCAGACCCATACCACCCCGATTCTGCTGA 2024201449   05 Mar 2024 GCAATAACTTTATTGAACCGCTGGAAATCACCAAAGAGATCTACGATCTGAATAACCCGGAAAAAGAGCCGA AAAAATTCCAGACCGCATATGCAAAAAAAACCGGTGATCAGAAAGGTTATCGTGAAGCGCTGTGTAAATGGA TTGATTTCACCCGTGATTTTCTGAGCAAATACACCAAAACCACCAGTATCGATCTGAGCAGCCTGCGTCCGAGC AGCCAGTATAAAGATCTGGGCGAATATTATGCAGAACTGAATCCGCTGCTGTATCATATTAGCTTTCAGCGTA TTGCCGAGAAAGAAATCATGGACGCAGTTGAAACCGGTAAACTGTACCTGTTCCAGATCTACAATAAAGATTT TGCCAAAGGCCATCATGGCAAACCGAATCTGCATACCCTGTATTGGACCGGTCTGTTTAGCCCTGAAAATCTG GCAAAAACCTCGATTAAACTGAATGGTCAGGCGGAACTGTTTTATCGTCCGAAAAGCCGTATGAAACGTATG GCACATCGTCTGGGTGAAAAAATGCTGAACAAAAAACTGAAAGACCAGAAAACCCCGATCCCGGATACACTG TATCAAGAACTGTATGATTATGTGAACCATCGTCTGAGCCATGATCTGAGTGATGAAGCACGTGCCCTGCTGC CGAATGTTATTACCAAAGAAGTTAGCCACGAGATCATTAAAGATCGTCGTTTTACCAGCGACAAATTCTTTTTT CATGTG CCGATTACCCTGAATTATCAG G CAG CAAATAG CCCG AG CAAATTTAACCAG CGTGTTAATGCATATC TGAAAGAACATCCAGAAACGCCGATTATTGGTATTGATCGTGGTGAACGTAACCTGATTTATATCACCGTTATT GATAGCACCGGCAAAATCCTGGAACAGCGTAGCCTGAATACCATTCAGCAGTTTGATTACCAGAAAAAACTG GATAATCGCGAGAAAGAACGTGTTGCAGCACGTCAGGCATGGTCAGTTGTTGGTACAATTAAAGACCTGAAA CAG G GTTATCTG AG CCAG GTTATTCATG AAATTGTG G ATCTG ATG ATTCACTATCAG G CCGTTGTTGTG CTG G AAAACCTGAATTTTGGCTTTAAAAGCAAACGTACCGGCATTGCAGAAAAAGCAGTTTATCAGCAGTTCGAGAA AATGCTGATTGACAAACTGAATTGCCTGGTGCTGAAAGATTATCCGGCTGAAAAAGTTGGTGGTGTTCTGAAT CCGTATCAG CTG ACCG ATCAGTTTACCAG CTTTG CAAAAATG G G CACCCAG AG CG G ATTTCTGTTTTATGTTCC G G CACCGTATACG AG CAAAATTG ATCCG CTG ACCG GTTTTGTTGATCCGTTTGTTTG GAAAACCATCAAAAAC CATGAAAGCCGCAAACATTTTCTGGAAGGTTTCGATTTTCTGCATTACGACGTTAAAACGGGTGATTTCATCCT G CACTTTAAAATG AATCG CAATCTG AGTTTTCAG CGTGG CCTG CCTG GTTTTATG CCTG CATG G G ATATTGTGT TTG AG AAAAACG AAACACAGTTCG ATG CAAAAG G CACCCCGTTTATTG CAG GTAAACGTATTGTTCCG GTG AT TGAAAATCATCGTTTCACCGGTCGTTATCGCGATCTGTATCCGGCAAATGAACTGATCGCACTGCTGGAAGAG AAAG GTATTGTTTTTCGTG ATG G CTCAAACATTCTG CCG AAACTG CTG G AAAATG ATG ATAG CCATG CAATTG ATACCATG GTTG CACTG ATTCGTAG CGTTCTG CAG ATG CGTAATAG CAATG CAG CAACCG GTG AAG ATTACAT TAATAGTCCGGTTCGTGATCTGAATGGTGTTTGTTTTGATAGCCGTTTTCAGAATCCGGAATGGCCGATGGAT GCAGATGCAAATGGTGCATATCATATTGCACTGAAAGGACAGCTGCTGCTGAACCACCTGAAAGAAAGCAAA GATCTGAAACTGCAAAACGGCATTAGCAATCAGGATTGGCTGGCATATATCCAAGAACTGCGTAACCCGAAA AAAAAACG CAAAGTG CTCG AG CACCACCACCACCACCACTG A

[0103] SEQIDNO.9

[0104] ATG G G CAG CAGCCATCATCATCATCATCACAG CAG CG G CCTG GTG CCG CG CG G CAG CCATA TGGCTAGCATGACTGGTGGACAGCAAATGGGTCGGGATCCAACCCAGTTTGAAGGTTTCACCAATCTGTATCA G GTTAG CAAAACCCTG CGTTTTG AACTG ATTCCG CAG GGTAAAACCCTG AAACATATTCAAG AACAG G G CTTC ATCGAAGAGGATAAAGCACGTAACGATCACTACAAAGAACTGAAACCGATTATCGACCGCATCTATAAAACCT ATGCAGATCAGTGTCTGCAGCTGGTTCAGCTGGATTGGGAAAATCTGAGCGCAGCAATTGATAGTTATCGCA AAGAAAAAACCGAAGAAACCCGTAATGCACTGATTGAAGAACAGGCAACCTATCGTAATGCCATCCATGATT ATTTCATTGGTCGTACCGATAATCTGACCGATGCAATTAACAAACGTCACGCCGAAATCTATAAAGGCCTGTTT AAAG CCG AACTGTTTAATG G CAAAGTTCTG AAACAG CTG GG CACCGTTACCACCACCG AACATG AAAATGCAC TGCTG CGTAG CTTTG ATAAATTCACCACCTATTTCAG CG G CTTTTATG AG AATCG CAAAAACGTGTTTAG CG CA GAAGATATTAGCACCGCAATTCCGCATCGTATTGTGCAGGATAATTTCCCGAAATTCAAAGAGAACTGCCACA TTTTTACCCGTCTG ATTACCG CAGTTCCG AG CCTG CGTG AACATTTTG AAAACGTTAAAAAAG CCATCG G CATC TTTGTTAGCACCAGCATTGAAGAAGTTTTTAGCTTCCCGTTTTACAATCAGCTGCTGACCCAGACCCAGATTGA 2024201449   05 Mar 2024 TCTGTATAACCAACTGCTGGGTGGTATTAGCCGTGAAGCAGGCACCGAAAAAATCAAAGGTCTGAATGAAGT G CTG AATCTG G CCATTCAG AAAAATG ATG AAACCG CACATATTATTGCAAG CCTG CCG CATCGTTTTATTCCG C TGTTCAAACAAATTCTGAGCGATCGTAATACCCTGAGCTTTATTCTGGAAGAATTCAAATCCGATGAAGAGGT GATTCAGAGCTTTTGCAAATACAAAACGCTGCTGCGCAATGAAAATGTTCTGGAAACTGCCGAAGCACTGTTT AACGAACTGAATAGCATTGATCTGACCCACATCTTTATCAGCCACAAAAAACTGGAAACCATTTCAAGCGCACT GTGTGATCATTGGGATACCCTGCGTAATGCCCTGTATGAACGTCGTATTAGCGAACTGACCGGTAAAATTACC AAAAGCGCGAAAGAAAAAGTTCAGCGCAGTCTGAAACATGAGGATATTAATCTGCAAGAGATTATTAGCGCA GCCGGTAAAGAACTGTCAGAAGCATTTAAACAGAAAACCAGCGAAATTCTGTCACATGCACATGCAGCACTG GATCAGCCGCTGCCGACCACCCTGAAAAAACAAGAAGAAAAAGAAATCCTGAAAAGCCAGCTGGATAGCCTG CTGGGTCTGTATCATCTGCTGGACTGGTTTGCAGTTGATGAAAGCAATGAAGTTGATCCGGAATTTAGCGCAC GTCTGACCGGCATTAAACTGGAAATGGAACCGAGCCTGAGCTTTTATAACAAAGCCCGTAATTATGCCACCAA AAAACCGTATAGCGTCGAAAAATTCAAACTGAACTTTCAGATGCCGACCCTGGCAAGCGGTTGGGATGTTAAT AAAG AAAAAAACAACG GTG CCATCCTGTTCGTG AAAAATG G CCTGTATTATCTG G GTATTATG CCG AAACAG A AAGGTCGTTATAAAGCGCTGAGCTTTGAACCGACGGAAAAAACCAGTGAAGGTTTTGATAAAATGTACTACG ACTATTTTCCG G ATG CAG CCAAAATG ATTCCG AAATGTAG CACCCAG CTG AAAG CAGTTACCG CACATTTTCA GACCCATACCACCCCGATTCTGCTGAGCAATAACTTTATTGAACCGCTGGAAATCACCAAAGAGATCTACGAT CTGAATAACCCGGAAAAAGAGCCGAAAAAATTCCAGACCGCATATGCAAAAAAAACCGGTGATCAGAAAGGT TATCGTGAAGCGCTGTGTAAATGGATTGATTTCACCCGTGATTTTCTGAGCAAATACACCAAAACCACCAGTAT CGATCTGAGCAGCCTGCGTCCGAGCAGCCAGTATAAAGATCTGGGCGAATATTATGCAGAACTGAATCCGCT GCTGTATCATATTAGCTTTCAGCGTATTGCCGAGAAAGAAATCATGGACGCAGTTGAAACCGGTAAACTGTAC CTGTTCCAG ATCTACAATAAAG ATTTTG CCAAAG G CCATCATG G CAAACCG AATCTG CATACCCTGTATTG G AC CGGTCTGTTTAGCCCTGAAAATCTGGCAAAAACCTCGATTAAACTGAATGGTCAGGCGGAACTGTTTTATCGT CCGAAAAGCCGTATGAAACGTATGGCACATCGTCTGGGTGAAAAAATGCTGAACAAAAAACTGAAAGACCAG AAAACCCCGATCCCGGATACACTGTATCAAGAACTGTATGATTATGTGAACCATCGTCTGAGCCATGATCTGA GTGATGAAGCACGTGCCCTGCTGCCGAATGTTATTACCAAAGAAGTTAGCCACGAGATCATTAAAGATCGTCG TTTTACCAGCGACAAATTCTTTTTTCATGTGCCGATTACCCTGAATTATCAGGCAGCAAATAGCCCGAGCAAAT TTAACCAGCGTGTTAATGCATATCTGAAAGAACATCCAGAAACGCCGATTATTGGTATTGATCGTGGTGAACG TAACCTGATTTATATCACCGTTATTGATAGCACCGGCAAAATCCTGGAACAGCGTAGCCTGAATACCATTCAGC AGTTTGATTACCAGAAAAAACTGGATAATCGCGAGAAAGAACGTGTTGCAGCACGTCAGGCATGGTCAGTTG TTGGTACAATTAAAGACCTGAAACAGGGTTATCTGAGCCAGGTTATTCATGAAATTGTGGATCTGATGATTCA CTATCAGGCCGTTGTTGTGCTGGAAAACCTGAATTTTGGCTTTAAAAGCAAACGTACCGGCATTGCAGAAAAA GCAGTTTATCAGCAGTTCGAGAAAATGCTGATTGACAAACTGAATTGCCTGGTGCTGAAAGATTATCCGGCTG AAAAAGTTG GTG GTGTTCTG AATCCGTATCAG CTG ACCG ATCAGTTTACCAGCTTTG CAAAAATG G G CACCCA GAGCGGATTTCTGTTTTATGTTCCGGCACCGTATACGAGCAAAATTGATCCGCTGACCGGTTTTGTTGATCCGT TTGTTTGGAAAACCATCAAAAACCATGAAAGCCGCAAACATTTTCTGGAAGGTTTCGATTTTCTGCATTACGAC GTTAAAACG G GTG ATTTCATCCTG CACTTTAAAATG AATCG CAATCTG AGTTTTCAG CGTG G CCTG CCTG GTTT TATGCCTGCATGGGATATTGTGTTTGAGAAAAACGAAACACAGTTCGATGCAAAAGGCACCCCGTTTATTGCA G GTAAACGTATTGTTCCG GTG ATTG AAAATCATCGTTTCACCGGTCGTTATCG CG ATCTGTATCCG G CAAATG AACTGATCGCACTGCTGGAAGAGAAAGGTATTGTTTTTCGTGATGGCTCAAACATTCTGCCGAAACTGCTGGA AAATGATGATAGCCATGCAATTGATACCATGGTTGCACTGATTCGTAGCGTTCTGCAGATGCGTAATAGCAAT G CAG CAACCG GTG AAG ATTACATTAATAGTCCG GTTCGTG ATCTG AATG GTGTTTGTTTTG ATAG CCGTTTTCA GAATCCGGAATGGCCGATGGATGCAGATGCAAATGGTGCATATCATATTGCACTGAAAGGACAGCTGCTGCT GAACCACCTGAAAGAAAGCAAAGATCTGAAACTGCAAAACGGCATTAGCAATCAGGATTGGCTGGCATATAT 2024201449   05 Mar 2024 CCAAGAACTGCGTAACGGTCGTAGCAGTGATGATGAAGCAACCGCAGATAGCCAGCATGCAGCACCGCCTAA AAAG AAACGTAAAGTTG GTG GTAG CG GTG GTTCAG GTG GTAGTG GCG GTAGTG GTG G CTCAG G G G GTTCTG GTGGCTCTGGTGGTAGCCTCGAGCACCACCACCACCACCACTGA

[0105] SEQIDNO.10

[0106] ATG ACCCAGTTTG AAG GTTTCACCAATCTGTATCAG GTTAG CAAAACCCTG CGTTTTG AACT GATTCCGCAGGGTAAAACCCTGAAACATATTCAAGAACAGGGCTTCATCGAAGAGGATAAAGCACGTAACGA TCACTACAAAGAACTGAAACCGATTATCGACCGCATCTATAAAACCTATGCAGATCAGTGTCTGCAGCTGGTT CAGCTGGATTGGGAAAATCTGAGCGCAGCAATTGATAGTTATCGCAAAGAAAAAACCGAAGAAACCCGTAAT GCACTGATTGAAGAACAGGCAACCTATCGTAATGCCATCCATGATTATTTCATTGGTCGTACCGATAATCTGAC CG ATG CAATTAACAAACGTCACG CCG AAATCTATAAAG G CCTGTTTAAAG CCG AACTGTTTAATG G CAAAGTT CTGAAACAGCTGGGCACCGTTACCACCACCGAACATGAAAATGCACTGCTGCGTAGCTTTGATAAATTCACCA CCTATTTCAGCGGCTTTTATGAGAATCGCAAAAACGTGTTTAGCGCAGAAGATATTAGCACCGCAATTCCGCA TCGTATTGTGCAGGATAATTTCCCGAAATTCAAAGAGAACTGCCACATTTTTACCCGTCTGATTACCGCAGTTC CG AG CCTG CGTG AACATTTTG AAAACGTTAAAAAAG CCATCG G CATCTTTGTTAG CACCAG CATTG AAG AAGT TTTTAGCTTCCCGTTTTACAATCAGCTGCTGACCCAGACCCAGATTGATCTGTATAACCAACTGCTGGGTGGTA TTAGCCGTGAAGCAGGCACCGAAAAAATCAAAGGTCTGAATGAAGTGCTGAATCTGGCCATTCAGAAAAATG ATG AAACCG CACATATTATTG CAAG CCTG CCG CATCGTTTTATTCCG CTGTTCAAACAAATTCTG AG CG ATCGT AATACCCTGAGCTTTATTCTGGAAGAATTCAAATCCGATGAAGAGGTGATTCAGAGCTTTTGCAAATACAAAA CGCTGCTGCGCAATGAAAATGTTCTGGAAACTGCCGAAGCACTGTTTAACGAACTGAATAGCATTGATCTGAC CCACATCTTTATCAG CCACAAAAAACTGG AAACCATTTCAAG CG CACTGTGTG ATCATTG G G ATACCCTG CGTA ATGCCCTGTATGAACGTCGTATTAGCGAACTGACCGGTAAAATTACCAAAAGCGCGAAAGAAAAAGTTCAGC GCAGTCTGAAACATGAGGATATTAATCTGCAAGAGATTATTAGCGCAGCCGGTAAAGAACTGTCAGAAGCAT TTAAACAGAAAACCAGCGAAATTCTGTCACATGCACATGCAGCACTGGATCAGCCGCTGCCGACCACCCTGAA AAAACAAGAAGAAAAAGAAATCCTGAAAAGCCAGCTGGATAGCCTGCTGGGTCTGTATCATCTGCTGGACTG GTTTGCAGTTGATGAAAGCAATGAAGTTGATCCGGAATTTAGCGCACGTCTGACCGGCATTAAACTGGAAAT GGAACCGAGCCTGAGCTTTTATAACAAAGCCCGTAATTATGCCACCAAAAAACCGTATAGCGTCGAAAAATTC AAACTGAACTTTCAGATGCCGACCCTGGCAAGCGGTTGGGATGTTAATAAAGAAAAAAACAACGGTGCCATC CTGTTCGTG AAAAATG G CCTGTATTATCTG G GTATTATG CCG AAACAG AAAG GTCGTTATAAAG CG CTG AG CT TTGAACCGACGGAAAAAACCAGTGAAGGTTTTGATAAAATGTACTACGACTATTTTCCGGATGCAGCCAAAAT GATTCCGAAATGTAGCACCCAGCTGAAAGCAGTTACCGCACATTTTCAGACCCATACCACCCCGATTCTGCTGA GCAATAACTTTATTGAACCGCTGGAAATCACCAAAGAGATCTACGATCTGAATAACCCGGAAAAAGAGCCGA AAAAATTCCAGACCGCATATGCAAAAAAAACCGGTGATCAGAAAGGTTATCGTGAAGCGCTGTGTAAATGGA TTGATTTCACCCGTGATTTTCTGAGCAAATACACCAAAACCACCAGTATCGATCTGAGCAGCCTGCGTCCGAGC AGCCAGTATAAAGATCTGGGCGAATATTATGCAGAACTGAATCCGCTGCTGTATCATATTAGCTTTCAGCGTA TTGCCGAGAAAGAAATCATGGACGCAGTTGAAACCGGTAAACTGTACCTGTTCCAGATCTACAATAAAGATTT TGCCAAAGGCCATCATGGCAAACCGAATCTGCATACCCTGTATTGGACCGGTCTGTTTAGCCCTGAAAATCTG GCAAAAACCTCGATTAAACTGAATGGTCAGGCGGAACTGTTTTATCGTCCGAAAAGCCGTATGAAACGTATG GCACATCGTCTGGGTGAAAAAATGCTGAACAAAAAACTGAAAGACCAGAAAACCCCGATCCCGGATACACTG TATCAAGAACTGTATGATTATGTGAACCATCGTCTGAGCCATGATCTGAGTGATGAAGCACGTGCCCTGCTGC CGAATGTTATTACCAAAGAAGTTAGCCACGAGATCATTAAAGATCGTCGTTTTACCAGCGACAAATTCTTTTTT CATGTG CCG ATTACCCTG AATTATCAG G CAG CAAATAG CCCG AG CAAATTTAACCAG CGTGTTAATGCATATC TGAAAGAACATCCAGAAACGCCGATTATTGGTATTGATCGTGGTGAACGTAACCTGATTTATATCACCGTTATT 2024201449   05 Mar 2024 GATAGCACCGGCAAAATCCTGGAACAGCGTAGCCTGAATACCATTCAGCAGTTTGATTACCAGAAAAAACTG GATAATCGCGAGAAAGAACGTGTTGCAGCACGTCAGGCATGGTCAGTTGTTGGTACAATTAAAGACCTGAAA CAG G GTTATCTG AG CCAG GTTATTCATG AAATTGTG G ATCTG ATG ATTCACTATCAG G CCGTTGTTGTG CTG G AAAACCTG AATTTTG G CTTTAAAAG CAAACGTACCG G CATTG CAG AAAAAG CAGTTTATCAGCAGTTCG AG AA AATGCTGATTGACAAACTGAATTGCCTGGTGCTGAAAGATTATCCGGCTGAAAAAGTTGGTGGTGTTCTGAAT CCGTATCAG CTG ACCG ATCAGTTTACCAG CTTTG CAAAAATG G G CACCCAG AG CG G ATTTCTGTTTTATGTTCC G G CACCGTATACG AG CAAAATTG ATCCG CTG ACCG GTTTTGTTGATCCGTTTGTTTG GAAAACCATCAAAAAC CATGAAAGCCGCAAACATTTTCTGGAAGGTTTCGATTTTCTGCATTACGACGTTAAAACGGGTGATTTCATCCT G CACTTTAAAATG AATCG CAATCTG AGTTTTCAG CGTGG CCTG CCTG GTTTTATG CCTG CATG G G ATATTGTGT TTG AG AAAAACG AAACACAGTTCG ATG CAAAAG G CACCCCGTTTATTG CAG GTAAACGTATTGTTCCG GTG AT TGAAAATCATCGTTTCACCGGTCGTTATCGCGATCTGTATCCGGCAAATGAACTGATCGCACTGCTGGAAGAG AAAG GTATTGTTTTTCGTG ATG G CTCAAACATTCTG CCG AAACTG CTG G AAAATG ATG ATAG CCATG CAATTG ATACCATG GTTG CACTG ATTCGTAG CGTTCTG CAG ATG CGTAATAG CAATG CAG CAACCG GTG AAG ATTACAT TAATAGTCCGGTTCGTGATCTGAATGGTGTTTGTTTTGATAGCCGTTTTCAGAATCCGGAATGGCCGATGGAT G CAG ATG CAAATG GTG CATATCATATTG CACTG AAAG GACAG CTG CTG CTG AACCACCTG AAAG AAAG CAAA G ATCTG AAACTG CAAAACG G CATTAG CAATCAG G ATTG G CTG G CATATATCCAAG AACTG CGTAACG GTCGT AGCAGTGATGATGAAGCAACCGCAGATAGCCAGCATGCAGCACCGCCTAAAAAGAAACGTAAAGTTGGTGG TAGCGGTGGTTCAGGTGGTAGTGGCGGTAGTGGTGGCTCAGGGGGTTCTGGTGGCTCTGGTGGTAGCCTCG AGCACCACCACCACCACCACTGA

[0107] SEQIDNO.il

[0108] ATGGGCAGCAGCAGCAGCGGCCTGGTGCCGCGCGGCAGCCATATGGCTAGCATGACTGGT G GACAG CAAATG G GTCG G G ATCCAACCCAGTTTG AAG GTTTCACCAATCTGTATCAG GTTAG CAAAACCCTG C GTTTTGAACTGATTCCGCAGGGTAAAACCCTGAAACATATTCAAGAACAGGGCTTCATCGAAGAGGATAAAG CACGTAACGATCACTACAAAGAACTGAAACCGATTATCGACCGCATCTATAAAACCTATGCAGATCAGTGTCT GCAGCTGGTTCAGCTGGATTGGGAAAATCTGAGCGCAGCAATTGATAGTTATCGCAAAGAAAAAACCGAAGA AACCCGTAATGCACTGATTGAAGAACAGGCAACCTATCGTAATGCCATCCATGATTATTTCATTGGTCGTACCG ATAATCTGACCGATGCAATTAACAAACGTCACGCCGAAATCTATAAAGGCCTGTTTAAAGCCGAACTGTTTAA TGGCAAAGTTCTGAAACAGCTGGGCACCGTTACCACCACCGAACATGAAAATGCACTGCTGCGTAGCTTTGAT AAATTCACCACCTATTTCAG CG G CTTTTATG AG AATCG CAAAAACGTGTTTAG CG CAG AAG ATATTAG CACCG CAATTCCGCATCGTATTGTGCAGGATAATTTCCCGAAATTCAAAGAGAACTGCCACATTTTTACCCGTCTGATT ACCGCAGTTCCG AG CCTG CGTG AACATTTTG AAAACGTTAAAAAAG CCATCG G CATCTTTGTTAG CACCAG CA TTGAAGAAGTTTTTAGCTTCCCGTTTTACAATCAGCTGCTGACCCAGACCCAGATTGATCTGTATAACCAACTG CTGGGTGGTATTAGCCGTGAAGCAGGCACCGAAAAAATCAAAGGTCTGAATGAAGTGCTGAATCTGGCCATT CAG AAAAATG ATG AAACCG CACATATTATTG CAAG CCTG CCG CATCGTTTTATTCCG CTGTTCAAACAAATTCT GAGCGATCGTAATACCCTGAGCTTTATTCTGGAAGAATTCAAATCCGATGAAGAGGTGATTCAGAGCTTTTGC AAATACAAAACGCTGCTGCGCAATGAAAATGTTCTGGAAACTGCCGAAGCACTGTTTAACGAACTGAATAGCA TTG ATCTG ACCCACATCTTTATCAG CCACAAAAAACTG GAAACCATTTCAAG CG CACTGTGTG ATCATTG G G AT ACCCTGCGTAATGCCCTGTATGAACGTCGTATTAGCGAACTGACCGGTAAAATTACCAAAAGCGCGAAAGAA AAAGTTCAGCGCAGTCTGAAACATGAGGATATTAATCTGCAAGAGATTATTAGCGCAGCCGGTAAAGAACTG TCAGAAGCATTTAAACAGAAAACCAGCGAAATTCTGTCACATGCACATGCAGCACTGGATCAGCCGCTGCCGA CCACCCTGAAAAAACAAGAAGAAAAAGAAATCCTGAAAAGCCAGCTGGATAGCCTGCTGGGTCTGTATCATC TGCTGGACTGGTTTGCAGTTGATGAAAGCAATGAAGTTGATCCGGAATTTAGCGCACGTCTGACCGGCATTAA 2024201449   05 Mar 2024 ACTG G AAATG G AACCG AG CCTG AG CTTTTATAACAAAG CCCGTAATTATG CCACCAAAAAACCGTATAG CGTC GAAAAATTCAAACTGAACTTTCAGATGCCGACCCTGGCAAGCGGTTGGGATGTTAATAAAGAAAAAAACAAC G GTG CCATCCTGTTCGTG AAAAATG G CCTGTATTATCTG GGTATTATG CCG AAACAG AAAGGTCGTTATAAAG CGCTGAGCTTTGAACCGACGGAAAAAACCAGTGAAGGTTTTGATAAAATGTACTACGACTATTTTCCGGATGC AGCCAAAATGATTCCGAAATGTAGCACCCAGCTGAAAGCAGTTACCGCACATTTTCAGACCCATACCACCCCG ATTCTGCTGAGCAATAACTTTATTGAACCGCTGGAAATCACCAAAGAGATCTACGATCTGAATAACCCGGAAA AAGAGCCGAAAAAATTCCAGACCGCATATGCAAAAAAAACCGGTGATCAGAAAGGTTATCGTGAAGCGCTGT GTAAATGGATTGATTTCACCCGTGATTTTCTGAGCAAATACACCAAAACCACCAGTATCGATCTGAGCAGCCT GCGTCCGAGCAGCCAGTATAAAGATCTGGGCGAATATTATGCAGAACTGAATCCGCTGCTGTATCATATTAGC TTTCAGCGTATTGCCGAGAAAGAAATCATGGACGCAGTTGAAACCGGTAAACTGTACCTGTTCCAGATCTACA ATAAAG ATTTTG CCAAAG GCCATCATG G CAAACCG AATCTG CATACCCTGTATTG G ACCG GTCTGTTTAG CCCT GAAAATCTGGCAAAAACCTCGATTAAACTGAATGGTCAGGCGGAACTGTTTTATCGTCCGAAAAGCCGTATGA AACGTATGGCACATCGTCTGGGTGAAAAAATGCTGAACAAAAAACTGAAAGACCAGAAAACCCCGATCCCGG ATACACTGTATCAAGAACTGTATGATTATGTGAACCATCGTCTGAGCCATGATCTGAGTGATGAAGCACGTGC CCTGCTGCCGAATGTTATTACCAAAGAAGTTAGCCACGAGATCATTAAAGATCGTCGTTTTACCAGCGACAAA TTCTTTTTTCATGTG CCGATTACCCTGAATTATCAG G CAG CAAATAG CCCG AG CAAATTTAACCAG CGTGTTAA TGCATATCTGAAAGAACATCCAGAAACGCCGATTATTGGTATTGATCGTGGTGAACGTAACCTGATTTATATC ACCGTTATTGATAGCACCGGCAAAATCCTGGAACAGCGTAGCCTGAATACCATTCAGCAGTTTGATTACCAGA AAAAACTGGATAATCGCGAGAAAGAACGTGTTGCAGCACGTCAGGCATGGTCAGTTGTTGGTACAATTAAAG ACCTGAAACAGGGTTATCTGAGCCAGGTTATTCATGAAATTGTGGATCTGATGATTCACTATCAGGCCGTTGT TGTG CTG G AAAACCTG AATTTTG G CTTTAAAAG CAAACGTACCG G CATTGCAG AAAAAG CAGTTTATCAG CAG TTCGAGAAAATGCTGATTGACAAACTGAATTGCCTGGTGCTGAAAGATTATCCGGCTGAAAAAGTTGGTGGT GTTCTGAATCCGTATCAG CTG ACCG ATCAGTTTACCAGCTTTG CAAAAATG G G CACCCAG AG CG G ATTTCTGTT TTATGTTCCG G CACCGTATACG AG CAAAATTG ATCCG CTG ACCG GTTTTGTTGATCCGTTTGTTTG GAAAACCA TCAAAAACCATGAAAGCCGCAAACATTTTCTGGAAGGTTTCGATTTTCTGCATTACGACGTTAAAACGGGTGA TTTCATCCTG CACTTTAAAATG AATCG CAATCTG AGTTTTCAG CGTG G CCTG CCTG GTTTTATG CCTG CATG G G ATATTGTGTTTGAGAAAAACGAAACACAGTTCGATGCAAAAGGCACCCCGTTTATTGCAGGTAAACGTATTGT TCCG GTG ATTG AAAATCATCGTTTCACCG GTCGTTATCG CGATCTGTATCCG G CAAATG AACTG ATCG CACTG C TGGAAGAGAAAGGTATTGTTTTTCGTGATGGCTCAAACATTCTGCCGAAACTGCTGGAAAATGATGATAGCCA TGCAATTGATACCATGGTTGCACTGATTCGTAGCGTTCTGCAGATGCGTAATAGCAATGCAGCAACCGGTGAA GATTACATTAATAGTCCGGTTCGTGATCTGAATGGTGTTTGTTTTGATAGCCGTTTTCAGAATCCGGAATGGCC GATGGATGCAGATGCAAATGGTGCATATCATATTGCACTGAAAGGACAGCTGCTGCTGAACCACCTGAAAGA AAG CAAAG ATCTG AAACTG CAAAACG GCATTAG CAATCAG G ATTG G CTG G CATATATCCAAG AACTG CGTAA CGGTCGTAGCAGTGATGATGAAGCAACCGCAGATAGCCAGCATGCAGCACCGCCTAAAAAGAAACGTAAAGT TGGTG GTAG CG GTG GTTCAG GTG GTAGTG G CG GTAGTG GTGG CTCAG G G G GTTCTG GTG G CTCTGGTG GTA GCCTCGAGCACCACCACCACCACCACTGA

[0109] SEQIDNO.12

[0110] ATGCCGCCTCCGAAACGTCCGCGTCTGGATGGTATCCACGGAGTCCCAGCAGCCACCCAGT TTG AAG GTTTCACCAATCTGTATCAG GTTAG CAAAACCCTG CGTTTTG AACTG ATTCCG CAG G GTAAAACCCTG AAACATATTCAAGAACAGGGCTTCATCGAAGAGGATAAAGCACGTAACGATCACTACAAAGAACTGAAACCG ATTATCGACCGCATCTATAAAACCTATGCAGATCAGTGTCTGCAGCTGGTTCAGCTGGATTGGGAAAATCTGA GCGCAGCAATTGATAGTTATCGCAAAGAAAAAACCGAAGAAACCCGTAATGCACTGATTGAAGAACAGGCAA CCTATCGTAATGCCATCCATGATTATTTCATTGGTCGTACCGATAATCTGACCGATGCAATTAACAAACGTCAC 2024201449   05 Mar 2024 G CCG AAATCTATAAAG G CCTGTTTAAAG CCG AACTGTTTAATGG CAAAGTTCTG AAACAG CTG G G CACCGTTA CCACCACCGAACATGAAAATGCACTGCTGCGTAGCTTTGATAAATTCACCACCTATTTCAGCGGCTTTTATGAG AATCGCAAAAACGTGTTTAGCGCAGAAGATATTAGCACCGCAATTCCGCATCGTATTGTGCAGGATAATTTCC CGAAATTCAAAGAGAACTGCCACATTTTTACCCGTCTGATTACCGCAGTTCCGAGCCTGCGTGAACATTTTGAA AACGTTAAAAAAG CCATCG G CATCTTTGTTAG CACCAG CATTG AAG AAGTTTTTAG CTTCCCGTTTTACAATCA GCTGCTGACCCAGACCCAGATTGATCTGTATAACCAACTGCTGGGTGGTATTAGCCGTGAAGCAGGCACCGA AAAAATCAAAGGTCTGAATGAAGTGCTGAATCTGGCCATTCAGAAAAATGATGAAACCGCACATATTATTGCA AGCCTGCCGCATCGTTTTATTCCGCTGTTCAAACAAATTCTGAGCGATCGTAATACCCTGAGCTTTATTCTGGA AGAATTCAAATCCGATGAAGAGGTGATTCAGAGCTTTTGCAAATACAAAACGCTGCTGCGCAATGAAAATGTT CTGGAAACTGCCGAAGCACTGTTTAACGAACTGAATAGCATTGATCTGACCCACATCTTTATCAGCCACAAAA AACTGGAAACCATTTCAAGCGCACTGTGTGATCATTGGGATACCCTGCGTAATGCCCTGTATGAACGTCGTAT TAGCGAACTGACCGGTAAAATTACCAAAAGCGCGAAAGAAAAAGTTCAGCGCAGTCTGAAACATGAGGATAT TAATCTGCAAGAGATTATTAGCGCAGCCGGTAAAGAACTGTCAGAAGCATTTAAACAGAAAACCAGCGAAAT TCTGTCACATGCACATGCAGCACTGGATCAGCCGCTGCCGACCACCCTGAAAAAACAAGAAGAAAAAGAAAT CCTGAAAAGCCAGCTGGATAGCCTGCTGGGTCTGTATCATCTGCTGGACTGGTTTGCAGTTGATGAAAGCAAT GAAGTTGATCCGGAATTTAGCGCACGTCTGACCGGCATTAAACTGGAAATGGAACCGAGCCTGAGCTTTTATA ACAAAGCCCGTAATTATGCCACCAAAAAACCGTATAGCGTCGAAAAATTCAAACTGAACTTTCAGATGCCGAC CCTG G CAAGCG GTTG G G ATGTTAATAAAG AAAAAAACAACG GTG CCATCCTGTTCGTG AAAAATG G CCTGTA TTATCTGGGTATTATGCCGAAACAGAAAGGTCGTTATAAAGCGCTGAGCTTTGAACCGACGGAAAAAACCAG TGAAGGTTTTGATAAAATGTACTACGACTATTTTCCGGATGCAGCCAAAATGATTCCGAAATGTAGCACCCAG CTGAAAGCAGTTACCGCACATTTTCAGACCCATACCACCCCGATTCTGCTGAGCAATAACTTTATTGAACCGCT GGAAATCACCAAAGAGATCTACGATCTGAATAACCCGGAAAAAGAGCCGAAAAAATTCCAGACCGCATATGC AAAAAAAACCGGTGATCAGAAAGGTTATCGTGAAGCGCTGTGTAAATGGATTGATTTCACCCGTGATTTTCTG AGCAAATACACCAAAACCACCAGTATCGATCTGAGCAGCCTGCGTCCGAGCAGCCAGTATAAAGATCTGGGC GAATATTATGCAGAACTGAATCCGCTGCTGTATCATATTAGCTTTCAGCGTATTGCCGAGAAAGAAATCATGG ACG CAGTTG AAACCG GTAAACTGTACCTGTTCCAG ATCTACAATAAAG ATTTTG CCAAAG G CCATCATG G CAA ACCGAATCTGCATACCCTGTATTGGACCGGTCTGTTTAGCCCTGAAAATCTGGCAAAAACCTCGATTAAACTGA ATG GTCAG G CG G AACTGTTTTATCGTCCG AAAAGCCGTATG AAACGTATG G CACATCGTCTG G GTG AAAAAA TGCTGAACAAAAAACTGAAAGACCAGAAAACCCCGATCCCGGATACACTGTATCAAGAACTGTATGATTATGT GAACCATCGTCTGAGCCATGATCTGAGTGATGAAGCACGTGCCCTGCTGCCGAATGTTATTACCAAAGAAGTT AGCCACGAGATCATTAAAGATCGTCGTTTTACCAGCGACAAATTCTTTTTTCATGTGCCGATTACCCTGAATTAT CAG G CAG CAAATAGCCCG AG CAAATTTAACCAG CGTGTTAATG CATATCTG AAAG AACATCCAG AAACG CCG ATTATTGGTATTGATCGTGGTGAACGTAACCTGATTTATATCACCGTTATTGATAGCACCGGCAAAATCCTGGA ACAGCGTAGCCTGAATACCATTCAGCAGTTTGATTACCAGAAAAAACTGGATAATCGCGAGAAAGAACGTGT TGCAGCACGTCAGGCATGGTCAGTTGTTGGTACAATTAAAGACCTGAAACAGGGTTATCTGAGCCAGGTTATT CATGAAATTGTGGATCTGATGATTCACTATCAGGCCGTTGTTGTGCTGGAAAACCTGAATTTTGGCTTTAAAA GCAAACGTACCGGCATTGCAGAAAAAGCAGTTTATCAGCAGTTCGAGAAAATGCTGATTGACAAACTGAATT GCCTGGTGCTGAAAGATTATCCGGCTGAAAAAGTTGGTGGTGTTCTGAATCCGTATCAGCTGACCGATCAGTT TACCAG CTTTG CAAAAATG G G CACCCAG AG CG G ATTTCTGTTTTATGTTCCG G CACCGTATACG AG CAAAATT GATCCGCTGACCGGTTTTGTTGATCCGTTTGTTTGGAAAACCATCAAAAACCATGAAAGCCGCAAACATTTTCT GGAAGGTTTCGATTTTCTGCATTACGACGTTAAAACGGGTGATTTCATCCTGCACTTTAAAATGAATCGCAATC TG AGTTTTCAG CGTG G CCTG CCTG GTTTTATG CCTG CATG G G ATATTGTGTTTG AG AAAAACG AAACACAGTT CG ATG CAAAAG GCACCCCGTTTATTG CAG GTAAACGTATTGTTCCG GTG ATTG AAAATCATCGTTTCACCG GT CGTTATCGCGATCTGTATCCGGCAAATGAACTGATCGCACTGCTGGAAGAGAAAGGTATTGTTTTTCGTGATG GCTCAAACATTCTGCCGAAACTGCTGGAAAATGATGATAGCCATGCAATTGATACCATGGTTGCACTGATTCG TAGCGTTCTGCAGATGCGTAATAGCAATGCAGCAACCGGTGAAGATTACATTAATAGTCCGGTTCGTGATCTG AATGGTGTTTGTTTTGATAGCCGTTTTCAGAATCCGGAATGGCCGATGGATGCAGATGCAAATGGTGCATATC ATATTGCACTGAAAGGACAGCTGCTGCTGAACCACCTGAAAGAAAGCAAAGATCTGAAACTGCAAAACGGCA TTAGCAATCAGGATTGGCTGGCATATATCCAAGAACTGCGTAACGGTCGTAGCAGTGATGATGAAGCAACCG 2024201449   05 Mar 2024 CAG ATAG CCAG CATG CAG CACCG CCTAAAAAGAAACGTAAAGTTG GTG GTAG CG GTG GTTCAG GTG GTAGT G G CG GTAGTG GTGG CTCAG G G G GTTCTG GTG G CTCTGGTG GTAG CCTCG AG CACCACCACCACCACCACTG A

[0111] SEQIDNO.13

[0112] ATGAGCAGTGATGATGAAGCAACCGCAGATAGCCAGCATGCAGCACCGCCTAAAAAGAAA CGTAAAGTTG GTATCCACG G AGTCCCAG CAG CCACCCAGTTTG AAG GTTTCACCAATCTGTATCAG GTTAG CA AAACCCTGCGTTTTGAACTGATTCCGCAGGGTAAAACCCTGAAACATATTCAAGAACAGGGCTTCATCGAAGA GGATAAAGCACGTAACGATCACTACAAAGAACTGAAACCGATTATCGACCGCATCTATAAAACCTATGCAGAT CAGTGTCTG CAG CTG GTTCAG CTG G ATTG G G AAAATCTG AG CG CAG CAATTG ATAGTTATCG CAAAG AAAAA ACCG AAG AAACCCGTAATG CACTG ATTG AAG AACAG G CAACCTATCGTAATG CCATCCATG ATTATTTCATTG GTCGTACCGATAATCTGACCGATGCAATTAACAAACGTCACGCCGAAATCTATAAAGGCCTGTTTAAAGCCGA ACTGTTTAATG G CAAAGTTCTG AAACAG CTG G G CACCGTTACCACCACCG AACATG AAAATG CACTG CTG CGT AGCTTTGATAAATTCACCACCTATTTCAGCGGCTTTTATGAGAATCGCAAAAACGTGTTTAGCGCAGAAGATAT TAG CACCG CAATTCCG CATCGTATTGTG CAG GATAATTTCCCG AAATTCAAAG AG AACTG CCA CATTTTTACCC GTCTGATTACCGCAGTTCCGAGCCTGCGTGAACATTTTGAAAACGTTAAAAAAGCCATCGGCATCTTTGTTAGC ACCAGCATTGAAGAAGTTTTTAGCTTCCCGTTTTACAATCAGCTGCTGACCCAGACCCAGATTGATCTGTATAA CCAACTG CTG G GTG GTATTAG CCGTG AAG CAG G CACCG AAAAAATCAAAG GTCTGAATGAAGTG CTG AATCT G G CCATTCAG AAAAATG ATG AAACCG CACATATTATTGCAAG CCTG CCG CATCGTTTTATTCCG CTGTTCAAAC AAATTCTGAGCGATCGTAATACCCTGAGCTTTATTCTGGAAGAATTCAAATCCGATGAAGAGGTGATTCAGAG CTTTTG CAAATACAAAACG CTG CTG CG CAATG AAAATGTTCTG G AAACTG CCG AAG CACTGTTTAACG AACTG AATAGCATTGATCTGACCCACATCTTTATCAGCCACAAAAAACTGGAAACCATTTCAAGCGCACTGTGTGATCA TTGGGATACCCTGCGTAATGCCCTGTATGAACGTCGTATTAGCGAACTGACCGGTAAAATTACCAAAAGCGCG AAAGAAAAAGTTCAGCGCAGTCTGAAACATGAGGATATTAATCTGCAAGAGATTATTAGCGCAGCCGGTAAA G AACTGTCAG AAG CATTTAAACAG AAAACCAG CG AAATTCTGTCACATG CACATG CAG CACTG GATCAG CCG C TGCCGACCACCCTGAAAAAACAAGAAGAAAAAGAAATCCTGAAAAGCCAGCTGGATAGCCTGCTGGGTCTGT ATCATCTGCTGGACTGGTTTGCAGTTGATGAAAGCAATGAAGTTGATCCGGAATTTAGCGCACGTCTGACCGG CATTAAACTGGAAATGGAACCGAGCCTGAGCTTTTATAACAAAGCCCGTAATTATGCCACCAAAAAACCGTAT AGCGTCGAAAAATTCAAACTGAACTTTCAGATGCCGACCCTGGCAAGCGGTTGGGATGTTAATAAAGAAAAA AACAACG GTG CCATCCTGTTCGTG AAAAATG G CCTGTATTATCTG G GTATTATG CCG AAACAG AAAG GTCGTT ATAAAGCGCTGAGCTTTGAACCGACGGAAAAAACCAGTGAAGGTTTTGATAAAATGTACTACGACTATTTTCC GGATGCAGCCAAAATGATTCCGAAATGTAGCACCCAGCTGAAAGCAGTTACCGCACATTTTCAGACCCATACC ACCCCGATTCTGCTGAGCAATAACTTTATTGAACCGCTGGAAATCACCAAAGAGATCTACGATCTGAATAACC CGGAAAAAGAGCCGAAAAAATTCCAGACCGCATATGCAAAAAAAACCGGTGATCAGAAAGGTTATCGTGAA GCGCTGTGTAAATGGATTGATTTCACCCGTGATTTTCTGAGCAAATACACCAAAACCACCAGTATCGATCTGA GCAGCCTGCGTCCGAGCAGCCAGTATAAAGATCTGGGCGAATATTATGCAGAACTGAATCCGCTGCTGTATCA TATTAGCTTTCAGCGTATTGCCGAGAAAGAAATCATGGACGCAGTTGAAACCGGTAAACTGTACCTGTTCCAG ATCTACAATAAAG ATTTTG CCAAAG G CCATCATGG CAAACCG AATCTG CATACCCTGTATTG G ACCG GTCTGTT TAG CCCTG AAAATCTG GCAAAAACCTCG ATTAAACTGAATG GTCAG G CG G AACTGTTTTATCGTCCG AAAAG C CGTATGAAACGTATGGCACATCGTCTGGGTGAAAAAATGCTGAACAAAAAACTGAAAGACCAGAAAACCCCG ATCCCGGATACACTGTATCAAGAACTGTATGATTATGTGAACCATCGTCTGAGCCATGATCTGAGTGATGAAG CACGTGCCCTGCTGCCGAATGTTATTACCAAAGAAGTTAGCCACGAGATCATTAAAGATCGTCGTTTTACCAG CGACAAATTCTTTTTTCATGTGCCGATTACCCTGAATTATCAGGCAGCAAATAGCCCGAGCAAATTTAACCAGC GTGTTAATGCATATCTGAAAGAACATCCAGAAACGCCGATTATTGGTATTGATCGTGGTGAACGTAACCTGAT TTATATCACCGTTATTGATAGCACCGGCAAAATCCTGGAACAGCGTAGCCTGAATACCATTCAGCAGTTTGATT 2024201449   05 Mar 2024 ACCAGAAAAAACTGGATAATCGCGAGAAAGAACGTGTTGCAGCACGTCAGGCATGGTCAGTTGTTGGTACAA TTAAAGACCTGAAACAGGGTTATCTGAGCCAGGTTATTCATGAAATTGTGGATCTGATGATTCACTATCAGGC CGTTGTTGTGCTGGAAAACCTGAATTTTGGCTTTAAAAGCAAACGTACCGGCATTGCAGAAAAAGCAGTTTAT CAGCAGTTCGAGAAAATGCTGATTGACAAACTGAATTGCCTGGTGCTGAAAGATTATCCGGCTGAAAAAGTT GGTGGTGTTCTGAATCCGTATCAGCTGACCGATCAGTTTACCAGCTTTGCAAAAATGGGCACCCAGAGCGGAT TTCTGTTTTATGTTCCGGCACCGTATACGAGCAAAATTGATCCGCTGACCGGTTTTGTTGATCCGTTTGTTTGG AAAACCATCAAAAACCATGAAAGCCGCAAACATTTTCTGGAAGGTTTCGATTTTCTGCATTACGACGTTAAAAC G G GTG ATTTCATCCTG CACTTTAAAATG AATCG CAATCTG AGTTTTCAG CGTG GCCTG CCTG GTTTTATG CCTG CATG G G ATATTGTGTTTG AG AAAAACG AAACACAGTTCGATG CAAAAG G CACCCCGTTTATTG CAG GTAAAC GTATTGTTCCGGTGATTGAAAATCATCGTTTCACCGGTCGTTATCGCGATCTGTATCCGGCAAATGAACTGATC GCACTGCTGGAAGAGAAAGGTATTGTTTTTCGTGATGGCTCAAACATTCTGCCGAAACTGCTGGAAAATGATG ATAGCCATGCAATTGATACCATGGTTGCACTGATTCGTAGCGTTCTGCAGATGCGTAATAGCAATGCAGCAAC CGGTGAAGATTACATTAATAGTCCGGTTCGTGATCTGAATGGTGTTTGTTTTGATAGCCGTTTTCAGAATCCGG AATGGCCGATGGATGCAGATGCAAATGGTGCATATCATATTGCACTGAAAGGACAGCTGCTGCTGAACCACC TGAAAGAAAGCAAAGATCTGAAACTGCAAAACGGCATTAGCAATCAGGATTGGCTGGCATATATCCAAGAAC TGCGTAACGGTCGTAGCAGTGATGATGAAGCAACCGCAGATAGCCAGCATGCAGCACCGCCTAAAAAGAAAC GTAAAGTTGGTGGTAGCGGTGGTTCAGGTGGTAGTGGCGGTAGTGGTGGCTCAGGGGGTTCTGGTGGCTCT GGTGGTAGCCTCGAGCACCACCACCACCACCACTGA

[0113] SEQIDNO.14

[0114] ATG ACCCAGTTTG AAG GTTTCACCAATCTGTATCAG GTTAG CAAAACCCTG CGTTTTG AACT GATTCCGCAGGGTAAAACCCTGAAACATATTCAAGAACAGGGCTTCATCGAAGAGGATAAAGCACGTAACGA TCACTACAAAGAACTGAAACCGATTATCGACCGCATCTATAAAACCTATGCAGATCAGTGTCTGCAGCTGGTT CAGCTGGATTGGGAAAATCTGAGCGCAGCAATTGATAGTTATCGCAAAGAAAAAACCGAAGAAACCCGTAAT GCACTGATTGAAGAACAGGCAACCTATCGTAATGCCATCCATGATTATTTCATTGGTCGTACCGATAATCTGAC CG ATG CAATTAACAAACGTCACG CCG AAATCTATAAAG G CCTGTTTAAAG CCG AACTGTTTAATG G CAAAGTT CTGAAACAGCTGGGCACCGTTACCACCACCGAACATGAAAATGCACTGCTGCGTAGCTTTGATAAATTCACCA CCTATTTCAGCGGCTTTTATGAGAATCGCAAAAACGTGTTTAGCGCAGAAGATATTAGCACCGCAATTCCGCA TCGTATTGTGCAGGATAATTTCCCGAAATTCAAAGAGAACTGCCACATTTTTACCCGTCTGATTACCGCAGTTC CG AG CCTG CGTG AACATTTTG AAAACGTTAAAAAAG CCATCG G CATCTTTGTTAG CACCAG CATTG AAG AAGT TTTTAGCTTCCCGTTTTACAATCAGCTGCTGACCCAGACCCAGATTGATCTGTATAACCAACTGCTGGGTGGTA TTAGCCGTGAAGCAGGCACCGAAAAAATCAAAGGTCTGAATGAAGTGCTGAATCTGGCCATTCAGAAAAATG ATG AAACCG CACATATTATTG CAAG CCTG CCG CATCGTTTTATTCCG CTGTTCAAACAAATTCTG AG CG ATCGT AATACCCTGAGCTTTATTCTGGAAGAATTCAAATCCGATGAAGAGGTGATTCAGAGCTTTTGCAAATACAAAA CGCTGCTGCGCAATGAAAATGTTCTGGAAACTGCCGAAGCACTGTTTAACGAACTGAATAGCATTGATCTGAC CCACATCTTTATCAG CCACAAAAAACTG G AAACCATTTCAAG CG CACTGTGTG ATCATTG G G ATACCCTG CGTA ATGCCCTGTATGAACGTCGTATTAGCGAACTGACCGGTAAAATTACCAAAAGCGCGAAAGAAAAAGTTCAGC GCAGTCTGAAACATGAGGATATTAATCTGCAAGAGATTATTAGCGCAGCCGGTAAAGAACTGTCAGAAGCAT TTAAACAGAAAACCAGCGAAATTCTGTCACATGCACATGCAGCACTGGATCAGCCGCTGCCGACCACCCTGAA AAAACAAGAAGAAAAAGAAATCCTGAAAAGCCAGCTGGATAGCCTGCTGGGTCTGTATCATCTGCTGGACTG GTTTGCAGTTGATGAAAGCAATGAAGTTGATCCGGAATTTAGCGCACGTCTGACCGGCATTAAACTGGAAAT GGAACCGAGCCTGAGCTTTTATAACAAAGCCCGTAATTATGCCACCAAAAAACCGTATAGCGTCGAAAAATTC AAACTGAACTTTCAGATGCCGACCCTGGCAAGCGGTTGGGATGTTAATAAAGAAAAAAACAACGGTGCCATC CTGTTCGTG AAAAATG G CCTGTATTATCTG G GTATTATG CCG AAACAG AAAG GTCGTTATAAAG CG CTG AG CT 2024201449   05 Mar 2024 TTGAACCGACGGAAAAAACCAGTGAAGGTTTTGATAAAATGTACTACGACTATTTTCCGGATGCAGCCAAAAT GATTCCGAAATGTAGCACCCAGCTGAAAGCAGTTACCGCACATTTTCAGACCCATACCACCCCGATTCTGCTGA GCAATAACTTTATTGAACCGCTGGAAATCACCAAAGAGATCTACGATCTGAATAACCCGGAAAAAGAGCCGA AAAAATTCCAGACCGCATATGCAAAAAAAACCGGTGATCAGAAAGGTTATCGTGAAGCGCTGTGTAAATGGA TTGATTTCACCCGTGATTTTCTGAGCAAATACACCAAAACCACCAGTATCGATCTGAGCAGCCTGCGTCCGAGC AG CCAGTATAAAG ATCTG G G CG AATATTATGCAG AACTG AATCCG CTG CTGTATCATATTAG CTTTCAG CGTA TTGCCGAGAAAGAAATCATGGACGCAGTTGAAACCGGTAAACTGTACCTGTTCCAGATCTACAATAAAGATTT TGCCAAAG G CCATCATG G CAAACCG AATCTG CATACCCTGTATTG G ACCG GTCTGTTTAG CCCTG AAAATCTG GCAAAAACCTCGATTAAACTGAATGGTCAGGCGGAACTGTTTTATCGTCCGAAAAGCCGTATGAAACGTATG GCACATCGTCTGGGTGAAAAAATGCTGAACAAAAAACTGAAAGACCAGAAAACCCCGATCCCGGATACACTG TATCAAGAACTGTATGATTATGTGAACCATCGTCTGAGCCATGATCTGAGTGATGAAGCACGTGCCCTGCTGC CGAATGTTATTACCAAAGAAGTTAGCCACGAGATCATTAAAGATCGTCGTTTTACCAGCGACAAATTCTTTTTT CATGTG CCGATTACCCTGAATTATCAG G CAG CAAATAG CCCG AG CAAATTTAACCAG CGTGTTAATG CATATC TGAAAGAACATCCAGAAACGCCGATTATTGGTATTGATCGTGGTGAACGTAACCTGATTTATATCACCGTTATT GATAGCACCGGCAAAATCCTGGAACAGCGTAGCCTGAATACCATTCAGCAGTTTGATTACCAGAAAAAACTG GATAATCGCGAGAAAGAACGTGTTGCAGCACGTCAGGCATGGTCAGTTGTTGGTACAATTAAAGACCTGAAA CAGGGTTATCTGAGCCAGGTTATTCATGAAATTGTGGATCTGATGATTCACTATCAGGCCGTTGTTGTGCTGG AAAACCTG AATTTTG G CTTTAAAAG CAAACGTACCG G CATTG CAG AAAAAG CAGTTTATCAG CAGTTCGAGAA AATGCTGATTGACAAACTGAATTGCCTGGTGCTGAAAGATTATCCGGCTGAAAAAGTTGGTGGTGTTCTGAAT CCGTATCAGCTGACCGATCAGTTTACCAGCTTTGCAAAAATGGGCACCCAGAGCGGATTTCTGTTTTATGTTCC G G CACCGTATACG AG CAAAATTGATCCG CTG ACCG GTTTTGTTGATCCGTTTGTTTG GAAAACCATCAAAAAC CATGAAAGCCGCAAACATTTTCTGGAAGGTTTCGATTTTCTGCATTACGACGTTAAAACGGGTGATTTCATCCT G CACTTTAAAATG AATCG CAATCTG AGTTTTCAG CGTGG CCTG CCTG GTTTTATG CCTG CATG G G ATATTGTGT TTG AG AAAAACG AAACACAGTTCG ATG CAAAAG G CACCCCGTTTATTG CAG GTAAACGTATTGTTCCG GTG AT TGAAAATCATCGTTTCACCGGTCGTTATCGCGATCTGTATCCGGCAAATGAACTGATCGCACTGCTGGAAGAG AAAG GTATTGTTTTTCGTG ATG G CTCAAACATTCTG CCG AAACTG CTG G AAAATG ATG ATAG CCATG CAATTG ATACCATG GTTG CACTG ATTCGTAG CGTTCTG CAG ATG CGTAATAGCAATG CAG CAACCG GTG AAG ATTACAT TAATAGTCCGGTTCGTGATCTGAATGGTGTTTGTTTTGATAGCCGTTTTCAGAATCCGGAATGGCCGATGGAT G CAG ATG CAAATG GTG CATATCATATTG CACTG AAAG GACAG CTG CTG CTG AACCACCTG AAAG AAAG CAAA G ATCTG AAACTG CAAAACG G CATTAG CAATCAG G ATTG G CTG G CATATATCCAAG AACTG CGTAACG GTCGT AAACGTCCG G CAG CAACCAAAAAAG CAG GTCAG G CAAAAAAGAAAAAAG GTG GTAG CG GTG GTTCAG GTG GTAGTG G CG GTAGTG GTGG CTCAG G G G GTTCTG GTG G CTCTG GTG GTAG CCTCG AG CACCACCACCACCACC ACTGA

[0115] SEQIDNO.15

[0116] ATG ACCCAGTTTG AAG GTTTCACCAATCTGTATCAG GTTAG CAAAACCCTG CGTTTTG AACT GATTCCGCAGGGTAAAACCCTGAAACATATTCAAGAACAGGGCTTCATCGAAGAGGATAAAGCACGTAACGA TCACTACAAAGAACTGAAACCGATTATCGACCGCATCTATAAAACCTATGCAGATCAGTGTCTGCAGCTGGTT CAGCTGGATTGGGAAAATCTGAGCGCAGCAATTGATAGTTATCGCAAAGAAAAAACCGAAGAAACCCGTAAT GCACTGATTGAAGAACAGGCAACCTATCGTAATGCCATCCATGATTATTTCATTGGTCGTACCGATAATCTGAC CG ATG CAATTAACAAACGTCACG CCG AAATCTATAAAG G CCTGTTTAAAG CCG AACTGTTTAATG G CAAAGTT CTGAAACAGCTGGGCACCGTTACCACCACCGAACATGAAAATGCACTGCTGCGTAGCTTTGATAAATTCACCA CCTATTTCAGCGGCTTTTATGAGAATCGCAAAAACGTGTTTAGCGCAGAAGATATTAGCACCGCAATTCCGCA TCGTATTGTGCAGGATAATTTCCCGAAATTCAAAGAGAACTGCCACATTTTTACCCGTCTGATTACCGCAGTTC 2024201449   05 Mar 2024 CG AG CCTG CGTG AACATTTTG AAAACGTTAAAAAAG CCATCG G CATCTTTGTTAG CACCAG CATTG AAG AAGT TTTTAGCTTCCCGTTTTACAATCAGCTGCTGACCCAGACCCAGATTGATCTGTATAACCAACTGCTGGGTGGTA TTAGCCGTGAAGCAGGCACCGAAAAAATCAAAGGTCTGAATGAAGTGCTGAATCTGGCCATTCAGAAAAATG ATG AAACCG CACATATTATTG CAAG CCTG CCG CATCGTTTTATTCCG CTGTTCAAACAAATTCTG AG CG ATCGT AATACCCTGAGCTTTATTCTGGAAGAATTCAAATCCGATGAAGAGGTGATTCAGAGCTTTTGCAAATACAAAA CGCTGCTGCGCAATGAAAATGTTCTGGAAACTGCCGAAGCACTGTTTAACGAACTGAATAGCATTGATCTGAC CCACATCTTTATCAGCCACAAAAAACTGGAAACCATTTCAAGCGCACTGTGTGATCATTGGGATACCCTGCGTA ATGCCCTGTATGAACGTCGTATTAGCGAACTGACCGGTAAAATTACCAAAAGCGCGAAAGAAAAAGTTCAGC GCAGTCTGAAACATGAGGATATTAATCTGCAAGAGATTATTAGCGCAGCCGGTAAAGAACTGTCAGAAGCAT TTAAACAGAAAACCAGCGAAATTCTGTCACATGCACATGCAGCACTGGATCAGCCGCTGCCGACCACCCTGAA AAAACAAGAAGAAAAAGAAATCCTGAAAAGCCAGCTGGATAGCCTGCTGGGTCTGTATCATCTGCTGGACTG GTTTGCAGTTGATGAAAGCAATGAAGTTGATCCGGAATTTAGCGCACGTCTGACCGGCATTAAACTGGAAAT GGAACCGAGCCTGAGCTTTTATAACAAAGCCCGTAATTATGCCACCAAAAAACCGTATAGCGTCGAAAAATTC AAACTGAACTTTCAGATGCCGACCCTGGCAAGCGGTTGGGATGTTAATAAAGAAAAAAACAACGGTGCCATC CTGTTCGTG AAAAATG G CCTGTATTATCTG G GTATTATG CCG AAACAG AAAG GTCGTTATAAAG CG CTG AG CT TTGAACCGACGGAAAAAACCAGTGAAGGTTTTGATAAAATGTACTACGACTATTTTCCGGATGCAGCCAAAAT GATTCCGAAATGTAGCACCCAGCTGAAAGCAGTTACCGCACATTTTCAGACCCATACCACCCCGATTCTGCTGA GCAATAACTTTATTGAACCGCTGGAAATCACCAAAGAGATCTACGATCTGAATAACCCGGAAAAAGAGCCGA AAAAATTCCAGACCGCATATGCAAAAAAAACCGGTGATCAGAAAGGTTATCGTGAAGCGCTGTGTAAATGGA TTGATTTCACCCGTGATTTTCTGAGCAAATACACCAAAACCACCAGTATCGATCTGAGCAGCCTGCGTCCGAGC AGCCAGTATAAAGATCTGGGCGAATATTATGCAGAACTGAATCCGCTGCTGTATCATATTAGCTTTCAGCGTA TTGCCGAGAAAGAAATCATGGACGCAGTTGAAACCGGTAAACTGTACCTGTTCCAGATCTACAATAAAGATTT TGCCAAAG G CCATCATG G CAAACCG AATCTG CATACCCTGTATTG G ACCG GTCTGTTTAG CCCTG AAAATCTG GCAAAAACCTCGATTAAACTGAATGGTCAGGCGGAACTGTTTTATCGTCCGAAAAGCCGTATGAAACGTATG GCACATCGTCTGGGTGAAAAAATGCTGAACAAAAAACTGAAAGACCAGAAAACCCCGATCCCGGATACACTG TATCAAGAACTGTATGATTATGTGAACCATCGTCTGAGCCATGATCTGAGTGATGAAGCACGTGCCCTGCTGC CGAATGTTATTACCAAAGAAGTTAGCCACGAGATCATTAAAGATCGTCGTTTTACCAGCGACAAATTCTTTTTT CATGTGCCGATTACCCTGAATTATCAGGCAGCAAATAGCCCGAGCAAATTTAACCAGCGTGTTAATGCATATC TGAAAGAACATCCAGAAACGCCGATTATTGGTATTGATCGTGGTGAACGTAACCTGATTTATATCACCGTTATT GATAGCACCGGCAAAATCCTGGAACAGCGTAGCCTGAATACCATTCAGCAGTTTGATTACCAGAAAAAACTG GATAATCGCGAGAAAGAACGTGTTGCAGCACGTCAGGCATGGTCAGTTGTTGGTACAATTAAAGACCTGAAA CAGGGTTATCTGAGCCAGGTTATTCATGAAATTGTGGATCTGATGATTCACTATCAGGCCGTTGTTGTGCTGG AAAACCTG AATTTTG G CTTTAAAAG CAAACGTACCG G CATTG CAG AAAAAG CAGTTTATCAG CAGTTCG AG AA AATGCTGATTGACAAACTGAATTGCCTGGTGCTGAAAGATTATCCGGCTGAAAAAGTTGGTGGTGTTCTGAAT CCGTATCAG CTG ACCG ATCAGTTTACCAG CTTTG CAAAAATG G G CACCCAG AG CG G ATTTCTGTTTTATGTTCC G G CACCGTATACG AG CAAAATTG ATCCG CTG ACCG GTTTTGTTGATCCGTTTGTTTG GAAAACCATCAAAAAC CATGAAAGCCGCAAACATTTTCTGGAAGGTTTCGATTTTCTGCATTACGACGTTAAAACGGGTGATTTCATCCT G CACTTTAAAATG AATCG CAATCTG AGTTTTCAG CGTGG CCTG CCTG GTTTTATG CCTG CATG G G ATATTGTGT TTGAGAAAAACGAAACACAGTTCGATGCAAAAGGCACCCCGTTTATTGCAGGTAAACGTATTGTTCCGGTGAT TGAAAATCATCGTTTCACCGGTCGTTATCGCGATCTGTATCCGGCAAATGAACTGATCGCACTGCTGGAAGAG AAAG GTATTGTTTTTCGTG ATG G CTCAAACATTCTG CCG AAACTG CTG G AAAATG ATG ATAG CCATG CAATTG ATACCATG GTTG CACTG ATTCGTAG CGTTCTG CAG ATG CGTAATAGCAATG CAG CAACCG GTG AAG ATTACAT TAATAGTCCGGTTCGTGATCTGAATGGTGTTTGTTTTGATAGCCGTTTTCAGAATCCGGAATGGCCGATGGAT 2024201449   05 Mar 2024 G CAG ATG CAAATG GTG CATATCATATTG CACTG AAAG G ACAG CTG CTG CTG AACCACCTG AAAG AAAG CAAA G ATCTG AAACTG CAAAACG G CATTAG CAATCAG G ATTG G CTG G CATATATCCAAG AACTG CGTAACG GTCGT AAACGTACCGCAGATGGTAGCGAATTTGAAAGCCCGAAAAAAAAGCGTAAGGTGGAAGGTGGTAGCGGTGG TTCAG GTG GTAGTG G CG GTAGTG GTG G CTCAG GG G GTTCTG GTG G CTCTG GTG GTAG CCTCG AG CACCACCA CCACCACCACTGA

[0117] SEQIDNO.16

[0118] ATG ACCCAGTTTG AAG GTTTCACCAATCTGTATCAG GTTAG CAAAACCCTG CGTTTTG AACT GATTCCGCAGGGTAAAACCCTGAAACATATTCAAGAACAGGGCTTCATCGAAGAGGATAAAGCACGTAACGA TCACTACAAAGAACTGAAACCGATTATCGACCGCATCTATAAAACCTATGCAGATCAGTGTCTGCAGCTGGTT CAGCTGGATTGGGAAAATCTGAGCGCAGCAATTGATAGTTATCGCAAAGAAAAAACCGAAGAAACCCGTAAT GCACTGATTGAAGAACAGGCAACCTATCGTAATGCCATCCATGATTATTTCATTGGTCGTACCGATAATCTGAC CG ATG CAATTAACAAACGTCACG CCG AAATCTATAAAG G CCTGTTTAAAG CCG AACTGTTTAATG G CAAAGTT CTGAAACAGCTGGGCACCGTTACCACCACCGAACATGAAAATGCACTGCTGCGTAGCTTTGATAAATTCACCA CCTATTTCAGCGGCTTTTATGAGAATCGCAAAAACGTGTTTAGCGCAGAAGATATTAGCACCGCAATTCCGCA TCGTATTGTGCAGGATAATTTCCCGAAATTCAAAGAGAACTGCCACATTTTTACCCGTCTGATTACCGCAGTTC CG AG CCTG CGTG AACATTTTG AAAACGTTAAAAAAG CCATCG G CATCTTTGTTAG CACCAG CATTG AAG AAGT TTTTAGCTTCCCGTTTTACAATCAGCTGCTGACCCAGACCCAGATTGATCTGTATAACCAACTGCTGGGTGGTA TTAGCCGTGAAGCAGGCACCGAAAAAATCAAAGGTCTGAATGAAGTGCTGAATCTGGCCATTCAGAAAAATG ATG AAACCG CACATATTATTG CAAG CCTG CCG CATCGTTTTATTCCG CTGTTCAAACAAATTCTG AG CG ATCGT AATACCCTGAGCTTTATTCTGGAAGAATTCAAATCCGATGAAGAGGTGATTCAGAGCTTTTGCAAATACAAAA CGCTGCTGCGCAATGAAAATGTTCTGGAAACTGCCGAAGCACTGTTTAACGAACTGAATAGCATTGATCTGAC CCACATCTTTATCAG CCACAAAAAACTGG AAACCATTTCAAG CG CACTGTGTG ATCATTG G G ATACCCTG CGTA ATGCCCTGTATGAACGTCGTATTAGCGAACTGACCGGTAAAATTACCAAAAGCGCGAAAGAAAAAGTTCAGC GCAGTCTGAAACATGAGGATATTAATCTGCAAGAGATTATTAGCGCAGCCGGTAAAGAACTGTCAGAAGCAT TTAAACAGAAAACCAGCGAAATTCTGTCACATGCACATGCAGCACTGGATCAGCCGCTGCCGACCACCCTGAA AAAACAAGAAGAAAAAGAAATCCTGAAAAGCCAGCTGGATAGCCTGCTGGGTCTGTATCATCTGCTGGACTG GTTTGCAGTTGATGAAAGCAATGAAGTTGATCCGGAATTTAGCGCACGTCTGACCGGCATTAAACTGGAAAT GGAACCGAGCCTGAGCTTTTATAACAAAGCCCGTAATTATGCCACCAAAAAACCGTATAGCGTCGAAAAATTC AAACTGAACTTTCAGATGCCGACCCTGGCAAGCGGTTGGGATGTTAATAAAGAAAAAAACAACGGTGCCATC CTGTTCGTG AAAAATG G CCTGTATTATCTG G GTATTATG CCG AAACAG AAAG GTCGTTATAAAG CG CTG AG CT TTGAACCGACGGAAAAAACCAGTGAAGGTTTTGATAAAATGTACTACGACTATTTTCCGGATGCAGCCAAAAT GATTCCGAAATGTAGCACCCAGCTGAAAGCAGTTACCGCACATTTTCAGACCCATACCACCCCGATTCTGCTGA GCAATAACTTTATTGAACCGCTGGAAATCACCAAAGAGATCTACGATCTGAATAACCCGGAAAAAGAGCCGA AAAAATTCCAGACCGCATATGCAAAAAAAACCGGTGATCAGAAAGGTTATCGTGAAGCGCTGTGTAAATGGA TTGATTTCACCCGTGATTTTCTGAGCAAATACACCAAAACCACCAGTATCGATCTGAGCAGCCTGCGTCCGAGC AGCCAGTATAAAGATCTGGGCGAATATTATGCAGAACTGAATCCGCTGCTGTATCATATTAGCTTTCAGCGTA TTGCCGAGAAAGAAATCATGGACGCAGTTGAAACCGGTAAACTGTACCTGTTCCAGATCTACAATAAAGATTT TGCCAAAG G CCATCATG G CAAACCG AATCTG CATACCCTGTATTG G ACCG GTCTGTTTAG CCCTG AAAATCTG GCAAAAACCTCGATTAAACTGAATGGTCAGGCGGAACTGTTTTATCGTCCGAAAAGCCGTATGAAACGTATG GCACATCGTCTGGGTGAAAAAATGCTGAACAAAAAACTGAAAGACCAGAAAACCCCGATCCCGGATACACTG TATCAAGAACTGTATGATTATGTGAACCATCGTCTGAGCCATGATCTGAGTGATGAAGCACGTGCCCTGCTGC CGAATGTTATTACCAAAGAAGTTAGCCACGAGATCATTAAAGATCGTCGTTTTACCAGCGACAAATTCTTTTTT CATGTG CCG ATTACCCTG AATTATCAG G CAG CAAATAG CCCG AG CAAATTTAACCAG CGTGTTAATGCATATC 2024201449   05 Mar 2024 TGAAAGAACATCCAGAAACGCCGATTATTGGTATTGATCGTGGTGAACGTAACCTGATTTATATCACCGTTATT GATAGCACCGGCAAAATCCTGGAACAGCGTAGCCTGAATACCATTCAGCAGTTTGATTACCAGAAAAAACTG GATAATCGCGAGAAAGAACGTGTTGCAGCACGTCAGGCATGGTCAGTTGTTGGTACAATTAAAGACCTGAAA CAG G GTTATCTG AG CCAG GTTATTCATG AAATTGTG G ATCTG ATG ATTCACTATCAG G CCGTTGTTGTG CTG G AAAACCTG AATTTTG G CTTTAAAAG CAAACGTACCG G CATTG CAG AAAAAG CAGTTTATCAG CAGTTCGAGAA AATGCTGATTGACAAACTGAATTGCCTGGTGCTGAAAGATTATCCGGCTGAAAAAGTTGGTGGTGTTCTGAAT CCGTATCAG CTG ACCG ATCAGTTTACCAG CTTTG CAAAAATG G G CACCCAG AG CG G ATTTCTGTTTTATGTTCC G G CACCGTATACG AG CAAAATTG ATCCG CTG ACCG GTTTTGTTGATCCGTTTGTTTG GAAAACCATCAAAAAC CATGAAAGCCGCAAACATTTTCTGGAAGGTTTCGATTTTCTGCATTACGACGTTAAAACGGGTGATTTCATCCT G CACTTTAAAATG AATCG CAATCTG AGTTTTCAG CGTGG CCTG CCTG GTTTTATG CCTG CATG G G ATATTGTGT TTG AG AAAAACG AAACACAGTTCG ATG CAAAAG G CACCCCGTTTATTG CAG GTAAACGTATTGTTCCG GTG AT TGAAAATCATCGTTTCACCGGTCGTTATCGCGATCTGTATCCGGCAAATGAACTGATCGCACTGCTGGAAGAG AAAGGTATTGTTTTTCGTGATGGCTCAAACATTCTGCCGAAACTGCTGGAAAATGATGATAGCCATGCAATTG ATACCATG GTTG CACTG ATTCGTAG CGTTCTG CAG ATG CGTAATAG CAATG CAG CAACCG GTG AAG ATTACAT TAATAGTCCGGTTCGTGATCTGAATGGTGTTTGTTTTGATAGCCGTTTTCAGAATCCGGAATGGCCGATGGAT G CAG ATG CAAATG GTG CATATCATATTG CACTG AAAG GACAG CTG CTG CTG AACCACCTG AAAG AAAG CAAA G ATCTG AAACTG CAAAACG G CATTAG CAATCAG G ATTG G CTG G CATATATCCAAG AACTG CGTAACG GTCGT AGCAGTGATGATGAAGCAACCGCAGATAGCCAGCATGCAGCACCGCCTAAAAAGAAACGTAAAGTTGGTGG TAGCGGCGGTAGTAAACGTACCGCAGATGGTAGCGAATTTGAAAGCCCGAAAAAAAAGCGTAAGGTGGAAG GTG GTAG CG GTG GTTCAG GTG GTAGTG G CG GTAGTG GTGG CTCAG G G G GTTCTG GTG G CTCTG GTG GTAGC CTCGAGCACCACCACCACCACCACTGA

[0119] SEQIDNO.17

[0120] ATG ACCCAGTTTG AAG GTTTCACCAATCTGTATCAG GTTAG CAAAACCCTG CGTTTTG AACT GATTCCGCAGGGTAAAACCCTGAAACATATTCAAGAACAGGGCTTCATCGAAGAGGATAAAGCACGTAACGA TCACTACAAAGAACTGAAACCGATTATCGACCGCATCTATAAAACCTATGCAGATCAGTGTCTGCAGCTGGTT CAGCTGGATTGGGAAAATCTGAGCGCAGCAATTGATAGTTATCGCAAAGAAAAAACCGAAGAAACCCGTAAT GCACTGATTGAAGAACAGGCAACCTATCGTAATGCCATCCATGATTATTTCATTGGTCGTACCGATAATCTGAC CG ATG CAATTAACAAACGTCACG CCG AAATCTATAAAG G CCTGTTTAAAG CCG AACTGTTTAATG G CAAAGTT CTGAAACAGCTGGGCACCGTTACCACCACCGAACATGAAAATGCACTGCTGCGTAGCTTTGATAAATTCACCA CCTATTTCAGCGGCTTTTATGAGAATCGCAAAAACGTGTTTAGCGCAGAAGATATTAGCACCGCAATTCCGCA TCGTATTGTGCAGGATAATTTCCCGAAATTCAAAGAGAACTGCCACATTTTTACCCGTCTGATTACCGCAGTTC CG AG CCTG CGTG AACATTTTG AAAACGTTAAAAAAG CCATCG G CATCTTTGTTAG CACCAG CATTG AAG AAGT TTTTAGCTTCCCGTTTTACAATCAGCTGCTGACCCAGACCCAGATTGATCTGTATAACCAACTGCTGGGTGGTA TTAGCCGTGAAGCAGGCACCGAAAAAATCAAAGGTCTGAATGAAGTGCTGAATCTGGCCATTCAGAAAAATG ATG AAACCG CACATATTATTG CAAG CCTG CCG CATCGTTTTATTCCG CTGTTCAAACAAATTCTG AG CG ATCGT AATACCCTGAGCTTTATTCTGGAAGAATTCAAATCCGATGAAGAGGTGATTCAGAGCTTTTGCAAATACAAAA CGCTGCTGCGCAATGAAAATGTTCTGGAAACTGCCGAAGCACTGTTTAACGAACTGAATAGCATTGATCTGAC CCACATCTTTATCAG CCACAAAAAACTGG AAACCATTTCAAG CG CACTGTGTG ATCATTG G G ATACCCTG CGTA ATGCCCTGTATGAACGTCGTATTAGCGAACTGACCGGTAAAATTACCAAAAGCGCGAAAGAAAAAGTTCAGC GCAGTCTGAAACATGAGGATATTAATCTGCAAGAGATTATTAGCGCAGCCGGTAAAGAACTGTCAGAAGCAT TTAAACAGAAAACCAGCGAAATTCTGTCACATGCACATGCAGCACTGGATCAGCCGCTGCCGACCACCCTGAA AAAACAAGAAGAAAAAGAAATCCTGAAAAGCCAGCTGGATAGCCTGCTGGGTCTGTATCATCTGCTGGACTG GTTTGCAGTTGATGAAAGCAATGAAGTTGATCCGGAATTTAGCGCACGTCTGACCGGCATTAAACTGGAAAT 2024201449   05 Mar 2024 GGAACCGAGCCTGAGCTTTTATAACAAAGCCCGTAATTATGCCACCAAAAAACCGTATAGCGTCGAAAAATTC AAACTGAACTTTCAGATGCCGACCCTGGCAAGCGGTTGGGATGTTAATAAAGAAAAAAACAACGGTGCCATC CTGTTCGTGAAAAATG G CCTGTATTATCTG G GTATTATG CCG AAACAG AAAG GTCGTTATAAAG CG CTG AG CT TTGAACCGACGGAAAAAACCAGTGAAGGTTTTGATAAAATGTACTACGACTATTTTCCGGATGCAGCCAAAAT GATTCCGAAATGTAGCACCCAGCTGAAAGCAGTTACCGCACATTTTCAGACCCATACCACCCCGATTCTGCTGA GCAATAACTTTATTGAACCGCTGGAAATCACCAAAGAGATCTACGATCTGAATAACCCGGAAAAAGAGCCGA AAAAATTCCAGACCGCATATGCAAAAAAAACCGGTGATCAGAAAGGTTATCGTGAAGCGCTGTGTAAATGGA TTGATTTCACCCGTGATTTTCTGAGCAAATACACCAAAACCACCAGTATCGATCTGAGCAGCCTGCGTCCGAGC AGCCAGTATAAAGATCTGGGCGAATATTATGCAGAACTGAATCCGCTGCTGTATCATATTAGCTTTCAGCGTA TTGCCGAGAAAGAAATCATGGACGCAGTTGAAACCGGTAAACTGTACCTGTTCCAGATCTACAATAAAGATTT TGCCAAAG G CCATCATG G CAAACCG AATCTG CATACCCTGTATTG G ACCG GTCTGTTTAG CCCTG AAAATCTG GCAAAAACCTCGATTAAACTGAATGGTCAGGCGGAACTGTTTTATCGTCCGAAAAGCCGTATGAAACGTATG GCACATCGTCTGGGTGAAAAAATGCTGAACAAAAAACTGAAAGACCAGAAAACCCCGATCCCGGATACACTG TATCAAGAACTGTATGATTATGTGAACCATCGTCTGAGCCATGATCTGAGTGATGAAGCACGTGCCCTGCTGC CGAATGTTATTACCAAAGAAGTTAGCCACGAGATCATTAAAGATCGTCGTTTTACCAGCGACAAATTCTTTTTT CATGTG CCG ATTACCCTG AATTATCAG G CAG CAAATAG CCCG AG CAAATTTAACCAG CGTGTTAATGCATATC TGAAAGAACATCCAGAAACGCCGATTATTGGTATTGATCGTGGTGAACGTAACCTGATTTATATCACCGTTATT GATAGCACCGGCAAAATCCTGGAACAGCGTAGCCTGAATACCATTCAGCAGTTTGATTACCAGAAAAAACTG GATAATCGCGAGAAAGAACGTGTTGCAGCACGTCAGGCATGGTCAGTTGTTGGTACAATTAAAGACCTGAAA CAG G GTTATCTG AG CCAG GTTATTCATG AAATTGTG G ATCTG ATG ATTCACTATCAG G CCGTTGTTGTG CTG G AAAACCTG AATTTTG G CTTTAAAAG CAAACGTACCG G CATTG CAG AAAAAG CAGTTTATCAG CAGTTCG AG AA AATGCTGATTGACAAACTGAATTGCCTGGTGCTGAAAGATTATCCGGCTGAAAAAGTTGGTGGTGTTCTGAAT CCGTATCAG CTG ACCG ATCAGTTTACCAG CTTTG CAAAAATG G G CACCCAG AG CG G ATTTCTGTTTTATGTTCC G G CACCGTATACG AG CAAAATTGATCCG CTG ACCG GTTTTGTTGATCCGTTTGTTTG GAAAACCATCAAAAAC CATGAAAGCCGCAAACATTTTCTGGAAGGTTTCGATTTTCTGCATTACGACGTTAAAACGGGTGATTTCATCCT G CACTTTAAAATG AATCG CAATCTG AGTTTTCAG CGTGG CCTG CCTG GTTTTATG CCTG CATG G G ATATTGTGT TTG AG AAAAACG AAACACAGTTCG ATG CAAAAG G CACCCCGTTTATTG CAG GTAAACGTATTGTTCCG GTG AT TGAAAATCATCGTTTCACCGGTCGTTATCGCGATCTGTATCCGGCAAATGAACTGATCGCACTGCTGGAAGAG AAAG GTATTGTTTTTCGTG ATG G CTCAAACATTCTG CCG AAACTG CTG G AAAATG ATG ATAG CCATG CAATTG ATACCATG GTTG CACTG ATTCGTAG CGTTCTG CAG ATG CGTAATAG CAATG CAG CAACCG GTG AAG ATTACAT TAATAGTCCGGTTCGTGATCTGAATGGTGTTTGTTTTGATAGCCGTTTTCAGAATCCGGAATGGCCGATGGAT G CAG ATG CAAATG GTG CATATCATATTG CACTG AAAG GACAG CTG CTG CTG AACCACCTG AAAG AAAG CAAA G ATCTG AAACTG CAAAACG G CATTAG CAATCAG G ATTG G CTG G CATATATCCAAG AACTG CGTAACG GTCGT AAACGTCCG G CAG CAACCAAAAAAG CAG GTCAG G CAAAAAAG AAAAAAG GTG GTAG CG G CG GTAGTAAAC GTACCG CAG ATG GTAG CGAATTTG AAAG CCCG AAAAAAAAG CGTAAG GTG G AAG GTG GTAG CG GTG GTTCA G GTG GTAGTG G CGGTAGTG GTG GCTCAG G G G GTTCTG GTG G CTCTG GTG GTAG CCTCG AG CACCACCACCA CCACCACTGA

[0121] The following amino acid sequences of preferred Cas 12a polypeptides are depicted below.

[0122] SEQIDNO.18

[0123] MGSSSSGLVPRGSHMASMTGGQQMGRDPGKPIPNPLLGLDSTAPKKKRKVGIHGVPAATQF EGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNDHYKELKPIIDRIYKTYADQCLQLVQLDWENLSAAIDSY 2024201449   05 Mar 2024 RKEKTEETRNALIEEQATYRNAIHDYFIGRTDNLTDAINKRHAEIYKGLFKAELFNGKVLKQLGTVTTTEHENALLRSF DKFTTYFSGFYENRKNVFSAEDISTAIPHRIVQDNFPKFKENCHIFTRLITAVPSLREHFENVKKAIGIFVSTSIEEVFSFP FYNQLLTQTQIDLYNQLLGGISREAGTEKIKGLNEVLNLAIQKNDETAHIIASLPHRFIPLFKQILSDRNTLSFILEEFKSD EEVIQSFCKYKTLLRNENVLETAEALFNELNSIDLTHIFISHKKLETISSALCDHWDTLRNALYERRISELTGKITKSAKEK VQRSLKHEDINLQEIISAAGKELSEAFKQKTSEILSHAHAALDQPLPTTLKKQEEKEILKSQLDSLLGLYHLLDWFAVDE SNEVDPEFSARLTGIKLEMEPSLSFYNKARNYATKKPYSVEKFKLNFQMPTLASGWDVNKEKNNGAILFVKNGLYYL GIMPKQKGRYKALSFEPTEKTSEGFDKMYYDYFPDAAKMIPKCSTQLKAVTAHFQTHTTPILLSNNFIEPLEITKEIYD LNNPEKEPKKFQTAYAKKTGDQKGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQYKDLGEYYAELNPLLYHISF QRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLYWTGLFSPENLAKTSIKLNGQAELFYRPKSRMKRMA HRLGEKMLNKKLKDQKTPIPDTLYQELYDYVNHRLSHDLSDEARALLPNVITKEVSHEIIKDRRFTSDKFFFHVPITLN YQAANSPSKFNQRVNAYLKEHPETPIIGIDRGERNLIYITVIDSTGKILEQRSLNTIQQFDYQKKLDNREKERVAARQA WSVVGTIKDLKQGYLSQVIHEIVDLMIHYQAVVVLENLNFGFKSKRTGIAEKAVYQQFEKMLIDKLNCLVLKDYPAE KVGGVLNPYQLTDQFTSFAKMGTQSGFLFYVPAPYTSKIDPLTGFVDPFVWKTIKNHESRKHFLEGFDFLHYDVKT GDFILHFKMNRNLSFQRGLPGFMPAWDIVFEKNETQFDAKGTPFIAGKRIVPVIENHRFTGRYRDLYPANELIALLE EKGIVFRDGSNILPKLLENDDSHAIDTMVALIRSVLQMRNSNAATGEDYINSPVRDLNGVCFDSRFQNPEWPMDA DANGAYHIALKGQLLLNHLKESKDLKLQNGISNQDWLAYIQELRNPKKKRKVKLAAALEHHHHHH

[0124] SEQIDNO.19

[0125] MGSSSSGLVPRGSHMASMTGGQQMGRDPAPKKKRKVGIHGVPAATQFEGFTNLYQVSKTLR FELIPQGKTLKHIQEQGFIEEDKARNDHYKELKPIIDRIYKTYADQCLQLVQLDWENLSAAIDSYRKEKTEETRNALIEE QATYRNAIHDYFIGRTDNLTDAINKRHAEIYKGLFKAELFNGKVLKQLGTVTTTEHENALLRSFDKFTTYFSGFYENR KNVFSAEDISTAIPHRIVQDNFPKFKENCHIFTRLITAVPSLREHFENVKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLY NQLLGGISREAGTEKIKGLNEVLNLAIQKNDETAHIIASLPHRFIPLFKQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLL RNENVLETAEALFNELNSIDLTHIFISHKKLETISSALCDHWDTLRNALYERRISELTGKITKSAKEKVQRSLKHEDINLQ EIISAAGKELSEAFKQKTSEILSHAHAALDQPLPTTLKKQEEKEILKSQLDSLLGLYHLLDWFAVDESNEVDPEFSARLT GIKLEMEPSLSFYNKARNYATKKPYSVEKFKLNFQMPTLASGWDVNKEKNNGAILFVKNGLYYLGIMPKQKGRYKA LSFEPTEKTSEGFDKMYYDYFPDAAKMIPKCSTQLKAVTAHFQTHTTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQ TAYAKKTGDQKGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQYKDLGEYYAELNPLLYHISFQRIAEKEIMDAV ETGKLYLFQIYNKDFAKGHHGKPNLHTLYWTGLFSPENLAKTSIKLNGQAELFYRPKSRMKRMAHRLGEKMLNKKL KDQKTPIPDTLYQELYDYVNHRLSHDLSDEARALLPNVITKEVSHEIIKDRRFTSDKFFFHVPITLNYQAANSPSKFNQ RVNAYLKEHPETPIIGIDRGERNLIYITVIDSTGKILEQRSLNTIQQFDYQKKLDNREKERVAARQAWSVVGTIKDLKQ GYLSQVIHEIVDLMIHYQAVVVLENLNFGFKSKRTGIAEKAVYQQFEKMLIDKLNCLVLKDYPAEKVGGVLNPYQLT DQFTSFAKMGTQSGFLFYVPAPYTSKIDPLTGFVDPFVWKTIKNHESRKHFLEGFDFLHYDVKTGDFILHFKMNRNL SFQRGLPGFMPAWDIVFEKNETQFDAKGTPFIAGKRIVPVIENHRFTGRYRDLYPANELIALLEEKGIVFRDGSNILP KLLENDDSHAIDTMVALIRSVLQMRNSNAATGEDYINSPVRDLNGVCFDSRFQNPEWPMDADANGAYHIALKG QLLLNHLKESKDLKLQNGISNQDWLAYIQELRNPKKKRKVKLAAALEHHHHHH

[0126] SEQIDNO.20

[0127] MPKKKRKVGIHGVPAATQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNDHYKEL KPIIDRIYKTYADQCLQLVQLDWENLSAAIDSYRKEKTEETRNALIEEQATYRNAIHDYFIGRTDNLTDAINKRHAEIY KGLFKAELFNGKVLKQLGTVTTTEHENALLRSFDKFTTYFSGFYENRKNVFSAEDISTAIPHRIVQDNFPKFKENCHIF TRLITAVPSLREHFENVKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLYNQLLGGISREAGTEKIKGLNEVLNLAIQKND ETAHIIASLPHRFIPLFKQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETAEALFNELNSIDLTHIFISHKKLETI 2024201449   05 Mar 2024 SSALCDHWDTLRNALYERRISELTGKITKSAKEKVQRSLKHEDINLQEIISAAGKELSEAFKQKTSEILSHAHAALDQPL PTTLKKQEEKEILKSQLDSLLGLYHLLDWFAVDESNEVDPEFSARLTGIKLEMEPSLSFYNKARNYATKKPYSVEKFKL NFQMPTLASGWDVNKEKNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTEKTSEGFDKMYYDYFPDAAKMIPKC STQLKAVTAHFQTHTTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKTGDQKGYREALCKWIDFTRDFLSKY TKTTSIDLSSLRPSSQYKDLGEYYAELNPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLYWT GLFSPENLAKTSIKLNGQAELFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPIPDTLYQELYDYVNHRLSHDLSDEA RALLPNVITKEVSHEIIKDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKEHPETPIIGIDRGERNLIYITVIDST GKILEQRSLNTIQQFDYQKKLDNREKERVAARQAWSVVGTIKDLKQGYLSQVIHEIVDLMIHYQAVVVLENLNFGF KSKRTGIAEKAVYQQFEKMLIDKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAKMGTQSGFLFYVPAPYTSKIDPL TGFVDPFVWKTIKNHESRKHFLEGFDFLHYDVKTGDFILHFKMNRNLSFQRGLPGFMPAWDIVFEKNETQFDAKG TPFIAGKRIVPVIENHRFTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDDSHAIDTMVALIRSVLQMRNSNA ATGEDYINSPVRDLNGVCFDSRFQNPEWPMDADANGAYHIALKGQLLLNHLKESKDLKLQNGISNQDWLAYIQEL RNPKKKRKVLEHHHHHH

[0128] SEQIDNO.21

[0129] MTQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNDHYKELKPIIDRIYKTYADQCL QLVQLDWENLSAAIDSYRKEKTEETRNALIEEQATYRNAIHDYFIGRTDNLTDAINKRHAEIYKGLFKAELFNGKVLK QLGTVTTTEHENALLRSFDKFTTYFSGFYENRKNVFSAEDISTAIPHRIVQDNFPKFKENCHIFTRLITAVPSLREHFEN VKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLYNQLLGGISREAGTEKIKGLNEVLNLAIQKNDETAHIIASLPHRFIPLF KQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETAEALFNELNSIDLTHIFISHKKLETISSALCDHWDTLRNA LYERRISELTGKITKSAKEKVQRSLKHEDINLQEIISAAGKELSEAFKQKTSEILSHAHAALDQPLPTTLKKQEEKEILKSQ LDSLLGLYHLLDWFAVDESNEVDPEFSARLTGIKLEMEPSLSFYNKARNYATKKPYSVEKFKLNFQMPTLASGWDV NKEKNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTEKTSEGFDKMYYDYFPDAAKMIPKCSTQLKAVTAHFQTH TTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKTGDQKGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQ YKDLGEYYAELNPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLYWTGLFSPENLAKTSIKLN GQAELFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPIPDTLYQELYDYVNHRLSHDLSDEARALLPNVITKEVSHEII KDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKEHPETPIIGIDRGERNLIYITVIDSTGKILEQRSLNTIQQFD YQKKLDNREKERVAARQAWSVVGTIKDLKQGYLSQVIHEIVDLMIHYQAVVVLENLNFGFKSKRTGIAEKAVYQQF EKMLIDKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAKMGTQSGFLFYVPAPYTSKIDPLTGFVDPFVWKTIKNHE SRKHFLEGFDFLHYDVKTGDFILHFKMNRNLSFQRGLPGFMPAWDIVFEKNETQFDAKGTPFIAGKRIVPVIENHR FTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDDSHAIDTMVALIRSVLQMRNSNAATGEDYINSPVRDLNG VCFDSRFQNPEWPMDADANGAYHIALKGQLLLNHLKESKDLKLQNGISNQDWLAYIQELRNPKKKRKVLEHHHH HH

[0130] SEQIDNO.22

[0131] MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRDPTQFEGFTNLYQVSKTLRFELIPQGKTL KHIQEQGFIEEDKARNDHYKELKPIIDRIYKTYADQCLQLVQLDWENLSAAIDSYRKEKTEETRNALIEEQATYRNAIH DYFIGRTDNLTDAINKRHAEIYKGLFKAELFNGKVLKQLGTVTTTEHENALLRSFDKFTTYFSGFYENRKNVFSAEDIS TAIPHRIVQDNFPKFKENCHIFTRLITAVPSLREHFENVKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLYNQLLGGISR EAGTEKIKGLNEVLNLAIQKNDETAHIIASLPHRFIPLFKQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETA EALFNELNSIDLTHIFISHKKLETISSALCDHWDTLRNALYERRISELTGKITKSAKEKVQRSLKHEDINLQEIISAAGKEL SEAFKQKTSEILSHAHAALDQPLPmKKQEEKEILKSQLDSLLGLYHLLDWFAVDESNEVDPEFSARLTGIKLEMEPS LSFYNKARNYATKKPYSVEKFKLNFQMPTLASGWDVNKEKNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTEKT 2024201449   05 Mar 2024 SEGFDKMYYDYFPDAAKMIPKCSTQLKAVTAHFQTHTTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKTG DQKGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQYKDLGEYYAELNPLLYHISFQRIAEKEIMDAVETGKLYLFQ IYNKDFAKGHHGKPNLHTLYWTGLFSPENLAKTSIKLNGQAELFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPIP DTLYQELYDYVNHRLSHDLSDEARALLPNVITKEVSHEIIKDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKE HPETPIIGIDRGERNLIYITVIDSTGKILEQRSLNTIQQFDYQKKLDNREKERVAARQAWSVVGTIKDLKQGYLSQVIH EIVDLMIHYQAVVVLENLNFGFKSKRTGIAEKAVYQQFEKMLIDKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAK MGTQSGFLFYVPAPYTSKIDPLTGFVDPFVWKTIKNHESRKHFLEGFDFLHYDVKTGDFILHFKMNRNLSFQRGLP GFMPAWDIVFEKNETQFDAKGTPFIAGKRIVPVIENHRFTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDD SHAIDTMVALIRSVLQMRNSNAATGEDYINSPVRDLNGVCFDSRFQNPEWPMDADANGAYHIALKGQLLLNHLK ESKDLKLQNGISNQDWLAYIQELRNGRSSDDEATADSQHAAPPKKKRKVGGSGGSGGSGGSGGSGGSGGSGGSL EHHHHHH

[0132] SEQIDNO.23

[0133] MTQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNDHYKELKPIIDRIYKTYADQCL QLVQLDWENLSAAIDSYRKEKTEETRNALIEEQATYRNAIHDYFIGRTDNLTDAINKRHAEIYKGLFKAELFNGKVLK QLGTVTTTEHENALLRSFDKFTTYFSGFYENRKNVFSAEDISTAIPHRIVQDNFPKFKENCHIFTRLITAVPSLREHFEN VKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLYNQLLGGISREAGTEKIKGLNEVLNLAIQKNDETAHIIASLPHRFIPLF KQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETAEALFNELNSIDLTHIFISHKKLETISSALCDHWDTLRNA LYERRISELTGKITKSAKEKVQRSLKHEDINLQEIISAAGKELSEAFKQKTSEILSHAHAALDQPLPTTLKKQEEKEILKSQ LDSLLGLYHLLDWFAVDESNEVDPEFSARLTGIKLEMEPSLSFYNKARNYATKKPYSVEKFKLNFQMPTLASGWDV NKEKNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTEKTSEGFDKMYYDYFPDAAKMIPKCSTQLKAVTAHFQTH TTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKTGDQKGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQ YKDLGEYYAELNPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLYWTGLFSPENLAKTSIKLN GQAELFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPIPDTLYQELYDYVNHRLSHDLSDEARALLPNVITKEVSHEII KDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKEHPETPIIGIDRGERNLIYITVIDSTGKILEQRSLNTIQQFD YQKKLDNREKERVAARQAWSVVGTIKDLKQGYLSQVIHEIVDLMIHYQAVVVLENLNFGFKSKRTGIAEKAVYQQF EKMLIDKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAKMGTQSGFLFYVPAPYTSKIDPLTGFVDPFVWKTIKNHE SRKHFLEGFDFLHYDVKTGDFILHFKMNRNLSFQRGLPGFMPAWDIVFEKNETQFDAKGTPFIAGKRIVPVIENHR FTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDDSHAIDTMVALIRSVLQMRNSNAATGEDYINSPVRDLNG VCFDSRFQNPEWPMDADANGAYHIALKGQLLLNHLKESKDLKLQNGISNQDWLAYIQELRNGRSSDDEATADSQ HAAPPKKKRKVGGSGGSGGSGGSGGSGGSGGSGGSLEHHHHHH

[0134] SEQIDNO.24

[0135] MGSSSSGLVPRGSHMASMTGGQQMGRDPTQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQG FIEEDKARNDHYKELKPIIDRIYKTYADQCLQLVQLDWENLSAAIDSYRKEKTEETRNALIEEQATYRNAIHDYFIGRT DNLTDAINKRHAEIYKGLFKAELFNGKVLKQLGTVTTTEHENALLRSFDKFTTYFSGFYENRKNVFSAEDISTAIPHRI VQDNFPKFKENCHIFTRLITAVPSLREHFENVKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLYNQLLGGISREAGTEKI KGLNEVLNLAIQKNDETAHIIASLPHRFIPLFKQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETAEALFNEL NSIDLTHIFISHKKLETISSALCDHWDTLRNALYERRISELTGKITKSAKEKVQRSLKHEDINLQEIISAAGKELSEAFKQK TSEILSHAHAALDQPLPTTLKKQEEKEILKSQLDSLLGLYHLLDWFAVDESNEVDPEFSARLTGIKLEMEPSLSFYNKA RNYATKKPYSVEKFKLNFQMPTLASGWDVNKEKNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTEKTSEGFDK MYYDYFPDAAKMIPKCSTQLKAVTAHFQTHTTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKTGDQKGYR EALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQYKDLGEYYAELNPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFA 2024201449   05 Mar 2024 KGHHGKPNLHTLYWTGLFSPENLAKTSIKLNGQAELFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPIPDTLYQELY DYVNHRLSHDLSDEARALLPNVITKEVSHEIIKDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKEHPETPIIGI DRGERNLIYITVIDSTGKILEQRSLNTIQQFDYQKKLDNREKERVAARQAWSVVGTIKDLKQGYLSQVIHEIVDLMIH YQAVVVLENLNFGFKSKRTGIAEKAVYQQFEKMLIDKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAKMGTQSGF LFYVPAPYTSKIDPLTGFVDPFVWKTIKNHESRKHFLEGFDFLHYDVKTGDFILHFKMNRNLSFQRGLPGFMPAWD IVFEKNETQFDAKGTPFIAGKRIVPVIENHRFTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDDSHAIDTMV ALIRSVLQMRNSNAATGEDYINSPVRDLNGVCFDSRFQNPEWPMDADANGAYHIALKGQLLLNHLKESKDLKLQ NGISNQDWLAYIQELRNGRSSDDEATADSQHAAPPKKKRKVGGSGGSGGSGGSGGSGGSGGSGGSLEHHHHHH

[0136] SEQIDNO.25

[0137] MPPPKRPRLDGIHGVPAATQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNDHYK ELKPIIDRIYKTYADQCLQLVQLDWENLSAAIDSYRKEKTEETRNALIEEQATYRNAIHDYFIGRTDNLTDAINKRHAEI YKGLFKAELFNGKVLKQLGTVTTTEHENALLRSFDKFTTYFSGFYENRKNVFSAEDISTAIPHRIVQDNFPKFKENCHI FTRLITAVPSLREHFENVKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLYNQLLGGISREAGTEKIKGLNEVLNLAIQKN DETAHIIASLPHRFIPLFKQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETAEALFNELNSIDLTHIFISHKKLE TISSALCDHWDTLRNALYERRISELTGKITKSAKEKVQRSLKHEDINLQEIISAAGKELSEAFKQKTSEILSHAHAALDQ PLPTTLKKQEEKEILKSQLDSLLGLYHLLDWFAVDESNEVDPEFSARLTGIKLEMEPSLSFYNKARNYATKKPYSVEKF KLNFQMPTLASGWDVNKEKNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTEKTSEGFDKMYYDYFPDAAKMIP KCSTQLKAVTAHFQTHTTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKTGDQKGYREALCKWIDFTRDFLS KYTKTTSIDLSSLRPSSQYKDLGEYYAELNPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLY WTGLFSPENLAKTSIKLNGQAELFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPIPDTLYQELYDYVNHRLSHDLSD EARALLPNVITKEVSHEIIKDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKEHPETPIIGIDRGERNLIYITVID STGKILEQRSLNTIQQFDYQKKLDNREKERVAARQAWSVVGTIKDLKQGYLSQVIHEIVDLMIHYQAVVVLENLNF GFKSKRTGIAEKAVYQQFEKMLIDKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAKMGTQSGFLFYVPAPYTSKID PLTGFVDPFVWKTIKNHESRKHFLEGFDFLHYDVKTGDFILHFKMNRNLSFQRGLPGFMPAWDIVFEKNETQFDA KGTPFIAGKRIVPVIENHRFTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDDSHAIDTMVALIRSVLQMRNS NAATGEDYINSPVRDLNGVCFDSRFQNPEWPMDADANGAYHIALKGQLLLNHLKESKDLKLQNGISNQDWLAYI QELRNGRSSDDEATADSQHAAPPKKKRKVGGSGGSGGSGGSGGSGGSGGSGGSLEHHHHHH

[0138] SEQIDNO.26

[0139] MSSDDEATADSQHAAPPKKKRKVGIHGVPAATQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQ GFIEEDKARNDHYKELKPIIDRIYKTYADQCLQLVQLDWENLSAAIDSYRKEKTEETRNALIEEQATYRNAIHDYFIGR TDNLTDAINKRHAEIYKGLFKAELFNGKVLKQLGTVTTTEHENALLRSFDKFTTYFSGFYENRKNVFSAEDISTAIPHRI VQDNFPKFKENCHIFTRLITAVPSLREHFENVKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLYNQLLGGISREAGTEKI KGLNEVLNLAIQKNDETAHIIASLPHRFIPLFKQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETAEALFNEL NSIDLTHIFISHKKLETISSALCDHWDTLRNALYERRISELTGKITKSAKEKVQRSLKHEDINLQEIISAAGKELSEAFKQK TSEILSHAHAALDQPLPTTLKKQEEKEILKSQLDSLLGLYHLLDWFAVDESNEVDPEFSARLTGIKLEMEPSLSFYNKA RNYATKKPYSVEKFKLNFQMPTLASGWDVNKEKNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTEKTSEGFDK MYYDYFPDAAKMIPKCSTQLKAVTAHFQTHTTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKTGDQKGYR EALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQYKDLGEYYAELNPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFA KGHHGKPNLHTLYWTGLFSPENLAKTSIKLNGQAELFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPIPDTLYQELY DYVNHRLSHDLSDEARALLPNVITKEVSHEIIKDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKEHPETPIIGI DRGERNLIYITVIDSTGKILEQRSLNTIQQFDYQKKLDNREKERVAARQAWSVVGTIKDLKQGYLSQVIHEIVDLMIH 2024201449   05 Mar 2024 YQAVVVLENLNFGFKSKRTGIAEKAVYQQFEKMLIDKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAKMGTQSGF LFYVPAPYTSKIDPLTGFVDPFVWKTIKNHESRKHFLEGFDFLHYDVKTGDFILHFKMNRNLSFQRGLPGFMPAWD IVFEKNETQFDAKGTPFIAGKRIVPVIENHRFTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDDSHAIDTMV ALIRSVLQMRNSNAATGEDYINSPVRDLNGVCFDSRFQNPEWPMDADANGAYHIALKGQLLLNHLKESKDLKLQ NGISNQDWLAYIQELRNGRSSDDEATADSQHAAPPKKKRKVGGSGGSGGSGGSGGSGGSGGSGGSLEHHHHHH

[0140] SEQIDNO.27

[0141] MTQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNDHYKELKPIIDRIYKTYADQCL QLVQLDWENLSAAIDSYRKEKTEETRNALIEEQATYRNAIHDYFIGRTDNLTDAINKRHAEIYKGLFKAELFNGKVLK QLGTVTTTEHENALLRSFDKFTTYFSGFYENRKNVFSAEDISTAIPHRIVQDNFPKFKENCHIFTRLITAVPSLREHFEN VKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLYNQLLGGISREAGTEKIKGLNEVLNLAIQKNDETAHIIASLPHRFIPLF KQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETAEALFNELNSIDLTHIFISHKKLETISSALCDHWDTLRNA LYERRISELTGKITKSAKEKVQRSLKHEDINLQEIISAAGKELSEAFKQKTSEILSHAHAALDQPLPTTLKKQEEKEILKSQ LDSLLGLYHLLDWFAVDESNEVDPEFSARLTGIKLEMEPSLSFYNKARNYATKKPYSVEKFKLNFQMPTLASGWDV NKEKNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTEKTSEGFDKMYYDYFPDAAKMIPKCSTQLKAVTAHFQTH TTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKTGDQKGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQ YKDLGEYYAELNPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLYWTGLFSPENLAKTSIKLN GQAELFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPIPDTLYQELYDYVNHRLSHDLSDEARALLPNVITKEVSHEII KDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKEHPETPIIGIDRGERNLIYITVIDSTGKILEQRSLNTIQQFD YQKKLDNREKERVAARQAWSVVGTIKDLKQGYLSQVIHEIVDLMIHYQAVVVLENLNFGFKSKRTGIAEKAVYQQF EKMLIDKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAKMGTQSGFLFYVPAPYTSKIDPLTGFVDPFVWKTIKNHE SRKHFLEGFDFLHYDVKTGDFILHFKMNRNLSFQRGLPGFMPAWDIVFEKNETQFDAKGTPFIAGKRIVPVIENHR FTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDDSHAIDTMVALIRSVLQMRNSNAATGEDYINSPVRDLNG VCFDSRFQNPEWPMDADANGAYHIALKGQLLLNHLKESKDLKLQNGISNQDWLAYIQELRNGRKRPAATKKAGQ AKKKKGGSGGSGGSGGSGGSGGSGGSGGSLEHHHHHH

[0142] SEQIDNO.28

[0143] MTQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNDHYKELKPIIDRIYKTYADQCL QLVQLDWENLSAAIDSYRKEKTEETRNALIEEQATYRNAIHDYFIGRTDNLTDAINKRHAEIYKGLFKAELFNGKVLK QLGTVTTTEHENALLRSFDKFTTYFSGFYENRKNVFSAEDISTAIPHRIVQDNFPKFKENCHIFTRLITAVPSLREHFEN VKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLYNQLLGGISREAGTEKIKGLNEVLNLAIQKNDETAHIIASLPHRFIPLF KQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETAEALFNELNSIDLTHIFISHKKLETISSALCDHWDTLRNA LYERRISELTGKITKSAKEKVQRSLKHEDINLQEIISAAGKELSEAFKQKTSEILSHAHAALDQPLPTTLKKQEEKEILKSQ LDSLLGLYHLLDWFAVDESNEVDPEFSARLTGIKLEMEPSLSFYNKARNYATKKPYSVEKFKLNFQMPTLASGWDV NKEKNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTEKTSEGFDKMYYDYFPDAAKMIPKCSTQLKAVTAHFQTH TTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKTGDQKGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQ YKDLGEYYAELNPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLYWTGLFSPENLAKTSIKLN GQAELFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPIPDTLYQELYDYVNHRLSHDLSDEARALLPNVITKEVSHEII KDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKEHPETPIIGIDRGERNLIYITVIDSTGKILEQRSLNTIQQFD YQKKLDNREKERVAARQAWSVVGTIKDLKQGYLSQVIHEIVDLMIHYQAVVVLENLNFGFKSKRTGIAEKAVYQQF EKMLIDKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAKMGTQSGFLFYVPAPYTSKIDPLTGFVDPFVWKTIKNHE SRKHFLEGFDFLHYDVKTGDFILHFKMNRNLSFQRGLPGFMPAWDIVFEKNETQFDAKGTPFIAGKRIVPVIENHR FTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDDSHAIDTMVALIRSVLQMRNSNAATGEDYINSPVRDLNG 2024201449   05 Mar 2024 VCFDSRFQNPEWPMDADANGAYHIALKGQLLLNHLKESKDLKLQNGISNQDWLAYIQELRNGRKRTADGSEFES PKKKRKVEGGSGGSGGSGGSGGSGGSGGSGGSLEHHHHHH

[0144] SEQIDNO.29

[0145] MTQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNDHYKELKPIIDRIYKTYADQCL QLVQLDWENLSAAIDSYRKEKTEETRNALIEEQATYRNAIHDYFIGRTDNLTDAINKRHAEIYKGLFKAELFNGKVLK QLGTVTTTEHENALLRSFDKFTTYFSGFYENRKNVFSAEDISTAIPHRIVQDNFPKFKENCHIFTRLITAVPSLREHFEN VKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLYNQLLGGISREAGTEKIKGLNEVLNLAIQKNDETAHIIASLPHRFIPLF KQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETAEALFNELNSIDLTHIFISHKKLETISSALCDHWDTLRNA LYERRISELTGKITKSAKEKVQRSLKHEDINLQEIISAAGKELSEAFKQKTSEILSHAHAALDQPLPTTLKKQEEKEILKSQ LDSLLGLYHLLDWFAVDESNEVDPEFSARLTGIKLEMEPSLSFYNKARNYATKKPYSVEKFKLNFQMPTLASGWDV NKEKNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTEKTSEGFDKMYYDYFPDAAKMIPKCSTQLKAVTAHFQTH TTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKTGDQKGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQ YKDLGEYYAELNPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLYWTGLFSPENLAKTSIKLN GQAELFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPIPDTLYQELYDYVNHRLSHDLSDEARALLPNVITKEVSHEII KDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKEHPETPIIGIDRGERNLIYITVIDSTGKILEQRSLNTIQQFD YQKKLDNREKERVAARQAWSVVGTIKDLKQGYLSQVIHEIVDLMIHYQAVVVLENLNFGFKSKRTGIAEKAVYQQF EKMLIDKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAKMGTQSGFLFYVPAPYTSKIDPLTGFVDPFVWKTIKNHE SRKHFLEGFDFLHYDVKTGDFILHFKMNRNLSFQRGLPGFMPAWDIVFEKNETQFDAKGTPFIAGKRIVPVIENHR FTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDDSHAIDTMVALIRSVLQMRNSNAATGEDYINSPVRDLNG VCFDSRFQNPEWPMDADANGAYHIALKGQLLLNHLKESKDLKLQNGISNQDWLAYIQELRNGRSSDDEATADSQ HAAPPKKKRKVGGSGGSKRTADGSEFESPKKKRKVEGGSGGSGGSGGSGGSGGSGGSGGSLEHHHHHH

[0146] SEQIDNO.30

[0147] MTQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNDHYKELKPIIDRIYKTYADQCL QLVQLDWENLSAAIDSYRKEKTEETRNALIEEQATYRNAIHDYFIGRTDNLTDAINKRHAEIYKGLFKAELFNGKVLK QLGTVTTTEHENALLRSFDKFTTYFSGFYENRKNVFSAEDISTAIPHRIVQDNFPKFKENCHIFTRLITAVPSLREHFEN VKKAIGIFVSTSIEEVFSFPFYNQLLTQTQIDLYNQLLGGISREAGTEKIKGLNEVLNLAIQKNDETAHIIASLPHRFIPLF KQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETAEALFNELNSIDLTHIFISHKKLETISSALCDHWDTLRNA LYERRISELTGKITKSAKEKVQRSLKHEDINLQEIISAAGKELSEAFKQKTSEILSHAHAALDQPLPTTLKKQEEKEILKSQ LDSLLGLYHLLDWFAVDESNEVDPEFSARLTGIKLEMEPSLSFYNKARNYATKKPYSVEKFKLNFQMPTLASGWDV NKEKNNGAILFVKNGLYYLGIMPKQKGRYKALSFEPTEKTSEGFDKMYYDYFPDAAKMIPKCSTQLKAVTAHFQTH TTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKTGDQKGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQ YKDLGEYYAELNPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLYWTGLFSPENLAKTSIKLN GQAELFYRPKSRMKRMAHRLGEKMLNKKLKDQKTPIPDTLYQELYDYVNHRLSHDLSDEARALLPNVITKEVSHEII KDRRFTSDKFFFHVPITLNYQAANSPSKFNQRVNAYLKEHPETPIIGIDRGERNLIYITVIDSTGKILEQRSLNTIQQFD YQKKLDNREKERVAARQAWSVVGTIKDLKQGYLSQVIHEIVDLMIHYQAVVVLENLNFGFKSKRTGIAEKAVYQQF EKMLIDKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAKMGTQSGFLFYVPAPYTSKIDPLTGFVDPFVWKTIKNHE SRKHFLEGFDFLHYDVKTGDFILHFKMNRNLSFQRGLPGFMPAWDIVFEKNETQFDAKGTPFIAGKRIVPVIENHR FTGRYRDLYPANELIALLEEKGIVFRDGSNILPKLLENDDSHAIDTMVALIRSVLQMRNSNAATGEDYINSPVRDLNG VCFDSRFQNPEWPMDADANGAYHIALKGQLLLNHLKESKDLKLQNGISNQDWLAYIQELRNGRKRPAATKKAGQ AKKKKGGSGGSKRTADGSEFESPKKKRKVEGGSGGSGGSGGSGGSGGSGGSGGSLEHHHHHH 2024201449   05 Mar 2024 Example 2. Novel Cpfl mutants enhance the DNA cleavage activity at TTTT PAM site in the bacterial-based activity assay.

[0148] The following Example demonstrates the enhanced activity of the invention at both TTTT and TTTC PAM sites in a bacterial-based activity assay (FIG. 2). The screening strains harboring the toxin plasmid were transformed with WT, M537R or F870L AsCpfl expression plasmid. After recovery and IPTG induction, cells were plated on LB-Chloramphenicol media with or without arabinose. The degree of cell survival under the arabinose selection compared to the transformation input control (without arabinose) is indicative of the cleavage activity of Cpfl variants at the HPRT-38346 protospacer on the toxin plasmid, in the context of TTTT or TTTC PAM.

[0149] For WT-Cpfl, the survival rate of transformed E.coli at TTTC is significantly higher than the TTTT PAM, which is in good agreement with the prior knowledge that the TTTT is a low activity PAM site [6]. In contrast, both M537R and F870L increased the survival rate at TTTT PAM, indicating these mutants broadened the PAM compatibility of AsCpfl at this alternative PAM site. More importantly, the survival rate of both mutants at the canonical TTTC PAM is even higher than the WT-Cpfl, suggesting these mutants generally enhanced the performance of AsCpfl protein at other TTTV sites as well. Given these positive results, individual AsCpfl variant and the double mutant (M537R / F870L) were expressed and purified to determine their intrinsic cleavage activities in vitro. Example 3. Novel Cpfl mutants enhances the intrinsic DNA cleavage activity at TTTT PAM sites in vitro

[0150] The intrinsic DNA cleavage activities of AsCpfl variants (M537R, F870L and M537R / F870L) were compared to the wild type protein using in vitro cleavage assay. Briefly, the Cpfl-crRNA ribonucleoprotein (RNP) complex was first assembled by incubating the purified proteins (FIG. 3A) with HPRT-38346 crRNA in IX cleavage buffer (20 mM HEPES, pH 7.5, 150 mM KC1, 5 mM MgCl2, 10% Glycerol, and 1 mM DTT) for 15 minutes at 37 °C. The cleavage reactions were initiated by titrating RNP complex (8-500 nM) in 10 nM dsDNA substrate containing the HPRT-38346 protospacer, in the context of TTTC or TTTT PAM. Cleavage reactions at various time points were sampled and quenched by 50 mM EDTA. After removing the AsCpfl protein by Proteanise K treatment (56°C, 30 minutes), reactions were resolved using capillary electrophoresis (Fragment Analyzer, 2024201449   05 Mar 2024 AATI). The relative concentration of cleavage products and uncleaved dsDNA were quantified to calculate the percentage of DNA cleavage.

[0151] The intrinsic DNA cleavage activities of WT and Cpfl variants at the TTTT and TTTC PAM sites were compared in FIG. 3B. Only a single RNP concentration (31 nM) at 20 seconds time-point was shown for simplicity. As expected, the single-nucleotide change of PAM sequence from TTTC to TTTT reduced the cleavage activity of WT-Cpfl from -95% to -40%. Consistent with the observations in the bacterial-based activity assay, both mutants significantly increased the DNA cleavage at TTTT PAM, while maintaining high activity at TTTC PAM (FIG. 3B). The double-mutant (M537R / F870L) has similar activities to the M537R in this assay. However, it is worth to note that this is likely due to the limited resolution of this particular assay, to resolve further differences among those high-activity variants. Overall, these results demonstrated that the reported mutations improved the activity of Cpfl by enhancing the intrinsic DNA cleavage. Therefore, we anticipate that the observed benefits of these mutants will be broadly applicable and independent of the delivery methods and / or cellular contexts of the specific experiment. Example 4. Novel mutants broadly enhance the targeting efficiency of TTTN PAM sites in human cell line.

[0152] The following Example demonstrates the ability of the invention to increase the efficiency of gene editing at TTTN PAM sites when the Cpfl-crRNA complex is delivered into cells as an RNP.

[0153] CRISPR / Cpfl cellular editing experiments were performed by first forming 4 mM RNP complex with purified Cpfl protein and the Alt-R™ crRNAs in Opti-MEM for 5 min at 25 °C. The targeted protospacers and PAM sequences in CTNNB1 loci are shown in Table 2. RNP complexes were then transfected into HEK293 cells by Lonza nucleofection. Experiments were performed in biological triplicate. After 48 hr at 37° C with 5% CO2, adherent cells were washed with 0.1 ml PBS and lysed with 0.05 ml QuickExtract™ DNA extraction solution. Cell lysates were incubated at 65° C for 15 min followed by heatinactivation at 98° C for 3 min. Crude DNA samples were then diluted 3-fold with 0.1 ml ddH2O and used as PCR templates. PCR primers are indicated in Table 2. PCR was used to amplify 1 kb fragments of the CTNNB1 loci using the KAPA HiFi DNA Polymerase and the following cycling parameters: 955 00, (98° 20, 64° 15, 72°30) repeated 29 times, 72 2 00. 2024201449   05 Mar 2024 Heteroduplexes were formed using the following cycling parameters: 9510 00 cooled to 85 over 1 min, 85 1 00 cooled to 75 over 1 min, 751 00 cooled to 65 over 1 min, 651 00 cooled to 55 over 1 min, 55 1 00 cooled to 45 over 1 min, 451 00 cooled to 35 over 1 min, 35 1 00 cooled to 25 over 1 min, 251 00. Heteroduplexes were cleaved by the addition of 2U T7 Endonuclease I (New England Biolabs) for 1 hr at 37 C, and cut products were analyzed by capillary electrophoresis (Fragment Analyzer, Advanced Analytical).

[0154] Table 2. Sequence of DNA target sites and primer used for PCR amplification (SEQ ID NOs.: 31-58). Name Sequence (5’-3’) SEQ ID NO.: HPRT38346 TTTT PAM TTTTACATAAAACTCTTTTAGGTTA SEQ ID NO. : : 31 HPRT38346 TTTC PAM TTTCACATAAAACTCTTTTAGGTTA SEQ ID NO. : : 32 CTNNB1 111-S TTTTCCCCTCCCTGGCTTTTATTAT SEQ ID NO. : : 33 CTNNB1 112-S TTTCCCCTCCCTGGCTTTTATTATT SEQ ID NO. : : 34 CTNNB1 127-S TTTTATTATTACAACTCTGTGCTTT SEQ ID NO. : : 35 CTNNB1 128-S TTTATTATTACAACTCTGTGCTTTT SEQ ID NO. : : 36 CTNNB1 149-S TTTTTCATCACCATCCTGAATATCT SEQ ID NO. : : 37 CTNNB1 150-S TTTT CAT CAC CAT C C T GAAT AT C TA SEQ ID NO. : : 38 CTNNB1 151-S T T T CAT CAC CAT C C T GAAT AT C TAT SEQ ID NO. : : 39 CTNNB1 184-S T T TAT AC TAT T AAT AAAAAGACAT T SEQ ID NO. : : 40 CTNNB1 193-AS T T TAT TAATAGTATAAATAT TAAT T SEQ ID NO. : : 41 CTNNB1 194-AS T T T TAT TAATAGTATAAATAT TAAT SEQ ID NO. : : 42 CTNNB1 195-AS TTTT TAT TAATAGTATAAATAT TAA SEQ ID NO. : : 43 CTNNB1 207-S TTTTTGGTAAGGAGGAGTTTTCACT SEQ ID NO. : : 44 CTNNB1 208-S TTTTGGTAAGGAGGAGTTTTCACTG SEQ ID NO. : : 45 CTNNB1 209-S TTTGGTAAGGAGGAGTTTTCACTGA SEQ ID NO. : : 46 CTNNB1 224-S TTTT CACT GAAGT T CAGCAGT GAT G SEQ ID NO. : : 47 CTNNB1 225-S T T T CACT GAAGT T CAGCAGT GAT GG SEQ ID NO. : : 48 CTNNB1 291-S T T T CAC T AAC C T G G T AAAAGAG GAT SEQ ID NO. : : 49 CTNNB1 301-AS T T TACCAGGT TAGT GAAACGCAGAC SEQ ID NO. : : 50 CTNNB1 302-AS T T T TACCAGGT TAGT GAAACGCAGA SEQ ID NO. : : 51 CTNNB1 321-S TTTTTTTTGTGGGTGTAATAGTGAC SEQ ID NO. : : 52 CTNNB1 322-S TTTTTTTGTGGGT GTAATAGT GACA SEQ ID NO. : : 53 CTNNB1 323-S T T T T T T GT GGGT GTAATAGT GACAT SEQ ID NO. : : 54 CTNNB1 324-S T T T T T GT GGGT GTAATAGT GACAT T SEQ ID NO. : : 55 CTNNB1 325-S T T T T GT GGGT GTAATAGT GACAT T T SEQ ID NO. : : 56 CTNNB1 FWD TCCCACTGTACCTCTGTTATCCA SEQ ID NO. : : 57 CTNNB1 REV TGGTCCTCGTCATTTAGCAGTTT SEQ ID NO. : : 58

[0155] Referring to FIG. 4, T7EI assay revealed significant improvement of the targeting efficiency by M537R and F870L mutations. First, M537R, F870L or the double-mutant (M537R / F870L) enabled efficient cleavage at all 15 sites with TTTT PAM, where 11 of 15 have no detectable cleavage by WT-Cpfl. For other sites with canonical TTTV PAM, these variants maintained or improved the targeting efficiency. The benefit is particularly significant at those low-activity sites, such as CTNNB1 111-s (3-fold improvement over WT). Among these variants, the double-mutant (M537R / F870) has the most consistent improvement of targeting efficiency across all tested sites, where the singly mutants 2024201449   05 Mar 2024 exhibited more site-dependent variations, such as F870L at 323-S (no activity, same as WT). Overall, the described invention exhibits vastly superior on-target potency than the WT-Cpfl. Example 5. High-throughput measurement of the DNA cleavage activity of AsCaslla variants at TTTT PAM site in E. coli.

[0156] The following Example demonstrates the robustness of our novel high-throughput screening strategy to directly measure the cleavage activity of thousands AsCasl2a variants at TTTT PAM site in the bacterial-based activity assay (FIG. 5). FIG. 5A-F shows exemplary high-throughput phenotype measurement of AsCasl2a point mutations by deepscanning mutagenesis. A library encompassing every possible single point mutation of AsCasl2a in the targeted region (499-640 and 840-913) was generated in the context of WT-AsCasl2a or M537R / F870LM5Cfl572a. The relative survival rate of each variant over the reference protein in an E. coli-basvX activity assay was determined by deep-sequencing. The phenotype of individual point mutations was measured under multiple selection stringencies in the context of M537R / F870L (condition 1 and 2), and a third condition in the WT-AsCasl2a background (condition 3). As shown in FIG. 5A-C, the phenotype scores (i.e. natural logarithm of relative survival rate) of variants are positively correlated under different conditions (p ~ 0.7), demonstrating the consistency and reproducibility of this approach. As the positive control, only the M537R and F870L / I, but not any other substitutions at these positions, survived more than the W£-AsCasl2a (FIG. 5D). Conversely, mutating R537 or L870 on the M537R / F870LM5Cfl572a ubiquitously reduced the survival rate (FIG. 5E). These results demonstrated that the phenotype score measured by the bacterial screening reflects the DNA cleavage activity of previously characterized AsCasl2a variants at TTTT PAM.

[0157] To further validate the result of our bacterial screen, we studied four point mutations of AsCasl2a with greater survival rate than the reference under all three conditions (L505K, S510L, P569D and P599G, FIG. 5F), Of note, P599G has been shown to enhance the cleavage activity of AsCasl2a at TTCC PAM. The other three point mutations have not been characterized by any published studies so far. We therefore measured the survival rate of E. coli cells transformed with plasmids expressing individual AsCasl2a variant under selection. Compared to W£-AsCasl2a, all selected point mutations increased the survival rate when targeting a TTTT-PAM site (FIG. 6). Unexpectedly, the benefits of these point 2024201449   05 Mar 2024 mutations held true even in the context of M537R / F870L-AsQ / .s72a, where the survival rate was further elevated (FIG. 7). Collectively, these results demonstrated that our high-throughput screening can accurately predict the phenotype of uncharacterized AsCasl2a variants.

[0158] The phenotype scores of 3,194 AsCasl2a variants with single point mutation covered by the screening with sufficient sequencing count are listed in Table 3. Overall, -60% exhibited some benefits (i.e. phenotype score > 0) in one of the three condition.

[0159] Table 3. Summary of selected variants in different background conditions.1 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? R499C 0.14 0.08 0.60 0.07 0.06 0.10 Yes Yes R499L 0.08 0.05 0.05 0.06 0.09 0.15 Yes Yes R499K 0.54 0.06 0.23 0.06 0.38 0.10 Yes Yes R499A -0.29 0.05 0.27 0.04 0.22 0.07 Yes No R499N 0.39 0.11 -0.49 0.15 -0.13 0.29 Yes No R499D 0.03 0.09 -1.01 0.12 -0.51 0.44 Yes No R499Q -0.10 0.08 0.42 0.07 0.19 0.20 Yes No R499E -0.23 0.06 0.50 0.05 -0.10 0.10 Yes No R499G -0.11 0.03 0.12 0.03 0.14 0.06 Yes No R499H -0.45 0.11 0.50 0.09 NA NA Yes No R499I -0.14 0.10 0.09 0.09 -0.18 0.13 Yes No R499M -0.44 0.09 0.50 0.07 0.27 0.21 Yes No R499F 0.01 0.15 -0.31 0.17 NA NA Yes No R499P -0.56 0.08 -0.06 0.07 -0.70 0.26 No No R499S -0.14 0.05 0.02 0.05 -0.04 0.06 Yes No R499* -0.76 0.10 -0.61 0.10 -1.06 0.18 No No R499T -0.01 0.07 0.56 0.06 0.23 0.16 Yes No R499W -0.27 0.05 0.11 0.05 -0.53 0.11 Yes No R499V 0.09 0.05 0.09 0.05 -0.10 0.14 Yes No L500M 0.01 0.05 0.30 0.05 0.28 0.12 Yes Yes L500A -0.27 0.04 0.21 0.03 -0.15 0.07 Yes No L500R -0.35 0.03 -0.40 0.03 -0.47 0.05 No No L500N -1.11 0.14 -0.60 0.12 -0.50 0.16 No No L500D -1.03 0.08 -1.98 0.13 -1.26 0.19 No No L500C -0.19 0.05 0.26 0.05 0.00 0.10 Yes No L500Q -0.67 0.06 -0.63 0.06 -0.13 0.07 No No L500E -1.00 0.06 -1.22 0.07 -1.29 0.07 No No L500G -0.72 0.03 -0.79 0.03 -0.84 0.03 No No L500H -0.30 0.09 0.01 0.08 0.01 0.22 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? L500I -0.31 0.09 0.07 0.08 0.26 0.15 Yes No L500K -1.21 0.09 -0.32 0.07 -0.28 0.07 No No L500F -0.19 0.08 -0.33 0.09 0.09 0.21 Yes No L500P -0.79 0.05 -0.80 0.05 -0.91 0.07 No No L500S -0.84 0.04 -0.43 0.04 -0.37 0.07 No No L500* -1.39 0.09 -1.60 0.11 -1.66 0.16 No No L500T -0.19 0.05 -0.37 0.06 -0.17 0.06 No No L500W -0.25 0.04 -0.29 0.04 0.01 0.11 Yes No L500Y -0.01 0.09 0.04 0.09 0.05 0.22 Yes No L500V -0.13 0.03 0.11 0.03 -0.03 0.06 Yes No T501L 0.18 0.04 0.32 0.04 0.12 0.07 Yes Yes T501M 0.32 0.07 0.35 0.07 0.17 0.29 Yes Yes T501V 0.22 0.06 0.29 0.06 0.13 0.20 Yes Yes T501A -0.06 0.03 -0.13 0.03 -0.07 0.10 No No T501R 0.01 0.03 -0.16 0.03 0.54 0.07 Yes No T501N 0.69 0.14 0.16 0.15 NA NA Yes No T501D 0.12 0.12 -0.12 0.13 NA NA Yes No T501C 0.52 0.09 -0.40 0.11 0.31 0.26 Yes No T501Q -0.19 0.10 -0.04 0.10 -0.24 0.31 No No T501E -0.39 0.09 0.05 0.08 -0.34 0.26 Yes No T501G 0.12 0.04 0.44 0.04 -0.03 0.09 Yes No T501I 0.13 0.07 0.05 0.07 -0.19 0.11 Yes No T501K -0.30 0.09 0.21 0.08 0.55 0.24 Yes No T501F 0.08 0.08 -0.12 0.08 -0.12 0.14 Yes No T501P -0.29 0.07 0.14 0.06 -0.39 0.13 Yes No T501S 0.06 0.05 0.14 0.05 -0.10 0.09 Yes No T501* -1.18 0.12 -0.58 0.10 -0.85 0.21 No No T501W -0.02 0.07 0.26 0.06 -0.30 0.09 Yes No T501Y -0.08 0.12 0.11 0.12 -0.29 0.29 Yes No G502R 0.14 0.05 0.28 0.05 0.98 0.07 Yes Yes G502E 0.42 0.08 0.17 0.08 0.19 0.30 Yes Yes G502L 0.45 0.07 0.10 0.07 0.00 0.11 Yes Yes G502S 0.08 0.06 0.23 0.06 0.16 0.12 Yes Yes G502W 0.14 0.07 0.65 0.06 0.36 0.14 Yes Yes G502V 0.21 0.05 0.21 0.05 0.13 0.07 Yes Yes G502A -0.05 0.05 -0.34 0.05 0.08 0.07 Yes No G502D -0.14 0.08 0.37 0.07 0.10 0.15 Yes No G502C -0.17 0.08 0.23 0.08 -0.04 0.13 Yes No G502Q 0.78 0.11 0.02 0.13 -0.06 0.55 Yes No G502H 0.61 0.15 0.01 0.17 NA NA Yes No G502M -0.34 0.13 0.35 0.11 NA NA Yes No G502F NA NA NA NA 0.08 0.37 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? G502P -0.41 0.14 0.01 0.13 NA NA Yes No G502* -1.16 0.15 -0.82 0.13 NA NA Yes No G502T 0.69 0.10 -0.23 0.13 0.24 0.35 Yes No I503A -0.76 0.09 0.32 0.07 -0.16 0.21 Yes No I503R -0.86 0.07 -0.67 0.07 -0.51 0.17 No No I503N -0.03 0.09 -0.30 0.10 -0.26 0.17 No No I503D -0.50 0.13 -0.57 0.13 NA NA Yes No I503C -0.24 0.11 0.84 0.09 0.00 0.33 Yes No I503E NA NA NA NA -0.71 0.36 Yes No I503G -0.69 0.06 -0.30 0.05 -0.53 0.15 No No I503L 0.13 0.06 -0.46 0.07 -0.31 0.15 Yes No I503K 0.03 0.12 -0.51 0.15 NA NA Yes No I503M -0.08 0.10 -0.17 0.10 -0.13 0.27 No No I503F -0.17 0.09 -0.17 0.09 -0.25 0.19 No No I503S -0.45 0.07 -0.27 0.07 -0.23 0.19 No No I503T -0.23 0.08 0.33 0.07 0.20 0.14 Yes No I503W -1.21 0.11 -0.88 0.10 -0.61 0.28 No No 1503V -0.09 0.05 0.34 0.04 -0.03 0.09 Yes No K504A -0.15 0.07 -0.33 0.07 -0.30 0.20 No No K504R -0.05 0.03 0.04 0.03 -0.08 0.06 Yes No K504N 0.01 0.03 -0.54 0.04 -0.50 0.04 Yes No K504C -0.46 0.13 0.02 0.12 NA NA Yes No K504Q -0.16 0.05 -0.25 0.05 -0.22 0.07 No No K504E -0.03 0.05 -0.32 0.06 -0.65 0.11 No No K504G -0.84 0.05 -0.46 0.05 -0.52 0.15 No No K504H -0.59 0.13 -0.01 0.11 -0.51 0.16 No No K504I -0.07 0.08 0.12 0.07 -0.31 0.14 Yes No K504L -0.39 0.05 -0.05 0.05 -0.10 0.14 No No K504M -0.32 0.08 -0.06 0.08 -0.06 0.10 No No K504F -0.71 0.14 -0.24 0.12 NA NA Yes No K504S -0.50 0.08 -0.45 0.08 -0.19 0.23 No No K504* -0.43 0.09 -0.59 0.10 -0.76 0.15 No No K504T -0.22 0.08 0.08 0.07 -0.15 0.14 Yes No K504W -0.48 0.08 0.09 0.07 -0.53 0.24 Yes No K504V -0.48 0.05 -0.27 0.05 -0.36 0.12 No No L505A 0.61 0.05 0.50 0.05 0.47 0.13 Yes Yes L505R 0.40 0.03 0.56 0.03 0.81 0.05 Yes Yes L505Q 0.30 0.07 0.82 0.07 0.16 0.11 Yes Yes L505E 0.18 0.06 0.03 0.07 0.14 0.21 Yes Yes L505G 0.18 0.03 0.72 0.03 0.40 0.05 Yes Yes L505H 0.33 0.11 0.83 0.10 0.34 0.32 Yes Yes L505K 0.02 0.10 1.00 0.08 1.00 0.13 Yes Yes 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? L505S 0.13 0.06 0.32 0.06 0.60 0.07 Yes Yes L505N -0.53 0.17 0.27 0.14 NA NA Yes No L505D -0.28 0.11 0.59 0.10 0.10 0.49 Yes No L505C 0.26 0.07 -0.14 0.08 0.47 0.27 Yes No L505M -0.05 0.09 -0.06 0.09 -0.18 0.18 No No L505F -0.97 0.15 0.28 0.11 -0.33 0.41 Yes No L505P -0.55 0.07 -0.09 0.06 -0.09 0.11 No No L505T -0.23 0.09 0.44 0.08 0.59 0.17 Yes No L505W -0.03 0.06 0.28 0.05 -0.19 0.17 Yes No L505V -0.03 0.04 0.15 0.04 0.45 0.11 Yes No E506A 0.33 0.03 0.47 0.03 0.70 0.05 Yes Yes E506R 0.46 0.03 0.81 0.03 1.20 0.04 Yes Yes E506N 0.24 0.09 0.53 0.09 0.50 0.29 Yes Yes E506C 0.20 0.06 0.29 0.06 0.49 0.19 Yes Yes E506Q 0.09 0.07 0.74 0.06 0.33 0.15 Yes Yes E506G 0.24 0.02 0.39 0.02 0.53 0.03 Yes Yes E506H 0.35 0.09 0.10 0.10 0.98 0.31 Yes Yes E506I 0.47 0.09 0.45 0.09 0.69 0.13 Yes Yes E506L 0.30 0.04 0.61 0.04 0.56 0.07 Yes Yes E506K 0.18 0.06 0.59 0.05 1.08 0.08 Yes Yes E506M 0.53 0.06 0.28 0.07 0.47 0.17 Yes Yes E506S 0.01 0.05 0.47 0.04 0.50 0.06 Yes Yes E506T 0.39 0.06 0.12 0.07 0.90 0.23 Yes Yes E506Y 0.16 0.09 0.29 0.09 0.43 0.25 Yes Yes E506V 0.45 0.03 0.51 0.03 0.75 0.05 Yes Yes E506D 0.19 0.04 -0.30 0.05 -0.08 0.08 Yes No E506F -0.21 0.10 0.47 0.08 0.20 0.25 Yes No E506P -0.07 0.08 0.37 0.07 0.52 0.26 Yes No E506* -0.79 0.08 -0.79 0.08 -1.11 0.07 No No E506W 0.43 0.04 0.10 0.04 -0.07 0.05 Yes No M507A -0.47 0.06 -0.34 0.06 -0.32 0.19 No No M507R -0.42 0.02 -0.58 0.03 -0.64 0.04 No No M507C -0.41 0.09 -0.31 0.09 0.15 0.28 Yes No M507Q -0.68 0.07 -0.56 0.07 -0.44 0.17 No No M507E NA NA NA NA -1.23 0.19 Yes No M507G -0.98 0.05 -0.71 0.05 -1.24 0.12 No No M507H -0.65 0.12 0.68 0.09 -0.86 0.28 Yes No M507I -0.06 0.04 -0.12 0.04 0.01 0.07 Yes No M507L -0.20 0.03 -0.35 0.03 -0.16 0.03 No No M507K -1.42 0.13 -0.06 0.09 -1.00 0.19 No No M507F 0.05 0.09 -0.78 0.12 -0.05 0.36 Yes No M507P -2.08 0.12 -2.19 0.13 -1.58 0.18 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? M507S -1.03 0.09 -0.34 0.07 -0.46 0.18 No No M507* -1.68 0.15 -0.72 0.11 NA NA Yes No M507T -0.11 0.06 -0.30 0.07 -0.03 0.13 No No M507W -0.94 0.08 -0.59 0.07 -0.82 0.18 No No M507V -0.17 0.03 0.06 0.03 -0.28 0.06 Yes No E508A 0.36 0.03 0.20 0.03 0.18 0.06 Yes Yes E508R 0.54 0.03 0.80 0.03 0.82 0.06 Yes Yes E508Q 0.25 0.06 0.11 0.07 0.51 0.13 Yes Yes E508G 0.16 0.02 0.17 0.02 0.22 0.04 Yes Yes E508L 0.03 0.04 0.10 0.04 0.26 0.11 Yes Yes E508K 0.20 0.06 0.49 0.06 0.66 0.08 Yes Yes E508M 0.25 0.07 0.57 0.06 0.54 0.11 Yes Yes E508F 0.27 0.08 0.19 0.08 0.39 0.29 Yes Yes E508S 0.31 0.05 0.62 0.04 0.34 0.06 Yes Yes E508T 0.19 0.06 0.73 0.06 0.55 0.10 Yes Yes E508Y 0.35 0.09 0.19 0.10 0.21 0.27 Yes Yes E508V 0.16 0.03 0.22 0.03 0.34 0.05 Yes Yes E508N -0.08 0.11 -0.10 0.11 0.55 0.20 Yes No E508D 0.09 0.04 -0.15 0.04 -0.16 0.06 Yes No E508C -0.15 0.08 0.18 0.07 0.02 0.24 Yes No E508H -0.25 0.11 0.57 0.09 0.65 0.24 Yes No E508I 0.29 0.09 -0.12 0.10 0.54 0.15 Yes No E508P -0.52 0.08 -0.67 0.08 -0.63 0.20 No No E508* -0.63 0.06 -0.82 0.07 -0.79 0.09 No No E508W -0.29 0.05 0.45 0.05 0.07 0.09 Yes No P509R 0.23 0.03 0.27 0.03 1.04 0.05 Yes Yes P509K 0.01 0.07 0.12 0.07 1.29 0.13 Yes Yes P509M 0.34 0.07 0.34 0.07 0.10 0.22 Yes Yes P509S 0.10 0.04 0.14 0.04 0.14 0.10 Yes Yes P509W 0.04 0.05 0.33 0.05 0.61 0.18 Yes Yes P509Y 0.18 0.09 0.20 0.09 0.53 0.30 Yes Yes P509A 0.45 0.04 -0.19 0.04 -0.04 0.05 Yes No P509N 0.18 0.09 -0.33 0.11 0.63 0.29 Yes No P509D -0.12 0.08 -0.12 0.08 -0.01 0.21 No No P509C 0.00 0.06 -0.37 0.07 0.05 0.20 Yes No P509Q 0.08 0.05 -0.10 0.06 0.36 0.08 Yes No P509E -0.27 0.06 0.33 0.05 0.38 0.17 Yes No P509G -0.06 0.03 0.19 0.03 0.00 0.05 Yes No P509H 0.09 0.03 -0.31 0.03 -0.19 0.05 Yes No P509I -0.10 0.09 -0.34 0.10 -0.56 0.28 No No P509L 0.11 0.04 0.17 0.04 -0.17 0.05 Yes No P509F -0.12 0.09 0.24 0.08 0.52 0.11 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? P509* -2.22 0.15 -0.93 0.09 NA NA Yes No P509T 0.10 0.06 0.58 0.05 -0.04 0.11 Yes No P509V 0.09 0.04 0.07 0.04 -0.45 0.08 Yes No S510G 0.18 0.03 0.49 0.03 0.21 0.06 Yes Yes S510L 0.57 0.06 0.72 0.06 0.74 0.09 Yes Yes S510A 0.29 0.06 -0.25 0.07 0.04 0.22 Yes No S510R -0.38 0.03 -0.43 0.03 -0.53 0.04 No No S510N -0.36 0.09 -0.11 0.09 0.06 0.17 Yes No S510D -1.40 0.15 -1.36 0.15 NA NA Yes No S510C -0.14 0.06 0.03 0.06 0.28 0.14 Yes No S510E -0.71 0.09 -1.10 0.11 -1.07 0.25 No No S510I 0.02 0.05 -0.39 0.06 -0.76 0.03 Yes No S510M -1.15 0.14 -0.15 0.10 0.36 0.23 Yes No S510F -0.15 0.12 0.48 0.11 NA NA Yes No S510* -1.11 0.13 -1.36 0.15 NA NA Yes No S510T 0.18 0.08 0.64 0.08 -0.17 0.16 Yes No S510W -0.06 0.06 -0.94 0.08 -0.37 0.17 No No S510V -0.05 0.05 0.44 0.05 0.44 0.18 Yes No L511A 0.07 0.10 -0.06 0.11 -0.31 0.15 Yes No L511R 0.00 0.03 -0.21 0.04 0.09 0.06 Yes No L511Q -0.72 0.15 0.45 0.11 NA NA Yes No L511E -0.31 0.12 -0.25 0.13 -0.81 0.34 No No L511G -0.42 0.07 0.08 0.06 -0.02 0.27 Yes No L511K 0.26 0.13 0.44 0.12 NA NA Yes No L511M -0.67 0.11 0.33 0.08 0.25 0.20 Yes No L511P 0.04 0.08 0.00 0.09 0.26 0.13 Yes No L511S -0.12 0.12 -0.37 0.13 0.02 0.33 Yes No L511W 0.61 0.08 0.02 0.09 -0.40 0.38 Yes No L511V -0.26 0.06 0.38 0.06 -0.02 0.16 Yes No S512R 0.07 0.07 0.34 0.07 0.07 0.19 Yes Yes S512A 0.11 0.05 -0.15 0.06 -0.16 0.06 Yes No S512N -0.12 0.19 0.58 0.16 NA NA Yes No S512D -0.14 0.12 -0.33 0.13 0.47 0.39 Yes No S512C 0.06 0.08 0.61 0.08 -0.18 0.19 Yes No S512E 0.44 0.10 -0.11 0.12 0.21 0.36 Yes No S512G -0.15 0.05 -0.15 0.05 0.10 0.12 Yes No S512L -0.16 0.10 0.53 0.09 -0.21 0.20 Yes No S512K 0.65 0.15 0.57 0.15 NA NA Yes No S512M 0.28 0.14 0.24 0.15 NA NA Yes No S512F -0.28 0.08 -0.16 0.08 -0.32 0.13 No No S512P -0.22 0.08 -0.09 0.08 -0.16 0.13 No No S512T -0.17 0.09 0.05 0.08 -0.07 0.15 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? S512W -0.13 0.10 0.13 0.10 NA NA Yes No S512Y -0.26 0.13 -0.68 0.15 NA NA Yes No S512V -0.38 0.08 -0.54 0.09 -0.64 0.19 No No F513L 0.53 0.04 0.63 0.04 0.41 0.07 Yes Yes F513W 0.04 0.06 0.35 0.06 0.28 0.13 Yes Yes F513A -1.58 0.11 0.20 0.06 -0.49 0.25 Yes No F513R -1.56 0.09 -1.47 0.09 -0.89 0.06 No No F513D -1.02 0.15 0.12 0.11 NA NA Yes No F513C -0.83 0.10 -0.27 0.09 -0.27 0.14 No No F513Q 0.00 0.13 0.58 0.12 NA NA Yes No F513E -0.37 0.09 0.33 0.08 -0.38 0.38 Yes No F513G -1.33 0.06 -0.80 0.05 -1.00 0.13 No No F513I 0.78 0.10 0.21 0.11 NA NA Yes No F513M -0.36 0.12 0.73 0.10 0.49 0.23 Yes No F513S -0.59 0.07 -0.47 0.07 -0.61 0.10 No No F513T NA NA NA NA -0.35 0.19 Yes No F513Y -0.10 0.10 0.26 0.09 0.44 0.12 Yes No F513V -0.53 0.06 -0.27 0.06 0.06 0.19 Yes No Y514A -0.28 0.05 -0.43 0.05 -0.73 0.13 No No Y514R -0.23 0.04 -0.47 0.05 -0.86 0.14 No No Y514N -0.17 0.09 0.07 0.08 -0.53 0.17 Yes No Y514D -1.11 0.10 -1.20 0.11 -1.22 0.16 No No Y514C -0.39 0.05 -0.35 0.05 -0.55 0.09 No No Y514Q -1.35 0.13 -0.62 0.10 -1.01 0.29 No No Y514E -1.08 0.08 -0.93 0.08 -1.50 0.19 No No Y514G -0.76 0.04 -0.49 0.04 -1.06 0.11 No No Y514H 0.39 0.06 0.29 0.06 -0.31 0.12 Yes No Y514I -0.14 0.09 -0.84 0.11 NA NA Yes No Y514L -0.37 0.05 -0.57 0.05 -0.73 0.10 No No Y514K -0.52 0.09 -1.28 0.12 NA NA Yes No Y514M -0.50 0.07 -0.38 0.07 -0.59 0.19 No No Y514F -0.29 0.07 0.14 0.06 -0.35 0.11 Yes No Y514S -0.33 0.05 -0.32 0.05 -0.86 0.11 No No Y514* -0.91 0.08 -1.20 0.10 -1.18 0.13 No No Y514T -1.01 0.09 -1.31 0.10 -0.98 0.18 No No Y514W 0.17 0.05 0.46 0.05 -0.09 0.23 Yes No Y514V -0.45 0.04 -0.41 0.04 -0.92 0.06 No No N515A 0.60 0.06 0.82 0.06 0.12 0.11 Yes Yes N515R 0.63 0.06 0.82 0.05 0.19 0.11 Yes Yes N515I 0.23 0.07 0.30 0.07 0.16 0.14 Yes Yes N515L 0.33 0.06 0.53 0.06 0.07 0.20 Yes Yes N515T 0.41 0.08 0.14 0.08 0.29 0.16 Yes Yes 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? N515V 0.50 0.05 0.49 0.05 0.45 0.09 Yes Yes N515D 0.05 0.06 -0.17 0.06 -0.30 0.10 Yes No N515C 0.59 0.12 0.62 0.12 -0.02 0.30 Yes No N515Q. 0.46 0.11 0.69 0.11 NA NA Yes No N515E 0.47 0.07 0.56 0.07 -0.14 0.19 Yes No N515G -0.10 0.05 0.37 0.04 -0.13 0.07 Yes No N515H 0.09 0.10 -0.59 0.13 -0.25 0.21 Yes No N515K 0.07 0.08 0.16 0.08 -0.13 0.16 Yes No N515M 0.73 0.09 0.45 0.10 -0.01 0.12 Yes No N515F 0.49 0.12 0.48 0.12 NA NA Yes No N515P -1.10 0.16 -0.13 0.12 -0.32 0.38 No No N515S 0.08 0.05 -0.15 0.05 0.19 0.08 Yes No N515W 0.79 0.08 0.42 0.09 -0.60 0.31 Yes No N515Y -0.30 0.12 -0.55 0.13 0.03 0.22 Yes No K516R 0.01 0.03 0.26 0.03 0.40 0.06 Yes Yes K516A 0.25 0.05 0.13 0.06 -0.33 0.21 Yes No K516N 0.37 0.09 0.01 0.11 -0.01 0.16 Yes No K516D NA NA NA NA -0.48 0.31 Yes No K516C -1.37 0.13 0.14 0.08 -0.36 0.16 Yes No K516Q 0.08 0.07 -0.76 0.10 -0.08 0.16 Yes No K516E -0.23 0.04 -0.32 0.05 -0.33 0.09 No No K516G -0.34 0.03 -0.01 0.03 -0.34 0.05 No No K516I -0.29 0.14 -0.03 0.14 NA NA Yes No K516L -0.29 0.06 -0.06 0.06 -0.56 0.18 No No K516M -0.29 0.08 -0.21 0.08 -0.31 0.17 No No K516P -0.37 0.10 -0.96 0.12 NA NA Yes No K516S -0.34 0.06 0.23 0.06 -0.22 0.21 Yes No K516* -0.66 0.09 -0.86 0.10 -1.08 0.19 No No K516T -0.18 0.04 -0.43 0.04 -0.09 0.06 No No K516W -0.42 0.06 -0.55 0.07 -1.18 0.16 No No K516V -0.47 0.05 -0.20 0.05 -1.04 0.11 No No A517R -2.02 0.07 -1.56 0.06 -1.46 0.07 No No A517D -1.35 0.11 -0.85 0.09 -1.19 0.18 No No A517C -0.35 0.08 0.68 0.07 0.14 0.17 Yes No A517E -1.34 0.09 -1.16 0.09 -1.86 0.16 No No A517G -0.69 0.03 -0.65 0.03 -0.77 0.04 No No A517I 0.77 0.10 -0.42 0.13 NA NA Yes No A517L -0.30 0.06 -0.44 0.06 -1.22 0.17 No No A517M -0.50 0.10 -0.24 0.10 -0.57 0.30 No No A517F -0.50 0.12 -0.90 0.14 NA NA Yes No A517P -0.75 0.08 -1.06 0.09 -0.86 0.12 No No A517S -0.28 0.05 -0.24 0.05 -0.65 0.14 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? A517T -0.34 0.06 0.06 0.06 -0.42 0.11 Yes No A517W -1.22 0.07 -0.27 0.05 -1.43 0.16 No No A517Y 0.02 0.13 0.04 0.13 NA NA Yes No A517V -0.33 0.04 -0.14 0.04 -0.44 0.07 No No R518K 0.20 0.09 0.72 0.08 0.05 0.17 Yes Yes R518A -0.12 0.07 -0.28 0.07 -0.87 0.24 No No R518C -1.13 0.12 -0.21 0.09 NA NA Yes No R518E -0.72 0.10 -1.08 0.12 NA NA Yes No R518G -1.34 0.05 -0.78 0.04 -0.87 0.08 No No R518L -1.49 0.12 -1.84 0.15 NA NA Yes No R518F -0.96 0.16 0.45 0.11 NA NA Yes No R518S -0.74 0.08 -1.20 0.09 -0.73 0.12 No No R518* -0.33 0.08 -0.34 0.08 -0.69 0.13 No No R518T -0.50 0.10 -0.37 0.10 -0.40 0.15 No No R518W -1.01 0.09 -1.13 0.10 -1.22 0.19 No No R518V -0.44 0.06 -1.39 0.09 -1.43 0.09 No No N519A 0.64 0.06 1.07 0.06 -0.06 0.25 Yes No N519R 0.47 0.05 0.46 0.05 -0.02 0.08 Yes No N519D 0.10 0.05 -0.13 0.05 -0.29 0.07 Yes No N519C 0.21 0.11 0.23 0.11 NA NA Yes No N519Q 0.14 0.12 0.71 0.11 NA NA Yes No N519E -0.66 0.10 -0.38 0.09 -0.89 0.23 No No N519G 0.21 0.04 0.10 0.04 -0.54 0.08 Yes No N519H 0.10 0.09 -0.67 0.11 NA NA Yes No N519I 0.29 0.09 0.18 0.09 -0.02 0.15 Yes No N519L 0.28 0.06 0.47 0.06 -0.37 0.08 Yes No N519K -0.17 0.09 -0.35 0.10 -0.46 0.19 No No N519M -0.19 0.10 0.36 0.09 -0.05 0.13 Yes No N519F 0.38 0.14 0.21 0.15 NA NA Yes No N519P -0.72 0.13 -0.23 0.11 NA NA Yes No N519S 0.08 0.05 -0.03 0.05 0.02 0.12 Yes No N519T 0.24 0.08 0.01 0.09 -0.37 0.16 Yes No N519W -0.02 0.08 0.38 0.08 -0.12 0.31 Yes No N519Y 0.10 0.12 0.65 0.11 -0.09 0.22 Yes No N519V 0.12 0.05 0.14 0.05 -0.39 0.06 Yes No Y520A -1.19 0.12 -0.30 0.09 NA NA Yes No Y520R -0.37 0.08 -1.30 0.11 -1.04 0.24 No No Y520N -0.05 0.09 -0.45 0.10 -0.62 0.14 No No Y520D -0.50 0.12 -0.04 0.10 NA NA Yes No Y520C -0.23 0.07 -0.24 0.07 -0.52 0.12 No No Y520E -0.61 0.13 -0.85 0.15 NA NA Yes No Y520G -1.91 0.10 -1.08 0.08 -1.47 0.09 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? Y520H 0.12 0.07 -0.14 0.07 -0.34 0.10 Yes No Y520F 0.19 0.13 -0.21 0.15 NA NA Yes No Y520S -0.73 0.11 -0.66 0.11 -1.13 0.18 No No Y520* -0.19 0.07 -0.42 0.08 -0.48 0.15 No No Y520W -0.38 0.10 0.06 0.09 -0.03 0.16 Yes No Y520V -1.45 0.13 -1.16 0.12 NA NA Yes No A521D -0.72 0.13 -0.50 0.13 NA NA Yes No A521C 0.90 0.16 1.29 0.16 NA NA Yes No A521G -0.52 0.05 -0.73 0.06 -0.98 0.12 No No A521L -0.61 0.10 -0.13 0.09 -0.98 0.12 No No A521P -0.19 0.11 -0.78 0.14 NA NA Yes No A521S 0.00 0.09 0.04 0.10 -0.51 0.27 Yes No A521T -0.23 0.07 0.10 0.06 -0.33 0.11 Yes No A521V -0.40 0.06 -0.88 0.07 -0.60 0.13 No No T522L 1.10 0.05 0.92 0.05 0.28 0.10 Yes Yes T522M 0.92 0.07 0.81 0.08 0.53 0.21 Yes Yes T522V 0.16 0.05 0.28 0.05 0.04 0.07 Yes Yes T522A -0.01 0.05 -0.37 0.06 -0.55 0.08 No No T522R -0.17 0.04 0.31 0.04 -0.40 0.12 Yes No T522N 0.11 0.07 -1.14 0.11 -0.50 0.13 Yes No T522C 0.09 0.08 0.38 0.08 -0.41 0.38 Yes No T522Q 0.71 0.09 0.47 0.10 -0.51 0.36 Yes No T522E -0.22 0.08 -1.54 0.13 -0.72 0.27 No No T522G -0.37 0.04 -0.18 0.04 -0.85 0.08 No No T522I 0.23 0.07 -0.06 0.08 -0.11 0.17 Yes No T522K -0.16 0.11 -0.23 0.11 -0.67 0.26 No No T522F 0.08 0.13 0.34 0.12 NA NA Yes No T522P -1.16 0.11 -1.52 0.14 -1.14 0.16 No No T522S 0.23 0.05 -0.20 0.05 -0.38 0.10 Yes No T522W -0.26 0.07 -0.35 0.07 -0.90 0.13 No No K523R 0.17 0.02 0.37 0.02 0.00 0.03 Yes Yes K523A -0.19 0.03 0.15 0.03 -0.48 0.09 Yes No K523N -0.31 0.07 -0.48 0.07 -1.00 0.08 No No K523D -1.14 0.07 -1.35 0.08 -1.21 0.09 No No K523C -0.22 0.05 0.07 0.04 -0.81 0.12 Yes No K523Q -0.12 0.04 -0.22 0.04 0.01 0.06 Yes No K523E -0.57 0.04 -0.56 0.04 -0.86 0.06 No No K523G -0.16 0.02 0.09 0.02 -0.56 0.03 Yes No K523H -1.08 0.11 -0.05 0.08 -1.04 0.28 No No K523I -0.20 0.07 0.41 0.06 -1.23 0.21 Yes No K523L -0.78 0.04 -0.30 0.03 -0.70 0.07 No No K523M -0.19 0.04 -0.18 0.04 -0.52 0.06 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? K523F -1.08 0.08 -0.93 0.08 -1.27 0.09 No No K523P -1.41 0.08 -0.39 0.06 -1.21 0.15 No No K523S 0.13 0.03 0.10 0.03 -0.36 0.07 Yes No K523* -1.40 0.07 -1.46 0.08 -1.19 0.12 No No K523T -0.19 0.04 -0.19 0.04 -0.49 0.08 No No K523W -0.97 0.04 -0.87 0.04 -1.41 0.09 No No K523Y -1.25 0.10 -0.43 0.08 -1.36 0.19 No No K523V -0.57 0.03 -0.57 0.03 -1.12 0.08 No No K524A -0.88 0.09 -0.32 0.08 -0.50 0.24 No No K524R -0.32 0.04 0.15 0.04 -0.28 0.09 Yes No K524N 0.04 0.04 -0.48 0.05 -0.19 0.09 Yes No K524C 0.06 0.10 0.03 0.10 NA NA Yes No K524Q -0.42 0.09 -0.54 0.10 -0.47 0.14 No No K524E -0.53 0.06 -0.11 0.06 -0.49 0.10 No No K524G -0.43 0.04 -0.19 0.04 -0.80 0.06 No No K524L -0.25 0.07 0.32 0.06 -0.81 0.21 Yes No K524M -1.28 0.15 -0.75 0.13 -0.69 0.15 No No K524P -0.70 0.12 -0.10 0.10 0.02 0.29 Yes No K524S -0.67 0.08 -0.04 0.07 -0.73 0.12 No No K524* -0.92 0.11 -0.75 0.11 -0.76 0.13 No No K524T -0.10 0.04 -0.26 0.04 -0.15 0.06 No No K524W -0.58 0.08 -1.54 0.12 -1.19 0.22 No No K524V -0.71 0.07 -0.01 0.06 -0.68 0.22 No No P525A -0.21 0.03 0.06 0.03 -0.29 0.07 Yes No P525R -0.30 0.02 -0.10 0.02 -0.62 0.05 No No P525N -0.38 0.09 -0.35 0.10 -0.10 0.19 No No P525D 0.42 0.05 -0.02 0.05 -0.30 0.08 Yes No P525C -0.28 0.05 -0.12 0.05 -0.48 0.14 No No P525Q -0.21 0.06 -0.19 0.06 -0.35 0.13 No No P525E -0.22 0.04 0.24 0.04 -0.30 0.05 Yes No P525G -0.24 0.02 -0.17 0.02 -0.51 0.05 No No P525H 0.17 0.06 0.18 0.07 -0.24 0.12 Yes No P525I -0.48 0.09 0.06 0.08 0.19 0.22 Yes No P525L -0.37 0.03 0.25 0.03 -0.61 0.06 Yes No P525K -0.90 0.08 -1.00 0.09 -0.57 0.17 No No P525M -0.55 0.06 -0.18 0.06 -0.54 0.13 No No P525F -0.17 0.07 -0.61 0.08 -0.70 0.16 No No P525S -0.06 0.03 0.04 0.03 -0.42 0.08 Yes No P525* -1.61 0.09 -1.54 0.09 -1.56 0.08 No No P525T -0.25 0.05 -0.31 0.05 -0.45 0.11 No No P525W -0.25 0.04 -0.04 0.03 -0.59 0.11 No No P525Y -1.08 0.10 -1.08 0.10 -0.77 0.08 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? P525V -0.31 0.03 -0.08 0.03 -0.39 0.08 No No Y526A -0.28 0.07 0.17 0.06 -0.89 0.19 Yes No Y526R -0.71 0.07 -0.17 0.06 -1.09 0.19 No No Y526N -0.64 0.11 -0.15 0.09 -0.25 0.17 No No Y526D -0.44 0.09 0.07 0.08 -0.69 0.15 Yes No Y526C 0.04 0.06 -0.03 0.06 -0.26 0.12 Yes No Y526Q -0.10 0.11 -0.64 0.13 NA NA Yes No Y526E -0.46 0.08 -0.87 0.10 -0.84 0.21 No No Y526G -0.22 0.05 -0.17 0.05 -0.65 0.16 No No Y526H -0.32 0.08 -0.25 0.08 -0.19 0.12 No No Y526I -0.40 0.13 -0.52 0.14 NA NA Yes No Y526L -0.53 0.06 -0.18 0.05 -0.73 0.12 No No Y526M -0.47 0.10 -0.40 0.10 -1.12 0.27 No No Y526F -0.02 0.07 -0.01 0.07 -0.44 0.13 No No Y526P -0.19 0.10 -0.88 0.13 NA NA Yes No Y526S -0.57 0.06 -0.68 0.07 -0.68 0.12 No No Y526* -0.42 0.05 -0.44 0.06 -0.61 0.09 No No Y526T -0.01 0.09 -0.22 0.10 -0.69 0.21 No No Y526W -1.02 0.10 -0.19 0.08 -0.32 0.13 No No Y526V -0.61 0.05 -0.14 0.05 -0.86 0.14 No No S527D 0.13 0.11 0.01 0.11 0.34 0.41 Yes Yes S527A 0.00 0.06 -0.37 0.07 -0.07 0.20 Yes No S527R -0.14 0.04 -0.73 0.05 -0.70 0.07 No No S527N -0.10 0.10 -0.43 0.11 0.01 0.19 Yes No S527C -0.21 0.09 -0.35 0.09 -0.10 0.22 No No S527Q 0.09 0.12 -0.39 0.14 NA NA Yes No S527E -0.49 0.10 0.57 0.08 0.03 0.16 Yes No S527G -0.43 0.04 -0.21 0.04 -0.53 0.09 No No S527H 0.47 0.15 0.10 0.17 NA NA Yes No S527I -1.06 0.16 -0.43 0.14 NA NA Yes No S527L -0.12 0.07 -0.24 0.07 -0.44 0.27 No No S527K -0.09 0.11 -0.57 0.13 NA NA Yes No S527P 0.07 0.10 -0.33 0.11 -0.47 0.36 Yes No S527T 0.01 0.09 -0.30 0.10 -0.22 0.18 Yes No S527W 0.03 0.07 0.15 0.07 -0.50 0.23 Yes No S527Y 0.31 0.17 0.05 0.18 NA NA Yes No S527V -0.54 0.07 -0.52 0.07 -0.52 0.10 No No V528D 0.01 0.07 0.27 0.07 0.12 0.12 Yes Yes V528L 0.55 0.03 0.59 0.03 0.31 0.07 Yes Yes V528M 0.19 0.05 0.02 0.05 0.13 0.10 Yes Yes V528A -0.09 0.04 0.29 0.04 -0.13 0.06 Yes No V528R -0.04 0.04 0.07 0.04 -0.03 0.07 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? V528N 0.01 0.11 -0.47 0.14 0.31 0.42 Yes No V528C 0.16 0.07 0.20 0.07 -0.06 0.24 Yes No V528Q -0.44 0.09 -0.29 0.09 0.07 0.11 Yes No V528E -0.66 0.06 0.16 0.05 0.00 0.11 Yes No V528G -0.14 0.02 -0.19 0.02 -0.19 0.03 No No V528H -0.62 0.15 1.01 0.11 NA NA Yes No V528I 0.16 0.08 -0.09 0.09 0.07 0.11 Yes No V528K -0.14 0.08 0.36 0.08 0.13 0.14 Yes No V528F -0.10 0.09 0.39 0.08 -0.59 0.21 Yes No V528P -0.10 0.08 -0.66 0.10 0.10 0.11 Yes No V528S -0.12 0.05 0.26 0.05 0.11 0.06 Yes No V528* -1.66 0.13 -1.20 0.12 NA NA Yes No V528T 0.29 0.07 0.00 0.07 0.18 0.17 Yes No V528W -1.31 0.07 -1.47 0.08 -0.99 0.14 No No V528Y -0.77 0.13 -0.50 0.12 0.24 0.12 Yes No E529A -0.38 0.08 -0.18 0.08 0.04 0.15 Yes No E529R NA NA NA NA -0.70 0.34 Yes No E529D 0.02 0.07 -0.61 0.08 0.10 0.15 Yes No E529Q -0.43 0.14 -0.49 0.15 NA NA Yes No E529G -0.25 0.05 -0.16 0.05 -0.61 0.11 No No E529L -0.45 0.11 -0.56 0.11 NA NA Yes No E529K 0.21 0.10 -0.28 0.11 -0.65 0.19 Yes No E529P 0.08 0.15 -0.30 0.17 NA NA Yes No E529S -0.18 0.11 -0.08 0.11 -0.20 0.45 No No E529* -0.22 0.11 -0.69 0.14 -0.58 0.17 No No E529W -0.19 0.13 -0.11 0.13 NA NA Yes No E529V -0.35 0.06 0.08 0.06 -0.48 0.10 Yes No K530A -0.96 0.10 -0.76 0.10 -0.90 0.14 No No K530R -0.56 0.04 -0.32 0.04 -0.59 0.08 No No K530N -0.78 0.15 -0.73 0.16 NA NA Yes No K530C -0.10 0.10 -0.43 0.11 NA NA Yes No K530Q -0.22 0.05 -0.56 0.05 -0.60 0.10 No No K530E -0.48 0.05 -0.35 0.05 -0.85 0.09 No No K530G -1.18 0.07 -1.09 0.07 -1.15 0.14 No No K530L -1.74 0.09 -1.04 0.07 -1.40 0.14 No No K530M -0.72 0.07 -0.42 0.07 -0.83 0.13 No No K530F -1.17 0.15 -0.40 0.12 NA NA Yes No K530S -1.15 0.09 -0.65 0.08 -1.15 0.13 No No K530* -0.63 0.07 -0.43 0.07 -0.68 0.09 No No K530T -0.51 0.07 -0.72 0.07 -0.68 0.10 No No K530W -1.73 0.12 -0.35 0.08 -1.35 0.20 No No K530V -0.98 0.08 -1.46 0.10 -1.55 0.23 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? F531A -1.39 0.13 -1.72 0.15 NA NA Yes No F531R -1.90 0.12 -1.41 0.10 -1.75 0.23 No No F531C -0.40 0.05 -0.81 0.06 -0.85 0.09 No No F531G -1.68 0.08 -1.22 0.07 -1.58 0.14 No No F531I -0.43 0.09 -0.86 0.11 -0.62 0.11 No No F531L -0.35 0.05 -0.40 0.05 -0.55 0.07 No No F531S -0.56 0.07 -0.79 0.08 -0.98 0.11 No No F531W -1.68 0.13 -0.86 0.10 -0.27 0.21 No No F531Y -0.99 0.16 -0.55 0.14 NA NA Yes No F531V -0.22 0.02 -0.64 0.03 -0.74 0.05 No No K532A NA NA NA NA -0.93 0.19 Yes No K532R -0.63 0.05 -0.63 0.05 -0.56 0.10 No No K532N -0.39 0.11 -0.71 0.13 -0.45 0.12 No No K532Q -0.42 0.08 -0.74 0.10 -0.96 0.11 No No K532E -0.49 0.05 -0.38 0.05 -0.64 0.12 No No K532G -1.74 0.08 -1.15 0.07 -1.35 0.11 No No K532L -1.28 0.11 -1.26 0.11 -1.36 0.21 No No K532M -0.48 0.09 -0.58 0.10 -0.65 0.09 No No K532S NA NA NA NA -0.93 0.25 Yes No K532* -0.42 0.06 -0.27 0.06 -0.65 0.12 No No K532T -0.37 0.06 -1.05 0.07 -0.52 0.10 No No K532V -1.99 0.11 -1.32 0.09 -1.19 0.12 No No L533R -0.17 0.04 -0.41 0.04 -0.57 0.08 No No L533G -1.82 0.14 -1.54 0.13 NA NA Yes No L533M -0.36 0.12 -0.29 0.12 -0.12 0.17 No No L533P -0.18 0.07 -0.06 0.07 -0.28 0.12 No No L533V -1.49 0.12 -0.64 0.09 -0.58 0.19 No No N534A -1.49 0.08 -1.30 0.08 -0.31 0.09 No No N534R -1.13 0.05 -1.37 0.06 -0.52 0.04 No No N534D -1.07 0.08 -0.72 0.07 -0.75 0.11 No No N534C -1.50 0.13 -1.27 0.12 0.19 0.20 Yes No N534Q. NA NA NA NA -0.67 0.24 Yes No N534E -2.05 0.10 -1.48 0.08 -1.32 0.13 No No N534G -1.43 0.04 -0.96 0.04 -1.10 0.04 No No N534H -0.18 0.03 -0.50 0.04 -0.20 0.06 No No N534I -0.54 0.08 0.00 0.07 -0.60 0.18 Yes No N534L -1.92 0.11 -1.79 0.11 -0.26 0.07 No No N534K -1.00 0.07 -0.74 0.07 -0.01 0.10 No No N534M -1.72 0.12 -0.90 0.09 0.88 0.19 Yes No N534F 0.11 0.10 -1.16 0.16 0.16 0.30 Yes No N534P -0.33 0.07 -0.26 0.07 -1.27 0.16 No No N534S -1.00 0.06 -0.72 0.06 0.22 0.05 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? N534* -1.20 0.09 -2.22 0.15 -1.84 0.10 No No N534T -0.38 0.04 -0.40 0.04 0.49 0.06 Yes No N534W -1.54 0.08 -0.69 0.06 -0.29 0.07 No No N534Y -0.97 0.12 -0.47 0.10 -0.57 0.17 No No N534V -1.35 0.07 -1.17 0.06 -0.59 0.06 No No N534A NA NA NA NA -0.33 0.09 Yes No N534R NA NA NA NA -0.55 0.04 Yes No N534D -0.11 0.09 -0.10 0.09 -0.69 0.10 No No N534C NA NA NA NA 0.16 0.19 Yes No N534Q. NA NA NA NA -0.72 0.24 Yes No N534E NA NA NA NA -1.34 0.13 Yes No N534G NA NA NA NA -1.11 0.04 Yes No N534H NA NA NA NA -0.19 0.24 Yes No N534I -0.14 0.19 -0.05 0.19 -0.61 0.19 No No N534L NA NA NA NA -0.22 0.07 Yes No N534K -0.47 0.14 -0.26 0.13 -0.06 0.09 No No N534M NA NA NA NA 0.83 0.18 Yes No N534F NA NA NA NA 0.26 0.30 Yes No N534S -0.15 0.07 -0.03 0.07 0.20 0.05 Yes No N534* NA NA NA NA -1.73 0.10 Yes No N534T NA NA NA NA 0.91 0.15 Yes No N534W NA NA NA NA -0.32 0.07 Yes No N534Y -0.01 0.13 0.04 0.13 -0.53 0.16 Yes No N534V NA NA NA NA -0.57 0.06 Yes No F535A -1.29 0.08 -1.38 0.09 -1.53 0.15 No No F535R -2.11 0.10 -1.42 0.08 -1.73 0.13 No No F535C -0.48 0.06 -0.52 0.06 -0.79 0.05 No No F535E -2.40 0.14 -1.29 0.09 -1.54 0.09 No No F535G -1.68 0.06 -1.41 0.05 -1.60 0.04 No No F535I -0.99 0.13 -0.63 0.12 NA NA Yes No F535L -0.97 0.06 -0.52 0.05 -0.92 0.05 No No F535M -0.78 0.11 -0.99 0.13 -0.68 0.24 No No F535S -0.91 0.06 -0.54 0.06 -1.11 0.09 No No F535W -2.13 0.11 -1.41 0.09 -1.73 0.15 No No F535Y -0.65 0.10 -0.50 0.10 -0.62 0.16 No No F535V -0.87 0.04 -1.00 0.05 -0.98 0.04 No No F535A NA NA NA NA -1.47 0.15 Yes No F535R NA NA NA NA -1.74 0.12 Yes No F535C -0.09 0.06 0.09 0.05 -0.54 0.06 Yes No F535E NA NA NA NA -1.65 0.09 Yes No F535G NA NA NA NA -1.93 0.04 Yes No F535L -0.04 0.06 0.03 0.06 -0.69 0.05 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? F535M NA NA NA NA -0.67 0.21 Yes No F535S -0.14 0.08 0.00 0.08 -1.14 0.09 No No F535W NA NA NA NA -1.68 0.14 Yes No F535Y -0.19 0.12 -0.06 0.12 -0.53 0.17 No No F535V -0.05 0.05 -0.01 0.05 -0.76 0.06 No No Q536A NA NA NA NA -0.02 0.19 Yes No Q536R 0.02 0.08 -0.02 0.09 0.08 0.05 Yes No Q536D NA NA NA NA 0.23 0.28 Yes No Q536C NA NA NA NA -1.02 0.28 Yes No Q536E 0.00 0.16 0.02 0.16 -0.66 0.08 Yes No Q536G NA NA NA NA 1.22 0.05 Yes No Q536H -0.05 0.19 -0.05 0.19 -0.34 0.22 No No Q536L -0.10 0.15 -0.11 0.15 -1.09 0.14 No No Q536K 0.56 0.09 -0.36 0.11 -0.09 0.13 Yes No Q536S NA NA NA NA 0.60 0.09 Yes No Q536* 0.15 0.09 0.03 0.10 -0.74 0.10 Yes No Q536V NA NA NA NA -1.88 0.09 Yes No R537A -1.11 0.10 -1.99 0.15 NA NA Yes No R537Q -0.56 0.13 -1.08 0.16 NA NA Yes No R537E -1.40 0.13 -1.33 0.13 NA NA Yes No R537G -1.10 0.05 -1.07 0.05 NA NA Yes No R537L -1.50 0.13 -1.38 0.12 NA NA Yes No R537K -0.58 0.09 -0.81 0.10 NA NA Yes No R537M -1.57 0.02 -1.19 0.02 NA NA Yes No R537S -1.30 0.11 -0.65 0.08 NA NA Yes No R537W -1.42 0.10 -1.60 0.11 NA NA Yes No R537V -1.52 0.11 -1.85 0.12 NA NA Yes No M537A NA NA NA NA -1.52 0.24 Yes No M537R NA NA NA NA 1.70 0.04 Yes No M537G NA NA NA NA -1.55 0.08 Yes No M537I NA NA NA NA -0.01 0.15 Yes No M537L NA NA NA NA -0.09 0.13 Yes No M537K NA NA NA NA 0.19 0.14 Yes No M537T NA NA NA NA -0.29 0.13 Yes No M537W NA NA NA NA -1.30 0.19 Yes No M537V NA NA NA NA -0.62 0.10 Yes No P538A NA NA NA NA -1.19 0.06 Yes No P538R NA NA NA NA -1.72 0.08 Yes No P538Q NA NA NA NA -1.46 0.11 Yes No P538E NA NA NA NA -1.79 0.22 Yes No P538G NA NA NA NA -1.67 0.09 Yes No P538H -0.20 0.17 -0.19 0.17 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? P538L -0.23 0.12 -0.09 0.11 -1.49 0.05 No No P538S 0.19 0.12 0.18 0.12 -1.47 0.11 Yes No P538T -0.08 0.06 0.13 0.06 -0.38 0.06 Yes No P538W NA NA NA NA -1.82 0.17 Yes No P538V NA NA NA NA -0.71 0.14 Yes No T539A 0.08 0.07 -0.03 0.08 -1.10 0.06 Yes No T539R NA NA NA NA -1.51 0.10 Yes No T539N 0.16 0.14 0.06 0.15 -1.00 0.17 Yes No T539C NA NA NA NA -1.11 0.14 Yes No T539Q NA NA NA NA -1.19 0.20 Yes No T539E NA NA NA NA -1.61 0.12 Yes No T539G NA NA NA NA -1.63 0.05 Yes No T539I -0.20 0.13 0.00 0.13 -1.04 0.16 No No T539L NA NA NA NA -2.07 0.13 Yes No T539K NA NA NA NA -1.23 0.26 Yes No T539M NA NA NA NA -1.64 0.18 Yes No T539P -0.33 0.14 -0.40 0.14 -1.51 0.14 No No T539S -0.03 0.05 -0.17 0.05 -0.14 0.04 No No T539V NA NA NA NA -1.65 0.11 Yes No L540R -0.17 0.15 -0.30 0.15 -1.27 0.14 No No L540Q 0.12 0.08 0.13 0.08 -0.05 0.08 Yes No L540G NA NA NA NA -1.83 0.13 Yes No L540M 0.04 0.08 -0.02 0.09 -0.13 0.07 Yes No L540P 0.05 0.09 0.09 0.09 -0.40 0.13 Yes No L540V NA NA NA NA -1.58 0.24 Yes No A541R NA NA NA NA -1.71 0.09 Yes No A541D 0.11 0.12 0.35 0.11 -0.22 0.06 Yes No A541C NA NA NA NA 0.02 0.39 Yes No A541G 0.38 0.07 0.36 0.07 -0.06 0.12 Yes No A541L NA NA NA NA 0.32 0.23 Yes No A541S -0.11 0.15 -0.14 0.15 -1.66 0.14 No No A541T -0.11 0.05 -0.11 0.05 -0.50 0.12 No No A541V -0.06 0.09 0.00 0.09 -0.77 0.12 No No S542N 0.24 0.09 0.02 0.09 0.29 0.07 Yes Yes S542C 0.03 0.17 0.15 0.17 0.42 0.16 Yes Yes S542A NA NA NA NA 0.79 0.05 Yes No S542R -0.37 0.10 -0.13 0.10 1.34 0.04 Yes No S542D NA NA NA NA -0.70 0.14 Yes No S542Q NA NA NA NA 0.04 0.23 Yes No S542E NA NA NA NA -1.68 0.07 Yes No S542G 0.23 0.07 -0.10 0.08 -0.79 0.06 Yes No S542H NA NA NA NA 0.08 0.35 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? S542I NA NA NA NA -0.13 0.32 Yes No S542L NA NA NA NA 0.67 0.10 Yes No S542K NA NA NA NA 1.36 0.09 Yes No S542M NA NA NA NA 1.10 0.11 Yes No S542P NA NA NA NA -0.85 0.27 Yes No S542T 0.68 0.17 0.24 0.19 -0.08 0.10 Yes No S542W NA NA NA NA -0.34 0.06 Yes No S542V NA NA NA NA 0.38 0.08 Yes No G543A -2.33 0.07 -1.64 0.05 -2.12 0.10 No No G543R -1.78 0.05 -1.75 0.05 -1.89 0.07 No No G543D -1.02 0.07 -1.88 0.09 NA NA Yes No G543C -0.32 0.04 -0.29 0.04 -0.07 0.06 No No G543E -2.56 0.11 -1.80 0.08 -2.09 0.18 No No G543I -1.30 0.14 -1.24 0.13 NA NA Yes No G543L -1.74 0.08 -1.17 0.06 -1.85 0.22 No No G543F -0.91 0.09 -0.77 0.08 -0.93 0.14 No No G543P -1.28 0.08 -1.18 0.08 -1.40 0.22 No No G543S -1.21 0.05 -1.22 0.05 -1.63 0.08 No No G543* -1.66 0.13 -1.93 0.14 NA NA Yes No G543W -1.55 0.08 -1.49 0.07 NA NA Yes No G543V -0.80 0.03 -0.81 0.03 -0.80 0.06 No No W544A -1.17 0.05 -1.90 0.06 -1.67 0.09 No No W544R -1.30 0.03 -1.40 0.03 -1.35 0.04 No No W544N -1.11 0.10 -1.78 0.13 NA NA Yes No W544D -1.61 0.09 -1.58 0.09 -1.51 0.14 No No W544C -0.88 0.06 -1.34 0.07 -1.21 0.10 No No W544Q -1.24 0.08 -1.17 0.08 NA NA Yes No W544E -1.14 0.05 -1.44 0.05 -1.54 0.06 No No W544G -1.68 0.03 -1.47 0.03 -1.55 0.04 No No W544H -0.01 0.08 -1.46 0.13 NA NA Yes No W544L -1.76 0.06 -1.40 0.05 -1.41 0.04 No No W544K -2.26 0.11 -1.33 0.07 -1.39 0.08 No No W544M -2.09 0.11 -1.42 0.08 -1.45 0.15 No No W544F -0.96 0.09 -1.72 0.12 NA NA Yes No W544P -1.84 0.09 -1.34 0.08 -1.51 0.09 No No W544S -0.66 0.03 -0.59 0.03 -0.57 0.03 No No W544* -0.85 0.05 -1.05 0.05 -1.09 0.07 No No W544T -1.81 0.09 -1.08 0.07 -1.83 0.17 No No W544V -1.60 0.05 -1.52 0.05 -1.52 0.09 No No D545A -1.34 0.06 -1.18 0.06 -1.75 0.13 No No D545R -2.22 0.08 -1.82 0.06 -1.53 0.12 No No D545N -1.00 0.10 -0.89 0.09 -1.05 0.15 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? D545C -2.14 0.13 -1.41 0.10 NA NA Yes No D545E -1.54 0.07 -2.07 0.09 -1.66 0.14 No No D545G -1.30 0.04 -1.13 0.04 -1.44 0.07 No No D545H -1.20 0.14 -0.72 0.12 NA NA Yes No D545L -1.77 0.08 -1.23 0.06 -1.75 0.21 No No D545K -1.83 0.15 -1.54 0.14 NA NA Yes No D545M -1.30 0.11 -0.90 0.10 NA NA Yes No D545P -1.73 0.12 -1.07 0.09 NA NA Yes No D545S -0.99 0.06 -0.97 0.06 -1.65 0.18 No No D545T -2.02 0.14 -1.36 0.10 -1.24 0.25 No No D545W -2.52 0.12 -2.44 0.12 -1.79 0.16 No No D545Y -1.34 0.12 -1.40 0.12 NA NA Yes No D545V -1.90 0.07 -1.31 0.05 -1.58 0.10 No No V546A 0.05 0.04 -0.28 0.04 -1.03 0.08 Yes No V546R -0.34 0.04 -0.10 0.04 -0.24 0.05 No No V546D -1.89 0.14 -0.98 0.10 -1.80 0.23 No No V546C -0.63 0.08 0.12 0.06 -1.17 0.18 Yes No V546Q -0.14 0.09 -0.04 0.08 -0.37 0.22 No No V546E -0.85 0.06 -0.72 0.06 -1.16 0.10 No No V546G -0.89 0.03 -0.75 0.03 -1.38 0.06 No No V546I 0.17 0.09 -0.21 0.10 -0.01 0.36 Yes No V546L -0.09 0.04 -0.03 0.04 -0.77 0.12 No No V546K -0.23 0.09 -0.07 0.09 -0.28 0.09 No No V546M -0.48 0.06 -0.39 0.06 -0.14 0.11 No No V546F -0.58 0.10 -1.20 0.13 NA NA Yes No V546S -0.24 0.05 -0.75 0.06 -1.19 0.07 No No V546* -1.55 0.12 -1.19 0.10 -1.56 0.23 No No V546T 0.15 0.07 -0.59 0.09 -0.82 0.09 Yes No V546W -1.75 0.08 -1.06 0.06 -1.43 0.15 No No V546Y 0.40 0.10 -0.50 0.13 -0.45 0.39 Yes No N547A -0.97 0.06 -0.81 0.06 -1.74 0.12 No No N547R -0.75 0.04 -0.98 0.05 -1.25 0.05 No No N547D -1.06 0.08 -0.98 0.08 -1.08 0.12 No No N547E -1.13 0.07 -1.64 0.09 NA NA Yes No N547G -0.99 0.04 -1.38 0.05 -1.68 0.04 No No N547I -0.57 0.10 -0.69 0.10 -0.97 0.15 No No N547L -2.14 0.12 -1.01 0.07 -1.56 0.18 No No N547K -0.72 0.08 -0.48 0.07 -0.83 0.12 No No N547S -0.69 0.06 -0.98 0.06 -1.07 0.09 No No N547T -2.13 0.13 -1.62 0.11 NA NA Yes No N547W -1.69 0.09 -1.84 0.10 NA NA Yes No N547Y -0.39 0.10 -0.94 0.12 -1.04 0.21 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? N547V -1.63 0.07 -1.46 0.07 -1.86 0.15 No No K548A -1.24 0.04 -1.12 0.04 -1.74 0.03 No No K548R -0.59 0.02 -0.51 0.02 -0.18 0.03 No No K548N -0.98 0.07 -1.11 0.08 -1.10 0.09 No No K548D -2.69 0.13 -1.63 0.08 -2.01 0.14 No No K548C -0.97 0.06 -0.64 0.05 -1.44 0.14 No No K548Q -0.31 0.04 -0.24 0.04 -0.41 0.06 No No K548E -1.54 0.05 -1.45 0.05 -1.51 0.04 No No K548G -1.14 0.02 -0.95 0.02 -1.61 0.02 No No K548H -1.58 0.14 -1.58 0.14 NA NA Yes No K548I -1.05 0.07 -1.27 0.08 -0.98 0.06 No No K548L -1.72 0.06 -1.56 0.05 -1.96 0.08 No No K548M -0.27 0.04 -0.19 0.04 -1.10 0.10 No No K548F -2.01 0.12 -1.60 0.10 NA NA Yes No K548P -1.78 0.09 -1.04 0.07 -1.86 0.16 No No K548S -0.97 0.04 -0.55 0.03 -1.40 0.08 No No K548* -1.65 0.08 -0.85 0.06 -1.40 0.13 No No K548T -0.12 0.04 -0.74 0.05 -1.19 0.07 No No K548W -2.13 0.07 -1.65 0.05 -1.44 0.07 No No K548Y -1.07 0.09 -1.63 0.11 NA NA Yes No K548V -0.72 0.03 -0.39 0.03 -0.97 0.05 No No E549A -1.80 0.06 -1.49 0.05 -1.69 0.07 No No E549R -1.64 0.05 -1.69 0.05 -1.80 0.09 No No E549D -1.63 0.09 -1.13 0.07 -1.53 0.14 No No E549C -2.08 0.12 -1.84 0.11 -1.56 0.18 No No E549Q -0.41 0.05 -0.41 0.05 -0.80 0.10 No No E549G -1.50 0.03 -1.53 0.03 -1.60 0.04 No No E549I -1.07 0.12 -1.12 0.13 NA NA Yes No E549L -1.62 0.07 -1.31 0.06 -1.65 0.13 No No E549K -0.91 0.07 -0.89 0.07 -0.99 0.08 No No E549M -2.06 0.12 -1.66 0.10 -1.57 0.17 No No E549F -1.59 0.14 -1.27 0.13 NA NA Yes No E549S -2.21 0.08 -1.69 0.07 -1.91 0.05 No No E549* -1.66 0.09 -1.47 0.09 -1.59 0.14 No No E549T NA NA NA NA -1.39 0.10 Yes No E549W -0.99 0.05 -1.72 0.07 -1.85 0.11 No No E549V -1.01 0.04 -0.79 0.04 -1.37 0.04 No No K550R 0.05 0.03 0.18 0.03 0.17 0.07 Yes Yes K550A -0.24 0.04 -0.06 0.04 -0.91 0.13 No No K550N 0.11 0.07 -0.13 0.07 -0.46 0.13 Yes No K550D -0.86 0.09 0.22 0.07 -1.48 0.23 Yes No K550C -0.08 0.07 -0.18 0.07 -0.84 0.21 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? K550Q -0.18 0.07 0.45 0.07 -0.64 0.18 Yes No K550E -0.86 0.06 -0.45 0.05 -1.11 0.09 No No K550G -0.25 0.02 -0.16 0.02 -1.14 0.04 No No K550H -0.22 0.15 -0.42 0.16 NA NA Yes No K550I -0.51 0.12 0.79 0.09 NA NA Yes No K550L 0.01 0.05 -0.17 0.05 -0.95 0.06 Yes No K550M -0.71 0.08 -0.17 0.07 -0.72 0.15 No No K550F -0.14 0.10 -0.39 0.11 NA NA Yes No K550P -0.02 0.08 -0.78 0.10 -0.95 0.27 No No K550S -0.07 0.05 -0.22 0.05 -1.05 0.08 No No K550* -0.98 0.08 -1.14 0.09 -1.19 0.10 No No K550T -0.13 0.06 -0.44 0.07 -0.87 0.14 No No K550W 0.18 0.04 0.20 0.04 -0.66 0.07 Yes No K550Y -0.12 0.11 -0.58 0.12 NA NA Yes No K550V -0.12 0.04 -0.70 0.05 -1.02 0.13 No No N551D 0.14 0.04 0.15 0.04 0.67 0.07 Yes Yes N551A -0.29 0.04 -0.42 0.04 -0.37 0.05 No No N551R -0.92 0.04 -1.40 0.05 -1.64 0.09 No No N551C -0.52 0.08 -0.26 0.08 -0.39 0.28 No No N551Q. -0.77 0.09 -0.58 0.08 -0.76 0.10 No No N551E -1.32 0.06 -0.66 0.05 -1.51 0.10 No No N551G -0.95 0.03 -0.96 0.03 -1.10 0.04 No No N551H 0.51 0.09 -1.02 0.14 0.55 0.13 Yes No N551I -0.01 0.05 0.20 0.05 -0.18 0.11 Yes No N551L -0.07 0.05 -0.83 0.06 -1.35 0.11 No No N551K -1.43 0.07 -1.28 0.07 -1.22 0.08 No No N551M -1.01 0.09 -0.58 0.08 -0.94 0.18 No No N551F -0.65 0.11 -0.19 0.09 -0.04 0.24 No No N551P -1.24 0.10 -0.91 0.09 -1.21 0.12 No No N551S -0.06 0.03 0.02 0.03 -0.23 0.05 Yes No N551* -1.09 0.10 -1.44 0.11 -1.45 0.20 No No N551T 0.21 0.05 -0.29 0.06 0.07 0.11 Yes No N551W -0.36 0.06 -0.69 0.06 -0.63 0.13 No No N551Y -0.28 0.07 0.04 0.06 0.95 0.10 Yes No N551V -0.31 0.04 -0.21 0.04 0.03 0.05 Yes No N552A -1.33 0.07 -1.21 0.07 -1.32 0.08 No No N552R -1.19 0.04 -1.37 0.05 -1.47 0.04 No No N552D -1.18 0.07 -1.04 0.06 -1.24 0.06 No No N552C -1.59 0.10 -1.44 0.09 -1.65 0.17 No No N552Q -1.21 0.11 -0.81 0.10 NA NA Yes No N552E -1.93 0.09 -0.57 0.05 -1.89 0.06 No No N552G -1.80 0.05 -1.17 0.04 -2.06 0.03 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? N552H -0.25 0.10 -0.21 0.10 NA NA Yes No N552I -0.34 0.05 -0.02 0.05 -0.50 0.09 No No N552L -1.13 0.07 -1.91 0.10 -1.73 0.12 No No N552K -1.34 0.08 -1.25 0.08 -1.07 0.10 No No N552M -1.92 0.12 -1.44 0.10 -1.67 0.11 No No N552P -1.69 0.12 -0.81 0.09 NA NA Yes No N552S -0.11 0.03 -0.20 0.03 -0.58 0.05 No No N552* NA NA NA NA -1.37 0.20 Yes No N552T -0.16 0.03 0.00 0.03 -1.04 0.10 No No N552W -1.97 0.10 -1.69 0.08 -1.53 0.15 No No N552Y -0.89 0.10 -0.99 0.10 -1.08 0.18 No No N552V -1.60 0.07 -1.17 0.06 -1.56 0.05 No No G553A -0.56 0.05 -0.61 0.05 -1.53 0.11 No No G553R -1.58 0.06 -1.17 0.05 -0.39 0.07 No No G553D -0.48 0.08 -0.91 0.09 -0.94 0.19 No No G553Q -1.38 0.15 -1.10 0.14 NA NA Yes No G553E -2.07 0.11 -1.79 0.10 -1.67 0.17 No No G553S -0.78 0.06 -0.54 0.06 -0.72 0.09 No No G553* -1.04 0.12 -1.39 0.14 NA NA Yes No G553W -1.11 0.07 -1.87 0.09 -1.59 0.16 No No G553V -0.34 0.03 -0.24 0.03 -0.30 0.05 No No A554I 0.15 0.09 0.71 0.08 0.39 0.34 Yes Yes A554T 0.45 0.04 0.32 0.05 0.93 0.07 Yes Yes A554V 0.57 0.03 0.48 0.03 0.54 0.04 Yes Yes A554R -1.28 0.05 -1.12 0.05 -2.05 0.11 No No A554N 0.04 0.09 -0.71 0.11 -0.12 0.13 Yes No A554D -1.96 0.10 -0.95 0.07 -0.83 0.04 No No A554C -0.05 0.07 0.32 0.06 1.05 0.09 Yes No A554Q -0.47 0.10 -0.57 0.10 -1.06 0.28 No No A554E -1.85 0.09 -0.79 0.06 -1.86 0.11 No No A554G -0.43 0.03 -0.54 0.03 -0.70 0.04 No No A554L -0.23 0.05 -0.11 0.05 -0.32 0.17 No No A554M 0.27 0.07 -0.26 0.08 -0.72 0.23 Yes No A554P -1.28 0.09 -1.84 0.12 NA NA Yes No A554S 0.14 0.03 0.15 0.03 -0.07 0.05 Yes No A554* -1.77 0.14 -1.03 0.11 NA NA Yes No A554W -1.54 0.09 -2.63 0.14 NA NA Yes No 1555V 0.41 0.03 0.13 0.03 0.14 0.06 Yes Yes I555A -0.39 0.05 -0.48 0.05 -0.79 0.14 No No I555R -0.47 0.04 -1.21 0.05 -0.58 0.09 No No I555N -0.51 0.08 -0.76 0.08 -0.76 0.13 No No I555D -1.00 0.09 -1.17 0.10 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? I555C -1.00 0.12 -0.93 0.12 -0.75 0.10 No No I555Q -0.79 0.11 -0.92 0.11 -0.84 0.21 No No I555E -2.31 0.12 -0.09 0.05 -1.79 0.15 No No I555G -1.15 0.04 -1.07 0.04 -1.57 0.03 No No I555L 0.18 0.05 -0.03 0.05 -0.30 0.14 Yes No I555K -0.71 0.09 -0.03 0.07 -1.33 0.11 No No I555M -0.04 0.05 -0.01 0.05 -0.27 0.08 No No I555F -0.18 0.09 -0.17 0.09 -0.32 0.13 No No I555P -1.29 0.11 -1.66 0.13 -1.11 0.36 No No I555S -0.16 0.03 -0.12 0.03 -0.31 0.05 No No I555T -0.01 0.05 -0.09 0.05 -0.45 0.11 No No I555W -1.78 0.11 -1.29 0.09 -1.81 0.15 No No I555Y -1.05 0.14 -1.16 0.15 NA NA Yes No L556M 0.08 0.08 0.10 0.08 0.11 0.21 Yes Yes L556A -0.52 0.07 -1.77 0.12 -1.33 0.24 No No L556R -1.06 0.06 -0.91 0.06 -1.39 0.10 No No L556C -1.31 0.13 -0.58 0.10 NA NA Yes No L556Q -0.06 0.06 -0.34 0.07 -0.36 0.11 No No L556G -1.55 0.07 -1.49 0.07 -1.60 0.06 No No L556I 0.58 0.12 0.07 0.14 NA NA Yes No L556P -0.19 0.07 -0.54 0.08 -0.91 0.13 No No L556S -1.56 0.11 -1.28 0.10 NA NA Yes No L556T -0.95 0.12 -0.69 0.11 NA NA Yes No L556W -1.77 0.12 -1.41 0.11 NA NA Yes No L556V -0.45 0.06 -0.17 0.05 -0.76 0.14 No No F557A -0.39 0.05 -0.06 0.05 -0.75 0.07 No No F557R -1.79 0.06 -1.05 0.05 -1.57 0.08 No No F557N NA NA NA NA -0.90 0.11 Yes No F557C -0.63 0.06 -0.55 0.06 -0.32 0.13 No No F557Q -1.87 0.15 -0.40 0.09 -0.98 0.25 No No F557E -1.90 0.10 -1.64 0.09 -1.50 0.16 No No F557G -1.17 0.04 -1.02 0.04 -0.98 0.06 No No F557I -0.32 0.05 -0.07 0.04 -0.05 0.08 No No F557L -0.04 0.04 -0.08 0.04 0.14 0.08 Yes No F557K -1.25 0.10 -0.84 0.09 -0.79 0.30 No No F557M 0.33 0.07 -0.19 0.08 -0.15 0.18 Yes No F557P -1.14 0.10 -1.38 0.11 -1.69 0.21 No No F557S -0.87 0.05 -0.74 0.05 -0.48 0.09 No No F557* -1.30 0.10 -2.32 0.15 NA NA Yes No F557T -1.21 0.09 -0.72 0.08 -0.44 0.25 No No F557W -0.87 0.06 -0.37 0.05 -1.24 0.11 No No F557Y -0.74 0.08 -0.15 0.07 -0.87 0.13 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? F557V -0.50 0.04 -0.91 0.05 -0.42 0.04 No No V558M 0.24 0.06 0.15 0.06 0.10 0.12 Yes Yes V558A -0.11 0.04 -0.13 0.04 0.26 0.09 Yes No V558R -0.63 0.06 -0.46 0.05 -0.26 0.14 No No V558D 0.64 0.09 0.05 0.10 -0.46 0.14 Yes No V558C -0.01 0.12 0.01 0.12 -0.28 0.55 Yes No V558Q 0.40 0.11 -0.65 0.14 -0.21 0.55 Yes No V558E 0.15 0.04 -0.31 0.05 -0.12 0.07 Yes No V558G -0.07 0.03 -0.48 0.04 -0.36 0.10 No No V558L 0.16 0.04 0.03 0.04 -0.16 0.09 Yes No V558K 0.05 0.10 -0.15 0.11 -0.02 0.48 Yes No V558F -0.21 0.13 -0.36 0.13 NA NA Yes No V558S -0.36 0.09 -0.49 0.09 -0.10 0.27 No No V558T -0.19 0.12 -0.28 0.12 0.15 0.41 Yes No V558W -0.76 0.10 -0.75 0.10 -0.93 0.30 No No K559A 0.17 0.04 0.08 0.04 0.13 0.08 Yes Yes K559R 0.14 0.03 -0.02 0.03 0.11 0.06 Yes No K559N 0.05 0.03 0.05 0.03 -0.04 0.05 Yes No K559D 0.25 0.08 -0.33 0.09 -0.39 0.25 Yes No K559C 0.31 0.08 -0.20 0.09 -0.05 0.22 Yes No K559Q -0.23 0.07 0.03 0.07 0.00 0.21 Yes No K559E -0.20 0.04 -0.52 0.04 -0.40 0.06 No No K559G -0.35 0.03 -0.41 0.03 -0.16 0.03 No No K559H 0.53 0.14 -0.21 0.16 NA NA Yes No K559I -0.62 0.12 0.01 0.10 NA NA Yes No K559L -0.39 0.06 -0.29 0.06 -0.71 0.13 No No K559M -0.27 0.06 -0.65 0.07 0.01 0.12 Yes No K559F -0.45 0.13 0.13 0.11 NA NA Yes No K559S -0.28 0.06 -0.32 0.06 0.22 0.20 Yes No K559* -0.63 0.07 -0.48 0.07 -1.15 0.09 No No K559T 0.30 0.06 0.52 0.06 -0.20 0.15 Yes No K559W -0.64 0.06 -0.34 0.06 -0.32 0.18 No No K559Y -0.13 0.11 -0.01 0.11 NA NA Yes No K559V -0.53 0.05 -0.50 0.05 -0.27 0.13 No No N560A 0.34 0.05 0.18 0.05 0.18 0.08 Yes Yes N560D 0.16 0.04 0.18 0.04 0.16 0.08 Yes Yes N560E 0.48 0.06 0.28 0.06 0.11 0.25 Yes Yes N560M 0.16 0.09 0.31 0.09 0.18 0.13 Yes Yes N560R 0.10 0.04 0.04 0.04 -0.07 0.06 Yes No N560C -0.11 0.08 -0.20 0.08 -0.15 0.09 No No N560Q 0.55 0.09 -1.07 0.14 -0.09 0.38 Yes No N560G 0.01 0.04 0.03 0.04 -0.02 0.09 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? N560H -0.35 0.13 -0.17 0.13 NA NA Yes No N560I 0.22 0.05 0.28 0.05 -0.13 0.10 Yes No N560L -0.64 0.08 -0.16 0.07 -0.12 0.11 No No N560K 0.11 0.06 -0.29 0.07 0.14 0.14 Yes No N560F 0.14 0.12 -0.03 0.13 NA NA Yes No N560P 0.19 0.09 -0.69 0.11 -0.13 0.29 Yes No N560S 0.03 0.03 0.18 0.03 -0.01 0.05 Yes No N560* -1.15 0.11 -1.78 0.15 NA NA Yes No N560T -0.40 0.08 0.00 0.07 0.01 0.14 Yes No N560W -0.36 0.07 -0.72 0.08 -0.27 0.16 No No N560Y -0.24 0.09 0.04 0.08 0.07 0.12 Yes No N560V 0.13 0.06 -0.15 0.06 -0.11 0.16 Yes No G561A -0.10 0.05 -0.36 0.06 -0.05 0.07 No No G561R -0.20 0.04 0.00 0.04 -0.16 0.05 No No G561N 0.20 0.16 1.09 0.14 NA NA Yes No G561D -0.43 0.11 0.54 0.08 -0.03 0.27 Yes No G561C -0.19 0.08 0.03 0.08 -0.26 0.27 Yes No G561Q -0.15 0.12 0.67 0.10 -0.08 0.26 Yes No G561E 0.14 0.06 -0.19 0.06 -0.05 0.14 Yes No G561H 0.74 0.14 1.07 0.14 NA NA Yes No G561L -0.57 0.09 -0.30 0.09 -0.60 0.09 No No G561K 0.24 0.12 0.17 0.12 NA NA Yes No G561M -0.33 0.14 0.12 0.12 NA NA Yes No G561P -0.84 0.12 -0.45 0.11 0.02 0.17 Yes No G561S 0.00 0.06 0.54 0.05 -0.09 0.18 Yes No G561* -0.53 0.11 -0.01 0.09 NA NA Yes No G561T 0.10 0.09 -0.87 0.13 -0.23 0.34 Yes No G561W -0.47 0.06 -0.34 0.06 -0.51 0.17 No No G561V -0.02 0.02 -0.04 0.02 0.08 0.06 Yes No L562A -0.46 0.07 -0.26 0.07 -0.17 0.22 No No L562R -0.38 0.05 0.08 0.04 -0.17 0.08 Yes No L562D -0.37 0.13 -0.90 0.15 -0.46 0.35 No No L562C 0.18 0.10 -0.63 0.12 0.13 0.29 Yes No L562Q -0.43 0.09 -0.20 0.08 -0.07 0.17 No No L562E -0.32 0.07 -0.62 0.08 -0.29 0.18 No No L562G -0.75 0.05 -0.60 0.05 -0.36 0.08 No No L562H 0.23 0.12 -0.50 0.15 NA NA Yes No L562K -0.69 0.12 0.32 0.09 -0.53 0.29 Yes No L562M 0.19 0.06 -0.26 0.07 -0.04 0.12 Yes No L562F 0.48 0.14 0.79 0.13 NA NA Yes No L562P -0.10 0.06 -0.05 0.06 -0.26 0.09 No No L562S -0.65 0.10 -0.27 0.09 -0.04 0.26 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? L562* -1.29 0.14 -1.10 0.13 NA NA Yes No L562T -1.14 0.15 -1.09 0.15 NA NA Yes No L562W -0.37 0.07 -0.38 0.07 -0.45 0.18 No No L562Y -0.63 0.16 -0.49 0.16 NA NA Yes No L562V -0.20 0.05 -0.49 0.06 -0.71 0.11 No No Y563A -1.58 0.09 -1.18 0.08 -1.03 0.07 No No Y563R -1.46 0.06 -1.08 0.05 -1.59 0.11 No No Y563N -0.16 0.08 0.04 0.07 -0.30 0.16 Yes No Y563D -0.56 0.07 -0.65 0.07 -0.73 0.07 No No Y563C -0.49 0.06 -0.50 0.06 -0.32 0.09 No No Y563Q -0.48 0.10 -0.52 0.10 -0.93 0.25 No No Y563E -1.21 0.08 0.07 0.06 -1.73 0.14 Yes No Y563G -1.13 0.04 -1.64 0.05 -1.26 0.03 No No Y563H -0.25 0.08 -0.14 0.08 -0.06 0.15 No No Y563L -1.95 0.12 -1.69 0.11 -1.15 0.19 No No Y563F 0.13 0.07 0.06 0.07 -0.06 0.11 Yes No Y563S -0.91 0.07 -0.95 0.07 -0.96 0.08 No No Y563* -0.54 0.08 -0.93 0.09 -1.33 0.14 No No Y563T -1.67 0.15 0.09 0.08 -0.51 0.22 Yes No Y563W -0.84 0.06 -0.78 0.05 -1.12 0.11 No No Y563V -1.32 0.08 -1.12 0.07 -1.13 0.17 No No Y564A -1.20 0.15 -0.93 0.14 NA NA Yes No Y564R -1.37 0.10 -1.99 0.13 -1.19 0.19 No No Y564N -0.18 0.12 0.08 0.11 -0.14 0.21 Yes No Y564D -0.05 0.06 -0.60 0.07 -0.25 0.10 No No Y564C 0.09 0.05 -0.22 0.05 -0.08 0.10 Yes No Y564G -1.96 0.11 -1.74 0.10 -1.32 0.19 No No Y564H -0.05 0.08 -0.10 0.08 0.04 0.13 Yes No Y564L -0.24 0.10 -1.01 0.13 NA NA Yes No Y564F -0.04 0.11 0.35 0.10 NA NA Yes No Y564S -0.47 0.09 -0.36 0.08 -0.35 0.20 No No Y564* -0.43 0.11 -0.68 0.12 NA NA Yes No Y564W -0.37 0.10 0.03 0.09 -0.52 0.29 Yes No Y564V -1.90 0.15 -0.72 0.10 NA NA Yes No L565A -0.65 0.07 -0.47 0.06 -1.27 0.23 No No L565R -0.27 0.03 -0.79 0.03 -0.12 0.05 No No L565C -1.21 0.13 -0.10 0.09 -0.66 0.24 No No L565Q -0.36 0.08 -0.84 0.09 -0.76 0.15 No No L565E -1.93 0.12 -1.02 0.09 -1.55 0.19 No No L565G -2.36 0.08 -1.62 0.06 -1.50 0.10 No No L565I -0.07 0.13 -0.42 0.14 NA NA Yes No L565M -0.20 0.07 -0.26 0.07 0.03 0.10 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? L565P -0.60 0.07 -0.92 0.08 -0.67 0.13 No No L565S -1.07 0.09 -0.75 0.08 -1.13 0.08 No No L565W -1.64 0.10 -2.31 0.13 NA NA Yes No L565V -0.57 0.06 -0.48 0.05 -1.19 0.13 No No G566A -0.36 0.08 -0.39 0.08 -0.57 0.21 No No G566R -1.37 0.09 -1.97 0.12 -1.83 0.11 No No G566D -0.67 0.11 -1.03 0.12 -0.62 0.18 No No G566C -0.08 0.11 -0.83 0.13 NA NA Yes No G566S -0.14 0.06 -0.40 0.07 -0.18 0.11 No No G566V -0.52 0.07 -0.99 0.08 -0.68 0.10 No No I567A -1.35 0.11 -1.01 0.09 -1.13 0.07 No No I567R -1.78 0.09 -0.11 0.05 -1.44 0.11 No No I567N -0.05 0.07 -0.10 0.07 0.15 0.10 Yes No I567E -1.64 0.12 -1.70 0.13 NA NA Yes No I567G -1.23 0.06 -1.14 0.06 -1.70 0.09 No No I567L -0.67 0.08 0.29 0.06 -0.48 0.13 Yes No I567M -0.51 0.09 -0.82 0.10 -0.88 0.10 No No I567F -0.43 0.12 0.00 0.11 -0.48 0.19 No No I567S -0.56 0.07 -0.67 0.07 -0.82 0.12 No No I567T -0.15 0.05 -0.27 0.06 0.13 0.09 Yes No I567W -1.85 0.12 -2.17 0.14 -1.22 0.13 No No 1567V -0.54 0.05 -0.26 0.05 -0.68 0.08 No No M568A -0.52 0.06 -0.34 0.06 -0.04 0.11 No No M568R -0.30 0.04 -0.82 0.05 -0.20 0.07 No No M568C -0.33 0.10 -0.78 0.11 -0.18 0.28 No No M568Q -0.61 0.12 -0.40 0.12 NA NA Yes No M568E -1.29 0.09 -0.86 0.08 -1.65 0.22 No No M568G -1.32 0.05 -0.45 0.04 -0.80 0.04 No No M568H 0.40 0.14 -0.11 0.15 NA NA Yes No M568I 0.16 0.05 -0.01 0.06 0.15 0.11 Yes No M568L -0.42 0.06 -0.23 0.05 -0.27 0.09 No No M568K -0.19 0.08 -0.20 0.08 -0.17 0.16 No No M568P -1.11 0.13 -0.81 0.12 NA NA Yes No M568S 0.29 0.06 -0.47 0.07 -0.54 0.22 Yes No M568T -0.13 0.06 -0.25 0.06 -0.07 0.12 No No M568W -0.20 0.06 0.14 0.05 -0.93 0.18 Yes No M568V -0.26 0.04 -0.28 0.04 0.06 0.08 Yes No P569D 0.60 0.08 0.33 0.08 1.25 0.11 Yes Yes P569A -0.12 0.05 -0.39 0.05 0.23 0.08 Yes No P569R -0.60 0.04 -0.52 0.04 -0.13 0.05 No No P569N -0.14 0.14 -0.71 0.16 NA NA Yes No P569C -1.16 0.09 -0.36 0.07 0.07 0.19 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? P569Q -0.26 0.09 -0.13 0.09 0.40 0.21 Yes No P569E -0.07 0.07 -0.16 0.07 -0.11 0.22 No No P569G -0.54 0.03 -0.49 0.03 -0.65 0.07 No No P569H 0.12 0.09 -0.25 0.10 0.16 0.17 Yes No P569I 0.03 0.13 -0.32 0.14 0.10 0.31 Yes No P569L -0.47 0.05 -0.21 0.04 -0.30 0.11 No No P569K -0.35 0.12 0.36 0.10 0.23 0.31 Yes No P569M -0.98 0.11 -0.54 0.10 -0.28 0.12 No No P569F NA NA NA NA -0.67 0.31 Yes No P569S -0.07 0.05 -0.24 0.05 0.02 0.11 Yes No P569T -0.38 0.07 -0.20 0.07 -0.06 0.15 No No P569W -0.74 0.06 -1.07 0.07 -1.18 0.14 No No P569V -0.34 0.04 -0.82 0.05 0.15 0.14 Yes No K570A -0.95 0.06 -0.28 0.05 -1.70 0.16 No No K570R -0.47 0.03 -0.56 0.04 -0.39 0.05 No No K570N -0.30 0.11 -0.73 0.12 NA NA Yes No K570D -1.38 0.12 -1.42 0.13 NA NA Yes No K570C -1.71 0.11 -1.70 0.11 NA NA Yes No K570Q -0.90 0.09 -0.32 0.08 -1.25 0.18 No No K570E -1.37 0.07 -0.71 0.05 -1.40 0.10 No No K570G -0.62 0.03 -0.33 0.03 -1.61 0.09 No No K570L -1.83 0.08 -1.48 0.07 -1.35 0.14 No No K570M -1.02 0.09 -0.76 0.09 -1.52 0.18 No No K570P -1.15 0.12 -0.12 0.09 NA NA Yes No K570S -1.28 0.09 -0.51 0.07 -1.52 0.14 No No K570* -1.31 0.10 -1.26 0.10 -1.24 0.15 No No K570T -0.02 0.03 0.11 0.03 -0.05 0.03 Yes No K570W -2.06 0.09 -2.64 0.12 -1.61 0.14 No No K570V -1.33 0.06 -0.81 0.05 -1.85 0.11 No No Q571A 0.64 0.07 0.39 0.08 1.09 0.23 Yes Yes Q571P 0.17 0.07 0.61 0.07 0.13 0.14 Yes Yes Q571S 0.25 0.09 0.20 0.09 0.89 0.23 Yes Yes Q571T 0.22 0.13 0.19 0.13 0.87 0.41 Yes Yes Q571R -0.03 0.04 -0.43 0.05 0.19 0.10 Yes No Q571C -0.60 0.16 0.23 0.12 -0.33 0.24 Yes No Q571E -0.22 0.05 -0.40 0.06 -0.17 0.05 No No Q571G 0.00 0.06 -0.25 0.06 -0.41 0.18 No No Q571H -0.23 0.11 -0.65 0.12 0.06 0.24 Yes No Q571L -0.41 0.07 -0.45 0.07 -0.66 0.11 No No Q571K -0.47 0.16 -0.33 0.15 0.08 0.31 Yes No Q571* -0.59 0.11 -0.27 0.10 -0.67 0.17 No No Q571W -0.09 0.08 -0.80 0.09 -0.51 0.24 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? Q571V -0.36 0.11 -0.20 0.10 -0.44 0.32 No No K572E 0.11 0.04 0.25 0.04 0.42 0.08 Yes Yes K572A -0.24 0.04 0.33 0.04 -0.11 0.11 Yes No K572R -0.08 0.03 -0.05 0.03 0.03 0.03 Yes No K572N -0.17 0.07 0.17 0.06 0.02 0.11 Yes No K572D -0.09 0.09 0.03 0.08 0.45 0.19 Yes No K572C 0.23 0.07 -0.87 0.09 -0.19 0.25 Yes No K572Q -0.21 0.06 0.11 0.06 0.37 0.16 Yes No K572G -0.17 0.03 -0.08 0.03 0.42 0.03 Yes No K572H NA NA NA NA 0.11 0.33 Yes No K572L -0.11 0.05 0.16 0.05 -0.32 0.15 Yes No K572M -0.71 0.08 0.02 0.06 0.21 0.06 Yes No K572P 0.09 0.06 0.91 0.06 -0.88 0.23 Yes No K572S 0.30 0.05 0.01 0.05 -0.29 0.15 Yes No K572* -1.34 0.08 -0.86 0.07 -0.86 0.08 No No K572T -0.04 0.04 -0.09 0.04 -0.24 0.07 No No K572W -0.46 0.05 -0.47 0.05 -0.68 0.14 No No K572Y -1.04 0.16 -1.01 0.15 NA NA Yes No K572V -0.08 0.04 -0.31 0.04 -0.71 0.04 No No G573A 0.04 0.04 -0.11 0.04 -0.99 0.09 Yes No G573R -0.04 0.03 -0.31 0.04 -0.66 0.08 No No G573N 0.45 0.12 -0.94 0.17 -0.29 0.41 Yes No G573D -0.05 0.06 -0.41 0.07 -0.95 0.13 No No G573C -0.22 0.06 -0.35 0.06 -0.42 0.11 No No G573Q 0.40 0.07 -0.29 0.08 -0.43 0.26 Yes No G573E -0.09 0.05 0.36 0.05 -0.50 0.08 Yes No G573H -0.77 0.12 0.37 0.09 -0.51 0.30 Yes No G573L -0.04 0.05 0.07 0.05 -0.43 0.05 Yes No G573K -1.43 0.13 -0.29 0.09 -0.32 0.25 No No G573M -0.32 0.10 -0.32 0.09 -0.28 0.26 No No G573F -0.45 0.14 -0.19 0.12 NA NA Yes No G573P 0.16 0.06 -0.38 0.06 -0.10 0.21 Yes No G573S 0.11 0.04 -0.42 0.05 -0.55 0.10 Yes No G573* -1.18 0.12 -1.27 0.12 -0.75 0.28 No No G573T 0.02 0.08 -0.53 0.09 -0.62 0.08 Yes No G573W -0.08 0.05 -0.60 0.05 -0.67 0.09 No No G573Y 0.13 0.11 -0.81 0.14 -0.48 0.30 Yes No G573V -0.06 0.04 -0.40 0.04 -0.71 0.06 No No R574A -0.83 0.07 -0.54 0.06 -0.64 0.10 No No R574N -0.85 0.17 -0.69 0.16 NA NA Yes No R574D -0.32 0.10 -1.05 0.13 NA NA Yes No R574C 0.58 0.07 0.15 0.07 -1.16 0.22 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? R574Q NA NA NA NA -1.08 0.26 Yes No R574E -0.53 0.08 -0.38 0.07 -1.34 0.15 No No R574G -0.21 0.03 -0.27 0.03 -0.60 0.07 No No R574I -0.50 0.11 -0.47 0.11 NA NA Yes No R574L -0.36 0.07 -0.25 0.07 -0.78 0.18 No No R574K -0.33 0.08 0.42 0.06 -0.33 0.17 Yes No R574M 0.51 0.07 -0.36 0.08 -0.64 0.07 Yes No R574F 0.06 0.12 -0.99 0.16 NA NA Yes No R574P -0.38 0.13 0.11 0.11 -0.72 0.23 Yes No R574S 0.12 0.04 0.02 0.04 -1.04 0.03 Yes No R574* -0.34 0.07 -0.51 0.07 -0.84 0.09 No No R574T -0.65 0.09 0.35 0.07 -0.83 0.16 Yes No R574W -0.10 0.05 -0.10 0.05 -0.73 0.06 No No R574Y -0.25 0.12 0.13 0.11 NA NA Yes No R574V 0.59 0.05 -0.27 0.05 -1.08 0.14 Yes No Y575G 0.53 0.04 0.21 0.04 0.32 0.07 Yes Yes Y575M 0.89 0.11 0.27 0.12 0.31 0.41 Yes Yes Y575A 0.55 0.05 0.01 0.06 -0.07 0.18 Yes No Y575R 0.15 0.05 -0.04 0.06 -0.56 0.10 Yes No Y575N -0.07 0.10 0.34 0.09 -0.21 0.10 Yes No Y575D -0.07 0.09 0.15 0.09 -0.45 0.25 Yes No Y575C 0.20 0.06 0.17 0.06 -0.26 0.09 Yes No Y575Q -0.22 0.13 -0.32 0.13 -0.16 0.30 No No Y575E 0.03 0.08 -0.32 0.09 -0.41 0.35 Yes No Y575H -0.24 0.08 -0.29 0.08 0.23 0.13 Yes No Y575I 0.04 0.14 -0.37 0.15 NA NA Yes No Y575L -0.05 0.07 -0.43 0.08 -0.22 0.23 No No Y575K 0.95 0.11 0.22 0.12 NA NA Yes No Y575F 0.14 0.08 -0.45 0.09 -0.16 0.12 Yes No Y575P -0.06 0.09 -0.22 0.09 -0.14 0.31 No No Y575S 0.02 0.06 0.01 0.06 -0.07 0.09 Yes No Y575* -0.20 0.07 -0.46 0.08 -0.51 0.12 No No Y575T -0.55 0.10 -0.40 0.09 -0.14 0.30 No No Y575W -0.44 0.09 0.31 0.07 -0.36 0.16 Yes No Y575V -0.10 0.07 -0.35 0.07 -0.29 0.24 No No K576C 0.27 0.07 0.25 0.07 0.10 0.26 Yes Yes K576A -0.05 0.05 0.16 0.05 0.27 0.06 Yes No K576R -0.31 0.03 -0.11 0.03 0.05 0.07 Yes No K576N -0.28 0.08 -0.47 0.08 -0.11 0.15 No No K576D -0.01 0.08 -0.22 0.09 -1.04 0.26 No No K576Q -0.06 0.06 0.02 0.05 0.57 0.08 Yes No K576E -0.63 0.05 -0.38 0.05 -0.27 0.09 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? K576G -0.03 0.03 -0.13 0.03 0.28 0.04 Yes No K576H -0.26 0.14 -0.46 0.14 NA NA Yes No K576I 0.10 0.11 -0.10 0.12 0.37 0.16 Yes No K576L -0.04 0.05 0.01 0.04 0.24 0.05 Yes No K576M 0.21 0.05 -0.14 0.06 0.07 0.09 Yes No K576F -0.41 0.13 -1.12 0.15 0.20 0.34 Yes No K576P -0.07 0.09 -1.70 0.14 -0.15 0.17 No No K576S -0.20 0.05 -0.43 0.06 0.64 0.15 Yes No K576* -1.75 0.10 -1.41 0.08 -0.09 0.15 No No K576T -0.05 0.06 0.30 0.05 0.20 0.08 Yes No K576W -0.33 0.05 -0.65 0.05 -0.56 0.13 No No K576Y -1.23 0.16 -0.48 0.12 NA NA Yes No K576V -0.36 0.04 -0.69 0.05 0.38 0.07 Yes No A577R -0.12 0.03 -0.60 0.04 0.88 0.06 Yes No A577N 0.11 0.09 -0.85 0.11 0.34 0.13 Yes No A577D -0.06 0.05 -0.11 0.05 -0.37 0.13 No No A577C -0.24 0.06 -0.02 0.06 -0.39 0.20 No No A577Q -0.37 0.07 0.63 0.06 0.10 0.23 Yes No A577E -0.66 0.05 -2.12 0.09 -0.27 0.14 No No A577G 0.22 0.02 -0.05 0.03 0.49 0.05 Yes No A577H 0.02 0.08 -0.59 0.10 0.25 0.22 Yes No A577I -0.94 0.12 -0.35 0.10 NA NA Yes No A577L -0.90 0.06 -0.37 0.05 -0.15 0.06 No No A577K -0.40 0.08 -0.80 0.09 1.09 0.07 Yes No A577M -0.40 0.08 -0.20 0.07 -0.28 0.20 No No A577F -0.79 0.11 -0.99 0.12 -0.78 0.19 No No A577P -0.25 0.06 -0.11 0.05 -0.29 0.11 No No A577S -0.31 0.04 -0.26 0.04 0.08 0.10 Yes No A577* -1.65 0.11 -1.75 0.11 NA NA Yes No A577T -0.09 0.05 -0.38 0.05 -0.02 0.08 No No A577W -0.63 0.05 -0.66 0.05 -0.66 0.08 No No A577Y -0.22 0.09 -0.20 0.09 0.05 0.32 Yes No A577V -0.06 0.03 -0.28 0.04 -0.42 0.09 No No L578A -0.22 0.03 -0.43 0.03 -0.20 0.07 No No L578R -0.11 0.02 -0.49 0.02 0.04 0.03 Yes No L578N -0.35 0.11 -0.09 0.10 -0.47 0.23 No No L578D -0.09 0.06 -0.41 0.06 -0.92 0.07 No No L578C 0.05 0.04 -0.34 0.05 -0.03 0.10 Yes No L578Q 0.11 0.04 -0.12 0.05 0.00 0.10 Yes No L578E -0.33 0.04 -0.53 0.04 -0.77 0.12 No No L578G -0.26 0.02 -0.45 0.02 -0.29 0.02 No No L578H -0.27 0.07 0.10 0.06 0.03 0.14 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? L578I -0.28 0.09 0.32 0.08 0.22 0.23 Yes No L578K -0.62 0.07 -1.21 0.09 0.50 0.20 Yes No L578M -0.12 0.03 -0.21 0.03 -0.03 0.05 No No L578F 0.36 0.06 0.21 0.06 -0.12 0.14 Yes No L578P -0.62 0.05 0.03 0.04 -0.31 0.06 Yes No L578S -0.37 0.04 -0.33 0.04 -0.08 0.09 No No L578* -1.90 0.09 -1.28 0.07 -1.24 0.09 No No L578T -0.29 0.06 -0.06 0.05 0.26 0.06 Yes No L578W -0.37 0.03 -0.41 0.03 -0.08 0.04 No No L578Y 0.36 0.07 -0.21 0.07 -0.24 0.07 Yes No L578V -0.19 0.03 -0.28 0.03 0.01 0.04 Yes No S579T 0.17 0.04 0.33 0.04 0.01 0.06 Yes Yes S579V 0.04 0.03 0.02 0.03 0.05 0.07 Yes Yes S579A -0.06 0.03 0.06 0.02 0.08 0.03 Yes No S579R 0.04 0.03 -0.11 0.03 -0.15 0.05 Yes No S579N -0.19 0.07 -0.45 0.08 -0.39 0.23 No No S579D -0.39 0.06 -0.43 0.06 0.03 0.06 Yes No S579C 0.02 0.03 0.07 0.03 -0.02 0.05 Yes No S579Q -0.19 0.07 -0.66 0.08 0.30 0.20 Yes No S579E -0.10 0.04 -0.54 0.05 -0.15 0.05 No No S579G -0.25 0.03 -0.12 0.02 0.11 0.05 Yes No S579H 0.09 0.08 -0.15 0.08 -0.18 0.12 Yes No S579I -0.05 0.06 0.25 0.06 0.04 0.15 Yes No S579L -0.65 0.04 -0.32 0.04 0.11 0.05 Yes No S579K -0.15 0.06 -0.55 0.07 0.13 0.22 Yes No S579M -0.18 0.06 0.05 0.05 0.28 0.19 Yes No S579F 0.27 0.04 0.16 0.04 -0.08 0.07 Yes No S579P -0.19 0.05 -0.75 0.05 -0.05 0.10 No No S579* -1.34 0.08 -1.06 0.07 -1.30 0.11 No No S579W -0.09 0.04 -0.35 0.04 -0.37 0.06 No No S579Y -0.06 0.05 -0.21 0.05 -0.36 0.04 No No F580A -0.80 0.08 -0.25 0.07 -1.44 0.19 No No F580R -1.58 0.09 -1.48 0.08 -1.26 0.19 No No F580C -0.22 0.09 -0.47 0.10 -0.11 0.18 No No F580E -0.96 0.12 -0.21 0.09 NA NA Yes No F580G -0.91 0.05 -1.05 0.05 -1.21 0.04 No No F580I -0.14 0.09 -0.06 0.09 -0.17 0.28 No No F580L -0.11 0.05 -0.28 0.05 0.01 0.09 Yes No F580M 0.31 0.12 -0.37 0.14 NA NA Yes No F580P NA NA NA NA -0.75 0.28 Yes No F580S -0.22 0.07 -0.70 0.07 -0.67 0.10 No No F580W -1.14 0.10 0.30 0.07 0.67 0.24 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? F580Y 0.39 0.11 -0.45 0.14 -0.09 0.23 Yes No F580V 0.18 0.06 -0.33 0.06 -0.52 0.13 Yes No E581A -0.08 0.03 0.16 0.03 -0.13 0.06 Yes No E581R -0.31 0.03 -0.14 0.03 -0.36 0.04 No No E581N -0.14 0.15 0.56 0.13 NA NA Yes No E581D 0.04 0.06 0.25 0.06 -0.21 0.09 Yes No E581C 0.12 0.07 0.54 0.06 -0.12 0.15 Yes No E581Q 0.01 0.04 0.09 0.04 -0.12 0.06 Yes No E581G -0.15 0.02 -0.05 0.02 -0.03 0.03 No No E581H -0.31 0.12 1.00 0.10 -0.67 0.35 Yes No E581I -0.12 0.14 0.03 0.13 0.40 0.44 Yes No E581L 0.09 0.04 -0.12 0.04 0.29 0.12 Yes No E581K -0.10 0.05 -0.02 0.05 -0.33 0.07 No No E581M -0.05 0.08 -0.79 0.09 0.12 0.13 Yes No E581F -0.32 0.11 -0.09 0.10 -0.40 0.30 No No E581P -0.49 0.07 -0.09 0.06 -0.25 0.13 No No E581S 0.00 0.05 -1.01 0.06 -0.11 0.06 Yes No E581* -1.00 0.07 -0.93 0.07 -0.92 0.13 No No E581T -0.23 0.07 -0.29 0.07 0.06 0.09 Yes No E581W 0.25 0.04 -0.31 0.04 0.04 0.05 Yes No E581Y NA NA NA NA 0.25 0.28 Yes No E581V -0.18 0.04 0.31 0.03 0.26 0.10 Yes No P582A -0.46 0.07 -0.64 0.07 -0.60 0.13 No No P582R 0.24 0.05 -0.24 0.06 -0.48 0.17 Yes No P582N -0.02 0.05 -0.24 0.05 -0.22 0.11 No No P582D -0.41 0.18 -0.64 0.18 NA NA Yes No P582C 0.14 0.11 -0.07 0.12 0.17 0.64 Yes No P582Q -0.74 0.13 -0.13 0.11 -0.07 0.25 No No P582G -0.10 0.06 -0.80 0.07 -0.50 0.18 No No P582H -0.03 0.02 -0.15 0.02 -0.12 0.04 No No P582L -0.14 0.07 -0.96 0.08 -0.26 0.13 No No P582K -0.33 0.19 0.97 0.15 NA NA Yes No P582F NA NA NA NA 0.02 0.55 Yes No P582S 0.19 0.06 0.48 0.05 -1.33 0.16 Yes No P582T -0.13 0.03 -0.19 0.03 -0.48 0.06 No No P582W -1.46 0.15 -0.73 0.11 -0.12 0.35 No No P582V -0.90 0.10 -0.27 0.08 -0.81 0.09 No No T583I 0.04 0.08 0.11 0.07 0.07 0.17 Yes Yes T583A 0.02 0.04 -0.22 0.04 -0.17 0.08 Yes No T583R 0.12 0.05 -0.31 0.05 -0.04 0.09 Yes No T583N 0.00 0.06 0.01 0.06 -0.20 0.09 Yes No T583D 0.23 0.12 -0.96 0.16 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? T583C 0.67 0.09 -0.82 0.12 -0.67 0.27 Yes No T583Q NA NA NA NA -0.28 0.36 Yes No T583E -0.62 0.10 0.01 0.09 -0.72 0.28 Yes No T583G -0.17 0.05 -0.35 0.05 0.16 0.06 Yes No T583L -0.09 0.06 -0.72 0.07 -0.24 0.22 No No T583K NA NA NA NA -0.15 0.44 Yes No T583M -0.72 0.13 -0.89 0.14 -0.12 0.32 No No T583F -0.41 0.13 -0.83 0.15 -0.13 0.36 No No T583P -0.14 0.08 -0.64 0.08 -0.37 0.14 No No T583S 0.18 0.05 0.11 0.05 -0.34 0.07 Yes No T583W -0.31 0.07 -0.54 0.08 -0.09 0.08 No No T583V 0.01 0.06 -0.05 0.06 0.15 0.22 Yes No E584H 0.09 0.07 0.22 0.07 0.17 0.14 Yes Yes E584V 0.10 0.03 0.06 0.03 0.12 0.04 Yes Yes E584A -0.01 0.03 0.09 0.03 0.10 0.06 Yes No E584R -0.23 0.03 -0.12 0.03 -0.10 0.05 No No E584N -0.50 0.09 -0.38 0.08 -0.11 0.20 No No E584D 0.46 0.04 0.51 0.04 -0.02 0.08 Yes No E584C -0.03 0.05 0.09 0.05 0.13 0.07 Yes No E584Q 0.09 0.07 -0.88 0.08 -0.09 0.10 Yes No E584G -0.02 0.02 0.06 0.02 0.16 0.04 Yes No E584I 0.32 0.07 -0.34 0.08 -0.03 0.20 Yes No E584L -0.27 0.04 0.00 0.04 -0.06 0.10 No No E584K -0.29 0.06 -0.78 0.07 0.39 0.09 Yes No E584M -0.17 0.07 -0.68 0.08 0.34 0.13 Yes No E584F -0.11 0.08 -0.41 0.09 0.27 0.19 Yes No E584P 0.12 0.05 -0.13 0.06 -0.24 0.17 Yes No E584S -0.44 0.04 0.09 0.04 0.26 0.09 Yes No E584* -1.22 0.09 -1.26 0.08 -1.15 0.13 No No E584T -0.03 0.05 -0.03 0.05 0.17 0.15 Yes No E584W -0.73 0.06 -0.52 0.05 -0.32 0.07 No No E584Y -0.13 0.07 0.55 0.06 0.05 0.25 Yes No K585R 0.07 0.03 0.32 0.03 0.06 0.05 Yes Yes K585F 0.51 0.09 0.04 0.09 0.61 0.36 Yes Yes K585A 0.21 0.04 -0.23 0.05 0.16 0.13 Yes No K585N -0.13 0.09 0.18 0.08 -0.67 0.12 Yes No K585D -0.05 0.07 -0.08 0.07 -0.05 0.23 No No K585C -0.25 0.07 -0.61 0.08 -0.11 0.29 No No K585Q 0.07 0.06 0.41 0.06 -0.09 0.08 Yes No K585E -0.33 0.05 -0.44 0.05 0.10 0.12 Yes No K585G -0.18 0.03 -0.04 0.03 0.16 0.04 Yes No K585H 0.12 0.11 -0.60 0.13 0.28 0.14 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? K585I -1.45 0.14 0.35 0.08 0.11 0.25 Yes No K585L -0.10 0.04 -0.06 0.04 0.27 0.13 Yes No K585M -0.25 0.07 -0.05 0.06 0.21 0.17 Yes No K585P 0.20 0.06 -0.04 0.07 0.15 0.21 Yes No K585S -0.17 0.05 0.24 0.04 0.20 0.11 Yes No K585* -0.91 0.07 -0.60 0.06 -0.61 0.11 No No K585T 0.08 0.05 -0.30 0.05 0.05 0.07 Yes No K585W -0.21 0.05 -0.15 0.05 0.18 0.16 Yes No K585Y 0.18 0.10 -0.92 0.13 0.07 0.40 Yes No K585V -0.16 0.04 -0.68 0.04 0.37 0.06 Yes No T586A -0.30 0.05 -0.02 0.04 -0.01 0.11 No No T586R -0.56 0.05 -0.06 0.04 -0.20 0.14 No No T586N -0.07 0.05 0.15 0.05 -0.02 0.07 Yes No T586D -0.41 0.12 1.10 0.09 0.41 0.30 Yes No T586C -0.60 0.11 -0.45 0.10 0.10 0.29 Yes No T586Q -0.65 0.14 0.28 0.11 NA NA Yes No T586E -0.29 0.09 0.04 0.08 0.16 0.37 Yes No T586G -0.21 0.04 0.22 0.03 -0.07 0.09 Yes No T586I -0.77 0.11 0.90 0.07 -0.48 0.19 Yes No T586L -0.06 0.06 -0.85 0.07 0.01 0.18 Yes No T586K -0.06 0.12 0.80 0.10 -0.12 0.13 Yes No T586M -0.62 0.11 -1.06 0.13 0.22 0.34 Yes No T586F 0.21 0.13 -0.21 0.14 0.02 0.54 Yes No T586P 0.38 0.06 -0.09 0.06 0.22 0.12 Yes No T586S -0.22 0.05 -0.08 0.05 0.01 0.08 Yes No T586W -0.48 0.07 -0.61 0.07 -0.29 0.24 No No T586Y NA NA NA NA 0.24 0.26 Yes No T586V -0.97 0.07 -0.13 0.05 0.13 0.17 Yes No S587A NA NA NA NA 0.45 0.32 Yes No S587R 0.15 0.08 -0.61 0.09 -0.34 0.15 Yes No S587N -0.30 0.13 -0.31 0.13 -0.26 0.18 No No S587C 0.01 0.15 0.00 0.14 NA NA Yes No S587E 0.33 0.16 -0.40 0.19 NA NA Yes No S587G -0.32 0.06 -0.81 0.07 -0.21 0.06 No No S587L 0.21 0.14 0.27 0.13 NA NA Yes No S587T 0.80 0.11 -0.41 0.14 -0.13 0.23 Yes No S587V 0.20 0.11 -0.25 0.12 -0.04 0.12 Yes No E588A -0.01 0.05 0.25 0.05 0.17 0.10 Yes No E588R -0.39 0.05 -0.61 0.05 -0.31 0.07 No No E588D 0.00 0.08 -0.12 0.08 -0.55 0.13 Yes No E588C -0.64 0.11 -0.35 0.10 0.00 0.10 No No E588Q 0.11 0.09 -0.25 0.09 -0.08 0.13 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? E588G -0.16 0.04 -0.19 0.04 -0.34 0.04 No No E588H -0.35 0.17 -0.26 0.16 NA NA Yes No E588L -0.31 0.07 -0.29 0.07 0.41 0.12 Yes No E588K 0.18 0.07 0.13 0.07 -0.25 0.15 Yes No E588M -0.50 0.12 -0.10 0.11 0.54 0.12 Yes No E588F -0.23 0.15 0.13 0.14 NA NA Yes No E588P -0.04 0.10 0.06 0.09 0.52 0.19 Yes No E588S -0.03 0.07 -0.34 0.08 -0.47 0.08 No No E588* -1.05 0.11 -1.06 0.11 -1.02 0.15 No No E588T 0.32 0.09 -1.53 0.15 NA NA Yes No E588W -0.02 0.07 0.03 0.07 -0.01 0.19 Yes No E588Y -0.11 0.17 0.93 0.14 NA NA Yes No E588V -0.70 0.06 -0.19 0.05 0.07 0.08 Yes No G589A -0.44 0.05 -0.09 0.04 -0.52 0.14 No No G589R -0.21 0.04 -0.73 0.04 -0.69 0.07 No No G589D -0.29 0.08 -0.88 0.10 -0.70 0.17 No No G589C -0.14 0.04 -0.12 0.04 -0.59 0.07 No No G589Q NA NA NA NA -0.13 0.27 Yes No G589E -0.39 0.06 -1.47 0.08 -0.59 0.24 No No G589L 0.07 0.06 -1.02 0.08 -1.07 0.20 Yes No G589M -0.45 0.12 -1.01 0.14 NA NA Yes No G589P -0.34 0.08 -2.17 0.15 -1.08 0.12 No No G589S -0.13 0.04 -0.30 0.04 -0.54 0.10 No No G589T -0.52 0.11 -0.51 0.10 -1.12 0.28 No No G589W -0.62 0.06 -0.77 0.07 -0.26 0.13 No No G589Y NA NA NA NA -0.01 0.41 Yes No G589V -0.65 0.05 -0.97 0.06 -0.22 0.13 No No F590A -0.43 0.05 -1.38 0.07 -1.07 0.15 No No F590R -0.22 0.05 -0.83 0.05 -0.62 0.15 No No F590N -0.95 0.17 -0.65 0.15 NA NA Yes No F590C -0.49 0.08 -0.73 0.08 -1.06 0.20 No No F590E -1.00 0.09 -1.26 0.10 -0.44 0.26 No No F590G -1.05 0.04 -1.44 0.05 -1.47 0.09 No No F590I 0.01 0.09 0.10 0.08 NA NA Yes No F590L -0.02 0.04 -0.21 0.04 -0.51 0.06 No No F590M -0.27 0.12 -0.41 0.12 NA NA Yes No F590P -1.08 0.10 -1.31 0.10 -1.37 0.17 No No F590S -0.03 0.05 -0.29 0.05 -0.61 0.07 No No F590T -1.50 0.15 -1.08 0.12 NA NA Yes No F590W 0.04 0.07 -0.11 0.07 -0.87 0.26 Yes No F590Y 0.07 0.06 -0.18 0.07 -0.19 0.17 Yes No F590V -1.03 0.06 -0.97 0.06 -0.98 0.14 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? D591A 0.20 0.04 0.07 0.04 -0.54 0.05 Yes No D591R -0.94 0.05 -1.06 0.05 -0.45 0.13 No No D591N -0.49 0.10 -0.61 0.10 -0.54 0.14 No No D591C -0.66 0.10 -0.68 0.09 -0.47 0.23 No No D591Q -0.34 0.10 0.11 0.09 -0.15 0.38 Yes No D591E -0.43 0.05 -0.39 0.05 -0.84 0.14 No No D591G -0.62 0.03 -0.81 0.03 -0.59 0.03 No No D591H -1.19 0.16 -0.84 0.14 NA NA Yes No D591L -0.17 0.06 -0.59 0.07 -0.99 0.20 No No D591K -0.51 0.12 -0.27 0.11 NA NA Yes No D591M -0.90 0.12 -0.93 0.12 -0.36 0.27 No No D591S -0.69 0.07 -1.41 0.09 -0.67 0.17 No No D591T -0.15 0.08 -0.93 0.10 -1.04 0.23 No No D591W -1.02 0.08 -0.91 0.07 -0.42 0.16 No No D591Y 0.08 0.10 -0.62 0.12 -0.50 0.17 Yes No D591V -0.76 0.05 -1.11 0.05 -1.12 0.11 No No K592A -1.60 0.09 -0.60 0.06 -1.42 0.15 No No K592R -0.98 0.05 -0.77 0.04 -1.03 0.05 No No K592N -0.12 0.10 0.07 0.10 -0.91 0.19 Yes No K592Q -0.52 0.07 -0.77 0.08 -0.30 0.10 No No K592E -0.52 0.07 -0.76 0.07 -1.22 0.10 No No K592G -1.76 0.06 -1.45 0.05 -1.64 0.08 No No K592L -1.72 0.08 -1.52 0.08 -1.24 0.13 No No K592M -0.70 0.07 -0.58 0.07 -0.68 0.07 No No K592P -1.70 0.14 -1.63 0.13 NA NA Yes No K592S -1.67 0.10 -1.56 0.10 NA NA Yes No K592* 0.00 0.08 -1.63 0.13 -0.91 0.18 Yes No K592T -1.38 0.11 -0.98 0.09 NA NA Yes No K592W -1.60 0.10 -1.14 0.08 -0.21 0.20 No No K592V -1.60 0.06 -1.14 0.05 -1.90 0.08 No No M593A -1.94 0.07 -1.00 0.05 -1.73 0.06 No No M593R -0.79 0.03 -0.81 0.03 -0.81 0.03 No No M593N -1.58 0.13 -1.89 0.15 NA NA Yes No M593D -2.12 0.13 -1.32 0.09 -1.77 0.18 No No M593C -0.95 0.07 -0.04 0.06 -1.27 0.10 No No M593Q NA NA NA NA -0.83 0.19 Yes No M593E -2.30 0.10 -2.14 0.09 -1.55 0.14 No No M593G -1.83 0.04 -1.88 0.04 -1.09 0.07 No No M593I -0.83 0.07 -1.05 0.08 -1.17 0.12 No No M593L -0.10 0.03 -0.33 0.03 -0.52 0.06 No No M593K -1.64 0.09 -1.56 0.08 -1.09 0.05 No No M593F -1.98 0.12 -0.83 0.08 -1.61 0.12 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? M593P -1.56 0.10 -2.23 0.12 -0.38 0.12 No No M593S -1.58 0.06 -1.88 0.07 -1.33 0.11 No No M593* -2.T1 0.12 -2.28 0.12 -1.55 0.18 No No M593T -1.01 0.06 -0.79 0.05 -0.64 0.10 No No M593W -0.92 0.05 -1.57 0.07 -2.41 0.16 No No M593V -0.56 0.03 -1.41 0.04 -1.07 0.07 No No Y594A -0.40 0.04 -1.29 0.05 -1.34 0.10 No No Y594R -0.02 0.03 -0.18 0.03 -1.14 0.08 No No Y594N -1.08 0.10 -0.80 0.08 -0.62 0.15 No No Y594D -1.17 0.07 -1.36 0.07 -1.43 0.13 No No Y594C -0.47 0.06 -0.08 0.06 -1.45 0.10 No No Y594Q -1.06 0.08 -0.26 0.06 -1.14 0.12 No No Y594E -0.42 0.04 -0.82 0.05 -2.58 0.11 No No Y594G -1.21 0.03 -1.58 0.03 -1.51 0.04 No No Y594H 0.04 0.07 -0.11 0.07 -0.42 0.12 Yes No Y594I -0.73 0.10 -0.78 0.10 -0.74 0.27 No No Y594L -0.88 0.05 -0.67 0.04 -1.45 0.10 No No Y594K -0.40 0.06 -0.88 0.07 -1.41 0.17 No No Y594M 0.05 0.06 -0.76 0.07 -1.47 0.18 Yes No Y594F -0.18 0.07 -0.07 0.06 -0.45 0.14 No No Y594S -1.00 0.05 -0.88 0.05 -1.40 0.06 No No Y594* -1.41 0.08 -0.73 0.06 -1.67 0.13 No No Y594T -1.66 0.09 -1.71 0.09 -1.37 0.15 No No Y594W -0.33 0.04 -0.93 0.05 -1.06 0.10 No No Y594V -0.40 0.04 -0.47 0.04 -0.96 0.08 No No Y595A -1.63 0.05 -1.08 0.04 -2.32 0.10 No No Y595R -1.29 0.04 -1.66 0.05 -2.00 0.06 No No Y595N -1.61 0.14 -0.78 0.10 -0.80 0.19 No No Y595D -1.27 0.09 -1.50 0.09 -1.84 0.06 No No Y595C -0.14 0.05 -0.50 0.05 -1.06 0.11 No No Y595Q -1.71 0.10 -1.18 0.08 -1.13 0.22 No No Y595E -2.05 0.08 -2.21 0.08 -2.32 0.03 No No Y595G -1.67 0.03 -1.31 0.03 -1.77 0.03 No No Y595H -0.86 0.09 -0.57 0.08 -0.77 0.13 No No Y595I -1.20 0.14 -1.49 0.15 NA NA Yes No Y595L -0.09 0.04 0.08 0.04 -0.83 0.12 Yes No Y595K -1.17 0.09 -1.74 0.11 NA NA Yes No Y595M 0.24 0.06 -0.10 0.07 -0.34 0.19 Yes No Y595F -1.21 0.09 -0.70 0.08 -1.09 0.14 No No Y595S -1.31 0.05 -1.19 0.05 -1.64 0.09 No No Y595* -1.32 0.07 -1.52 0.08 -1.60 0.09 No No Y595T -0.27 0.05 -0.81 0.06 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? Y595W -1.72 0.06 -1.71 0.06 -1.97 0.10 No No Y595V -0.32 0.03 -0.74 0.04 -2.00 0.06 No No D596E 0.04 0.04 0.24 0.04 0.69 0.05 Yes Yes D596A 0.07 0.03 -0.18 0.04 -0.99 0.09 Yes No D596R 0.01 0.03 0.07 0.03 -0.20 0.04 Yes No D596N -0.12 0.08 0.29 0.08 0.39 0.15 Yes No D596C -0.01 0.07 -0.24 0.07 -0.55 0.06 No No D596Q -0.04 0.09 0.42 0.08 0.46 0.31 Yes No D596G -0.23 0.02 -0.22 0.02 -1.16 0.05 No No D596H 0.24 0.10 -0.18 0.11 0.16 0.26 Yes No D596L -0.92 0.07 -0.10 0.05 -0.75 0.18 No No D596K 0.01 0.08 0.36 0.07 -0.07 0.19 Yes No D596M 0.26 0.08 0.29 0.07 -0.27 0.28 Yes No D596F 0.03 0.11 -0.55 0.13 0.09 0.13 Yes No D596P NA NA NA NA -0.56 0.24 Yes No D596S -0.58 0.06 -0.29 0.05 0.37 0.07 Yes No D596* -0.99 0.11 -1.29 0.12 NA NA Yes No D596T -1.56 0.12 0.65 0.06 -1.10 0.23 Yes No D596W -0.19 0.05 0.12 0.05 -1.34 0.11 Yes No D596Y -0.55 0.09 -0.32 0.08 -0.27 0.16 No No D596V -0.06 0.03 -0.22 0.03 -1.39 0.08 No No Y597A -2.00 0.06 -1.33 0.05 -2.10 0.12 No No Y597R -2.18 0.05 -2.13 0.05 -2.18 0.04 No No Y597N -1.28 0.11 -0.66 0.09 -1.35 0.13 No No Y597D -0.30 0.03 -0.28 0.03 -0.34 0.04 No No Y597C -0.79 0.06 -1.14 0.07 -1.47 0.05 No No Y597E -2.33 0.09 -2.41 0.09 NA NA Yes No Y597G -1.89 0.04 -2.15 0.04 -1.96 0.05 No No Y597H -0.45 0.07 -0.25 0.06 -0.71 0.10 No No Y597I -0.51 0.11 -1.26 0.13 NA NA Yes No Y597L 0.24 0.04 0.32 0.04 -0.31 0.09 Yes No Y597M -0.11 0.07 -1.15 0.10 NA NA Yes No Y597F -0.08 0.07 -0.16 0.07 0.56 0.06 Yes No Y597P -2.03 0.11 -2.30 0.11 NA NA Yes No Y597S -1.25 0.05 -1.04 0.05 -2.00 0.09 No No Y597* -0.94 0.06 -0.96 0.06 -2.02 0.13 No No Y597T -1.78 0.09 -2.62 0.12 -1.94 0.04 No No Y597W -1.16 0.05 -1.33 0.05 -2.30 0.08 No No Y597V -1.95 0.07 -1.63 0.06 -2.69 0.08 No No F598A -1.68 0.07 -1.98 0.08 -2.09 0.12 No No F598R -1.81 0.06 -2.21 0.07 -1.57 0.11 No No F598C -1.96 0.12 -2.25 0.13 -1.21 0.15 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? F598G -2.06 0.05 -1.79 0.04 -0.96 0.03 No No F598I -0.32 0.09 -0.44 0.09 -0.75 0.12 No No F598L -0.25 0.04 -0.09 0.04 -0.65 0.04 No No F598M -0.35 0.09 -0.55 0.09 -0.87 0.27 No No F598P NA NA NA NA -1.93 0.07 Yes No F598S -1.12 0.06 -1.33 0.06 -1.35 0.08 No No F598W -1.23 0.06 -0.34 0.05 -1.74 0.12 No No F598Y -0.52 0.09 -0.44 0.09 -0.60 0.15 No No F598V -1.37 0.06 -1.39 0.05 -2.25 0.09 No No P599G 0.84 0.04 0.83 0.04 1.01 0.05 Yes Yes P599A -1.03 0.07 -0.85 0.06 -1.42 0.11 No No P599R -1.89 0.09 -1.20 0.06 -2.08 0.14 No No P599N -0.66 0.16 -0.33 0.14 NA NA Yes No P599E -2.04 0.15 -2.07 0.15 NA NA Yes No P599H -1.01 0.14 -0.99 0.14 NA NA Yes No P599L -1.56 0.09 -1.36 0.08 -1.46 0.11 No No P599S -0.09 0.03 -0.10 0.03 -0.56 0.04 No No P599* -1.14 0.13 -1.42 0.14 NA NA Yes No P599T -0.42 0.07 -0.95 0.08 -1.37 0.14 No No P599V -1.88 0.12 -1.85 0.11 -1.81 0.14 No No D600A 0.43 0.06 -0.31 0.07 0.68 0.14 Yes No D600R -0.88 0.07 -0.40 0.06 -1.67 0.19 No No D600N -0.03 0.07 -0.16 0.07 0.67 0.14 Yes No D600C NA NA NA NA -0.32 0.48 Yes No D600Q -0.37 0.15 -0.01 0.13 NA NA Yes No D600E -0.44 0.07 -0.46 0.07 -0.95 0.22 No No D600G -0.19 0.04 -0.33 0.04 1.07 0.05 Yes No D600H -0.08 0.13 -0.54 0.14 NA NA Yes No D600L -1.26 0.13 -1.19 0.12 -0.50 0.29 No No D600P -0.14 0.11 -1.46 0.16 0.47 0.45 Yes No D600S 0.86 0.07 -0.03 0.08 0.74 0.14 Yes No D600T -1.42 0.15 -0.70 0.12 0.43 0.29 Yes No D600W -0.67 0.11 -0.51 0.10 NA NA Yes No D600Y -0.29 0.13 -0.19 0.12 NA NA Yes No D600V -0.05 0.06 -0.23 0.06 -0.56 0.13 No No A601R -1.65 0.07 -1.62 0.07 NA NA Yes No A601D -1.38 0.13 -1.10 0.11 NA NA Yes No A601C 0.26 0.08 0.26 0.08 -0.25 0.24 Yes No A601G -1.05 0.04 -0.63 0.04 -1.44 0.04 No No A601L -2.16 0.13 -1.44 0.09 NA NA Yes No A601P -1.40 0.13 -1.20 0.11 NA NA Yes No A601S -0.60 0.06 0.23 0.04 -0.52 0.08 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? A601T -0.84 0.08 -0.53 0.07 -0.99 0.12 No No A601W -1.89 0.12 -1.84 0.11 NA NA Yes No A601V -0.48 0.05 -0.23 0.04 -0.77 0.06 No No A602C 0.64 0.09 0.61 0.09 0.73 0.28 Yes Yes A602R -0.59 0.07 -0.97 0.08 NA NA Yes No A602D 0.04 0.04 -0.09 0.04 -0.40 0.05 Yes No A602G -0.52 0.05 -0.56 0.05 -1.62 0.06 No No A602H NA NA NA NA 0.37 0.35 Yes No A602L -1.97 0.14 -1.06 0.10 NA NA Yes No A602P -0.80 0.09 -0.42 0.08 -0.71 0.15 No No A602S -0.38 0.07 -0.14 0.06 -0.73 0.16 No No A602T -0.28 0.06 -0.03 0.06 -0.51 0.11 No No A602W NA NA NA NA -0.89 0.37 Yes No A602V -0.77 0.06 -0.66 0.05 -1.41 0.10 No No K603A -1.34 0.07 -1.59 0.07 -1.76 0.05 No No K603R -0.56 0.04 -0.37 0.03 -0.46 0.04 No No K603N -1.59 0.16 -1.11 0.13 NA NA Yes No K603C -1.03 0.10 -1.23 0.10 NA NA Yes No K603Q -1.30 0.11 -1.57 0.12 NA NA Yes No K603E -1.40 0.07 -0.68 0.05 -1.60 0.10 No No K603G -1.88 0.05 -1.70 0.04 -1.97 0.08 No No K603H NA NA NA NA -0.51 0.41 Yes No K603L -0.77 0.06 -0.60 0.06 -1.63 0.14 No No K603M 0.00 0.06 -0.57 0.07 -1.02 0.11 No No K603P -1.70 0.12 -1.06 0.09 NA NA Yes No K603S NA NA NA NA -2.06 0.05 Yes No K603* -1.20 0.09 -1.66 0.11 -1.37 0.16 No No K603T -1.11 0.08 -1.15 0.08 -1.13 0.13 No No K603W -2.79 0.14 -1.74 0.09 -1.45 0.14 No No K603V -1.72 0.07 -1.54 0.06 -2.40 0.07 No No M604A -2.19 0.15 -1.92 0.13 NA NA Yes No M604R -0.96 0.06 -1.76 0.08 -2.02 0.13 No No M604G -2.12 0.08 -0.82 0.05 -1.81 0.12 No No M604I -0.58 0.10 -0.71 0.10 -0.51 0.15 No No M604L -0.74 0.06 -0.50 0.06 -0.25 0.06 No No M604K -1.08 0.15 -0.78 0.13 NA NA Yes No M604T -0.14 0.06 0.01 0.06 -0.44 0.09 Yes No M604W -1.97 0.14 -2.03 0.14 NA NA Yes No M604V -1.38 0.08 -1.32 0.07 -1.38 0.09 No No I605A -1.32 0.09 -1.04 0.08 NA NA Yes No I605R -2.07 0.09 -2.36 0.10 -2.12 0.15 No No I605N -0.93 0.10 -0.19 0.08 -0.76 0.16 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? I605C 0.20 0.09 -0.98 0.13 NA NA Yes No I605G -1.69 0.07 -1.41 0.06 -2.04 0.14 No No I605L -0.93 0.07 -0.25 0.06 -1.49 0.14 No No I605M -1.09 0.09 -0.86 0.08 -1.44 0.15 No No I605F -0.50 0.11 -0.52 0.10 NA NA Yes No I605S -1.91 0.11 -1.82 0.10 -1.55 0.10 No No I605T -0.45 0.07 -0.67 0.07 -1.09 0.12 No No 1605V 0.13 0.05 -0.04 0.05 -0.33 0.11 Yes No I605A -1.42 0.10 -0.82 0.08 NA NA Yes No I605R -2.12 0.09 -2.15 0.10 -1.82 0.16 No No I605N 0.04 0.06 0.36 0.06 -0.41 0.09 Yes No I605D -1.00 0.09 -0.60 0.08 -0.72 0.14 No No I605C 0.10 0.10 -0.82 0.13 NA NA Yes No I605G -1.69 0.07 -1.23 0.06 -1.96 0.13 No No I605L -0.10 0.03 0.14 0.03 -1.00 0.08 Yes No I605M -0.89 0.09 -0.63 0.08 -1.25 0.21 No No I605F -0.55 0.10 -0.33 0.09 NA NA Yes No I605S -0.22 0.04 0.10 0.04 -1.29 0.08 Yes No I605T -0.02 0.04 0.21 0.04 -0.53 0.07 Yes No 1605V 0.19 0.05 0.25 0.05 -0.06 0.10 Yes No P606A -1.59 0.10 -2.27 0.12 -1.25 0.17 No No P606R -1.77 0.08 -2.62 0.12 -1.94 0.15 No No P606G -1.63 0.07 -2.12 0.08 -1.89 0.14 No No P606H -0.89 0.13 -0.93 0.13 NA NA Yes No P606L -0.77 0.07 -1.12 0.08 -1.30 0.15 No No P606S -1.42 0.10 -1.22 0.09 -1.16 0.14 No No P606T -0.06 0.06 -0.63 0.07 -0.40 0.08 No No P606W -0.88 0.11 -1.05 0.11 NA NA Yes No P606V NA NA NA NA -1.59 0.24 Yes No P606A -1.59 0.10 -2.27 0.14 -1.33 0.19 No No P606R -1.77 0.09 -1.59 0.08 -1.76 0.15 No No P606Q NA NA NA NA -0.43 0.12 Yes No P606G -1.73 0.08 -2.00 0.09 -1.79 0.16 No No P606H 0.13 0.07 0.17 0.07 -0.14 0.04 Yes No P606L -0.98 0.08 -1.23 0.09 -1.00 0.16 No No P606S -1.64 0.12 -1.35 0.11 -1.37 0.17 No No P606T -0.10 0.07 -0.63 0.08 -0.65 0.11 No No P606W -1.06 0.12 -0.93 0.11 NA NA Yes No P606V NA NA NA NA -1.33 0.27 Yes No K607A -1.61 0.05 -1.70 0.06 -2.05 0.10 No No K607R -1.65 0.04 -1.32 0.03 -2.05 0.03 No No K607N -0.51 0.07 -0.19 0.07 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? K607D -2.48 0.14 -1.83 0.11 NA NA Yes No K607C -1.09 0.07 -1.20 0.08 NA NA Yes No K607Q -1.77 0.09 -1.64 0.09 -1.87 0.13 No No K607E -1.93 0.06 -1.40 0.05 -1.61 0.07 No No K607G -1.81 0.03 -1.60 0.03 -1.79 0.03 No No K607H -1.16 0.12 -0.39 0.10 NA NA Yes No K607L -1.08 0.05 -1.66 0.06 -1.63 0.08 No No K607M -0.42 0.06 -1.47 0.08 -0.97 0.05 No No K607F -1.55 0.12 -1.20 0.11 NA NA Yes No K607P NA NA NA NA -1.84 0.14 Yes No K607S -1.89 0.06 -1.43 0.06 -1.53 0.04 No No K607* -1.44 0.07 -0.97 0.06 -1.20 0.14 No No K607T -2.23 0.09 -1.26 0.06 -1.98 0.11 No No K607W -1.92 0.06 -1.88 0.06 -1.81 0.10 No No K607V -1.80 0.05 -1.85 0.06 -1.86 0.03 No No C608A -1.60 0.09 -1.32 0.08 -1.81 0.15 No No C608R -0.90 0.04 -0.72 0.04 -1.23 0.09 No No C608E -1.06 0.09 -1.27 0.10 NA NA Yes No C608G -1.44 0.05 -0.58 0.04 -1.66 0.09 No No C608L -1.11 0.08 -0.49 0.07 NA NA Yes No C608F -1.13 0.12 -0.91 0.12 NA NA Yes No C608P -1.62 0.14 -1.13 0.12 NA NA Yes No C608S -0.62 0.05 -0.49 0.05 -1.56 0.12 No No C608* -1.61 0.13 -0.66 0.10 NA NA Yes No C608W -1.58 0.09 -1.31 0.08 NA NA Yes No C608Y -0.27 0.06 -0.09 0.06 -0.65 0.15 No No C608V -1.32 0.07 -2.23 0.11 NA NA Yes No S609A 0.10 0.07 0.21 0.07 -0.16 0.22 Yes No S609R -0.60 0.05 -0.45 0.05 -1.32 0.06 No No S609N -1.18 0.12 -0.49 0.10 NA NA Yes No S609C -0.69 0.12 0.21 0.09 -0.27 0.25 Yes No S609G 0.00 0.04 -0.27 0.04 -0.17 0.10 No No S609I -0.16 0.12 0.43 0.11 NA NA Yes No S609T -0.76 0.12 0.55 0.09 NA NA Yes No S609W -1.36 0.13 -0.51 0.10 NA NA Yes No T610A -0.40 0.05 -0.40 0.05 -0.93 0.09 No No T610R -1.61 0.07 -0.98 0.06 -1.76 0.15 No No T610N -0.27 0.10 -0.20 0.10 -0.58 0.12 No No T610C -0.26 0.09 -0.31 0.09 NA NA Yes No T610Q NA NA NA NA -0.53 0.36 Yes No T610G -1.36 0.05 -1.25 0.05 -1.62 0.12 No No T610I -0.82 0.11 -0.98 0.12 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? T610L -1.78 0.11 -2.29 0.14 NA NA Yes No T610P 0.07 0.04 0.33 0.04 -0.62 0.08 Yes No T610S -0.35 0.06 -0.62 0.06 -0.53 0.07 No No T610V 0.26 0.05 -1.14 0.08 -1.58 0.17 Yes No Q611A -2.61 0.13 -1.23 0.08 -1.40 0.13 No No Q611R -0.68 0.04 -0.69 0.04 -1.33 0.04 No No Q611E -1.22 0.07 -0.58 0.06 -1.18 0.11 No No Q611G -1.38 0.05 -1.84 0.06 -1.82 0.08 No No Q611H 0.04 0.07 -0.20 0.07 -0.91 0.13 Yes No Q611L -1.21 0.08 -1.74 0.10 -1.67 0.16 No No Q611K -0.93 0.09 -0.83 0.09 -1.38 0.16 No No Q611P 0.13 0.06 -0.14 0.06 -0.81 0.08 Yes No Q611S -2.07 0.11 -0.89 0.07 NA NA Yes No Q611* -0.75 0.09 -1.11 0.10 -1.17 0.16 No No Q611W -1.28 0.08 -0.88 0.07 NA NA Yes No Q611V -1.42 0.07 -1.15 0.07 NA NA Yes No L612M 0.70 0.07 0.70 0.07 0.01 0.03 Yes Yes L612A -1.32 0.11 -1.11 0.11 -0.98 0.22 No No L612R 0.03 0.05 0.16 0.05 -0.58 0.11 Yes No L612Q -0.94 0.10 -0.43 0.09 NA NA Yes No L612E -1.18 0.11 -1.65 0.13 NA NA Yes No L612G -0.97 0.07 -2.15 0.11 -1.70 0.17 No No L612I -0.18 0.13 0.66 0.11 -0.24 0.15 Yes No L612K -1.41 0.16 -0.48 0.12 NA NA Yes No L612P -0.34 0.06 -0.33 0.06 -0.72 0.11 No No L612* -1.69 0.15 -0.55 0.10 NA NA Yes No L612T -0.27 0.09 -1.35 0.13 NA NA Yes No L612V -1.05 0.08 -0.90 0.08 -1.51 0.05 No No K613R -0.22 0.06 -0.18 0.06 -0.40 0.05 No No K613N 0.04 0.10 0.16 0.10 NA NA Yes No K613Q 0.14 0.04 0.38 0.04 NA NA Yes No K613E -0.75 0.08 0.06 0.07 NA NA Yes No K613G -1.17 0.08 -1.36 0.09 NA NA Yes No K613L 0.12 0.09 0.49 0.09 -0.52 0.26 Yes No K613M -0.26 0.11 0.73 0.09 NA NA Yes No K613* -0.72 0.11 -0.72 0.11 NA NA Yes No K613T 0.26 0.05 0.46 0.05 -0.65 0.08 Yes No K613W -1.27 0.12 -1.60 0.14 NA NA Yes No K613V -0.89 0.10 -0.25 0.08 NA NA Yes No A614R 0.28 0.04 0.07 0.05 0.16 0.05 Yes Yes A614I 0.52 0.11 0.59 0.11 0.41 0.22 Yes Yes A614D -0.02 0.08 -0.34 0.09 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? A614C -0.54 0.09 -0.12 0.08 0.02 0.22 Yes No A614Q 0.50 0.10 0.17 0.11 NA NA Yes No A614E -0.71 0.08 -0.80 0.09 NA NA Yes No A614G -0.16 0.03 0.09 0.03 -0.21 0.08 Yes No A614L 0.09 0.06 -0.21 0.06 0.02 0.12 Yes No A614K NA NA NA NA 0.28 0.38 Yes No A614M -0.39 0.13 1.39 0.09 NA NA Yes No A614F -0.66 0.14 -0.11 0.12 NA NA Yes No A614P -0.22 0.09 -0.09 0.09 -0.68 0.25 No No A614S -0.46 0.07 0.19 0.06 -0.55 0.15 Yes No A614* NA NA NA NA -0.35 0.32 Yes No A614T 0.03 0.06 0.37 0.06 -0.49 0.14 Yes No A614W -0.74 0.07 -0.88 0.08 -0.97 0.14 No No A614V 0.17 0.04 0.29 0.04 -0.03 0.11 Yes No V615A -0.05 0.03 0.09 0.03 -0.35 0.04 Yes No V615R -1.73 0.05 -1.23 0.04 -1.21 0.07 No No V615N -0.21 0.08 -1.01 0.11 -0.72 0.15 No No V615D -0.95 0.07 -0.97 0.07 -1.54 0.13 No No V615C -0.18 0.06 -0.18 0.06 -0.01 0.19 No No V615Q -1.87 0.10 -1.41 0.09 NA NA Yes No V615E -0.82 0.04 -0.59 0.04 -1.03 0.05 No No V615G -0.57 0.03 -0.88 0.03 -1.19 0.04 No No V615I -0.51 0.09 -0.73 0.10 -0.67 0.23 No No V615L -0.07 0.03 0.05 0.03 -0.88 0.05 Yes No V615K -1.22 0.08 -1.81 0.10 -1.56 0.07 No No V615M -0.52 0.06 -0.54 0.06 -0.54 0.12 No No V615F -1.88 0.14 -1.30 0.12 NA NA Yes No V615P -1.53 0.10 -1.82 0.11 -1.42 0.06 No No V615S 0.17 0.04 -0.23 0.04 -0.63 0.05 Yes No V615* -1.04 0.07 -0.78 0.07 -1.35 0.16 No No V615T 0.19 0.05 -0.12 0.06 -0.07 0.17 Yes No V615W -1.19 0.06 -1.55 0.07 -1.90 0.05 No No T616A 0.32 0.03 0.24 0.04 0.09 0.05 Yes Yes T616R 0.19 0.03 0.12 0.03 0.62 0.04 Yes Yes T616Q 0.35 0.07 0.38 0.07 0.78 0.20 Yes Yes T616G 0.22 0.03 0.01 0.03 0.16 0.06 Yes Yes T616Y 0.54 0.09 0.64 0.09 0.05 0.38 Yes Yes T616N -0.11 0.08 0.20 0.08 0.16 0.07 Yes No T616D -0.66 0.08 0.14 0.07 -0.18 0.26 Yes No T616C 0.54 0.06 0.27 0.06 -0.24 0.11 Yes No T616E -0.28 0.06 -0.38 0.06 -0.17 0.07 No No T616H 0.62 0.08 -0.13 0.10 1.21 0.25 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? T616I -0.33 0.08 0.30 0.07 0.19 0.18 Yes No T616L -0.27 0.05 -0.43 0.05 -0.19 0.13 No No T616K -0.36 0.08 0.23 0.07 0.66 0.09 Yes No T616M -0.49 0.08 -0.40 0.08 -0.44 0.25 No No T616F -0.58 0.11 0.07 0.09 0.10 0.36 Yes No T616P -0.89 0.07 -0.68 0.07 -0.80 0.06 No No T616S -0.02 0.04 0.12 0.04 0.13 0.07 Yes No T616* NA NA NA NA -1.14 0.24 Yes No T616W -0.28 0.05 0.25 0.04 -0.22 0.19 Yes No T616V -0.07 0.04 -0.09 0.04 0.21 0.07 Yes No A617G 0.03 0.03 0.05 0.03 0.24 0.06 Yes Yes A617R -0.10 0.04 0.07 0.04 -0.32 0.11 Yes No A617N NA NA NA NA 0.12 0.42 Yes No A617D -0.76 0.09 -0.05 0.07 NA NA Yes No A617C -0.73 0.09 0.26 0.07 0.13 0.18 Yes No A617Q 0.25 0.08 0.07 0.09 -0.48 0.30 Yes No A617E -0.12 0.06 0.08 0.06 -0.40 0.20 Yes No A617H -0.11 0.11 -0.46 0.12 NA NA Yes No A617I -0.26 0.11 0.09 0.10 -0.52 0.38 Yes No A617L -0.11 0.05 0.18 0.05 -0.18 0.16 Yes No A617K NA NA NA NA -0.08 0.28 Yes No A617M 0.32 0.07 0.30 0.07 -0.34 0.27 Yes No A617F -0.17 0.10 -0.39 0.11 -0.42 0.36 No No A617P -0.48 0.08 -0.88 0.09 0.05 0.18 Yes No A617S -0.13 0.05 0.25 0.05 -0.58 0.06 Yes No A617* -0.96 0.11 -1.57 0.14 NA NA Yes No A617T -0.23 0.05 0.26 0.05 -0.30 0.10 Yes No A617W 0.17 0.05 -0.93 0.07 -0.69 0.15 Yes No A617V -0.03 0.04 -0.09 0.04 -0.42 0.12 No No H618A -0.73 0.14 -0.80 0.15 0.36 0.36 Yes No H618R -0.08 0.05 0.24 0.05 -0.46 0.06 Yes No H618N -0.37 0.17 -0.24 0.16 NA NA Yes No H618D 0.48 0.13 0.89 0.12 NA NA Yes No H618Q -0.62 0.14 0.01 0.12 NA NA Yes No H618G -0.56 0.07 -0.91 0.09 -0.91 0.19 No No H618L 0.02 0.06 0.10 0.06 -0.47 0.07 Yes No H618P 0.32 0.08 0.47 0.08 -0.51 0.08 Yes No H618S -0.50 0.14 -0.26 0.13 NA NA Yes No H618W NA NA NA NA 0.44 0.31 Yes No H618Y 0.23 0.10 -0.28 0.11 -0.26 0.19 Yes No F619M 0.12 0.07 0.55 0.07 0.22 0.25 Yes Yes F619A -0.57 0.05 -1.25 0.06 -0.78 0.05 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? F619R -1.24 0.05 -1.94 0.07 -0.66 0.07 No No F619N -0.61 0.13 -0.15 0.12 NA NA Yes No F619D -1.39 0.12 -0.62 0.09 NA NA Yes No F619C 0.07 0.03 0.08 0.03 -0.37 0.04 Yes No F619Q -1.13 0.12 -1.57 0.15 NA NA Yes No F619E -1.58 0.08 -2.40 0.12 -1.54 0.08 No No F619G -1.29 0.03 -1.03 0.03 -1.57 0.05 No No F619H NA NA NA NA -0.31 0.34 Yes No F619I -0.69 0.12 -0.28 0.11 -0.42 0.22 No No F619L 0.17 0.03 0.12 0.03 -0.48 0.05 Yes No F619P -1.00 0.09 -1.22 0.10 NA NA Yes No F619S -0.26 0.04 -0.95 0.06 -0.56 0.06 No No F619* -1.91 0.14 -0.92 0.10 NA NA Yes No F619T NA NA NA NA -1.08 0.24 Yes No F619W -0.08 0.04 -0.81 0.05 0.00 0.07 Yes No F619Y 0.06 0.08 -0.79 0.11 0.28 0.11 Yes No F619V -0.51 0.04 -0.49 0.04 -0.64 0.04 No No Q620A 0.22 0.04 0.00 0.05 0.18 0.09 Yes Yes Q620R 0.25 0.03 0.18 0.03 0.17 0.04 Yes Yes Q620N 0.26 0.14 0.28 0.14 0.36 0.21 Yes Yes Q620L 0.14 0.04 0.45 0.04 0.40 0.16 Yes Yes Q620K 0.10 0.07 0.24 0.07 0.04 0.10 Yes Yes Q620D -0.16 0.07 -0.25 0.08 0.24 0.23 Yes No Q620C -0.22 0.07 -0.95 0.10 0.03 0.23 Yes No Q620E 0.21 0.05 0.13 0.05 -0.09 0.10 Yes No Q620G -0.14 0.02 0.02 0.02 0.19 0.04 Yes No Q620H -0.08 0.08 0.16 0.08 -0.05 0.20 Yes No Q620I 0.27 0.11 -0.38 0.14 NA NA Yes No Q620M 0.70 0.07 -0.03 0.08 0.20 0.26 Yes No Q620F 0.37 0.11 1.00 0.10 -0.47 0.44 Yes No Q620P -0.04 0.06 0.12 0.06 -0.26 0.10 Yes No Q620S 0.17 0.05 -0.15 0.06 0.16 0.17 Yes No Q620* -0.82 0.08 -0.58 0.07 -0.64 0.15 No No Q620T -0.20 0.09 0.41 0.08 0.17 0.12 Yes No Q620W -0.12 0.04 0.09 0.04 0.08 0.11 Yes No Q620Y -0.74 0.14 0.21 0.11 -0.19 0.38 Yes No Q620V 0.29 0.03 -0.11 0.04 0.26 0.07 Yes No T621A 0.18 0.04 0.13 0.04 0.17 0.10 Yes Yes T621R -0.04 0.04 -0.45 0.05 -0.06 0.15 No No T621N -0.39 0.12 -0.09 0.11 0.02 0.21 Yes No T621D 0.12 0.12 0.26 0.12 -0.11 0.44 Yes No T621C 0.07 0.09 -0.29 0.10 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? T621Q -0.90 0.12 0.06 0.10 0.44 0.38 Yes No T621E -0.29 0.07 0.13 0.06 -0.05 0.24 Yes No T621G -0.02 0.03 -0.21 0.04 0.48 0.04 Yes No T621H 0.33 0.15 0.72 0.14 NA NA Yes No T621I 0.36 0.08 -0.09 0.10 0.21 0.20 Yes No T621L 0.16 0.06 -0.40 0.07 -0.30 0.10 Yes No T621K -0.02 0.09 -0.09 0.09 -0.08 0.37 No No T621M 0.21 0.07 -0.15 0.08 1.17 0.09 Yes No T621F -0.61 0.16 -0.16 0.14 NA NA Yes No T621P 0.04 0.04 0.18 0.04 -0.38 0.06 Yes No T621S -0.06 0.06 -0.08 0.06 0.28 0.09 Yes No T621W -0.21 0.06 0.08 0.06 0.12 0.17 Yes No T621Y -0.23 0.16 0.36 0.14 NA NA Yes No T621V -0.28 0.05 0.32 0.05 0.32 0.19 Yes No H622G 0.05 0.03 0.18 0.03 0.07 0.06 Yes Yes H622S 0.16 0.06 0.59 0.06 0.08 0.10 Yes Yes H622T 0.01 0.09 0.84 0.08 0.31 0.34 Yes Yes H622V 0.18 0.05 0.15 0.05 0.31 0.12 Yes Yes H622A -0.17 0.06 0.16 0.06 0.41 0.08 Yes No H622R -0.19 0.04 0.12 0.04 0.05 0.04 Yes No H622N -0.05 0.07 0.30 0.07 -0.11 0.12 Yes No H622D -0.84 0.11 0.63 0.07 0.48 0.10 Yes No H622C -0.50 0.09 -0.10 0.08 0.11 0.11 Yes No H622Q -0.06 0.08 0.29 0.07 -0.14 0.05 Yes No H622E -0.11 0.07 0.15 0.06 0.23 0.10 Yes No H622I -0.05 0.14 0.45 0.13 0.36 0.49 Yes No H622L -0.49 0.06 0.06 0.05 -0.14 0.11 Yes No H622K 0.29 0.10 1.39 0.08 0.00 0.28 Yes No H622M -0.07 0.11 -0.07 0.11 0.05 0.34 Yes No H622F 0.14 0.11 -0.61 0.14 0.07 0.13 Yes No H622P 0.14 0.03 0.25 0.03 -0.44 0.04 Yes No H622* -1.50 0.13 -1.18 0.12 -0.74 0.16 No No H622W 0.08 0.05 0.21 0.05 -0.08 0.19 Yes No H622Y 0.07 0.09 0.14 0.09 -0.08 0.18 Yes No T623E 0.32 0.05 0.23 0.05 0.02 0.05 Yes Yes T623H 0.60 0.10 0.01 0.11 0.58 0.55 Yes Yes T623L 0.33 0.05 0.18 0.05 0.17 0.16 Yes Yes T623M 0.21 0.07 0.28 0.07 0.59 0.22 Yes Yes T623F 0.80 0.10 0.61 0.10 0.47 0.32 Yes Yes T623A -0.14 0.04 0.35 0.03 -0.04 0.07 Yes No T623R -0.16 0.03 -0.40 0.04 0.15 0.09 Yes No T623N 0.02 0.09 0.19 0.09 -0.28 0.16 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? T623D -0.69 0.09 0.41 0.07 -0.34 0.14 Yes No T623C -0.39 0.08 0.01 0.08 0.40 0.28 Yes No T623Q 0.23 0.07 0.38 0.07 -0.01 0.32 Yes No T623G -0.40 0.03 -0.09 0.03 -0.05 0.03 No No T623I -0.59 0.10 0.11 0.08 -0.13 0.13 Yes No T623K 1.10 0.07 -0.02 0.08 0.53 0.17 Yes No T623P -0.16 0.06 -0.29 0.07 -0.11 0.17 No No T623S 0.67 0.04 0.21 0.04 -0.06 0.07 Yes No T623W -0.01 0.05 -0.29 0.06 -0.27 0.10 No No T623Y NA NA NA NA -0.11 0.29 Yes No T623V -0.26 0.04 -0.20 0.04 0.41 0.05 Yes No T624P 0.92 0.02 0.92 0.02 0.04 0.03 Yes Yes T624A 0.65 0.02 0.76 0.02 -0.07 0.03 Yes No T624R 0.41 0.07 0.34 0.07 -0.55 0.23 Yes No T624N 0.15 0.10 0.20 0.10 NA NA Yes No T624C -0.20 0.15 0.21 0.14 NA NA Yes No T624E 0.38 0.09 -0.63 0.12 -0.11 0.55 Yes No T624G -0.21 0.06 0.12 0.06 0.15 0.21 Yes No T624I 0.58 0.11 0.35 0.11 NA NA Yes No T624L 0.41 0.09 -0.84 0.13 0.96 0.48 Yes No T624S 1.15 0.04 1.20 0.04 -0.13 0.04 Yes No T624W 0.56 0.10 -0.20 0.12 0.10 0.16 Yes No T624V -0.12 0.08 -0.52 0.10 0.18 0.23 Yes No P625A -0.27 0.11 0.30 0.10 0.31 0.10 Yes No P625R 0.06 0.07 -1.01 0.10 -0.04 0.22 Yes No P625C 0.56 0.14 -0.17 0.16 -0.02 0.82 Yes No P625E -0.24 0.13 -0.22 0.13 -0.41 0.64 No No P625G -0.41 0.08 0.40 0.06 0.04 0.24 Yes No P625H -0.25 0.15 -0.02 0.15 NA NA Yes No P625L -0.48 0.09 -0.82 0.11 -0.56 0.17 No No P625S -0.38 0.08 -0.55 0.09 0.03 0.20 Yes No P625T 0.30 0.08 0.23 0.08 -0.06 0.10 Yes No P625W -0.60 0.13 -0.64 0.13 NA NA Yes No P625V -0.17 0.09 -0.63 0.11 NA NA Yes No I626A 0.16 0.12 0.80 0.11 NA NA Yes No I626R -0.89 0.12 0.14 0.09 -0.09 0.31 Yes No I626N 0.42 0.04 0.61 0.04 -0.37 0.06 Yes No I626E NA NA NA NA -0.15 0.55 Yes No I626G -1.04 0.10 -1.35 0.12 -0.48 0.27 No No I626L 0.61 0.11 -0.85 0.16 NA NA Yes No I626S 0.36 0.04 0.60 0.04 -0.65 0.07 Yes No I626T 0.17 0.02 0.34 0.02 -0.37 0.03 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? I626W -0.74 0.16 0.22 0.13 NA NA Yes No 1626V -0.51 0.10 0.05 0.09 0.10 0.18 Yes No L627C 0.14 0.13 0.84 0.11 0.57 0.48 Yes Yes L627A 0.00 0.08 0.24 0.08 1.31 0.29 Yes No L627R 0.29 0.04 0.03 0.04 -0.10 0.05 Yes No L627N 0.71 0.15 1.09 0.15 NA NA Yes No L627D 0.32 0.10 -1.12 0.16 1.13 0.55 Yes No L627Q 0.23 0.07 0.39 0.07 -0.27 0.11 Yes No L627E 0.29 0.07 -0.06 0.08 0.17 0.11 Yes No L627G -0.04 0.04 -0.01 0.04 0.23 0.10 Yes No L627K 0.57 0.11 0.27 0.12 NA NA Yes No L627M -0.57 0.12 0.33 0.10 -0.09 0.22 Yes No L627P 0.10 0.05 0.31 0.05 -0.25 0.08 Yes No L627S 0.34 0.08 0.18 0.08 -0.29 0.27 Yes No L627* 0.52 0.10 -0.87 0.15 NA NA Yes No L627T 0.60 0.09 -0.76 0.14 NA NA Yes No L627W -0.71 0.09 0.85 0.07 0.27 0.32 Yes No L627V -0.89 0.08 0.48 0.06 -0.23 0.19 Yes No L628C 0.31 0.09 0.10 0.10 0.29 0.31 Yes Yes L628W 0.25 0.06 0.01 0.07 0.67 0.15 Yes Yes L628A -0.22 0.06 -0.58 0.07 -0.36 0.11 No No L628R -0.13 0.04 -0.50 0.05 0.53 0.06 Yes No L628Q -0.10 0.10 -0.04 0.10 -0.36 0.23 No No L628E -0.73 0.10 -1.59 0.14 NA NA Yes No L628G -0.65 0.04 -1.57 0.06 -0.96 0.14 No No L628I -0.47 0.17 -0.57 0.17 NA NA Yes No L628K 0.75 0.11 -0.44 0.15 -0.21 0.31 Yes No L628M -0.49 0.09 -0.37 0.09 -0.21 0.12 No No L628P -0.27 0.08 -0.45 0.08 -0.39 0.14 No No L628S -0.78 0.08 -1.36 0.10 -0.83 0.21 No No L628T -0.16 0.10 -0.52 0.12 -0.60 0.27 No No L628V -0.13 0.05 0.34 0.05 -0.31 0.09 Yes No S629A -0.99 0.12 0.49 0.08 -0.09 0.29 Yes No S629R 0.10 0.02 0.29 0.02 -0.37 0.03 Yes No S629N 0.40 0.05 0.36 0.05 -0.32 0.08 Yes No S629D -0.54 0.18 -0.23 0.17 NA NA Yes No S629C 0.30 0.10 0.10 0.11 -0.08 0.21 Yes No S629Q 0.76 0.17 0.40 0.18 NA NA Yes No S629E 0.84 0.10 0.61 0.11 -0.08 0.48 Yes No S629G -0.30 0.05 0.40 0.05 0.09 0.08 Yes No S629I 0.05 0.14 0.42 0.13 NA NA Yes No S629L NA NA NA NA 0.03 0.36 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? S629K 0.37 0.13 0.80 0.12 NA NA Yes No S629P -0.03 0.15 -0.34 0.17 NA NA Yes No S629T -0.60 0.13 0.01 0.11 0.22 0.32 Yes No S629W -0.03 0.11 -0.66 0.13 0.42 0.54 Yes No S629V -0.87 0.11 -0.82 0.11 0.05 0.14 Yes No N630R 0.53 0.05 0.06 0.06 0.94 0.08 Yes Yes N630A -0.53 0.09 0.62 0.07 -0.06 0.23 Yes No N630D -0.33 0.09 0.49 0.07 -0.22 0.14 Yes No N630C 0.42 0.10 -0.12 0.12 NA NA Yes No N630E -0.67 0.09 0.69 0.07 -0.30 0.26 Yes No N630G 0.32 0.04 -0.11 0.04 0.22 0.10 Yes No N630H 0.06 0.10 0.51 0.09 -0.29 0.13 Yes No N630I -0.45 0.12 0.44 0.10 -0.27 0.18 Yes No N630L -0.24 0.09 0.55 0.08 -0.78 0.15 Yes No N630K 0.37 0.10 0.93 0.09 -0.25 0.18 Yes No N630F -0.58 0.18 -0.11 0.16 NA NA Yes No N630S 0.34 0.06 -0.21 0.07 0.16 0.13 Yes No N630T 0.16 0.03 0.38 0.02 -0.53 0.04 Yes No N630W -0.11 0.09 -1.04 0.12 NA NA Yes No N630Y -0.24 0.12 0.59 0.10 0.14 0.19 Yes No N630V -0.20 0.06 -0.90 0.08 -0.26 0.18 No No N631A -0.03 0.07 0.06 0.07 -0.70 0.25 Yes No N631R -0.11 0.06 0.27 0.05 1.20 0.07 Yes No N631D -0.56 0.10 -0.38 0.09 -0.77 0.13 No No N631C -0.71 0.15 -0.64 0.15 NA NA Yes No N631E NA NA NA NA -0.95 0.23 Yes No N631G -0.67 0.05 -0.39 0.05 -1.02 0.07 No No N631I 0.31 0.10 -0.62 0.13 NA NA Yes No N631L -1.12 0.10 -0.57 0.08 NA NA Yes No N631K -0.05 0.08 -0.20 0.09 0.70 0.11 Yes No N631M -0.10 0.10 0.36 0.09 -0.27 0.30 Yes No N631P 0.06 0.12 0.30 0.12 NA NA Yes No N631S 0.15 0.06 0.06 0.06 -0.36 0.13 Yes No N631T 0.07 0.04 0.24 0.04 -0.37 0.05 Yes No N631Y -0.48 0.12 -0.03 0.11 NA NA Yes No N631V -0.66 0.07 -1.17 0.08 -0.78 0.23 No No F632A -0.79 0.07 -1.34 0.09 -1.29 0.12 No No F632R -0.76 0.05 -0.40 0.05 -0.13 0.05 No No F632D -1.62 0.15 -1.61 0.15 NA NA Yes No F632C 0.66 0.02 0.78 0.02 -0.06 0.02 Yes No F632Q NA NA NA NA -0.18 0.55 Yes No F632E -1.35 0.10 -0.87 0.09 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? F632G -0.01 0.03 0.12 0.03 -0.03 0.02 Yes No F632H -0.31 0.16 0.08 0.15 NA NA Yes No F632I -0.33 0.10 -0.01 0.10 -0.87 0.13 No No F632L -0.28 0.05 0.22 0.05 -0.26 0.07 Yes No F632K -0.49 0.13 0.74 0.10 NA NA Yes No F632M 0.00 0.10 0.16 0.10 NA NA Yes No F632S -0.75 0.06 -0.56 0.06 -0.83 0.06 No No F632* -0.69 0.12 -0.55 0.12 NA NA Yes No F632T -0.09 0.09 -0.80 0.12 NA NA Yes No F632W 0.17 0.06 -0.14 0.06 -0.44 0.19 Yes No F632Y -0.15 0.08 0.38 0.07 -0.07 0.10 Yes No F632V 0.38 0.02 0.41 0.02 -0.07 0.02 Yes No I633N 0.16 0.06 0.65 0.06 0.15 0.10 Yes Yes I633M 0.17 0.07 0.28 0.07 0.10 0.19 Yes Yes I633S 0.02 0.04 0.35 0.04 0.22 0.08 Yes Yes I633A 0.15 0.05 -0.24 0.06 0.42 0.13 Yes No I633R -0.42 0.04 0.41 0.04 0.22 0.06 Yes No I633D -0.62 0.09 -0.01 0.08 -0.12 0.10 No No I633C 0.15 0.07 -0.34 0.08 -0.04 0.14 Yes No I633Q -0.26 0.10 1.05 0.08 -0.37 0.22 Yes No I633E -0.98 0.07 -0.34 0.06 0.30 0.11 Yes No I633G -0.09 0.03 0.10 0.03 0.05 0.06 Yes No I633H -0.71 0.14 -0.16 0.13 NA NA Yes No I633L -0.10 0.05 0.00 0.05 0.25 0.06 Yes No I633K -0.29 0.09 0.17 0.08 0.63 0.29 Yes No I633F -0.11 0.09 0.24 0.09 0.51 0.22 Yes No I633P 0.23 0.08 -0.90 0.12 0.19 0.31 Yes No 1633* -1.45 0.12 -1.53 0.13 NA NA Yes No I633T 0.13 0.04 0.40 0.04 -0.17 0.06 Yes No I633W -0.35 0.05 0.14 0.05 -0.07 0.09 Yes No I633Y NA NA NA NA -0.09 0.34 Yes No 1633V 0.09 0.04 -0.06 0.04 0.39 0.06 Yes No E634N 0.52 0.12 0.46 0.12 0.00 0.36 Yes Yes E634A 0.20 0.02 0.38 0.02 -0.36 0.03 Yes No E634R -0.06 0.04 0.30 0.04 0.33 0.08 Yes No E634D -0.10 0.06 0.30 0.06 0.01 0.10 Yes No E634C -0.12 0.08 -0.30 0.09 0.42 0.13 Yes No E634Q -0.28 0.09 0.79 0.07 0.35 0.10 Yes No E634G -0.12 0.03 0.10 0.02 0.33 0.03 Yes No E634I 0.43 0.13 -0.05 0.15 NA NA Yes No E634L 0.12 0.05 -0.46 0.06 0.47 0.19 Yes No E634K 0.14 0.06 -0.04 0.07 0.16 0.13 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? E634M -0.14 0.08 -0.22 0.08 0.42 0.27 Yes No E634F 0.25 0.14 0.08 0.15 NA NA Yes No E634P -0.23 0.10 -0.95 0.13 NA NA Yes No E634S -0.22 0.06 0.07 0.05 0.30 0.07 Yes No E634* 0.11 0.03 0.29 0.03 -0.34 0.05 Yes No E634T 0.01 0.09 0.30 0.08 -0.51 0.28 Yes No E634W -0.46 0.06 0.16 0.05 0.45 0.17 Yes No E634V -0.20 0.04 0.26 0.04 0.33 0.08 Yes No P635A 0.04 0.05 0.29 0.05 0.59 0.07 Yes Yes P635D 0.14 0.09 0.49 0.09 0.52 0.14 Yes Yes P635E 0.51 0.06 0.49 0.06 0.70 0.16 Yes Yes P635T 0.36 0.06 0.06 0.06 0.01 0.08 Yes Yes P635R -0.51 0.04 -0.39 0.04 0.24 0.08 Yes No P635N 0.13 0.14 -0.31 0.16 NA NA Yes No P635C -0.65 0.10 -0.70 0.11 0.26 0.25 Yes No P635Q -0.86 0.12 -0.40 0.11 0.43 0.38 Yes No P635G -0.01 0.03 -0.02 0.03 0.15 0.06 Yes No P635H -0.05 0.10 0.20 0.09 0.22 0.07 Yes No P635I NA NA NA NA 0.13 0.37 Yes No P635L -0.02 0.05 -0.33 0.06 0.22 0.10 Yes No P635K NA NA NA NA 0.18 0.41 Yes No P635M 0.96 0.08 -0.61 0.12 0.06 0.31 Yes No P635F 1.00 0.11 0.14 0.13 NA NA Yes No P635S -0.22 0.06 0.35 0.05 0.02 0.12 Yes No P635W -0.24 0.06 0.25 0.06 -0.12 0.20 Yes No P635Y -0.31 0.15 -0.01 0.14 NA NA Yes No P635V -0.06 0.05 -0.29 0.05 0.44 0.20 Yes No L636A -0.52 0.05 -1.17 0.06 0.08 0.11 Yes No L636R -1.28 0.04 -1.29 0.04 -1.27 0.08 No No L636C -0.14 0.07 -0.19 0.07 -0.07 0.17 No No L636Q -0.25 0.05 -0.09 0.05 -0.16 0.09 No No L636E -1.02 0.07 -0.96 0.07 -1.27 0.21 No No L636G -1.44 0.04 -1.31 0.04 -1.36 0.06 No No L636I -0.87 0.13 -0.24 0.11 NA NA Yes No L636K -0.17 0.08 -0.33 0.09 -1.00 0.28 No No L636M -0.40 0.07 -0.08 0.06 0.16 0.16 Yes No L636F -0.45 0.10 0.29 0.09 NA NA Yes No L636P 0.24 0.05 -0.84 0.06 -0.88 0.11 Yes No L636S -1.62 0.07 -1.47 0.07 -0.73 0.15 No No L636* -1.09 0.10 -1.51 0.12 NA NA Yes No L636T 0.12 0.06 -2.04 0.13 -0.41 0.09 Yes No L636W -0.55 0.05 -1.36 0.06 -0.68 0.11 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? L636V -0.35 0.04 -0.05 0.03 -0.65 0.08 No No E637A 0.15 0.04 0.23 0.04 -0.25 0.07 Yes No E637R -0.23 0.07 1.02 0.06 0.18 0.32 Yes No E637D -0.88 0.14 -0.01 0.11 NA NA Yes No E637Q 0.83 0.14 0.47 0.15 NA NA Yes No E637G -0.05 0.04 0.22 0.04 0.06 0.05 Yes No E637L NA NA NA NA 0.35 0.32 Yes No E637K -0.33 0.12 -0.66 0.13 NA NA Yes No E637M 0.60 0.15 1.04 0.14 NA NA Yes No E637S 0.23 0.10 -0.55 0.12 0.66 0.39 Yes No E637* -0.03 0.09 0.24 0.08 NA NA Yes No E637W -0.18 0.10 -0.73 0.12 -0.20 0.34 No No E637V -0.15 0.07 -0.36 0.07 -0.45 0.10 No No I638R -1.56 0.13 -0.55 0.10 NA NA Yes No I638N 0.35 0.16 0.42 0.16 -0.63 0.15 Yes No I638C 1.11 0.14 -0.05 0.17 NA NA Yes No I638L NA NA NA NA -0.24 0.30 Yes No I638S 0.04 0.05 0.05 0.05 -0.18 0.05 Yes No I638T -0.43 0.12 -0.42 0.12 -0.14 0.18 No No 1638V 0.39 0.07 -0.45 0.08 -0.04 0.13 Yes No T639G 0.52 0.06 0.44 0.06 0.06 0.23 Yes Yes T639A 0.25 0.05 0.47 0.05 -0.34 0.06 Yes No T639R -0.48 0.10 -0.68 0.11 -0.16 0.35 No No T639N 0.03 0.16 -0.02 0.17 NA NA Yes No T639D 0.61 0.17 0.43 0.18 NA NA Yes No T639E 0.71 0.12 0.82 0.12 NA NA Yes No T639I 0.17 0.13 -0.19 0.14 NA NA Yes No T639L -0.28 0.15 -0.39 0.16 NA NA Yes No T639P -0.10 0.12 0.08 0.12 -0.21 0.22 Yes No T639S 0.07 0.07 0.09 0.07 -0.53 0.12 Yes No T639V 0.75 0.09 -1.09 0.14 0.78 0.28 Yes No K640A -0.31 0.07 -0.59 0.07 0.20 0.26 Yes No K640R -0.15 0.04 0.07 0.04 0.01 0.11 Yes No K640N 0.07 0.03 0.32 0.03 -0.43 0.05 Yes No K640D -0.14 0.09 -0.73 0.11 -0.52 0.30 No No K640C 0.06 0.08 0.34 0.08 -0.51 0.27 Yes No K640Q -0.86 0.12 0.36 0.09 0.29 0.31 Yes No K640E -0.30 0.06 0.08 0.06 -0.03 0.15 Yes No K640G -0.26 0.04 -0.59 0.04 -0.48 0.12 No No K640H 0.81 0.12 -0.26 0.15 NA NA Yes No K640I -0.10 0.12 -0.11 0.12 NA NA Yes No K640L 0.21 0.06 0.05 0.06 -0.31 0.20 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? K640M -1.04 0.15 0.36 0.10 -0.12 0.31 Yes No K640F 0.24 0.12 -0.13 0.13 NA NA Yes No K640P 0.40 0.09 0.14 0.10 -0.03 0.55 Yes No K640S -0.60 0.07 0.52 0.06 -0.11 0.22 Yes No K640* -0.85 0.10 -0.19 0.09 -0.96 0.21 No No K640T 0.10 0.03 0.35 0.03 -0.52 0.06 Yes No K640W -0.53 0.07 0.41 0.06 0.12 0.25 Yes No K640Y -0.76 0.15 -0.28 0.14 0.36 0.37 Yes No K640V -0.26 0.05 -0.56 0.05 0.05 0.11 Yes No D840S 0.37 0.08 0.33 0.08 0.10 0.16 Yes Yes D840A -0.07 0.07 0.40 0.06 0.18 0.13 Yes No D840R -0.03 0.05 0.09 0.05 0.10 0.33 Yes No D840N -0.64 0.12 -0.31 0.11 -0.04 0.16 No No D840C 0.62 0.12 -1.20 0.16 0.07 0.48 Yes No D840Q -0.22 0.14 -0.03 0.13 0.34 NA Yes No D840E 0.32 0.07 -0.07 0.07 0.08 0.06 Yes No D840G 0.21 0.04 -0.26 0.04 0.02 0.05 Yes No D840L -0.64 0.10 -0.25 0.09 -0.27 0.82 No No D840K 0.13 0.13 0.33 0.12 -0.03 0.82 Yes No D840M NA NA NA NA -0.30 0.13 Yes No D840P -0.09 0.12 -0.12 0.12 0.11 0.82 Yes No D840T -1.14 0.14 0.11 0.10 0.29 0.15 Yes No D840W -0.33 0.09 0.05 0.08 -0.39 0.19 Yes No D840Y 0.13 0.08 0.11 0.08 -0.18 0.11 Yes No D840V 0.16 0.06 -0.03 0.06 -0.10 0.07 Yes No E841A -0.26 0.06 -0.54 0.06 0.08 0.08 Yes No E841R -0.66 0.06 -0.57 0.05 -0.18 0.10 No No E841N 0.04 0.14 -0.53 0.15 -0.14 0.48 Yes No E841D -0.33 0.09 -0.04 0.08 0.12 0.15 Yes No E841C -0.43 0.13 -0.39 0.12 -0.46 0.16 No No E841Q -0.64 0.12 -0.41 0.11 0.21 0.14 Yes No E841G 0.21 0.04 -0.11 0.04 -0.04 0.04 Yes No E841H -0.71 0.18 -0.82 0.18 NA NA Yes No E841L -1.39 0.10 -0.35 0.07 -0.41 0.06 No No E841K -0.55 0.09 -0.26 0.09 -0.34 0.17 No No E841M -1.21 0.14 -0.41 0.11 -0.24 0.54 No No E841P -0.22 0.11 -0.23 0.11 0.00 0.08 No No E841S -0.16 0.07 -0.22 0.07 0.04 0.10 Yes No E841* -0.19 0.06 -0.19 0.06 0.07 0.03 Yes No E841T 0.40 0.09 -0.59 0.10 -0.27 0.19 Yes No E841W -1.06 0.09 -1.15 0.09 -1.11 0.33 No No E841V -0.99 0.07 -0.68 0.06 -0.53 0.08 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? A842S 0.36 0.06 0.08 0.06 0.04 0.10 Yes Yes A842R -2.56 0.11 -1.06 0.06 -1.25 0.15 No No A842D -0.37 0.11 -1.49 0.15 -1.07 0.19 No No A842C 0.15 0.10 -0.39 0.11 -0.26 0.13 Yes No A842E NA NA NA NA -1.19 0.12 Yes No A842G -0.18 0.04 -0.18 0.04 -0.09 0.04 No No A842L -1.71 0.11 -1.29 0.09 -1.19 0.33 No No A842K -0.53 0.13 -1.41 0.16 NA NA Yes No A842P -0.87 0.10 -0.94 0.10 NA NA Yes No A842T -1.47 0.11 -0.57 0.08 -1.03 0.10 No No A842W -1.87 0.12 -1.92 0.12 -1.46 0.40 No No A842V -1.40 0.08 -0.77 0.06 -1.17 0.20 No No R843A -0.28 0.10 0.30 0.09 0.15 0.11 Yes No R843E -1.03 0.17 -1.31 0.17 0.09 0.64 Yes No R843G 0.18 0.05 -0.37 0.06 -0.43 0.07 Yes No R843L -0.31 0.13 -0.08 0.12 -0.05 0.30 No No R843K -0.16 0.13 0.01 0.12 0.45 0.16 Yes No R843M NA NA NA NA 0.26 0.83 Yes No R843S -0.08 0.07 0.08 0.07 -0.08 0.10 Yes No R843* -0.64 0.17 -0.23 0.15 NA NA Yes No R843T NA NA NA NA -0.19 0.30 Yes No R843W -0.99 0.15 0.22 0.12 -0.55 0.14 Yes No R843V -0.09 0.10 -0.23 0.10 0.04 0.17 Yes No A844E 0.38 0.10 0.06 0.10 0.13 0.21 Yes Yes A844R 0.45 0.07 -0.04 0.07 0.03 0.37 Yes No A844D NA NA NA NA 0.36 0.11 Yes No A844C NA NA NA NA 0.02 0.19 Yes No A844Q -0.26 0.18 0.84 0.15 -0.11 0.44 Yes No A844G -0.48 0.06 -0.26 0.05 -0.01 0.06 No No A844L 0.54 0.10 -0.25 0.11 0.18 0.14 Yes No A844K NA NA NA NA 0.14 0.27 Yes No A844M NA NA NA NA 0.23 0.41 Yes No A844P 0.28 0.11 -1.04 0.14 -0.72 0.25 Yes No A844S -0.22 0.08 -0.06 0.07 0.17 0.10 Yes No A844T -0.37 0.11 -0.05 0.10 0.22 0.21 Yes No A844W -1.01 0.13 -0.64 0.11 -0.10 NA No No A844V -0.19 0.08 0.12 0.07 0.06 0.08 Yes No L845A -0.70 0.08 -0.23 0.07 -0.59 0.11 No No L845R -2.01 0.10 -1.83 0.09 -1.29 0.05 No No L845C -0.27 0.14 -0.84 0.15 -0.37 0.82 No No L845Q NA NA NA NA -0.49 0.25 Yes No L845E -0.93 0.12 -1.26 0.13 -0.79 0.48 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? L845G -1.31 0.06 -1.09 0.06 -1.46 0.20 No No L845K -0.17 0.18 0.03 0.17 NA NA Yes No L845M -0.15 0.12 -0.17 0.12 -0.20 0.25 No No L845P -0.64 0.10 -0.71 0.10 -0.61 0.11 No No L845S -1.48 0.13 -0.91 0.10 -0.82 0.35 No No L845T -0.85 0.14 0.43 0.11 NA NA Yes No L845W -0.12 0.08 -1.89 0.13 -0.47 0.33 No No L845V -0.31 0.06 -0.80 0.07 -0.20 0.10 No No L846A -1.10 0.08 -0.78 0.07 -0.78 0.82 No No L846R -0.86 0.06 -0.85 0.05 -1.09 0.11 No No L846C -1.57 0.15 -1.32 0.13 -0.93 0.14 No No L846Q -1.21 0.15 -0.87 0.13 -0.99 0.27 No No L846E -0.34 0.08 -0.41 0.08 -0.71 0.17 No No L846G -1.11 0.05 -0.81 0.05 -1.29 0.15 No No L846I NA NA NA NA 0.11 0.49 Yes No L846M -0.29 0.09 0.19 0.08 -0.28 0.13 Yes No L846F -0.48 0.14 -0.27 0.13 NA NA Yes No L846P -1.04 0.10 -0.74 0.09 -0.74 0.13 No No L846S -0.77 0.09 -0.24 0.08 -1.23 0.37 No No L846T -0.74 0.12 -1.37 0.14 -0.56 0.12 No No L846W -1.13 0.09 -0.51 0.08 -0.35 0.06 No No L846Y -0.02 0.16 -0.98 0.19 NA NA Yes No L846V -1.23 0.07 -0.61 0.06 -0.40 0.06 No No P847A 0.24 0.11 -1.48 0.16 NA NA Yes No P847R -0.47 0.09 -0.88 0.10 -1.09 0.26 No No P847G -0.32 0.07 -1.12 0.08 -0.48 0.43 No No P847H -0.24 0.18 -0.19 0.17 -0.10 0.18 No No P847L -1.09 0.12 -0.92 0.11 -0.76 0.15 No No P847S -0.42 0.11 -0.55 0.11 -0.76 0.23 No No P847T -0.69 0.19 -0.89 0.19 NA NA Yes No P847V -0.31 0.12 -1.08 0.14 NA NA Yes No N848A -0.53 0.11 0.02 0.10 0.14 0.43 Yes No N848R -0.30 0.07 -0.60 0.07 -0.35 0.10 No No N848D 0.06 0.11 -0.08 0.11 -0.13 0.15 Yes No N848C -0.16 0.14 -0.15 0.14 -0.31 NA No No N848Q -0.31 0.18 -0.55 0.19 NA NA Yes No N848E -0.64 0.11 0.35 0.09 0.48 0.09 Yes No N848G -0.87 0.07 -0.40 0.06 -0.33 0.11 No No N848H -0.07 0.05 0.05 0.05 -0.06 0.05 Yes No N848I 0.00 0.17 -0.09 0.17 NA NA Yes No N848L 0.08 0.10 -1.50 0.14 -0.10 NA Yes No N848K -0.25 0.14 -0.45 0.14 -0.20 0.19 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? N848M NA NA NA NA 0.10 0.64 Yes No N848S -0.89 0.10 -0.37 0.08 -0.30 0.16 No No N848T 0.37 0.12 -0.11 0.12 -0.17 0.11 Yes No N848W -0.76 0.12 -0.04 0.10 0.22 0.40 Yes No N848Y -0.61 0.18 0.16 0.16 -0.20 0.24 Yes No N848V -0.51 0.09 -0.84 0.10 -0.29 0.64 No No V849A -0.93 0.12 0.41 0.09 -0.39 0.18 Yes No V849R -1.79 0.16 -1.96 0.16 -1.01 0.29 No No V849G -1.07 0.08 -1.40 0.08 -1.48 0.05 No No V849L 0.90 0.09 -0.43 0.11 -0.12 0.13 Yes No V849M -0.12 0.12 -0.31 0.12 -0.19 0.19 No No I850A 0.25 0.05 -0.76 0.06 -0.17 0.06 Yes No I850R -0.32 0.04 -0.27 0.04 -0.21 0.06 No No I850N -0.38 0.13 -0.44 0.13 -0.50 0.10 No No I850D -1.19 0.12 -0.73 0.10 -0.71 0.54 No No I850C -0.30 0.08 0.19 0.08 0.13 0.14 Yes No I850Q -0.08 0.11 -0.31 0.11 0.00 0.43 No No I850E -0.24 0.07 -0.45 0.07 -0.35 0.25 No No I850G -0.90 0.04 -0.86 0.04 -0.96 0.06 No No I850H 0.45 0.12 -0.44 0.13 -0.29 0.54 Yes No I850L -0.15 0.04 -0.17 0.04 -0.26 0.05 No No I850K -1.20 0.13 -0.19 0.10 -0.01 0.82 No No I850M -0.83 0.09 -0.82 0.09 -0.28 0.18 No No I850F -0.83 0.11 -0.97 0.11 -0.61 0.17 No No I850P -0.43 0.09 -1.72 0.12 -1.01 0.12 No No I850S -0.42 0.06 -0.18 0.05 -0.52 0.06 No No I850T 0.00 0.07 -0.22 0.07 0.06 0.07 Yes No I850W -1.02 0.07 -1.26 0.08 -0.97 0.10 No No 1850V -0.03 0.04 0.12 0.04 0.22 0.05 Yes No T851A 0.41 0.06 0.14 0.06 0.08 0.10 Yes Yes T851V 0.32 0.06 0.13 0.06 0.54 0.07 Yes Yes T851R -0.18 0.06 -0.82 0.06 -0.93 0.17 No No T851C 0.00 0.14 -0.03 0.14 -0.11 0.82 No No T851Q NA NA NA NA -0.17 0.29 Yes No T851E -0.44 0.09 -0.88 0.10 -0.08 0.08 No No T851G -1.22 0.06 -0.82 0.05 -0.95 0.19 No No T851I 0.21 0.13 -0.17 0.13 0.20 0.20 Yes No T851L 0.35 0.08 0.01 0.09 -0.05 0.37 Yes No T851K -0.23 0.14 -0.49 0.14 NA NA Yes No T851M 0.52 0.11 -0.71 0.14 -0.02 0.23 Yes No T851F -0.32 0.18 0.44 0.16 0.28 NA Yes No T851P -0.06 0.04 0.04 0.04 0.03 0.05 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? T851S -0.01 0.07 -0.04 0.07 -0.08 0.13 No No T851W 0.07 0.09 -0.34 0.09 -0.01 0.48 Yes No K852A -1.49 0.14 -1.41 0.13 NA NA Yes No K852R -0.07 0.06 -0.48 0.07 -0.37 0.10 No No K852N 0.12 0.10 -0.39 0.11 0.01 0.08 Yes No K852Q -0.04 0.05 0.10 0.04 0.14 0.06 Yes No K852E -0.99 0.12 -0.80 0.11 -1.03 0.07 No No K852G -1.42 0.09 -2.60 0.13 -1.20 0.18 No No K852P -0.25 0.07 -0.24 0.07 -0.22 0.08 No No K852S -1.14 0.13 -0.56 0.10 -0.56 0.48 No No K852* -0.98 0.15 -1.24 0.16 NA NA Yes No K852T -0.16 0.03 -0.02 0.03 0.16 0.04 Yes No K852V -0.65 0.09 -0.18 0.08 -0.78 0.48 No No E853V 0.14 0.07 0.10 0.07 0.38 0.09 Yes Yes E853A -0.49 0.08 -0.35 0.08 -0.05 0.09 No No E853R 0.23 0.06 -0.13 0.06 -0.20 0.31 Yes No E853D -0.30 0.10 -0.26 0.10 0.42 0.18 Yes No E853C 0.07 0.11 0.12 0.11 -0.24 0.13 Yes No E853Q -0.55 0.17 0.09 0.14 0.17 0.31 Yes No E853G -0.18 0.04 -0.41 0.05 -0.47 0.07 No No E853L -0.85 0.10 0.03 0.08 0.08 0.08 Yes No E853K 0.05 0.12 -0.95 0.15 0.21 0.20 Yes No E853M -0.08 0.15 -0.94 0.17 0.01 0.11 Yes No E853P 0.46 0.13 -0.02 0.14 0.28 0.40 Yes No E853S -0.30 0.09 -0.41 0.09 0.07 0.15 Yes No E853* -0.52 0.09 -0.38 0.09 -0.25 0.08 No No E853T -0.33 0.15 -0.61 0.15 0.57 0.25 Yes No E853W 0.25 0.08 -1.68 0.12 -0.52 0.14 Yes No V854A -0.95 0.08 -0.31 0.06 -0.94 0.15 No No V854R -1.42 0.07 -1.14 0.06 -1.31 0.13 No No V854D -0.58 0.13 -1.22 0.15 NA NA Yes No V854C -0.91 0.13 -0.17 0.11 -0.54 0.35 No No V854E -1.32 0.11 -1.01 0.09 -1.15 0.18 No No V854G -1.40 0.06 -1.44 0.06 -1.28 0.09 No No V854L -1.49 0.10 -0.60 0.07 -1.28 0.13 No No V854M -1.32 0.13 -1.02 0.11 -0.94 0.16 No No V854P -1.29 0.16 -1.22 0.15 NA NA Yes No V854S -1.58 0.12 -0.89 0.09 -1.26 0.21 No No V854W -1.48 0.10 -0.37 0.07 -1.34 0.06 No No S855A 0.70 0.10 -0.77 0.12 0.01 0.40 Yes No S855R 0.40 0.10 -0.66 0.11 0.61 0.12 Yes No S855C -0.24 0.17 0.37 0.15 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? S855G 0.01 0.07 -0.69 0.08 -0.49 0.48 Yes No S855L NA NA NA NA -0.20 0.82 Yes No S855F -0.02 0.17 0.31 0.16 NA NA Yes No S855P -0.31 0.12 0.14 0.10 -0.08 0.16 Yes No S855T 0.53 0.13 -0.42 0.15 0.41 0.24 Yes No S855Y NA NA NA NA 0.21 0.29 Yes No S855V 0.17 0.13 0.00 0.14 0.24 0.82 Yes No H856R -0.04 0.07 -0.29 0.07 -0.62 0.16 No No H856N -1.01 0.17 -0.62 0.15 NA NA Yes No H856E -0.49 0.12 -0.23 0.11 NA NA Yes No H856G -0.96 0.07 -1.35 0.07 -1.43 0.08 No No H856L -0.83 0.12 -0.29 0.10 -0.42 0.20 No No H856P -0.26 0.09 0.07 0.09 -0.29 0.09 Yes No H856S -1.39 0.17 -0.13 0.12 NA NA Yes No H856W NA NA NA NA -0.62 0.17 Yes No H856Y -0.65 0.16 -0.05 0.13 0.50 0.20 Yes No H856V NA NA NA NA -0.60 0.21 Yes No E857A -0.23 0.05 -0.30 0.05 -0.51 0.06 No No E857R -0.92 0.06 -1.30 0.06 -1.05 0.13 No No E857D 0.50 0.09 -0.31 0.10 -1.09 0.21 Yes No E857C -0.44 0.13 -1.14 0.15 -0.59 0.40 No No E857Q -0.89 0.14 -1.04 0.14 -0.73 0.29 No No E857G -0.98 0.04 -0.90 0.04 -1.19 0.03 No No E857L -0.09 0.08 -0.75 0.09 -0.99 0.22 No No E857K 0.23 0.09 -0.93 0.11 -0.76 0.14 Yes No E857M -0.36 0.13 -0.31 0.12 NA NA Yes No E857P -0.10 0.11 -0.53 0.12 -0.58 0.54 No No E857S -0.17 0.08 -0.67 0.08 -0.71 0.16 No No E857* -1.28 0.15 -0.53 0.12 NA NA Yes No E857T -1.10 0.14 0.08 0.10 -0.09 0.54 Yes No E857W -0.75 0.08 -1.02 0.08 -1.03 0.15 No No E857V -0.10 0.05 -0.43 0.05 -0.29 0.08 No No I858R -1.30 0.11 -1.37 0.10 -1.32 0.24 No No I858G -2.03 0.11 -0.89 0.07 -1.33 0.09 No No I858L -0.32 0.08 -0.64 0.08 -0.25 0.08 No No I858F -0.53 0.17 -0.64 0.17 NA NA Yes No I858S -1.55 0.16 -0.66 0.12 NA NA Yes No I858T -0.49 0.13 -0.72 0.13 -0.26 0.20 No No 1858V -0.43 0.08 -0.43 0.08 -0.69 0.11 No No I859A -2.25 0.14 -1.44 0.10 -0.96 0.35 No No I859R -1.46 0.08 -1.27 0.07 -1.13 0.07 No No I859N -0.63 0.17 -0.59 0.16 -0.31 0.21 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? I859D -1.17 0.15 -1.53 0.16 NA NA Yes No I859Q -0.35 0.17 0.41 0.15 NA NA Yes No I859E -0.25 0.09 -0.09 0.08 -0.48 0.11 No No I859G -1.65 0.07 -1.30 0.06 -1.32 0.22 No No I859L -0.20 0.04 -0.01 0.04 -0.26 0.04 No No I859M -0.66 0.12 0.38 0.10 -0.64 0.11 Yes No I859F -0.18 0.12 -0.15 0.12 -0.59 0.12 No No I859S -0.34 0.08 -1.05 0.09 -1.12 0.17 No No I859T -0.26 0.09 -0.27 0.09 -0.35 0.15 No No I859W -1.84 0.15 -0.31 0.09 -0.74 0.64 No No 1859V 0.30 0.04 -0.13 0.05 0.24 0.05 Yes No K860A -0.50 0.06 -0.35 0.06 -1.06 0.07 No No K860R -0.39 0.05 -0.83 0.05 -0.83 0.10 No No K860N -0.63 0.12 -1.47 0.14 -0.88 0.16 No No K860C -0.36 0.10 -0.81 0.11 NA NA Yes No K860Q -0.18 0.04 -0.19 0.04 -0.15 0.06 No No K860E -0.89 0.06 -1.15 0.07 -1.08 0.05 No No K860G -1.23 0.05 -1.22 0.05 -1.28 0.06 No No K860L -0.68 0.07 -1.58 0.09 -1.19 0.11 No No K860M -0.24 0.09 -0.56 0.09 -1.00 0.15 No No K860P -0.21 0.07 -0.49 0.07 -0.50 0.09 No No K860S -1.38 0.08 -1.80 0.09 -1.30 0.07 No No K860* -1.43 0.12 -1.23 0.11 -1.17 0.16 No No K860T -0.15 0.04 -0.15 0.04 -0.07 0.06 No No K860W -1.18 0.08 -1.46 0.09 -1.24 0.09 No No K860V -0.88 0.06 -1.87 0.08 -1.03 0.04 No No D861A -0.47 0.05 -0.76 0.06 -1.12 0.11 No No D861R -1.43 0.06 -1.83 0.06 -1.24 0.09 No No D861N -0.46 0.10 -0.59 0.10 -0.60 0.17 No No D861C -0.40 0.08 -0.50 0.08 -0.69 0.08 No No D861Q -0.65 0.11 0.09 0.09 NA NA Yes No D861E -0.97 0.07 -0.89 0.06 -0.50 0.12 No No D861G -0.85 0.03 -1.00 0.03 -1.03 0.03 No No D861H 0.92 0.12 -0.60 0.15 -0.36 0.21 Yes No D861L -0.37 0.07 0.09 0.06 -0.18 0.27 Yes No D861K 0.55 0.09 -1.49 0.13 -1.22 0.43 Yes No D861M -0.29 0.10 -0.57 0.10 -0.68 0.40 No No D861F -1.05 0.15 -0.55 0.13 -0.22 0.12 No No D861S -1.43 0.09 -1.60 0.09 -1.45 0.28 No No D861W -0.88 0.07 -0.84 0.07 -0.15 0.08 No No D861Y -0.18 0.17 0.14 0.16 -0.35 0.14 Yes No D861V -1.18 0.06 -0.99 0.05 -1.28 0.12 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? R862K 0.04 0.14 0.54 0.13 0.02 0.38 Yes Yes R862A -1.76 0.13 -0.42 0.08 -0.71 0.31 No No R862C -0.64 0.12 -1.78 0.16 -0.65 0.28 No No R862Q -0.27 0.10 -0.07 0.09 -0.28 0.13 No No R862E -0.64 0.12 -1.63 0.15 -0.76 0.09 No No R862G -0.72 0.05 -0.83 0.05 -0.85 0.07 No No R862L -0.90 0.08 -0.16 0.07 -0.39 0.09 No No R862M -1.06 0.17 -0.69 0.15 NA NA Yes No R862P -1.33 0.17 -1.10 0.15 NA NA Yes No R862W -1.35 0.11 -0.91 0.09 -1.10 0.14 No No R862V NA NA NA NA -1.61 0.43 Yes No R863Q -0.49 0.13 -0.79 0.14 NA NA Yes No R863G -1.68 0.09 -1.14 0.07 -1.45 0.07 No No R863L -1.18 0.15 -1.68 0.17 -1.02 0.13 No No R863W -1.27 0.11 -1.06 0.10 -1.17 0.14 No No F864I -0.25 0.11 -0.08 0.11 -0.19 0.12 No No F864L 0.01 0.07 -0.06 0.07 0.06 0.08 Yes No F864S -0.34 0.14 -0.27 0.14 -0.35 0.17 No No F864W -0.66 0.18 -0.77 0.18 NA NA Yes No F864V -0.11 0.06 -0.13 0.05 0.00 0.08 No No T865A -0.65 0.14 -0.29 0.12 -0.09 0.18 No No T865N 0.07 0.03 -0.05 0.03 -0.15 0.04 Yes No T865I -0.01 0.10 0.20 0.09 0.20 0.13 Yes No T865L NA NA NA NA 0.57 0.29 Yes No T865P -0.10 0.05 -0.07 0.05 -0.01 0.06 No No T865S -0.20 0.02 -0.20 0.02 0.01 0.03 Yes No T865Y -0.16 0.06 -0.17 0.05 -0.16 0.10 No No S866F 0.00 0.13 0.06 0.12 0.10 0.14 Yes Yes S866T 0.05 0.13 0.02 0.13 0.40 0.15 Yes Yes S866A -0.10 0.09 -0.40 0.10 0.05 0.07 Yes No S866R NA NA NA NA -0.33 0.09 Yes No S866D NA NA NA NA 0.02 0.24 Yes No S866C NA NA NA NA -0.05 0.43 Yes No S866Q NA NA NA NA -0.04 0.27 Yes No S866E NA NA NA NA 0.58 0.22 Yes No S866G NA NA NA NA -0.97 0.29 Yes No S866L NA NA NA NA 0.57 0.10 Yes No S866M NA NA NA NA 0.85 0.14 Yes No S866P 0.08 0.03 -0.07 0.03 0.00 0.03 Yes No S866W NA NA NA NA -0.67 0.37 Yes No S866Y 0.13 0.16 -0.17 0.17 0.03 0.11 Yes No S866V NA NA NA NA 1.00 0.08 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? D867A 0.05 0.02 -0.05 0.02 -0.05 0.02 Yes No D867R NA NA NA NA -1.39 0.06 Yes No D867N NA NA NA NA -0.17 0.14 Yes No D867C NA NA NA NA -0.98 0.17 Yes No D867E -0.16 0.11 -0.21 0.11 -0.99 0.09 No No D867G 0.06 0.02 0.00 0.02 -0.11 0.02 Yes No D867H -0.04 0.09 0.11 0.08 NA NA Yes No D867S NA NA NA NA -0.98 0.09 Yes No D867W NA NA NA NA -1.25 0.13 Yes No D867Y NA NA NA NA -1.02 0.12 Yes No D867V -0.04 0.10 -0.07 0.10 -0.92 0.07 No No K868A NA NA NA NA -1.23 0.28 Yes No K868R -0.01 0.02 0.02 0.02 -0.76 0.04 Yes No K868N NA NA NA NA -1.00 0.11 Yes No K868Q -0.14 0.09 -0.02 0.09 -0.11 0.08 No No K868E -0.43 0.19 -0.52 0.19 -1.33 0.19 No No K868G NA NA NA NA -1.49 0.08 Yes No K868P NA NA NA NA -1.00 0.09 Yes No K868S NA NA NA NA -1.32 0.15 Yes No K868* NA NA NA NA -1.02 0.18 Yes No K868T -0.15 0.03 -0.12 0.03 -0.14 0.07 No No K868W NA NA NA NA -1.50 0.15 Yes No K868V NA NA NA NA -1.12 0.16 Yes No F869A NA NA NA NA -1.10 0.15 Yes No F869R NA NA NA NA -1.47 0.27 Yes No F869C NA NA NA NA -1.20 0.15 Yes No F869E NA NA NA NA -1.41 0.09 Yes No F869G NA NA NA NA -1.40 0.04 Yes No F869I 0.06 0.10 -0.10 0.10 0.04 0.09 Yes No F869L -0.16 0.03 -0.17 0.03 -0.01 0.06 No No F869M NA NA NA NA 0.14 0.09 Yes No F869S NA NA NA NA -1.16 0.09 Yes No F869W NA NA NA NA -1.32 0.12 Yes No F869Y NA NA NA NA -0.21 0.24 Yes No F869V -0.16 0.05 -0.18 0.05 -0.62 0.05 No No L870A -0.86 0.11 -0.83 0.10 NA NA Yes No L870R -1.55 0.08 -1.55 0.07 NA NA Yes No L870E -1.23 0.14 -1.60 0.15 NA NA Yes No L870G -1.54 0.07 -1.47 0.07 NA NA Yes No L870M -0.94 0.16 -1.13 0.17 NA NA Yes No L870F -1.01 0.07 -0.78 0.07 NA NA Yes No L870P -0.29 0.06 -0.36 0.06 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? L870V -0.67 0.08 -0.82 0.08 NA NA Yes No F870A NA NA NA NA -1.06 0.37 Yes No F870R NA NA NA NA -1.61 0.14 Yes No F870C NA NA NA NA -0.66 0.43 Yes No F870G NA NA NA NA -1.20 0.19 Yes No F870I NA NA NA NA 0.71 0.17 Yes No F870L NA NA NA NA 1.11 0.06 Yes No F870M NA NA NA NA -0.04 0.44 Yes No F870S NA NA NA NA -0.82 0.17 Yes No F870V NA NA NA NA 0.05 0.09 Yes No F871R NA NA NA NA -1.55 0.28 Yes No F871C -0.24 0.17 -0.04 0.16 NA NA Yes No F871G NA NA NA NA -1.08 0.22 Yes No F871L -0.17 0.07 -0.16 0.07 -0.50 0.08 No No F871S NA NA NA NA -0.74 0.12 Yes No F871V 0.19 0.12 -0.06 0.12 -0.68 0.22 Yes No H872R -0.49 0.19 -0.27 0.18 -1.33 0.16 No No H872Q -0.40 0.10 -0.32 0.10 -0.60 0.11 No No H872G NA NA NA NA -1.61 0.11 Yes No H872L 0.00 0.08 -0.15 0.08 -0.43 0.08 No No H872P 0.04 0.02 -0.01 0.02 0.34 0.02 Yes No H872Y NA NA NA NA 0.10 0.21 Yes No H872V NA NA NA NA -1.51 0.48 Yes No V873A 0.16 0.11 0.05 0.11 0.08 0.16 Yes Yes V873E -0.40 0.14 -0.35 0.14 NA NA Yes No V873G -0.13 0.04 -0.20 0.03 -0.27 0.07 No No V873L -0.20 0.05 0.24 0.05 -0.40 0.08 Yes No V873M -0.48 0.12 -0.33 0.11 -0.16 0.16 No No P874A -0.12 0.06 0.06 0.06 0.03 0.11 Yes No P874G NA NA NA NA -0.22 0.17 Yes No P874S -0.06 0.10 -0.17 0.10 0.58 0.11 Yes No P874T -0.23 0.06 -0.24 0.06 -0.09 0.04 No No I875R -0.33 0.12 -0.24 0.11 -0.82 0.10 No No I875N -0.01 0.07 -0.09 0.07 0.03 0.08 Yes No I875G NA NA NA NA -1.64 0.10 Yes No I875H 0.10 0.11 -0.01 0.11 -0.25 0.11 Yes No I875L 0.08 0.02 0.02 0.02 -0.08 0.02 Yes No I875M -0.44 0.17 -0.26 0.16 0.05 0.17 Yes No I875F -0.20 0.09 -0.13 0.09 -0.12 0.10 No No I875S -0.06 0.07 -0.04 0.07 -0.22 0.07 No No I875T -0.01 0.10 -0.10 0.09 -0.11 0.11 No No 1875V -0.24 0.17 -0.16 0.16 -0.44 0.10 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? T876A NA NA NA NA -1.21 0.20 Yes No T876R NA NA NA NA -1.72 0.26 Yes No T876N -0.10 0.03 -0.09 0.03 -0.07 0.05 No No T876G NA NA NA NA -1.44 0.22 Yes No T876P -0.03 0.06 -0.07 0.06 -0.30 0.05 No No T876S NA NA NA NA -0.63 0.19 Yes No T876V NA NA NA NA -1.34 0.33 Yes No L877A 0.09 0.12 -0.51 0.13 NA NA Yes No L877R -0.89 0.08 -1.39 0.09 -1.53 0.08 No No L877C -0.26 0.17 -0.47 0.17 NA NA Yes No L877Q -0.43 0.11 -0.45 0.11 -0.39 0.13 No No L877G -1.42 0.09 -2.38 0.13 -1.74 0.35 No No L877P -0.08 0.07 -0.22 0.07 -0.40 0.12 No No L877S -1.11 0.16 -0.99 0.15 NA NA Yes No L877V -1.25 0.14 0.04 0.10 -0.96 0.08 Yes No L877A -0.03 0.10 -0.76 0.11 NA NA Yes No L877R -0.15 0.04 -0.31 0.04 -0.02 0.04 No No L877C -0.29 0.15 -0.65 0.15 NA NA Yes No L877Q -0.26 0.11 -0.47 0.11 NA NA Yes No L877E NA NA NA NA -0.74 0.64 Yes No L877G -1.40 0.08 -2.82 0.12 -1.79 0.22 No No L877M -0.19 0.11 0.18 0.10 0.26 0.10 Yes No L877P -0.28 0.09 -0.39 0.08 -0.46 0.15 No No L877S -1.31 0.14 -1.01 0.12 NA NA Yes No L877V -1.10 0.10 -0.29 0.08 -0.58 0.06 No No N878D 0.03 0.06 0.02 0.06 0.04 0.08 Yes Yes N878A 0.17 0.16 -0.41 0.17 -0.06 0.25 Yes No N878Q -0.22 0.17 -0.53 0.17 NA NA Yes No N878E -0.73 0.15 -0.44 0.13 -0.84 0.13 No No N878G -0.57 0.10 -0.98 0.11 -0.70 0.06 No No N878H -0.01 0.05 -0.10 0.05 0.03 0.05 Yes No N878L NA NA NA NA -0.13 0.64 Yes No N878K -0.01 0.02 -0.05 0.02 -0.06 0.02 No No N878S -1.08 0.15 -0.43 0.12 -0.38 0.10 No No N878T -0.16 0.06 0.09 0.06 0.15 0.07 Yes No N878Y -0.05 0.07 0.00 0.06 0.06 0.04 Yes No N878V -1.01 0.17 -0.32 0.14 -0.19 0.34 No No N878A 0.03 0.14 -0.32 0.14 -0.19 0.54 Yes No N878D -0.11 0.12 -0.34 0.12 -0.62 0.15 No No N878C NA NA NA NA 0.58 0.42 Yes No N878G -0.62 0.10 -1.09 0.11 -0.81 0.05 No No N878I -0.35 0.16 -0.02 0.15 -0.41 0.17 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? N878L NA NA NA NA -0.12 0.82 Yes No N878K -0.34 0.13 -0.40 0.13 -0.39 0.08 No No N878M NA NA NA NA 0.25 0.16 Yes No N878S -0.54 0.11 -0.30 0.10 -0.50 0.07 No No N878T -0.19 0.05 -0.20 0.05 -0.37 0.09 No No N878Y -0.34 0.18 -0.28 0.17 -0.12 0.21 No No N878V -0.98 0.15 -0.37 0.12 -0.51 0.32 No No Y879A -2.04 0.15 -1.14 0.10 NA NA Yes No Y879R -0.78 0.08 -1.40 0.08 -1.48 0.11 No No Y879D 0.39 0.05 -0.19 0.06 -0.18 0.07 Yes No Y879C 0.50 0.06 -0.02 0.07 -0.50 0.09 Yes No Y879Q -0.72 0.19 -0.38 0.17 NA NA Yes No Y879E -1.40 0.13 -1.23 0.11 NA NA Yes No Y879G -0.58 0.05 -1.93 0.07 -1.84 0.23 No No Y879H 0.35 0.09 0.04 0.09 -0.16 0.12 Yes No Y879L -1.45 0.13 0.26 0.08 -1.39 0.33 Yes No Y879K 0.13 0.14 -1.11 0.17 NA NA Yes No Y879F -0.05 0.12 -0.01 0.11 0.01 0.17 Yes No Y879S 0.37 0.04 -0.29 0.04 -0.43 0.07 Yes No Y879* -0.20 0.11 0.92 0.09 -0.81 0.15 Yes No Y879W -0.05 0.08 -0.07 0.07 0.60 0.07 Yes No Y879V -0.53 0.08 -0.97 0.08 NA NA Yes No Q880R 0.13 0.05 0.02 0.05 0.01 0.06 Yes Yes Q880G 0.25 0.04 0.19 0.04 0.64 0.05 Yes Yes Q880A -0.10 0.08 0.40 0.07 -0.19 0.20 Yes No Q880D 0.81 0.14 -1.10 0.18 NA NA Yes No Q880C -0.08 0.14 -1.19 0.17 0.17 0.14 Yes No Q880E -0.73 0.10 -1.06 0.10 -0.58 0.08 No No Q880H 0.24 0.08 -0.08 0.08 -0.10 0.08 Yes No Q880L -0.80 0.08 -0.59 0.07 -1.39 0.07 No No Q880K -0.23 0.13 -0.27 0.13 -0.44 0.09 No No Q880M -0.93 0.16 -0.77 0.14 -0.49 0.17 No No Q880P -0.07 0.10 -0.40 0.10 0.12 0.07 Yes No Q880S -0.31 0.09 -0.76 0.10 -0.09 0.07 No No Q880* -1.27 0.14 -0.76 0.11 -1.05 0.11 No No Q880T -0.52 0.14 -0.18 0.12 0.07 0.29 Yes No Q880W -0.68 0.08 -0.91 0.08 -0.82 0.06 No No Q880V -1.77 0.10 -0.81 0.07 -0.63 0.07 No No A881R -0.95 0.07 -1.75 0.08 -1.43 0.18 No No A881D -0.36 0.11 -0.32 0.10 -0.48 0.19 No No A881C -0.35 0.14 -0.78 0.15 -0.49 0.10 No No A881G 0.14 0.04 0.32 0.04 -0.41 0.04 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? A881L -1.36 0.11 -2.39 0.15 NA NA Yes No A881P -1.05 0.16 -0.99 0.14 -0.80 0.18 No No A881S 0.13 0.05 0.13 0.05 -0.13 0.06 Yes No A881T -0.73 0.10 -0.95 0.10 -0.44 0.14 No No A881W -1.25 0.12 -1.48 0.12 NA NA Yes No A881V -1.66 0.09 -1.28 0.07 -0.91 0.08 No No A882D 0.32 0.05 0.22 0.05 0.10 0.07 Yes Yes A882S 0.11 0.12 0.14 0.11 0.23 0.22 Yes Yes A882R -0.10 0.10 0.54 0.09 0.51 0.35 Yes No A882G -0.43 0.07 -0.32 0.06 -0.14 0.06 No No A882L -1.02 0.19 0.32 0.14 NA NA Yes No A882P -0.12 0.14 -0.11 0.13 -0.12 0.24 No No A882T -0.14 0.09 0.05 0.09 -0.09 0.13 Yes No A882V 0.39 0.08 0.04 0.08 -0.17 0.15 Yes No N883G 0.42 0.08 0.37 0.08 0.03 0.11 Yes Yes N883K 0.12 0.16 0.23 0.16 0.16 0.10 Yes Yes N883A -0.26 0.15 -1.10 0.17 0.05 0.55 Yes No N883R NA NA NA NA 0.84 0.11 Yes No N883D -0.02 0.13 -0.37 0.14 -0.36 0.18 No No N883I 0.00 0.16 0.08 0.15 -0.37 0.12 Yes No N883S 0.08 0.10 0.04 0.10 -0.13 0.09 Yes No N883T 0.27 0.11 -0.02 0.11 -0.21 0.12 Yes No S884V 0.05 0.11 0.61 0.10 0.03 0.14 Yes Yes S884A 0.07 0.13 -0.01 0.12 0.02 NA Yes No S884R -0.28 0.06 -0.11 0.06 0.34 0.07 Yes No S884N 0.14 0.14 0.48 0.13 -0.07 0.25 Yes No S884C NA NA NA NA 0.18 0.19 Yes No S884E -0.10 0.16 -0.04 0.15 NA NA Yes No S884G -0.09 0.06 -0.11 0.06 0.01 0.10 Yes No S884L NA NA NA NA 0.02 0.55 Yes No S884T -0.01 0.10 0.05 0.10 NA NA Yes No S884W -0.99 0.18 -0.38 0.14 0.43 0.82 Yes No P885A -0.36 0.06 -0.32 0.05 -0.12 0.13 No No P885R -0.03 0.04 -0.89 0.05 0.00 0.06 Yes No P885N -0.47 0.17 -0.73 0.17 NA NA Yes No P885D -0.73 0.12 -1.21 0.12 -0.83 0.35 No No P885C -1.54 0.14 -0.39 0.09 -0.01 0.09 No No P885Q -1.26 0.18 -0.04 0.13 -0.65 0.33 No No P885E -0.08 0.08 -1.01 0.09 -0.98 0.16 No No P885G -1.22 0.05 -0.98 0.04 -0.39 0.04 No No P885H -0.06 0.13 -0.41 0.13 0.09 0.12 Yes No P885I NA NA NA NA -0.01 0.44 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? P885L -0.66 0.07 -0.90 0.07 -0.60 0.05 No No P885K -0.12 0.12 -0.28 0.12 -0.32 0.22 No No P885M -1.32 0.15 -1.01 0.13 -0.52 0.13 No No P885F -0.98 0.16 -0.49 0.14 -0.31 0.10 No No P885S -0.88 0.07 -0.65 0.06 -0.11 0.12 No No P885T -0.35 0.04 -0.29 0.04 0.03 0.05 Yes No P885W -0.76 0.07 -1.20 0.08 -0.94 0.23 No No P885Y -0.19 0.16 0.72 0.13 0.22 0.48 Yes No P885V -0.86 0.06 -0.46 0.05 0.05 0.12 Yes No S886L 0.09 0.08 0.12 0.08 0.05 0.11 Yes Yes S886M 0.32 0.11 0.15 0.11 0.40 0.35 Yes Yes S886W 0.23 0.07 0.01 0.07 0.70 0.19 Yes Yes S886A -0.52 0.07 -0.42 0.07 -0.04 0.14 No No S886R 0.12 0.04 -0.08 0.04 0.36 0.04 Yes No S886N 0.34 0.10 -0.34 0.11 -0.03 0.14 Yes No S886D 0.60 0.10 -0.69 0.12 NA NA Yes No S886C 0.11 0.09 -0.64 0.09 0.34 0.23 Yes No S886Q -0.33 0.14 -0.65 0.14 0.19 0.64 Yes No S886E -0.60 0.10 -0.56 0.10 NA NA Yes No S886G -0.20 0.04 -0.18 0.04 0.10 0.05 Yes No S886I 0.89 0.13 -0.13 0.14 0.07 0.29 Yes No S886K -0.70 0.14 0.01 0.12 0.56 0.12 Yes No S886F NA NA NA NA 0.75 0.44 Yes No S886P NA NA NA NA -0.28 0.14 Yes No S886T 0.07 0.07 -0.05 0.07 -0.29 0.10 Yes No S886Y NA NA NA NA 0.79 0.55 Yes No S886V -0.10 0.07 -0.15 0.06 0.35 0.20 Yes No K887A 0.03 0.04 -0.38 0.05 -0.54 0.04 Yes No K887R -0.09 0.03 -0.04 0.03 0.21 0.03 Yes No K887N 0.24 0.10 0.07 0.10 -0.45 0.24 Yes No K887D -1.19 0.10 -0.97 0.09 -1.27 0.28 No No K887C -0.76 0.08 0.16 0.07 -0.59 0.06 Yes No K887Q 0.10 0.08 -0.05 0.07 -0.25 0.11 Yes No K887E -0.33 0.05 -0.39 0.05 -0.97 0.06 No No K887G -0.14 0.03 -0.22 0.02 -0.42 0.03 No No K887H -0.04 0.12 -1.21 0.15 -0.21 0.40 No No K887I -0.31 0.12 -0.04 0.11 NA NA Yes No K887L -0.88 0.06 -0.67 0.05 -0.68 0.07 No No K887M -0.12 0.07 -0.23 0.07 -0.44 0.16 No No K887F 0.22 0.11 -0.22 0.11 -0.74 0.25 Yes No K887P -0.29 0.08 -0.61 0.08 -0.32 0.18 No No K887S -0.03 0.05 -0.50 0.05 -0.66 0.08 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? K887* -0.88 0.08 -1.30 0.08 -1.22 0.10 No No K887T -0.79 0.08 -0.22 0.07 -0.74 0.11 No No K887W -0.59 0.05 -0.69 0.05 -0.65 0.07 No No K887Y 0.36 0.10 -0.98 0.13 -0.40 0.17 Yes No K887V 0.09 0.04 -0.88 0.04 -0.89 0.07 Yes No F888A -2.01 0.10 -1.31 0.07 -1.30 0.28 No No F888R -1.27 0.07 -1.04 0.06 -1.82 0.18 No No F888D -1.09 0.12 -1.32 0.12 NA NA Yes No F888C 0.01 0.04 -0.10 0.04 0.10 0.03 Yes No F888Q -0.58 0.13 -1.37 0.15 NA NA Yes No F888E -0.89 0.08 -2.09 0.11 -1.77 0.12 No No F888G -1.75 0.05 -1.53 0.05 -1.57 0.03 No No F888I 0.09 0.11 -0.24 0.11 -0.50 0.15 Yes No F888L -0.13 0.04 -0.06 0.03 -0.23 0.05 No No F888M -0.65 0.12 0.31 0.10 -0.04 0.10 Yes No F888P -0.69 0.12 -1.56 0.15 NA NA Yes No F888S -1.42 0.08 -1.17 0.07 -1.14 0.12 No No F888* -1.06 0.13 -0.77 0.11 -1.31 0.08 No No F888T -0.62 0.11 -1.69 0.13 -1.19 0.64 No No F888W -1.15 0.08 -2.14 0.11 -1.37 0.05 No No F888Y -0.73 0.13 -1.27 0.14 -0.60 0.12 No No F888V 0.07 0.04 0.10 0.04 -0.31 0.03 Yes No N889A NA NA NA NA -0.86 0.64 Yes No N889R -0.94 0.09 -0.07 0.07 -0.55 0.48 No No N889D -0.34 0.10 -0.44 0.10 -0.39 0.14 No No N889G -0.87 0.06 -1.32 0.07 -0.83 0.07 No No N889I -0.51 0.17 -0.43 0.16 NA NA Yes No N889K -0.76 0.17 -0.47 0.15 -0.34 0.24 No No N889S -1.13 0.11 0.08 0.08 -0.26 0.14 Yes No N889T -0.55 0.16 -0.45 0.14 -0.36 0.30 No No N889V -1.82 0.15 -1.28 0.12 -1.16 0.64 No No Q890C 0.03 0.11 0.64 0.10 0.08 0.54 Yes Yes Q890H 0.39 0.09 0.07 0.09 0.04 0.11 Yes Yes Q890W 0.03 0.08 0.23 0.07 0.03 0.08 Yes Yes Q890A 0.39 0.06 0.05 0.06 -0.02 0.11 Yes No Q890R -0.10 0.05 -0.24 0.05 -0.05 0.10 No No Q890N -0.25 0.15 -0.66 0.16 0.31 NA Yes No Q890D 0.54 0.10 -0.52 0.11 -0.35 0.20 Yes No Q890E 0.17 0.06 -0.62 0.07 -0.33 0.06 Yes No Q890G -0.35 0.04 -0.60 0.04 -0.15 0.07 No No Q890I -0.26 0.16 -0.94 0.18 NA NA Yes No Q890L 0.09 0.06 -0.14 0.06 0.29 0.17 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? Q890K 0.23 0.10 0.25 0.10 -0.22 0.16 Yes No Q890M 0.32 0.11 -0.13 0.11 -0.07 0.48 Yes No Q890F 0.25 0.15 -0.11 0.15 0.09 0.82 Yes No Q890P -1.20 0.12 -0.75 0.10 -0.11 0.17 No No Q890S -0.58 0.08 -0.01 0.07 -0.19 0.08 No No Q890* -1.12 0.11 -1.26 0.11 -0.88 0.13 No No Q890T -0.36 0.10 0.11 0.09 0.08 0.09 Yes No Q890Y NA NA NA NA 0.03 0.13 Yes No Q890V -0.39 0.06 -0.33 0.06 0.21 0.06 Yes No R891A -0.41 0.08 -0.46 0.07 -0.44 0.31 No No R891D -1.17 0.16 -0.76 0.14 -0.63 0.64 No No R891C -0.10 0.10 -0.56 0.11 -0.05 0.17 No No R891Q NA NA NA NA -0.08 0.64 Yes No R891E -1.06 0.11 -0.65 0.09 -0.59 0.64 No No R891G -0.70 0.04 -0.40 0.04 -0.11 0.04 No No R891L 0.07 0.08 -0.02 0.08 -0.25 0.33 Yes No R891K -0.04 0.11 -0.37 0.11 -0.03 0.26 No No R891M NA NA NA NA -0.14 NA Yes No R891S -0.18 0.07 -0.49 0.07 -0.28 0.08 No No R891* -0.88 0.13 -0.57 0.11 -0.74 0.20 No No R891T -0.20 0.10 -0.28 0.10 -0.16 0.10 No No R891W -1.03 0.08 -1.42 0.08 -0.78 0.43 No No R891V -0.28 0.07 -0.77 0.07 -0.53 0.09 No No V892A -1.02 0.08 -1.08 0.08 -0.18 0.07 No No V892R -1.49 0.09 -1.55 0.08 -1.41 0.09 No No V892C -0.58 0.14 -0.80 0.14 -0.01 0.13 No No V892E -0.97 0.10 -1.28 0.10 -0.93 0.17 No No V892G -1.01 0.05 -1.11 0.05 -0.90 0.05 No No V892L -0.58 0.09 -1.35 0.10 -0.93 0.14 No No V892M -0.59 0.12 -0.62 0.12 NA NA Yes No V892S -1.15 0.13 -1.21 0.12 NA NA Yes No V892T -0.34 0.15 0.05 0.13 0.11 0.64 Yes No V892W -1.99 0.15 -1.09 0.10 NA NA Yes No N893A -1.02 0.07 -0.18 0.05 -0.37 0.05 No No N893R -0.35 0.04 -0.57 0.04 -0.42 0.06 No No N893D -0.71 0.10 -0.39 0.08 -0.71 0.11 No No N893C -0.80 0.10 -0.20 0.09 -0.24 0.07 No No N893Q -1.58 0.15 -0.86 0.11 -0.57 0.20 No No N893E -0.89 0.07 -1.03 0.07 -1.10 0.10 No No N893G -0.30 0.03 -0.68 0.03 -0.34 0.04 No No N893H 0.02 0.13 -0.74 0.14 NA NA Yes No N893I 0.33 0.11 -0.24 0.12 -0.68 0.11 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? N893L -1.03 0.08 -0.46 0.07 -0.86 0.17 No No N893K -0.39 0.07 -0.07 0.06 -0.27 0.07 No No N893M 0.26 0.08 -0.81 0.10 -1.04 0.33 Yes No N893S 0.64 0.05 0.08 0.05 -0.47 0.06 Yes No N893* -1.54 0.12 -1.43 0.11 -1.26 0.17 No No N893T 1.09 0.06 -0.04 0.06 -0.62 0.08 Yes No N893W -0.63 0.06 -0.48 0.06 -0.78 0.10 No No N893Y -0.51 0.12 -0.87 0.12 -0.38 0.18 No No N893V -0.70 0.06 -0.74 0.06 -0.59 0.05 No No A894R 0.19 0.06 0.06 0.06 0.04 0.08 Yes Yes A894D 0.04 0.06 0.09 0.06 0.21 0.05 Yes Yes A894C -0.13 0.15 -0.29 0.14 NA NA Yes No A894Q 0.87 0.14 -0.47 0.16 NA NA Yes No A894E -0.35 0.10 -0.85 0.10 -0.45 0.20 No No A894G -0.47 0.05 0.09 0.05 0.21 0.06 Yes No A894L -0.45 0.11 0.57 0.09 0.08 0.12 Yes No A894K NA NA NA NA 0.27 0.15 Yes No A894M 0.14 0.13 -0.17 0.13 0.25 0.18 Yes No A894P -0.67 0.14 -1.05 0.15 NA NA Yes No A894S 0.57 0.08 -0.97 0.10 0.12 0.23 Yes No A894* -0.76 0.19 0.06 0.16 NA NA Yes No A894T -0.68 0.10 -0.49 0.09 0.21 0.15 Yes No A894W 0.67 0.09 -0.44 0.10 0.02 0.54 Yes No A894V -0.22 0.07 -0.05 0.06 0.12 0.18 Yes No Y895D 0.16 0.04 0.00 0.04 0.09 0.04 Yes Yes Y895A -1.08 0.12 -0.85 0.11 -0.53 0.37 No No Y895R NA NA NA NA -0.75 0.07 Yes No Y895N -0.12 0.11 -0.43 0.11 -0.07 0.23 No No Y895C 0.61 0.06 0.14 0.06 -0.26 0.07 Yes No Y895E -0.53 0.11 -0.74 0.10 -0.62 0.13 No No Y895G -0.59 0.06 -1.69 0.08 -1.72 0.07 No No Y895H -0.21 0.10 -0.10 0.10 -0.25 0.16 No No Y895F 0.70 0.12 -0.28 0.13 -0.20 0.21 Yes No Y895S 0.18 0.05 -0.17 0.05 -0.12 0.06 Yes No Y895* -0.03 0.05 -0.04 0.05 0.16 0.06 Yes No Y895W -0.08 0.11 0.17 0.10 -0.18 0.31 Yes No Y895V -1.60 0.12 -0.11 0.08 -0.61 0.40 No No L896A -1.48 0.09 -1.26 0.08 -1.68 0.35 No No L896R 0.19 0.04 -0.11 0.04 -0.30 0.04 Yes No L896Q 0.42 0.04 0.08 0.04 -0.17 0.05 Yes No L896E -1.31 0.11 -1.65 0.12 NA NA Yes No L896G -2.17 0.07 -1.66 0.05 -1.77 0.05 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? L896M 0.31 0.11 -0.22 0.11 -0.74 0.17 Yes No L896F -0.69 0.18 -0.97 0.18 NA NA Yes No L896P -0.37 0.08 -0.52 0.08 -0.53 0.10 No No L896S NA NA NA NA -1.38 0.48 Yes No L896W -1.69 0.12 -1.64 0.11 -0.97 0.54 No No L896V -0.04 0.06 -0.69 0.06 -0.81 0.07 No No K897A -0.76 0.08 -0.22 0.07 -0.07 0.15 No No K897R 0.03 0.04 -0.01 0.04 -0.05 0.05 Yes No K897N 0.58 0.11 0.26 0.11 -0.06 0.09 Yes No K897D -1.39 0.13 -0.61 0.10 -0.10 0.25 No No K897C 0.02 0.09 -0.54 0.10 -0.11 0.08 Yes No K897Q -0.06 0.10 0.16 0.10 -0.04 0.21 Yes No K897E 0.17 0.05 -0.03 0.05 -0.29 0.08 Yes No K897G 0.01 0.04 -0.29 0.04 -0.07 0.03 Yes No K897H -0.18 0.15 0.06 0.14 0.22 0.36 Yes No K897I -0.29 0.13 -1.02 0.14 -0.06 0.06 No No K897L -0.19 0.07 -0.26 0.07 0.28 0.35 Yes No K897M -0.35 0.09 -0.01 0.08 0.23 0.11 Yes No K897F -0.72 0.18 0.16 0.15 -0.08 0.64 Yes No K897P -1.22 0.13 -1.78 0.14 NA NA Yes No K897S -0.22 0.07 -0.29 0.07 -0.13 0.10 No No K897* -0.92 0.11 -0.93 0.11 -0.93 0.11 No No K897T 0.27 0.08 -0.32 0.08 -0.02 0.06 Yes No K897W -0.08 0.07 -0.54 0.07 0.00 0.19 No No K897Y -0.95 0.19 0.19 0.14 -0.23 0.13 Yes No K897V -0.30 0.05 -0.29 0.05 0.19 0.07 Yes No E898A -0.19 0.06 0.08 0.06 -0.25 0.07 Yes No E898R -0.44 0.07 -0.49 0.07 -0.10 0.31 No No E898D 0.42 0.10 -0.32 0.11 -0.12 0.16 Yes No E898C NA NA NA NA 0.23 0.15 Yes No E898Q -0.43 0.14 -0.57 0.13 0.29 0.39 Yes No E898G -0.27 0.05 -0.27 0.05 0.12 0.06 Yes No E898L 0.07 0.11 -0.46 0.12 0.15 0.12 Yes No E898K -0.93 0.16 -0.35 0.14 0.13 0.31 Yes No E898P -0.40 0.19 -0.60 0.19 NA NA Yes No E898S 0.17 0.14 -1.32 0.18 0.38 0.55 Yes No E898W -1.01 0.12 -1.33 0.12 -0.16 0.14 No No E898V -0.06 0.07 0.31 0.07 0.01 0.07 Yes No H899A 0.21 0.08 0.16 0.07 0.01 0.48 Yes Yes H899N 0.15 0.15 0.70 0.14 0.08 0.18 Yes Yes H899R -0.20 0.04 -0.12 0.04 -0.12 0.03 No No H899D -0.84 0.13 -0.16 0.11 -0.47 0.25 No No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? H899C -0.98 0.14 -0.02 0.11 -0.12 0.13 No No H899Q -0.15 0.05 -0.20 0.05 0.00 0.03 No No H899E -0.85 0.10 -0.64 0.09 -0.36 0.27 No No H899G -0.79 0.05 -0.96 0.05 -0.65 0.05 No No H899L -0.27 0.08 -0.41 0.08 -0.50 0.14 No No H899K NA NA NA NA 0.05 0.49 Yes No H899P -0.07 0.07 0.01 0.07 -0.33 0.10 Yes No H899S -0.31 0.10 -0.33 0.09 0.07 0.32 Yes No H899T -0.37 0.15 -0.14 0.14 -0.03 0.48 No No H899W -0.32 0.08 -0.24 0.07 -0.25 0.48 No No H899Y -0.09 0.12 -0.87 0.13 0.11 0.16 Yes No H899V -0.07 0.07 -0.99 0.08 0.05 0.22 Yes No P900A -0.09 0.05 0.03 0.04 0.04 0.11 Yes No P900R -0.17 0.04 -0.23 0.03 0.09 0.04 Yes No P900N -1.13 0.14 0.05 0.11 0.35 0.30 Yes No P900D -0.42 0.08 -0.19 0.07 0.19 0.12 Yes No P900C -0.28 0.07 0.15 0.06 0.12 0.15 Yes No P900Q 0.28 0.08 -0.19 0.09 0.23 0.30 Yes No P900E -0.19 0.06 0.18 0.05 0.29 0.08 Yes No P900G -0.03 0.03 -0.15 0.03 0.11 0.03 Yes No P900H 0.07 0.08 -0.18 0.08 0.25 0.12 Yes No P900I -0.83 0.12 -0.36 0.10 0.33 0.33 Yes No P900L 0.03 0.04 -0.20 0.04 0.07 0.04 Yes No P900K 0.16 0.08 -0.61 0.08 0.05 0.13 Yes No P900M -1.26 0.10 -0.21 0.07 0.06 0.12 Yes No P900F 0.33 0.10 -0.07 0.10 -0.19 0.09 Yes No P900S -0.10 0.05 0.15 0.04 0.14 0.04 Yes No P900* -0.32 0.08 -1.30 0.10 NA NA Yes No P900T 0.24 0.06 -0.22 0.06 0.19 0.09 Yes No P900W -0.16 0.05 -0.48 0.06 -0.04 0.06 No No P900Y -0.49 0.11 -0.86 0.11 -0.25 0.82 No No P900V 0.10 0.04 -0.35 0.04 0.14 0.05 Yes No E901D 0.07 0.10 0.05 0.10 0.14 0.15 Yes Yes E901A -0.81 0.08 0.24 0.07 0.08 0.08 Yes No E901R -0.15 0.06 -0.19 0.06 -0.03 0.06 No No E901C -0.08 0.13 -0.32 0.13 0.21 0.64 Yes No E901Q -0.69 0.16 0.04 0.13 -0.16 0.40 Yes No E901G -0.44 0.04 0.07 0.04 0.10 0.06 Yes No E901L -0.12 0.08 -0.80 0.09 -0.13 0.20 No No E901K -0.11 0.10 0.20 0.10 0.08 0.13 Yes No E901M 0.16 0.12 -0.14 0.12 0.03 0.82 Yes No E901P -0.99 0.19 -1.23 0.19 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? E901S -1.40 0.13 0.16 0.08 0.05 0.11 Yes No E901* -0.29 0.13 -1.11 0.15 -0.63 0.14 No No E901T NA NA NA NA -0.05 0.44 Yes No E901W 0.02 0.08 -0.49 0.09 0.21 0.08 Yes No E901V -1.13 0.07 -0.49 0.06 0.11 0.06 Yes No T902A -0.07 0.05 -0.35 0.05 -0.20 0.09 No No T902R -0.60 0.06 -1.09 0.07 -0.48 0.12 No No T902C 0.17 0.11 -0.55 0.12 -0.25 0.82 Yes No T902Q -0.92 0.15 -0.24 0.13 NA NA Yes No T902E -0.55 0.10 -1.12 0.11 NA NA Yes No T902G -1.03 0.06 -1.00 0.06 -0.74 0.15 No No T902I -0.22 0.14 0.19 0.12 -0.10 0.20 Yes No T902L -0.92 0.11 -0.09 0.09 -0.12 0.09 No No T902K -0.31 0.04 -0.01 0.04 0.13 0.06 Yes No T902M NA NA NA NA 0.01 0.54 Yes No T902P -1.06 0.13 -0.32 0.10 -0.81 0.21 No No T902S -0.15 0.07 -0.38 0.07 -0.15 0.07 No No T902W NA NA NA NA -0.80 0.54 Yes No T902V -0.15 0.07 0.06 0.07 -0.03 0.14 Yes No P903T 0.64 0.13 0.52 0.12 0.39 0.18 Yes Yes P903A -0.22 0.11 -0.37 0.10 -0.12 0.31 No No P903R -1.86 0.13 -0.87 0.09 -0.31 0.27 No No P903C 0.75 0.15 -0.71 0.18 NA NA Yes No P903E NA NA NA NA 0.05 0.22 Yes No P903G -1.37 0.10 -1.66 0.10 -0.49 0.35 No No P903H NA NA NA NA 0.04 0.17 Yes No P903L -0.52 0.11 -0.93 0.12 0.29 0.10 Yes No P903S -0.61 0.12 0.03 0.10 0.07 0.22 Yes No P903V -0.44 0.12 -0.77 0.12 0.25 0.16 Yes No I904A 0.28 0.05 0.32 0.05 -0.01 0.10 Yes No I904R -0.52 0.05 -0.28 0.04 -0.14 0.04 No No I904N -0.26 0.11 0.07 0.10 -0.29 0.13 Yes No I904D NA NA NA NA -1.33 0.37 Yes No I904C -0.37 0.09 -0.06 0.08 0.16 0.09 Yes No I904Q -0.28 0.11 0.17 0.10 0.03 0.37 Yes No I904E -1.15 0.08 -1.73 0.09 -0.77 0.30 No No I904G -1.05 0.04 -0.45 0.04 -0.39 0.03 No No I904H NA NA NA NA -0.20 0.48 Yes No I904L -0.35 0.07 0.47 0.06 0.12 0.09 Yes No I904K -1.71 0.15 -0.48 0.10 0.05 0.09 Yes No I904M 0.19 0.08 -0.04 0.08 0.03 0.05 Yes No I904F -0.71 0.13 0.38 0.11 0.15 0.20 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? I904S 0.20 0.04 -0.09 0.04 0.07 0.03 Yes No 1904* -1.37 0.12 -1.64 0.13 NA NA Yes No I904T 0.33 0.07 -0.20 0.07 -0.13 0.08 Yes No I904W -0.01 0.06 -0.07 0.06 -0.35 0.24 No No I904Y 0.53 0.12 -0.47 0.13 0.01 0.64 Yes No 1904V -0.13 0.05 0.08 0.04 0.00 0.04 Yes No I905A -0.31 0.06 -0.49 0.06 -0.02 0.14 No No I905R -1.93 0.08 -1.23 0.06 -1.47 0.09 No No I905N -0.95 0.15 -0.68 0.14 NA NA Yes No I905D -1.69 0.14 -1.47 0.12 NA NA Yes No I905C -0.01 0.10 0.49 0.09 -0.12 0.11 Yes No I905E -1.48 0.10 -2.09 0.12 -1.57 0.43 No No I905G -1.25 0.05 -0.83 0.04 -0.80 0.04 No No I905L -0.65 0.07 -0.31 0.06 -0.12 0.07 No No I905M 0.15 0.06 -0.40 0.07 -0.10 0.06 Yes No I905F -0.10 0.11 -0.09 0.11 -0.55 0.18 No No I905S -1.01 0.07 -1.06 0.07 -0.63 0.06 No No I905T -0.17 0.09 -0.86 0.09 -0.52 0.12 No No I905W -1.31 0.10 -1.78 0.11 -1.43 0.28 No No 1905V -0.18 0.05 -0.21 0.05 0.10 0.06 Yes No G906A 0.41 0.05 0.56 0.04 0.42 0.05 Yes Yes G906S 0.40 0.05 0.16 0.05 0.15 0.06 Yes Yes G906R -1.82 0.06 -2.39 0.07 -1.63 0.08 No No G906D -1.49 0.10 -1.05 0.08 -1.38 0.18 No No G906C -1.50 0.11 -1.21 0.09 -1.62 0.11 No No G906E -2.26 0.12 -1.63 0.09 -1.49 0.11 No No G906L -1.51 0.09 -2.32 0.11 -1.69 0.27 No No G906P -1.68 0.12 -1.05 0.09 -1.66 0.10 No No G906* NA NA NA NA -1.21 0.40 Yes No G906T -1.69 0.11 -2.68 0.15 NA NA Yes No G906W -2.22 0.11 -1.14 0.07 -1.71 0.08 No No G906V -0.85 0.05 -1.20 0.05 -1.27 0.06 No No I907A 0.70 0.10 0.42 0.10 0.27 0.54 Yes Yes 1907V 0.15 0.07 0.12 0.07 0.13 0.06 Yes Yes I907R -0.92 0.08 -1.15 0.08 -0.89 0.09 No No I907D -0.44 0.17 -0.97 0.18 NA NA Yes No I907C -0.16 0.16 0.84 0.13 0.12 0.64 Yes No I907E -1.06 0.15 -0.42 0.12 NA NA Yes No I907G -0.42 0.06 -0.40 0.06 -0.03 0.06 No No I907L 0.34 0.09 0.24 0.08 -0.33 0.09 Yes No I907M NA NA NA NA 0.12 0.25 Yes No I907F -0.50 0.19 -0.17 0.17 NA NA Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? I907S -0.29 0.03 -0.18 0.03 0.25 0.03 Yes No I907T -0.44 0.15 0.78 0.12 0.28 0.12 Yes No D908A -2.26 0.13 -1.92 0.11 -1.10 0.16 No No D908R NA NA NA NA -1.53 0.09 Yes No D908N -0.27 0.12 -0.30 0.12 -0.70 0.14 No No D908E -1.61 0.13 -1.42 0.11 -1.11 0.11 No No D908G -2.25 0.09 -2.15 0.08 -1.77 0.14 No No D908S -1.92 0.16 -1.78 0.14 NA NA Yes No D908W -1.93 0.15 -2.11 0.15 NA NA Yes No D908Y 0.26 0.11 -0.07 0.12 -0.15 0.12 Yes No D908V -1.74 0.10 -1.76 0.10 -1.52 0.09 No No R909A NA NA NA NA -1.45 0.37 Yes No R909Q -0.25 0.18 -0.94 0.20 NA NA Yes No R909G -1.30 0.05 -1.49 0.05 -1.38 0.06 No No R909K -0.87 0.16 -0.60 0.14 NA NA Yes No R909S -1.08 0.10 -0.84 0.09 -0.58 0.12 No No R909T -1.28 0.15 -0.89 0.13 NA NA Yes No R909W -0.96 0.10 -1.94 0.13 NA NA Yes No R909V -1.36 0.11 -2.33 0.14 -1.34 0.47 No No G910R -1.03 0.08 -1.62 0.09 -1.75 0.16 No No G910D NA NA NA NA -0.69 0.19 Yes No G910C -0.91 0.13 -1.29 0.14 NA NA Yes No G910S -1.15 0.10 -1.28 0.10 -1.41 0.19 No No G910W -1.93 0.15 -1.82 0.13 NA NA Yes No G910V -1.34 0.08 -1.15 0.07 -0.66 0.13 No No E911A -0.79 0.12 -1.56 0.14 -0.93 0.10 No No E911R -1.42 0.12 -2.19 0.14 NA NA Yes No E911D -0.45 0.14 -0.47 0.13 -0.18 0.25 No No E911G -0.65 0.06 -0.80 0.06 -0.83 0.08 No No E911L NA NA NA NA -0.50 0.15 Yes No E911K -0.39 0.13 -0.14 0.12 -0.57 0.15 No No E911* -0.20 0.11 0.12 0.10 -0.18 0.16 Yes No E911V -0.21 0.08 -0.62 0.08 -0.61 0.09 No No R912A 0.46 0.09 0.49 0.09 0.31 0.64 Yes Yes R912L 0.53 0.08 0.38 0.08 0.21 0.16 Yes Yes R912S 1.04 0.11 0.30 0.11 0.31 0.54 Yes Yes R912V 0.19 0.09 0.23 0.09 0.03 0.09 Yes Yes R912C 0.43 0.15 0.54 0.15 -0.29 0.16 Yes No R912Q 0.22 0.05 0.15 0.05 -0.05 0.09 Yes No R912E 0.53 0.12 -0.67 0.14 NA NA Yes No R912G -0.21 0.05 -1.04 0.06 -0.56 0.05 No No R912P 0.53 0.09 0.79 0.09 -0.40 0.14 Yes No 2024201449   05 Mar 2024 Mutant Enrich. Score (1) Stand. Error (1) Enrich. Score (2) Stand. Error (2) Enrich. Score (3) Stand. Error (3) Any positive enrichment? Consistent positive enrichment? R912T -0.54 0.17 -0.07 0.15 0.52 0.65 Yes No R912W -0.09 0.07 -0.14 0.07 -0.43 0.10 No No N913A -1.19 0.13 -0.97 0.11 -0.87 0.33 No No N913R -2.49 0.14 -0.64 0.07 -1.67 0.40 No No N913D -0.62 0.13 -0.44 0.12 -0.75 0.10 No No N913E -0.91 0.12 -1.92 0.16 NA NA Yes No N913G -1.34 0.07 -0.91 0.06 -1.56 0.30 No No N913H 0.12 0.07 0.13 0.07 -0.20 0.12 Yes No N913I -0.16 0.09 -0.18 0.09 -0.18 0.12 No No N913L -0.39 0.11 -0.72 0.11 NA NA Yes No N913K -0.37 0.05 -0.29 0.04 -0.27 0.08 No No N913S -0.29 0.08 -0.06 0.07 -0.20 0.12 No No N913T 0.09 0.11 -0.67 0.12 -0.35 0.24 Yes No N913Y -0.47 0.18 -0.44 0.17 NA NA Yes No N913V -1.32 0.12 -0.89 0.10 -1.09 0.18 No No

[0160] ’Key to Header abbreviations: Mutants are defined by single letter amino acid (wildtype) at a given position in the wild-type AsCasl2a polypeptide (e.g., amino acid position 500), followed by the variant amino acid change thereafter; “Enrich. Score (1)” refers to Enrichment score of the variant in a Condition 1 background; “Stand. Error (1) refers to the Standard error for experiments conducted for a given variant in a Condition 1 background; “Enrich. Score (2)” refers to Enrichment Score of the variant in a Condition 2 background; “Stand. Error (2) refers to the Standard Error for experiments conducted for a given variant in a Condition 2 background; “Enrich. Score (3)” refers to Enrichment Score of the variant in a Condition 3 background; “Stand. Error (3) refers to the Standard Error for experiments conducted for a given variant in a Condition 3 background; “Any Positive Enrichment?” refers to the occurrence of positive enrichment for a given variant under at least one experimental Condition background; “Consistent positive enrichment?” refers to the occurrence of positive enrichment for a given variant under all tested experimental Condition backgrounds.

[0161] One hundred eighty-seven (187) variants (~6% of total) consistently enhanced the survival rate under all conditions (Table 4). These variants, including the four validated individually, can be stacked on the WT- or M537R / F870L-A5Ca572a, to boost its DNA cleavage activity at TTTT-PAM.

[0162] Table 4. Point mutations consistently enriched over the reference proteins under all conditions.1 SEQ ID NO.: Mutant Position Variant score (condition 1) Variant score (condition 2) Variant score (condition 3) 59 R499C 499 0.14±0.08 0.6±0.07 0.06±0.1 60 R499L 499 0.08±0.05 0.05±0.06 0.09±0.15 61 R499K 499 0.54±0.06 0.23±0.06 0.38±0.1 62 L500M 500 0.01 ±0.05 0.3±0.05 0.28±0.12 tZOZ go 6PP10ZPZ0Z 2024201449   05 Mar 2024 SEQ ID NO.: ---- Mutant N515V Position ---- Variant score (condition 1) ..........0.5±0.05 Variant score (condition 2) ..........0.49±0.05 Variant score (condition 3) ..........0.45±0.09........... 124 K516R 516 0.01 ±0.03 0.26±0.03 0.4±0.06 125 R518K 518 0.2±0.09 0.72±0.08 0.05±0.17 126 T522L 522 1.1 ±0.05 0.92±0.05 0.28±0.1 127 T522M 522 0.92±0.07 0.81 ±0.08 0.53±0.21 128 T522V 522 0.16±0.05 0.28±0.05 0.04±0.07 129 K523R 523 0.17±0.02 0.37±0.02 0±0.03 130 S527D 527 0.13±0.11 0.01 ±0.11 0.34±0.41 131 V528D 528 0.01 ±0.07 0.27±0.07 0.12±0.12 132 V528L 528 0.55±0.03 0.59±0.03 0.31 ±0.07 133 V528M 528 0.19±0.05 0.02±0.05 0.13±0.1 134 S542N 542 0.24±0.09 0.02±0.09 0.29±0.07 135 S542C 542 0.03±0.17 0.15±0.17 0.42±0.16 136 K550R 550 0.05±0.03 0.18±0.03 0.17±0.07 137 N551D 551 0.14±0.04 0.15±0.04 0.67±0.07 138 A554I 554 0.15±0.09 0.71 ±0.08 0.39±0.34 139 A554T 554 0.45±0.04 0.32±0.05 0.93±0.07 140 A554V 554 0.57±0.03 0.48±0.03 0.54±0.04 141 I555V 555 0.41 ±0.03 0.13±0.03 0.14±0.06 142 L556M 556 0.08±0.08 0.1 ±0.08 0.11 ±0.21 143 V558M 558 0.24±0.06 0.15±0.06 0.1 ±0.12 144 K559A 559 0.17±0.04 0.08±0.04 0.13±0.08 145 N560A 560 0.34±0.05 0.18±0.05 0.18±0.08 146 N560D 560 0.16±0.04 0.18±0.04 0.16±0.08 147 N560E 560 0.48±0.06 0.28±0.06 0.11 ±0.25 148 N560M 560 0.16±0.09 0.31 ±0.09 0.18±0.13 149 P569D 569 0.6±0.08 0.33±0.08 1,25±0.11 150 Q571A 571 0.64±0.07 0.39±0.08 1.09±0.23 151 Q571P 571 0.17±0.07 0.61 ±0.07 0.13 ±0.14 152 Q571S 571 0.25±0.09 0.2±0.09 0.89±0.23 153 Q571T 571 0.22±0.13 0.19±0.13 0.87±0.41 154 K572E 572 0.11 ±0.04 0.25±0.04 0.42±0.08 155 Y575G 575 0.53±0.04 0.21 ±0.04 0.32±0.07 156 Y575M 575 0.89±0.11 0.27±0.12 0.31 ±0.41 157 K576C 576 0.27±0.07 0.25±0.07 0.1 ±0.26 158 S579T 579 0.17±0.04 0.33±0.04 0.01 ±0.06 159 S579V 579 0.04±0.03 0.02±0.03 0.05±0.07 160 T583I 583 0.04±0.08 0.11 ±0.07 0.07±0.17 161 E584H 584 0.09±0.07 0.22±0.07 0.17±0.14 162 E584V 584 0.1 ±0.03 0.06±0.03 0.12±0.04 163 K585R 585 0.07±0.03 0.32±0.03 0.06±0.05 164 K585F 585 0.51 ±0.09 0.04±0.09 0.61 ±0.36 165 D596E 596 0.04±0.04 0.24±0.04 0.69±0.05 166 P599G 599 0.84±0.04 0.83±0.04 1.01 ±0.05 167 A602C 602 0.64±0.09 0.61 ±0.09 0.73±0.28 168 L612M 612 0.7±0.07 0.7±0.07 0.01 ±0.03 169 A614R 614 0.28±0.04 0.07±0.05 0.16±0.05 170 A614I 614 0.52±0.11 0.59±0.11 0.41 ±0.22 171 T616A 616 0.32±0.03 0.24±0.04 0.09±0.05 172 T616R 616 0.19±0.03 0.12±0.03 0.62±0.04 173 T616Q 616 0.35±0.07 0.38±0.07 0.78±0.2 174 T616G 616 0.22±0.03 0.01 ±0.03 0.16±0.06 175 T616Y 616 0.54±0.09 0.64±0.09 0.05±0.38 176 A617G 617 0.03±0.03 0.05±0.03 0.24±0.06 177 F619M 619 0.12±0.07 0.55±0.07 0.22±0.25 178 Q620A 620 0.22±0.04 0±0.05 0.18±0.09 179 Q620R 620 0.25±0.03 0.18±0.03 0.17±0.04 180 Q620N 620 0.26±0.14 0.28±0.14 0.36±0.21 181 Q620L 620 0.14±0.04 0.45±0.04 0.4±0.16 182 Q620K 620 0.1 ±0.07 0.24±0.07 0.04±0.1 2024201449   05 Mar 2024 SEQ ID NO.: ---- Mutant T621A Position ----- Variant score (condition 1) ~.........0.18±0.04 Variant score (condition 2) ..........0.13±0.04 Variant score (condition 3) ...........017±01............. 184 H622G 622 0.05±0.03 0.18±0.03 0.07±0.06 185 H622S 622 0.16±0.06 0.59±0.06 0.08±0.1 186 H622T 622 0.01 ±0.09 0.84±0.08 0.31 ±0.34 187 H622V 622 0.18±0.05 0.15±0.05 0.31 ±0.12 188 T623E 623 0.32±0.05 0.23±0.05 0.02±0.05 189 T623H 623 0.6±0.1 0.01 ±0.11 0.58±0.55 190 T623L 623 0.33±0.05 0.18±0.05 0.17±0.16 191 T623M 623 0.21 ±0.07 0.28±0.07 0.59±0.22 192 T623F 623 0.8±0.1 0.61 ±0.1 0.47±0.32 193 T624P 624 0.92±0.02 0.92±0.02 0.04±0.03 194 L627C 627 0.14±0.13 0.84±0.11 0.57±0.48 195 L628C 628 0.31 ±0.09 0.1 ±0.1 0.29±0.31 196 L628W 628 0.25±0.06 0.01 ±0.07 0.67±0.15 197 N630R 630 0.53±0.05 0.06±0.06 0.94±0.08 198 I633N 633 0.16±0.06 0.65±0.06 0.15±0.1 199 I633M 633 0.17±0.07 0.28±0.07 0.1 ±0.19 200 I633S 633 0.02±0.04 0.35±0.04 0.22±0.08 201 E634N 634 0.52±0.12 0.46±0.12 0±0.36 202 P635A 635 0.04±0.05 0.29±0.05 0.59±0.07 203 P635D 635 0.14±0.09 0.49±0.09 0.52±0.14 204 P635E 635 0.51 ±0.06 0.49±0.06 0.7±0.16 205 P635T 635 0.36±0.06 0.06±0.06 0.01 ±0.08 206 T639G 639 0.52±0.06 0.44±0.06 0.06±0.23 207 D840S 840 0.37±0.08 0.33±0.08 0.1 ±0.16 208 A842S 842 0.36±0.06 0.08±0.06 0.04±0.1 209 A844E 844 0.38±0.1 0.06±0.1 0.13±0.21 210 T851A 851 0.41 ±0.06 0.14±0.06 0.08±0.1 211 T851V 851 0.32±0.06 0.13±0.06 0.54±0.07 212 E853V 853 0.14±0.07 0.1 ±0.07 0.38±0.09 213 R862K 862 0.04±0.14 0.54±0.13 0.02±0.38 214 S866F 866 0±0.13 0.06±0.12 0.1 ±0.14 215 S866T 866 0.05±0.13 0.02±0.13 0.4±0.15 216 V873A 873 0.16±0.11 0.05±0.11 0.08±0.16 217 N878D 878 0.03±0.06 0.02±0.06 0.04±0.08 218 Q880R 880 0.13±0.05 0.02±0.05 0.01 ±0.06 219 Q880G 880 0.25±0.04 0.19±0.04 0.64±0.05 220 A882D 882 0.32±0.05 0.22±0.05 0.1±0.07 221 A882S 882 0.11 ±0.12 0.14±0.11 0.23±0.22 222 N883G 883 0.42±0.08 0.37±0.08 0.03±0.11 223 N883K 883 0.12±0.16 0.23±0.16 0.16±0.1 224 S884V 884 0.05±0.11 0.61 ±0.1 0.03±0.14 225 S886L 886 0.09±0.08 0.12±0.08 0.05±0.11 226 S886M 886 0.32±0.11 0.15±0.11 0.4±0.35 227 S886W 886 0.23±0.07 0.01 ±0.07 0.7±0.19 228 Q890C 890 0.03±0.11 0.64±0.1 0.08±0.54 229 Q890H 890 0.39±0.09 0.07±0.09 0.04±0.11 230 Q890W 890 0.03±0.08 0.23±0.07 0.03±0.08 231 A894R 894 0.19±0.06 0.06±0.06 0.04±0.08 232 A894D 894 0.04±0.06 0.09±0.06 0.21 ±0.05 233 Y895D 895 0.16±0.04 0±0.04 0.09±0.04 234 H899A 899 0.21 ±0.08 0.16±0.07 0.01 ±0.48 235 H899N 899 0.15±0.15 0.7±0.14 0.08±0.18 236 E901D 901 0.07±0.1 0.05±0.1 0.14±0.15 237 P903T 903 0.64±0.13 0.52±0.12 0.39±0.18 328 G906A 906 0.41 ±0.05 0.56±0.04 0.42±0.05 239 G906S 906 0.4±0.05 0.16±0.05 0.15±0.06 240 I907A 907 0.7±0.1 0.42±0.1 0.27±0.54 241 I907V 907 0.15±0.07 0.12±0.07 0.13±0.06 242 R912A 912 0.46±0.09 0.49±0.09 0.31 ±0.64 2024201449   05 Mar 2024 SEQ ID Mutant Position Variant score Variant score Variant score N...

Claims

1. A CRISPR-associated protein consisting of a wild-type AsCas12a polypeptide sequence of SEQ ID NO: 462 and comprising at least two amino acid substitutions: M537R and F870L.

2. The CRISPR-associated protein of claim 1, wherein the CRISPR-associated protein comprises the amino acid sequence of SEQ ID NO: 465 or SEQ ID NO: 493.

3. The CRISPR-associated protein of claim 1, wherein the CRISPR-associated protein comprises an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 466, SEQ ID NO: 467, SEQ ID NO: 489, and SEQ ID NO: 491.

4. The CRISPR-associated protein of any one of claims 1 - 3, further comprising at least one nuclear localization signal.

5. The CRISPR-associated protein of any one of claims 1 - 4, wherein the isolated mutant Cas12a variant is mutant acidaminococcus sp. Cas12a (AsCas12a) variant.

6. The CRISPR-associated protein of any one of claims 1 - 5, wherein the isolated mutant Cas12a variant is a clustered regularly interspersed short palindromic repeats / CRISPR associated (CRISPR / Cas) endonuclease system protein.

7. The CRISPR-associated protein of any one of claims 1 - 6, wherein the isolated mutant Cas12a variant is active in the CRISPR / Cas endonuclease system, and wherein the CRISPR / Cas endonuclease system displays reduced off-target editing activity and maintains on-target editing activity relative to a wild-type CRISPR / Cas endonuclease system having SEQ ID NO: 462.

8. The CRISPR-associated protein of any one of claims 1 - 7, wherein the isolated mutant Cas12a variant comprises an amino acid sequence as recited in SEQ ID NO: 465 or SEQ ID NO: 493.

9. The CRISPR-associated protein of any one of claims 1 - 8, wherein the CRISPR-associated protein comprises an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO: 466, SEQ ID NO: 467, SEQ ID NO: 489, and SEQ ID NO: 491.2024201449   17 Jun 202610. An isolated nucleic acid encoding the CRISPR-associated protein of any one of claims 1 - 9.

11. The isolated nucleic acid of claim 10, wherein the isolated nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 466.

12. The isolated nucleic acid of claim 10, wherein the isolated nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 467.

13. The isolated nucleic acid of claim 10, wherein the isolated nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 489.

14. The isolated nucleic acid of claim 10, wherein the isolated nucleic acid comprises the nucleic acid sequence of SEQ ID NO: 491.

15. A composition comprising the CRISPR-associated protein of any one of claims 1 - 9.

16. A composition comprising the isolated nucleic acid of any one of claims 10 - 14.

17. An engineered CRISPR / Cas endonuclease system, comprising:a. the CRISPR-associated protein of any one of claims 1 - 9; andb. at least one guide RNA that hybridizes to a target sequence of a DNA molecule in a eukaryotic cell.

18. An engineered CRISPR / Cas endonuclease system, comprising:a. the isolated nucleic acid of any one of claims 10 - 14; andb. at least one guide RNA that hybridizes to a target sequence of a DNA molecule in a eukaryotic cell.

19. A complex, comprising:a. the isolated mutant Cas12a variant of any one of claims 1 - 9; andb. at least one guide RNA that hybridizes to a target sequence of a DNA molecule in a eukaryotic cell.

20. A method of performing genome editing in a eukaryotic cell, comprising introducing the CRISPR / Cas endonuclease system of any one of claims 17 - 18 or the complex of claim 19 into a eukaryotic cell.

21. A method of performing genome editing in a eukaryotic cell, comprising introducing a CRISPR / Cas endonuclease system into the eukaryotic cell, wherein the CRISPR / Cas endonuclease comprises an expression cassette encoding the Cas12a variant of any one of claims 1 - 9.

Images